standard_type,standard_units,count,activity_direction
Potency,nM,4471741,-1
GI50,nM,2612253,-1
IC50,nM,2530782,-1
Inhibition,%,1529105,1
Percent Effect,%,1328366,1
Ki,nM,650568,-1
Activity,,625329,0
MIC,ug.mL-1,608019,-1
Activity,%,560776,1
EC50,nM,487170,-1
INHIBITION,%,339133,1
AC50,nM,232772,-1
IC50,,192954,-1
Kd,nM,179228,-1
Z score,,147592,0
Ratio IC50,,135452,-1
Tissue Severity Score,,128999,0
Ki,,123897,-1
MIC,nM,114529,-1
Ratio,,114411,0
GI,%,101853,1
IZ,mm,90853,1
CC50,nM,89561,-1
T1/2,hr,84488,0
IC50,ug.mL-1,77190,-1
Residual Activity,%,73944,1
FC,,63132,0
Stability,%,53591,1
ED50,mg.kg-1,51862,-1
% Control,%,50544,1
LC50,nM,47192,-1
AC50,,45407,-1
TGI,nM,43111,-1
CL,mL.min-1.kg-1,42622,-1
Ratio Ki,,42544,-1
Growth Rate,,36972,0
AUC,ng.hr.mL-1,35822,0
Emax,%,35061,1
Solubility,nM,30200,0
F,%,29793,1
LogD,,29075,0
MIC90,ug.mL-1,27769,-1
Solubility,ug.mL-1,26380,0
GI,,26250,-1
MIC50,ug.mL-1,25072,-1
CL,mL.min-1.g-1,24405,-1
Cmax,nM,24217,0
Control DMSO Mitochondria Different-Phenotype Cells (%),%,22607,1
Population Pyknosed Nuclei (%),%,22607,1
Population Normal (%),%,22607,1
Population Mitotic Cells (%),%,22607,1
Population Mitochondria Different-Phenotype (%),%,22607,1
Population Membrane Permeable-Phenotype (%),%,22607,1
Population Hoechst High Intensity Objects (%),%,22607,1
Population Healthy Nuclei (%),%,22607,1
Population Fragmented Nuclei (%),%,22607,1
Population Apoptotic (%),%,22607,1
Control DMSO Tubulin Phenotype Different Cells (%),%,22607,1
Total Cell Count,,22607,0
Control DMSO Pyknosed Nuclei (%),%,22607,1
Control DMSO Mitotic Cells (%),%,22607,1
Control DMSO Membrane Permeable-Phenotype Cells (%),%,22607,1
Control DMSO Healthy Nuclei (%),%,22607,1
Control DMSO Fragmented Nuclei %,%,22607,1
Population Tubulin-Different-Phenotype (%),%,22607,1
Biotransformation,,22306,0
Ratio EC50,,21600,-1
Efficacy,%,21569,1
Selectivity Index,,21340,0
Selectivity ratio,,20974,-1
Ratio CC50/EC50,,20423,-1
LogP,,20279,0
LUCIFERASE EXPRESSION CONTROL - IC90,uM,19978,-1
LUCIFERASE EXPRESSION CONTROL - IC50,uM,19978,-1
LUCIFERASE INFECTION ASSAY - IC50,uM,19978,-1
LUCIFERASE INFECTION ASSAY - IC90,uM,19978,-1
HEPG2TOX ASSAY - CC90,uM,19978,-1
HEPG2TOX ASSAY - CC50,uM,19978,-1
Delta TM,C,19246,-1
IFI,%,19230,1
MIC,,19032,-1
EC50,,18930,-1
WEIGHT,g,18871,0
Drug metabolism,,16980,0
TIME,hr,16768,1
Delta Tm,degrees C,16667,1
mortality,%,16386,1
ED50,ug ml-1,16163,-1
EC50,ug.mL-1,15074,-1
Vdss,L.kg-1,14765,0
MIC80,ug.mL-1,14598,-1
Survival,%,14294,1
PPB,%,13695,1
XC50,nM,13587,-1
Tmax,hr,13103,0
Drug uptake,,13005,0
Fu,,12990,-1
Ratio CC50/IC50,,12909,-1
%Inhib (Mean),%,12829,1
Drug uptake,% ID/g,12663,1
ED50,uM,12659,-1
pKa,,12609,0
MBC,ug ml-1,12226,-1
Control DMSO Total Cells,,12143,0
Activity,uM,11992,-1
T/C,%,11858,1
Selectivity,,11179,1
Control DMSO Apoptotic Cells (%),%,10464,1
Control DMSO Growth Rate,%,10464,1
Control DMSO Total Cells,%,10464,1
% of control,%,10334,1
ED50,umol.kg-1,9751,-1
IC90,nM,9538,-1
Km,nM,9415,-1
Thermal melting change,degrees C,9183,1
ALB,ug.mL-1,8646,0
CHOL,ug.mL-1,8646,0
PHOS,ug.mL-1,8646,0
BUN,ug.mL-1,8646,0
GLUC,ug.mL-1,8646,0
CREAT,ug.mL-1,8646,0
PROT,ug.mL-1,8645,0
HCT,%,8645,1
MCV,fL,8645,0
RBC,cells.uL-1,8645,1
WBC,cells.uL-1,8644,1
SODIUM,mEq.L-1,8642,0
HGB,ug.mL-1,8642,1
POTASSIUM,mEq.L-1,8642,0
MCH,pg,8642,0
Drug metabolism,%,8636,1
Change,%,8629,1
PLAT,cells.uL-1,8626,1
BASOLE,%,8615,1
NEUTLE,%,8615,1
LYMLE,%,8615,1
MONOLE,%,8615,1
EOSLE,%,8615,1
BILI,ug.mL-1,8565,0
Ac50,uM,8340,-1
CLH,uL/min,7772,-1
solubility,,7707,0
Control,%,7387,1
MIC90,nM,7163,-1
%Max (Mean),%,7141,1
Imax,%,7022,1
DIZ,,6847,1
LD50,mg.kg-1,6838,-1
TI,,6751,0
%max,%,6658,1
Reduction,%,6318,1
MED,mg kg-1,6227,1
GI50,ug.mL-1,6197,-1
MFC,ug ml-1,6196,-1
Kb,nM,6004,-1
CC50,ug.mL-1,5696,-1
Activity,ug ml-1,5529,1
TGI,%,5466,1
Activity,g,5225,0
ILS,%,5215,1
GI50,,5186,-1
Intrinsic activity,,5152,1
APTT,s,5112,-1
FICI,,4947,-1
Kd,,4928,-1
ID50,uM,4911,-1
Relative potency,,4872,0
PT,s,4868,-1
PHOSLPD,ug.mL-1,4773,0
TRIG,ug.mL-1,4773,1
CALCIUM,ug.mL-1,4773,0
MCHC,%,4773,1
AST,IU.L-1,4773,1
LDH,IU.L-1,4773,1
Cl,meq/L,4773,0
TERMBW,g,4773,0
ALT,IU.L-1,4773,1
ALP,IU.L-1,4773,1
ALBGLOB,,4773,0
RETIRBC,%,4773,1
GGT,IU.L-1,4773,1
pKb,,4772,-1
BILDIR,ug.mL-1,4749,0
ID50,mg.kg-1,4698,-1
FIBRINO,ug.mL-1,4637,0
LogD7.4,,4557,0
Papp,10'-6 cm/s,4553,0
AbsAC40_uM,uM,4490,-1
Vd,L.kg-1,4489,0
MRT,hr,4415,0
Papp,ucm/s,4244,0
TC50,uM,4182,-1
Retention_time,min,4101,0
% of inhibition,%,4072,1
permeability,10'-6 cm/s,4009,0
Selectivity index,,3971,-1
MST,day,3962,1
log2FC,,3941,0
Hepatotoxicity,,3929,-1
MIC>99,uM,3921,-1
MCHC,ug.mL-1,3876,0
ALT,U.L-1,3873,-1
ALP,U.L-1,3873,1
AST,U.L-1,3873,-1
CHLORIDE,mEq.L-1,3869,0
CC50,,3844,-1
-logMIC,,3840,-1
IZ,,3803,1
Papp,10^-6 cm/s,3801,1
ID/g,%,3716,1
CK,U.L-1,3716,0
CLogP,,3694,0
RBA,,3598,-1
Emax,,3564,1
LD50,uM,3511,-1
EC90,uM,3500,-1
LIPASE,U.L-1,3460,0
URATE,ug.mL-1,3459,0
LDH,U.L-1,3438,1
Activity,mmHg,3398,1
CO2,nM,3370,0
ED50,nM,3362,-1
MIC99,ug ml-1,3359,-1
Activity,mg/dl,3357,0
INH,uM,3347,-1
Ke,nM,3343,-1
BASO,cells.uL-1,3331,1
RBA,%,3316,1
Drug uptake,%,3312,1
MONO,cells.uL-1,3307,-1
LYM,cells.uL-1,3307,1
EOS,cells.uL-1,3307,1
MIC50,nM,3301,-1
t1/2,,3256,0
permeability,nm/s,3246,0
NEUTSG,cells.uL-1,3201,1
ED50,,3181,-1
Intrinsic activity,%,3169,1
Cp,ng/ml,3167,0
Cp,uM,3158,-1
BPR,,3119,0
T/C,,3113,1
RBCNUC,/100WBC,3111,0
ID50,ug ml-1,3106,-1
MCC,nM,2908,-1
CI,,2837,-1
LC50,ug.mL-1,2817,-1
permeability,10^-6 cm/s,2781,1
Activity,nM,2774,-1
AbsAC35_uM,uM,2740,-1
Decrease,%,2725,1
Papp,nm/s,2693,1
% Ctrl,%,2684,1
MBC,uM,2669,-1
Activity,mg,2630,1
RatioGI50,,2624,-1
MIC100,ug ml-1,2579,-1
permeability,ucm/s,2572,0
Tm,degrees C,2565,1
PD50,mg kg-1,2507,1
MIC99,uM,2502,-1
Drug uptake,%ID,2501,1
Activity,mm,2493,1
Drug uptake,uM,2485,0
Toxicity,,2460,0
TD50,mg kg-1,2407,1
IC95,nM,2406,-1
% Cell Death,,2400,1
Kcat,/s,2366,-1
MIC80,nM,2358,-1
Activity_index,,2312,1
Relative activity,,2308,0
Residual activity,%,2283,1
Log 1/C,,2270,-1
Diet,%,2246,0
pD2,,2234,-1
Protection,%,2221,1
MCC,ug.mL-1,2220,-1
permeability,,2167,0
DOSE,mg.kg-1,2131,1
CLH,,2117,-1
Activity,mg kg-1,2054,1
Drug uptake,ng/g,2030,0
EC90,nM,2016,-1
pIC50,,2013,-1
Activity,s,2010,1
MIC,10'-2 umol/ml,1986,-1
Ratio,/M/s,1985,-1
Activity,pg/ml,1959,1
Efficacy,,1949,-1
Survivors,,1945,1
log(1/C),,1938,-1
log(activity),,1935,1
MIC95,uM,1929,-1
IC90,ug.mL-1,1862,-1
Survival,day,1843,1
pKB,,1832,-1
Increase,%,1828,1
Drug degradation,%,1823,1
IC50 ratio,,1786,-1
max activation,%,1778,1
Ratio ED50,,1747,-1
CL,uL.min-1.(10^6cells)-1,1737,-1
Cp,nM,1723,-1
MEC,uM,1714,-1
PXC50,,1705,-1
log K,,1698,0
Activity,mU/ml,1694,1
Activity,ml,1686,1
Hit score,,1669,1
Activity,pm/min/mg,1663,1
ERH,,1654,0
Drug recovery,%,1618,1
TGI,,1614,-1
KA,uM,1610,-1
Kinact,nM,1607,-1
Motility,%,1597,1
SI,,1578,-1
Inhibition index,,1577,1
Delta MST,day,1559,-1
Drug uptake,nM,1557,-1
Cytotoxicity,,1555,-1
IC50 relative,nM,1551,-1
MIC,ug,1548,-1
MTD,mg kg-1,1539,1
MEC,ug ml-1,1524,-1
AbsAC35,uM,1489,-1
log10cfu,,1482,-1
Papp,,1450,0
Log K,,1447,1
Ratio IC50/EC50,,1445,-1
CL,,1441,-1
Concentration,ug ml-1,1431,0
EC,uM,1427,-1
Potency,,1414,-1
AUC,,1411,0
SUV,,1403,1
AbsAC26_uM,uM,1390,-1
Fold change,,1389,0
DC50,nM,1388,-1
Dose/organ,%,1386,1
Activity,equiv,1377,1
Concentration,uM,1362,-1
Displacement,%,1345,1
Dose/g,%,1344,1
PI,,1336,1
Ratio TD50/ED50,,1330,1
Rm,,1326,0
pEC50,,1312,-1
MIC=>90,ug ml-1,1301,-1
Activity,U/L,1281,1
deltaT,degrees C,1279,-1
HC50,ug ml-1,1275,-1
Activity,mM,1273,1
AbsAC40,uM,1268,-1
ID/organ,%,1260,1
Concentration @ Maxi,um,1244,-1
MBC,,1243,-1
Activity,ng/ml,1222,1
Hepatotoxicity (acute),,1216,0
Hepatotoxicity (acute),%,1216,1
Hepatotoxicity (animal toxicity known),,1216,-1
Hepatotoxicity (association with vascular disease),,1216,0
Hepatotoxicity (malignant tumour),,1216,0
Hepatotoxicity (moderate),,1216,0
Hepatotoxicity (comment),,1216,0
Hepatotoxicity (cytolytic),,1216,0
Hepatotoxicity (granulomatous hepatitis),,1216,0
Hepatotoxicity (moderate),%,1216,1
Hepatotoxicity (mechanism),,1216,0
Hepatotoxicity (benign tumour),,1216,0
Hepatotoxicity (choleostasis),,1216,0
Hepatotoxicity (time to onset),,1216,1
Hepatotoxicity (chronic liver disease),,1216,0
Hepatotoxicity (successful reintroduction),,1216,1
Hepatotoxicity (cirrhosis),,1216,0
Hepatotoxicity (steatosis),,1216,0
Hepatotoxicity (severe hepatitis),,1216,0
Effect,,1203,0
Relative Growth,,1195,-1
ID50,nM,1191,-1
BP,mmHg,1187,1
K,/min,1164,-1
CLH,ml/min,1163,-1
LC50,ppm,1162,-1
LC50,,1145,-1
% inhibition,uM,1143,1
Response,%,1136,1
Cmax,ug.mL-1,1115,0
Max,%,1100,1
Ratio AUC,,1097,0
Inhibition,ug ml-1,1092,0
Survival,,1082,0
mortality,,1074,-1
Peff,10'-6 cm/s,1067,1
UI,,1063,0
Compound recovery,%,1061,1
Cytotoxicity,%,1059,1
K obs / 1,M-1 s-1,1058,1
Conc @ Max Fold Incr,um,1040,1
C50,uM,1039,-1
Activity,bpm,1027,1
Growth,%,1026,1
Activity,nm,1013,0
Activity,nmol,993,0
ID50,umol.kg-1,971,-1
Cures,,970,1
Activity,ug,968,0
log10CFU/ml,,967,-1
Inhibition,uM,965,-1
MSD,day,955,1
log Pe,,950,0
Drug uptake,ng/ml,942,0
Injected dose,%,942,1
Stimulation,%,942,1
ED50,M,938,-1
DILI_severity_class,,929,1
DILI_Concern,,929,0
Flu intensity,,928,1
"K(p,uu,brain)",,918,0
FIC,,903,-1
Activity,mm3,902,1
Kp,,896,0
Distribution,%,896,1
logPapp,,893,0
HepSE_hepatic necrosis,,888,1
HepSE_elevated liver function tests,,888,1
HepSE_hepatic failure,,888,1
HepSE_bilirubinemia,,888,1
HepSE_cholecystitis,,888,1
HepSE_liver function tests abnormal,,888,1
HepSE_liver fatty,,888,1
HepSE_cirrhosis,,888,1
HepSE_Combined Scores,,888,0
HepSE_hepatitis,,888,1
HepSE_liver disease,,888,1
HepSE_jaundice,,888,1
HepSE_cholelithiasis,,888,1
HepSE_hepatomegaly,,888,1
ID50,M,877,-1
Activity,um,870,1
NT,,869,0
TDI,,858,-1
Therapeutic index,,850,0
Stability,microL/min/mg,847,-1
Phospholipidosis,,846,0
Biodistribution,%,843,1
Dose,%,842,1
Rf,,840,0
logIC50,,834,-1
MBC>99.9,uM,829,-1
permeability,%,828,1
AD50,mg kg-1,822,1
MBC99.9,ug ml-1,815,-1
LD50,umol.kg-1,810,-1
Drug uptake,ug ml-1,804,1
CD,uM,802,-1
Imax,,802,1
Duration,min,795,1
Log 1/D50,,792,-1
Cp,ug ml-1,788,0
MED,,787,-1
PC50,uM,786,-1
Activity,mmol/L,783,0
RatioLC50,,782,-1
Log 1/LD10,,776,-1
MPE,%,770,1
Ratio pKi,,767,-1
Activity,cm,760,1
ILS,,758,1
MST,,757,1
MFC,uM,750,-1
CL_renal,mL.min-1.kg-1,746,0
pKi,,743,-1
Ratio,%,740,1
Activation,%,737,1
Potency ratio,,735,-1
OD,,731,1
MBC,10'-2 umol/ml,722,-1
% residual kinase activity,%,716,1
TD50,uM,712,-1
Injected dose/g,%,711,1
DC50,uM,710,-1
Ka,uM,705,-1
OD,mg kg-1,699,1
Concentration,,699,0
Reversal,%,699,1
LD50,ug ml-1,699,-1
pA2,,694,-1
MIC50,,679,-1
HC50,uM,673,-1
Compound recovery,,671,0
Kinetic_solubility,,670,0
ID50,,670,-1
AC40,uM,669,-1
Decrease in blood pressure,%,666,1
K,,663,-1
Delta Tm,,662,-1
,,662,0
MTC,uM,657,-1
Rmax,%,653,1
Delta mean survival time,,649,1
k_off,s-1,647,-1
Activity,umol/L,645,1
fT>MIC,%,643,0
Activity,log10CFU,641,-1
Max_Activity,uM,640,-1
Vmax,%,639,1
No. of survivors,,636,1
GI,uM,636,-1
Kcat/Km,/uM/s,636,-1
Relative binding affinity,,634,-1
k obs / 1,M-1 s-1,632,1
Activity,day,631,1
Activity,log10CFU/ml,631,-1
Activity,U/mg,630,1
IP,nM,628,-1
MPC,ug ml-1,627,-1
Binding,%,625,1
% Inhibition of Control Specific Binding (Mean n=2),%,623,1
ED90,mg kg-1,613,1
Reduction,,613,-1
Log 1/MMIC,,612,-1
MIC90,,611,-1
Rate of inhibition,%,609,1
Animals,%,608,1
log Ks,,607,-1
Delta TC,%,607,1
MFC,,606,-1
Delta MST,,604,-1
MFC,10'-2 umol/ml,604,-1
Kinact,/min,601,-1
Ratio pIC50,,594,-1
Activity,min,588,1
MIC100,uM,588,-1
Effect,%,581,1
CD50,uM,579,-1
Drug excretion,%,573,1
Inhibition (mean),%,572,1
HC10,uM,569,-1
CHI,,568,0
ILSmax,%,568,1
Variation,%,567,1
INH,nM,563,-1
ID,%,563,1
Suppression,%,562,1
pCC50,,561,-1
MIC=>90,uM,561,-1
LD10,mg kg-1,554,-1
IA,,551,-1
Log Ki,,550,-1
Zone of inhibition,mM,549,1
Diuretic activity,,549,-1
CL/F,mL.min-1.kg-1,547,1
Activity,pmol,545,1
Weight change,%,545,1
Log2 MIC,,543,-1
Viability,%,541,1
Max response,%,534,1
No. of cured mice,,534,1
LD50,,532,1
deltaTm,,532,-1
deltaG,kcal/mol,532,-1
EC,nM,529,-1
ED30,mg kg-1,526,-1
2PT,uM,517,-1
GI,ug ml-1,515,-1
IC90,,514,-1
AFI,%,512,1
MIC>90,ug ml-1,509,-1
T,degrees C,508,1
AbsAC1000_uM,uM,505,-1
Log S,,505,0
Kis,uM,504,-1
Virus rating,,503,0
EDmin,mg kg-1,501,-1
Delta IOP,mmHg,498,-1
Kinact,uM,498,-1
Cp(f),nM,497,-1
Activity,U,495,1
Activity,nmol/min,495,1
Log k',,493,0
MOTILITY REDUCTION/CYTOTOXICITY,%,491,1
Composite Activity - Active,,490,0
GGT Increase - Activity Score,,490,1
GGT Increase - Index Value,,490,1
GGT Increase - Number of Reports,,490,1
Composite Activity - Score,,490,0
Composite Activity - Marginal,,490,0
LDH Increase - Number of Reports,,490,1
LDH Increase - Index Value,,490,1
LDH Increase - Activity Score,,490,1
Alkaline Phosphatase Increase - Activity Score,,490,1
Alkaline Phosphatase Increase - Index Value,,490,1
Alkaline Phosphatase Increase - Number of Reports,,490,0
SGPT Increase - Number of Reports,,490,0
SGPT Increase - Index Value,,490,1
SGPT Increase - Activity Score,,490,1
SGOT Increase - Number of Reports,,490,0
SGOT Increase - Index Value,,490,1
SGOT Increase - Activity Score,,490,1
pGI50,,488,-1
Activity,IU/L,487,1
Activity,ms,487,1
Drug metabolism,uM,486,0
deltaTm,K,485,-1
Peff,ucm/s,484,1
Mortality,,484,1
Ratio Ke,,483,0
Kcat,/min,483,1
Activity,mV,483,1
Occ,%,483,1
K ass,l M-1,479,-1
Activity,ug/g,476,-1
-log(solubility),,474,-1
Drug uptake,nmol/g,474,-1
Concentration,%,472,1
Duration,hr,469,1
Activity,degrees C,467,1
Ratio Ki(app),,466,-1
deltaCT,,464,-1
MIC>95,uM,464,-1
Recovery,%,462,1
Cmax,,461,0
MBC,mg/L,461,-1
Locomotor activity,,461,1
RLU,,460,0
MED,g/acre,459,1
Log 1/Ki app,,458,-1
Drugexcretion,%,457,1
Vmax,,457,1
IA,%,454,1
% binding,%,454,1
pED50,,450,-1
log(ratio),,446,1
Ct,ng/ml,444,0
Ki ratio,,442,0
k3/Ki,M-1 s-1,440,-1
K app,M-1,439,-1
CLH,%,439,1
TC50,ug ml-1,438,-1
Radioactivity,%,438,1
MIC=>80,ug ml-1,435,1
Km,,430,0
Remaining,%,429,1
K,/M/s,423,-1
Weight change,g,422,1
k_obs,s-1,422,-1
Increase,,421,1
MBEC,uM,420,-1
MIC,ug cm**-2,420,-1
RFU,,419,1
IC80,umol/L,418,-1
CL,L/hr,418,-1
Score,,415,0
Activity,micromol/min,415,1
CL,%,413,1
Phytotoxicity,%,411,1
K,/s,410,-1
CD50,mg kg-1,410,1
MRT(t),hr,410,0
No. of animals,,410,0
In vitro activity,,409,-1
log(1/MIC),,407,-1
K app,uM,407,-1
delta Tm,,406,-1
delta Tm Staurosporine positive control,,406,-1
IZ,nm,405,1
Activity,nmol/min/mg,404,1
LCK,,401,-1
Max_Activity_Concent,uM,400,-1
T1/2,,400,0
Growth Inhibition,%,400,1
Permeability,nm s-1,400,0
Anticonvulsant activity,,399,0
GI90,ug ml-1,398,-1
EC50,ppm,397,-1
Block,%,397,1
LD50,ug,395,1
AbsAC1,uM,395,-1
pD'2,,390,-1
fluorescence,,390,0
k_on,M-1.s-1,390,-1
Biodistribution,%ID/g,387,0
Vd/F,L.kg-1,386,0
Radiolabel recovery,ngequiv/g,382,1
Kcat/Km,/s/microM,380,-1
Motility,,380,0
Cytotoxicity,uM,378,-1
Heart rate,beats min-1,378,0
MFC99.5,10'-2 umol/ml,378,-1
Injected,%,376,1
TGI,ug.mL-1,376,1
CLH,ml/min.g,375,-1
Paw swelling,mM,375,0
log(ILSmax),,374,1
EC1.5,uM,373,-1
Solubility ratio,,373,0
Ct,nM,372,-1
kon,Ms-1,372,1
Concentration,ug g-1,369,0
Cp,,368,0
-Log KB,,367,-1
Optimal dose,mg kg-1,367,1
MBC,uM/ml,366,-1
MIC95,ug ml-1,364,-1
IG50,uM,363,-1
Drug uptake,ug/g,362,1
EC90,,362,-1
IC20,uM,362,-1
Cured,%,361,1
FPDc,,361,-1
KE,,359,1
Activity,mg dl-1,359,1
Vmax,pmol/min,357,-1
Drug excretion,,357,0
Cmax,ng/g,357,0
deltaH,kcal/mol,357,-1
2aPTT,uM,356,-1
No. of mice cured,,355,1
Hill coefficient,,354,0
Relative affinity,,354,0
RUmax,%,354,1
MIC80,,352,-1
ED50,ug,352,1
Ka,,352,1
ED50,mg kg-1 day-1,351,-1
Cooperativity,,350,0
Relative IC50,,350,-1
Inhibition,mm,348,1
SDL,%,346,1
MLC,ug ml-1,345,-1
log(%),,344,1
Peff,10^-6 cm/s,344,1
Activity,RFU,344,1
INH,ug ml-1,340,-1
Activity,g/dl,339,0
ED,nM kg-1,339,-1
MIC>90,uM,339,-1
TD50,,336,-1
MIC95,umol/L,336,-1
CL,uL/min,335,-1
Kcat/Km,,334,-1
Activity,microM/min,334,1
Relative potency,%,333,1
% Residual activity with Skepinone-L,%,333,1
Delta blood pressure,mmHg,332,-1
MTC,mg kg-1,331,1
Distribution of radioactivity,dose g-1,330,0
Fa,,329,0
IC30,uM,329,-1
MPC8,ug ml-1,328,-1
MIC,10'-2umol,328,-1
Release,%,328,1
Ka,10'5/M,328,1
Activity,V,328,0
k cat,s-1,327,-1
IC80,ug ml-1,326,-1
AUC,uM.hr,326,0
-log(1/MIC),,324,-1
Radiolabel recovery,ugequiv,324,0
MBIC50,ug ml-1,324,-1
Max fall in blood pressure,mmHg,324,1
Change,,323,0
PFA,,323,0
Safety ratio,,322,-1
k',,322,0
QH,%,322,1
Activity,mg/ml,322,1
FPD measurement,,321,-1
Viable cells,%,321,1
CTD50,uM,321,-1
HR,beats min-1,320,1
No. of revertants per plate,,320,1
pKa2,,318,-1
Mean fold stimulation,,318,1
Drug uptake(free),nM,318,-1
Affinity,,317,-1
Activity,/min,316,1
Schizont size,um,315,1
ERH,%,315,1
Radiolabel recovery,%,314,1
MIC=>80,uM,314,-1
Activity rating,,314,0
IC80,uM,314,-1
Inhibition zone,mM,313,1
Vmax,nmol/min,313,1
CL,ml/min,311,-1
Decrease in SBP,%,311,1
MFC99.9,uM,310,-1
Fg,,310,0
Max,,310,0
Fh,,310,0
Ke,,309,-1
ED,mg kg-1,309,1
Activity,uEq/min,308,1
F_fraction,,308,0
Mean injected dose/g,,307,0
-Log C,mM l-1,306,-1
Inhibition,,304,-1
Cp(f),uM,304,-1
Activity,mg/L,304,0
Mean survival time,day,303,1
Relative activity,%,303,1
PAE,hr,303,1
Activity,mm2,303,1
Permeability,,300,0
IZ,mM,300,1
MIC,ppm,299,-1
Therm_solubility,,299,0
MIC99,,299,-1
pKa1,,299,0
Kii,uM,298,-1
log(10^6/IC50),,297,-1
MBC99.9,uM,297,-1
CD50,ug ml-1,295,-1
Kel,/hr,293,-1
ED50,10'-1 ug/ml,293,-1
Log 1/M,,291,-1
dTM,K,291,-1
Repellency,%,290,1
TC50,,289,-1
VR,,289,1
GR80,ppm,289,1
Kb,,288,-1
CCIC50,uM,287,-1
Drug uptake,kBq/ml,287,0
deltaH,kJ/mol,287,-1
IC100,uM,287,-1
LTKB_BD DILI severity score,,286,1
AUC/dose,uM.hr.kg/mg,286,0
Drug metabolism,pmol,284,0
EC80,mg/L,284,1
Ct,ng/g,284,0
EC50,mgAi/L,283,-1
Drug metabolism,nmol/min/mg,282,-1
Radiolabel recovery,ugequiv/g,282,0
Drug uptake,nmol,282,0
PF50,,282,-1
MBC99.5,10'-2 umol/ml,282,-1
Activity,umol,281,0
% Activity remaining,%,280,1
Cell survival,%,280,1
APD95,%,280,1
IC12,ug ml-1,279,-1
ED30,ug kg-1,279,1
pXC50,,279,-1
EC25,uM,279,-1
fAUC,ng.hr.mL-1,279,1
Drug metabolism,nmol/min,279,-1
pKD,,278,-1
MNCC,uM,278,-1
CC20,uM,278,-1
pKA,,278,0
MIC=<90,ug ml-1,277,-1
Solubility,,277,0
ED50 ratio,,276,1
Diameter of inhibition zone,mM,275,1
Activity,mol/mol,274,0
Log EC50,,273,-1
Average IC90,uM,273,-1
TD50,ug ml-1,273,-1
Inhibitory activity,,273,-1
Oral activity,,272,0
Relaxation,%,272,1
Cmin,ng/ml,272,0
delta logD,,272,0
ED20,mg kg-1,271,1
log(1/I50),,271,-1
HD50,uM,271,-1
Growth_index,,270,0
Complex formation,%,270,1
I.D./g,%,270,1
CC90,uM,269,-1
MBC90,ug ml-1,268,-1
%max,,268,1
CC10,uM,267,-1
EC150,uM,267,-1
Drug uptake,ng,266,0
D40,mg kg-1,266,1
Response,,266,0
MABP,mmHg,265,0
MBEC,ug ml-1,265,-1
logKi,,264,-1
Activity,Zone units,264,1
K,uM,264,-1
log(RBA),,261,-1
DILI positive/negative,,261,0
pKa_B1,,261,0
log(1/ID50),,260,-1
Time,,260,0
Ka,M-1,260,1
log(43000/Ki),nM,260,-1
T-C,day,259,1
MTD,uM kg-1,259,0
Polyamine,%,258,1
Fold reversion,,258,-1
Ratio LC50/IC50,,258,-1
Activity,umolequiv/umol,256,1
fAUC/MIC,,255,-1
MIC,10'-2mmol/ml,255,-1
EC50,mg kg-1,254,-1
Activity,IU/ml,254,1
RF,,253,-1
IOP,mmHg,253,-1
IC50,mg kg-1,253,-1
Concentration,ng ml-1,252,-1
MIC99.9,ug ml-1,252,-1
GIC50,nM,252,-1
BBR,,251,0
ID50,ng ml-1,251,-1
Amnesia reversal,%,251,1
MIC,ug mg-1,250,-1
Blood glucose,%,249,1
ID50,mM,249,-1
Fabs,%,248,1
RatioAUC/MIC,,247,-1
Ka,10'6/M,247,1
MBC,mg/ml,246,-1
Formation,%,246,1
LTS,,246,0
Log IC50,nM,246,-1
Drug uptake,pmol,246,1
deltaG,kJ/mol,246,-1
Relative Vmax,,245,1
Kcat/Km,/M/s,245,-1
Activity,g/L,245,1
ALD50,mg kg-1,245,-1
Kcat/Km,/mM/s,244,-1
Activity,10'2mEq,244,1
TDI,%,244,1
MFC,uM/ml,244,-1
fIC50,nM,244,-1
EC30,uM,243,-1
MBIC,uM,243,-1
ED50,10'-2 ug/ml,243,-1
Ke(app),nM,243,-1
Activity,deltalog10CFU,242,1
-TdeltaS,kcal/mol,242,-1
IC50,ug,241,-1
ED50,mg/kg/day,240,-1
ED50,10'-3 ug/ml,240,-1
C0,ng/ml,240,1
ED50,g ml-1,240,-1
MBC50,ug ml-1,239,-1
No. of mice,,238,0
Activity,pg,238,1
MRC,ug ml-1,237,-1
Activity,micromol/kg/min,237,1
Diet,,237,0
fCmax,uM,237,1
Antagonist potency,,237,-1
Stability,nmol/min,236,-1
MEC,nM,235,-1
Stability,ml/min.kg,235,1
MBIC50,uM,235,-1
MIC,p.p.m.,234,-1
MNTD,uM,234,-1
EC99,uM,234,-1
Growth inhibition,,234,-1
EC2,uM,234,-1
Activity,pmol/min,234,1
Ratio LD50/ED50,,233,1
Max inhibition,%,233,1
% of engagement,%,233,1
Mean survival days,day,232,1
Body weight,g,231,1
K,10'5/M/s,231,1
Potency,%,230,1
ED50,nmol,230,-1
Level,,229,-1
LC99,uM,229,-1
deltaA,,228,-1
Drug release,%,228,1
Decrease,,228,-1
Vmax,nmol/min/mg,227,1
Mole fraction,,227,0
LC90,ppm,227,-1
Drug degradation,,227,-1
Toxicity,%,227,0
Activity,milliequivalent,227,0
R,%,226,1
Mortality,%,226,1
OD,mg kg-1 day-1,226,1
MED50,mg kg-1,226,1
Binding affinity,,226,0
Toxic deaths,,225,-1
Activity,c.p.m. 50ul-1,225,1
Remaining (without cofactor),%,224,0
AP,uM,224,-1
AUC,uM.hr.Kg/mg,224,0
Kinetic,ug/ml,223,0
INH,min,223,-1
Max fall in blood pressure,%,222,1
pKa_A1,,221,0
Weight change,,221,0
Decrease in blood pressure,,221,-1
MEC,p.p.m.,221,-1
DNAUC,kg.min/L,220,0
Drug metabolism,pmol/min,220,-1
Smax,%,220,1
Retention,%,219,1
Fall,,219,-1
Control,,219,0
MIC,10'-3micromol/ml,219,-1
K,M-1,219,-1
ED25,mg kg-1,219,1
D,%,218,1
Biodistribution,,218,0
I,%,218,1
Saluretic activity,m equiv 5hr-1 kg-1,217,1
Activity rating,%,217,1
Log SP,,217,-1
Activity,cpm,216,-1
Activity,U/ml,216,1
EC90,ug ml-1,215,1
Activity,CFU,215,1
LogP app,,214,0
LED,uM,213,-1
pK,,213,-1
HC10,ug ml-1,213,1
Weight difference,g,213,1
Kic,uM,213,-1
Drug metabolism,nM,212,0
Antagonism,%,212,1
log Kp,,211,0
ED50,mM,211,-1
fCmax,nM,211,1
Log RA,,211,-1
nH,,211,-1
LD99,uM,210,-1
MES,,209,-1
Survivors,%,209,1
Alpha max,,208,1
Agonist potency,,208,-1
Stability,hr,207,0
MBIC,ug ml-1,207,-1
Residual_activity,%,207,1
NI,,207,0
BOTTOM,,206,-1
HILLSLOPE,,206,0
FPD measurement,FPDc,206,0
TOP,,206,-1
Plasma level,ng ml-1,205,0
Retention time,s,205,1
logKw,,205,0
IC50,molar ratio,205,-1
Hypoglycemic activity,%,204,1
Blood pressure,mmHg,204,-1
Mean survival,day,204,1
Activity,10'-2mm,204,1
CF,,203,-1
Weight change,g mouse-1,203,1
Parasitaemia,%,203,1
Activity,mg/kg/day,203,1
Activity,uMequiv/uM,203,1
Basal uptake,%,202,1
deltalog(Tau/KA),,202,1
Activity,pg/hr,202,1
Weight,mg,202,1
CL/F,L/hr,202,1
Vmax,microM/s,201,1
Resistance index,,201,-1
delta pIC50 wt-mutant,,200,-1
Ks,uM,200,-1
log(RatioIC50),,200,-1
Drug uptake,nmol/mg,200,-1
CLogD,,200,0
Drug uptake,ug,199,0
EC1.5,nM,199,-1
K,/hr,199,-1
Log kill,,199,1
K0.5,nM,199,-1
Acquisition time,s,199,1
DC50,,198,-1
Glucose normalisation,%,198,1
Taste character,,198,0
Log 1/K,,198,-1
Activity,MU,198,0
K inact,min-1,197,-1
Activity,10^-2mm,196,1
deltalog10CFU/ml,,196,-1
Dose/organ,,196,0
Survival time,day,196,1
k2,M-1 s-1,196,-1
Activity,a.u.,195,0
TDS,,195,1
AUC,uM,194,0
Efficiency,%,194,1
AD50,,194,-1
Peff,,194,0
Ct,uM,194,-1
K,10'-3/s,193,-1
Change in amplitude response,%,193,1
MBC,umol/ml,193,-1
Activity,/hr,192,1
Activity,nmol/g,192,1
RI,,192,-1
Saluretic activity,m equiv kg-1,192,1
IZ,%,192,1
Relative SEAP activity,%,192,1
Relative viability,%,192,1
Activity,IU/mg,192,1
Activity,ml/min,192,1
Activity,ppm,191,1
IZ,Zone units,191,1
% activity,%,191,1
Kinact,/s,190,-1
CFU/ml,,190,-1
Activity,milliequivalent/kg,190,1
Fu,nM,190,0
fAUC,uM.hr,190,0
FDI,%,190,1
C10,uM,190,-1
MBC99.5,10'-2microM,190,-1
RA,,189,0
MHC,ug ml-1,189,0
Delta A/min,,188,1
permeability,10'6cm/s,187,0
ILS max,,187,1
Emetic episodes,,187,0
MHC10,uM,187,-1
Activity,pg/microg/hr,187,1
IZ,mm2,186,1
MTD,uM,186,-1
ED90,gAi/ha,186,1
MFC90,ug ml-1,186,-1
MFC,10'-2umol,186,-1
k,hr-1,186,-1
Drugexcretion,,185,0
Binding energy,kCal mol-1,185,-1
MFC,umol/ml,184,-1
Survivals,,183,0
Activity,nmol/mg,183,1
EMR,,183,-1
Papp,10'6cm/s,183,1
Retention time,min,183,0
HD50,uM kg-1,182,-1
EC50 ratio,,182,-1
Max stimulation,%,182,1
Log PNalk,,182,0
MIC50,mmol/ml,181,-1
pLD50,,181,-1
MNEC,ug ml-1,181,-1
Drug uptake,%IDKg/g,180,1
K,nM,180,-1
AUC,ng.hr/g,180,0
PI,%,179,1
MNCC,ug ml-1,179,1
CT,%,178,1
Partition coefficient,,178,0
P,,178,0
Activity,ng g-1,178,0
k cat,min-1,178,-1
IC50 relative,uM,178,-1
Activity,RU,178,0
permeability,10'-7 cm/s,178,0
Log 1/T,,177,-1
max activation,,177,1
IC50,ppm,177,-1
ED50,ppm,177,1
Activity,mmol,177,0
Thermal melting change,,177,-1
CC100,ug ml-1,177,1
AUC/dose,uM.hr,176,0
MIC,10'-2micromol/ml,176,-1
I50,,176,-1
logPeff,,175,0
IC25,uM,175,-1
log1/IC50,,175,-1
Taq inhibition,,174,-1
HR,%,174,1
Log 1/MIC,,173,-1
Median survival time,,173,0
pIC25,,173,-1
MBC,10'-2micromol/ml,173,-1
Emin,%,173,1
GABA ratio,,173,-1
Reversion,%,172,1
AUC/dose,nM.hr,171,0
AB50,mg kg-1,171,-1
EC20,uM,171,-1
Growth inhibition,%,171,1
Aggregation,%,171,1
GE,%,171,1
Tissue distribution,,171,0
Delta HR,%,171,1
Activity,dose ratio,171,0
IC99,nM,171,-1
Activity,ng,170,1
EC,ug ml-1,170,1
Cell growth,%,170,1
Fall,%,170,1
GABA shift,,169,-1
HC50,,169,-1
MPR,,169,-1
R%,%,169,1
MFC,umol/L,168,-1
No. of cures,,168,1
Geometric mean,,167,0
Change in BP,mmHg,167,-1
k3/ki,1/m/s,167,-1
Average skin reaction,,166,1
PGI,%,166,1
ED90,uM,166,-1
K,10'5/M,166,-1
BP,,166,-1
Average weight change,g,166,1
Log LC50,,165,-1
Drugabsorption,%,165,1
AUC/dose,ng.hr/ml,165,0
Protected,%,165,1
RRT,s,165,1
LD50,mM,164,-1
Drug metabolism,ng/ml,164,0
AbsAC30_uM,uM,164,-1
solubility,uL,164,0
Vd,l,164,0
MBIC90,uM,164,-1
FRP,%,164,1
log(permeability),,163,0
K obs / 1,,163,-1
Normalization,%,163,1
ED1.5,mg kg-1,162,1
ID x kg of body weight/g of tissue,%,162,1
MTC,ug ml-1,162,-1
Analgesia,%,162,1
Vdss,,162,0
Response ratio,,162,1
Enhancement,%,161,1
Activity,g/day,161,1
Index,,160,0
&#256;,mm,160,1
No. of survivals,,159,1
Activity,MT/ha,159,1
pMIC50,,159,-1
MFC50,ug ml-1,159,-1
CFU,,159,0
Resistance factor,,159,-1
log10(%HIA +10),,159,1
Log IC50,,159,-1
RIS,%,158,1
Log kon,,158,0
pTC50,,158,-1
ED50,ng/ml,158,-1
Affinity,%,158,1
Drugexcretion,%ID,157,1
Conversion,%,157,1
Inhibition,radii mm-1,157,1
Vmax,microM/min,157,-1
Uptake,%,157,1
TCS50,uM,157,-1
Relative ED50,,157,1
absorbance,,156,0
MISS T/C,,156,-1
Residual insulin release,%,156,1
PT,uM,156,-1
IC50,%,156,0
Hydrolysis,%,156,1
Iron change,%,156,1
Delta blood pressure,,156,1
Incorporation,,156,-1
Proliferative response,,156,1
Relative efficacy,,155,1
FDI,,155,-1
Log kOH-,,155,-1
Mean arterial blood pressure,mmHg,154,0
MID,ug ml-1,154,1
Average weight,%,154,1
Decrease in SBP,,154,1
MFC99.5,10'-2microM,154,-1
Plasma level,uM,154,1
Uptake ratio,,154,0
HACU improvement,%,153,1
Peff,nm/s,153,1
IC70,ug ml-1,153,-1
Concentration,M,153,-1
Fold selectivity,,152,0
MFC99.9,ug ml-1,152,-1
Reduction of live worms,%,152,1
Disease control,%,152,1
NOAEL,uM,152,0
Zone size,mM,151,1
Max effect,%,151,1
MED,uM,151,-1
Cures/total,,151,1
Neurotoxicity,,151,0
Drug uptake,%ID/cc,151,1
Culture,%,150,0
P50,mmHg,150,-1
Css,uM,150,0
Survival time,,150,1
pRA,,150,-1
Kd,/s,149,-1
Survivors at day 4,,149,1
Cmin,ug ml-1,149,0
Parasitemia,%,149,1
Plasma concentration,ng ml-1,149,0
MAP,mmHg,149,-1
Activity_index,%,149,1
MIC>98,ug ml-1,149,1
Drug uptake,mg kg-1,149,0
Inhibition,nM,148,-1
Vdss,l,148,0
Kcat/Km,/mM/min,148,-1
LC80,ppm,148,1
Emax,uM,148,-1
Lethality,%,147,1
RA,%,147,1
HF,,147,-1
Log Kd,,147,-1
logEC50,,147,-1
Potentiation,%,147,1
Tumors,%,146,1
Radiolabel recovery,,146,0
XI50,molar excess,146,-1
MIC100,,145,-1
TD50,umol/Kg,145,1
pTGI,,145,-1
Kb,10'5/M,145,-1
Activity,radii mm-1,144,1
Mean relative potency,,144,0
-Log MIC,ug ml-1,144,-1
Activity,cm2,143,1
EC100,uM,143,-1
Swelling,%,143,1
Kd(app),,143,-1
Kb,10'6/M,142,-1
MIC=>95,uM,142,-1
pDC50,,142,-1
Recovery A to B (mean),%,142,1
Delta BG,%,142,1
MAD,mg kg-1,142,1
D10,mg kg-1,142,1
Relative IC50,nM,142,-1
MBC,10'-2umol,142,-1
Papp A to B (mean),10E-6 cm/s,142,1
Concentration,nM g-1,141,-1
Incorporation,%,141,1
Activity,mmolequiv/mmol,141,1
GC50,uM,141,-1
Ratio,/M/min,141,-1
Activity,umol/Kg,140,1
HCR,,140,-1
kHOX,M-1 min-1,140,1
Radioactivity,%ID/g,140,1
effect,%,140,1
BBC,ug ml-1,140,0
Max_Concentration,uM,140,0
SUV,%,140,1
Activity,ng/L,139,1
IC5,uM,139,-1
CMC,uM,139,0
k obs / 1,,139,1
pKi(uM),,139,-1
log(1/ED50),,138,-1
HD50,mg kg-1,138,-1
Kinact,min-1,138,-1
solubility,%,138,0
P50e,mmHg,138,-1
CPE index,,138,1
Leishmanicidal activity,,138,0
Average survival,day,138,1
Drug transport,,138,-1
DC50,microg/cm2,138,-1
Effective dose,nM kg-1,137,1
V1/2,mV,137,-1
Activity,mol,137,1
Range,,137,0
Selectivity index,uM,137,0
Activity,/m2,137,1
C/I ratio,,137,0
Uptake value,,136,1
Crop_yield,tons/ha,136,1
Activity,mg Kg-1,136,1
KB,,136,-1
Kcat/Km,10'6/M/s,136,1
LC70,ppm,136,-1
No. of toxic deaths,,135,1
UTC,%,135,1
Fa,%,135,1
IC70,uM,135,-1
ED40,uM kg-1,135,1
Cell Proliferation EC50,uM,135,-1
Papp,cm s-1,135,1
Ki,mM/min,135,-1
Toxic,,135,0
Normal beats,%,135,1
CLH,ug/min,135,1
PF,,134,1
% of activity,%,134,1
Ratio,uM,134,0
Heart rate,,134,0
Log koff,,134,-1
kDPPH,M-1 s-1,134,1
Change in IOP,mmHg,134,-1
pH,,134,0
Activity,tons/ha,134,1
Vmax/Km,,133,-1
Cleavage,%,133,1
Hypersensitivity factor,,133,0
No. of positive cases,,133,0
Alloste ic enhan er (AE),%,132,1
Diuretic effect,,132,-1
ED50,mg 2kg-1,132,1
GR50,gAi/ha,132,1
Concentration,ng/mL,132,0
MRTlast,hr,132,0
AUC/dose,,132,-1
Equieffective dose,mg kg-1,131,1
MIC,uL/ml,131,-1
NE,,131,0
AbsAC200_uM,uM,131,-1
EC200,uM,131,-1
T-C,g,131,0
Specificity,,131,0
Concentration,mM,130,-1
Log BR,,130,0
TT,s,130,-1
Selectivity,uM,130,-1
k cat/Km,M-1 s-1,130,-1
Kcat,,130,-1
LC30,mg/ml,129,-1
Activity,10^9/L,129,0
FR50,,129,-1
MIC99,mM,129,-1
AUC/dose,hr.Kg/L,128,0
MTL,ug ml-1,128,1
Fold increase,,128,1
ED90,mg/kg/day,128,1
CRC/CRC0,uM,128,-1
Activity,ng ml-1,128,1
Activity,CFU/ml,128,-1
MFC,10'-2mmol/ml,128,-1
Relative efficacy,%,127,1
Apoptosis,%,127,1
K,10'-2/s,127,-1
Number,,127,0
logFu,,127,0
Decrease in activity,%,127,1
Toxicity ratio,,127,-1
K,10^5/M,126,1
ED50,pmol,126,-1
Tlast,hr,126,0
Stability,ug ml-1,126,0
MCC,,126,-1
Tumor volume,mm**3,126,1
Max salt tolerance,,126,1
MEC,%,126,1
MFC<=99.9,uM,126,-1
MFC99,ug ml-1,126,-1
Plasma concentration,uM,125,-1
Log IC50,uM,125,-1
MBP,,125,-1
log(1/MLD),,125,-1
Protection,,125,1
Activity,nmol/ml,125,1
Bmax,fmol,125,0
Relative Potency,,125,1
p[A50],,125,-1
Kb,10'4/M,125,-1
ED80,gAi/ha,124,1
MBC,10'-2mmol/ml,124,-1
logP(lung),,124,0
Absorption,%,124,1
Vdss,mL/min/kg,124,0
ILSmax,,124,1
Activity,nmol/min/ml,123,-1
Ki(app),,123,-1
Ct,%,123,1
log10CFU/g,,123,-1
Heart rate,%,123,1
NS,,123,0
HI,,123,0
MBC99.9,,123,-1
CLH,L/min,123,-1
Enzyme activity,%,123,1
No. of tumors,,122,1
Accumulation,%,122,1
Log 1/MEC,,122,-1
Distribution (dose/g),%,122,1
MLD,mg kg-1,122,-1
DIZ,%,122,1
TR,,121,0
Level,nM (mg of protein)-1,121,0
LD50,nM,121,-1
Weight change difference,g,121,-1
Average weight,g mouse-1,121,1
Decrease in Systolic blood pressure,%,121,1
log(1/Km),,121,-1
Proliferation,%,121,1
Lysis,%,121,1
Relative potency,fold,120,1
MTD,g/acre,120,1
Cmax/dose,nM,120,0
Vmax,pmol/min/mg protein,120,1
Ki app,,120,-1
K app,,119,-1
Activity,mEq/L,119,1
No. of mice protected,,119,1
ILS max,%,119,1
CCh,%,119,1
AbsAC50_uM,uM,119,-1
Papp,cm/s * 10E6,119,0
MMC,ug ml-1,119,-1
NOAEL,mg kg-1,119,1
Dose,uM kg-1,118,-1
No. of animals protected/animals tested,,118,1
Ratio Ki,nM,118,-1
IC90,ug,118,-1
FIC50,,118,-1
Log (1/C),,118,-1
Lipophilicity,,118,0
KL,nM,118,-1
Kd,10'-3/s,118,-1
ND50,mg kg-1,118,-1
MBC,umol/L,118,-1
Log 1/Km,,117,1
TD50,mg Kg-1,117,1
Toxicity,uM,117,-1
pA2(app),,117,-1
Activity,mol/L,117,-1
MBC,10'-3micromol/ml,117,-1
Kis,nM,117,-1
Inhibition rate,%,117,1
Resistance,,116,-1
TC50,mM,116,-1
Stimulation index,,116,0
ED20,mM kg-1,116,-1
D50,mg kg-1,116,1
Saluretic potency,u equiv,116,-1
Drug uptake,ngequiv/g,116,1
Log Ki,nM,116,-1
EC25,nM,116,-1
Relative amplitude,%,115,1
Excretion,%,115,1
K,/mM/min,115,1
Cmin,nM,115,1
Change in Cl- current,,115,-1
TC50,nM,115,-1
Ratio,10^3/M/min,115,-1
C50,mM,115,-1
BWD,g,115,-1
MBC,mM,115,-1
Ratio,M-1 s-1,114,1
LC50,mgAi/L,114,-1
-Log ED50,M acre-1,114,1
Urine volume,ml,114,1
Rating,,114,0
Amount excreted,%,114,0
FIC,ug ml-1,114,-1
Drug transport,%,114,1
Plasma concentration,ug ml-1,114,0
MCD,mg kg-1,114,-1
Activity scale,nM,113,-1
ED40,mg kg-1,113,1
Cholesterol reduction,%,113,1
Kcat/Km,/s/M,113,-1
Delta t,degrees C,113,1
Change in heart rate,%,113,1
Hemolysis,%,113,1
deltalog10CFU,,113,-1
Urine volume,ml 6hr-1 100g-1,113,1
Max response,,113,1
MAC,uM,113,-1
FC,%,113,1
MLD,nmol,112,-1
Licking latency,s,112,1
Susceptibility,,112,-1
Uptake,%ID/g,112,1
Solubility (mean),uM,112,-1
Selectivity quotient,,112,0
Glucose utilization,uM,112,-1
Papp,10'-7 cm/s,112,1
LD99,ug ml-1,112,1
Bound,%,112,1
Max,mmHg s-1,112,1
AUC/dose,microM.hr/mg/kg,111,0
Q,uM,111,-1
IC100,ng ml-1,111,-1
mechanism based inhibition,,111,-1
IC80,nM,110,-1
Entry latency,s,110,1
MIC100,umol/L,110,-1
MIC>85,ug ml-1,110,1
Lowering,%,110,1
Activity,umol/min/mg,110,1
-Log C,mM kg-1,110,-1
Effective dose,,110,-1
TD50,uM kg-1,109,-1
Activity,/s,109,-1
Ratio,/mM/s,109,-1
SC50,uM,109,-1
AUC,hr.ng/g,109,0
pTD50,,109,-1
pKa3,,109,0
Na+/K+,,108,0
Kinact,,108,-1
Na,m equiv 6hr-1 100g-1,108,0
Relative hydrolysis rate,,108,1
SMT,s,108,1
Taste class,,108,0
"K(p,uu,CSF)",,108,0
Injected dose/organ,%,108,1
Activity,ug/mg/day,108,0
MGM,,108,-1
CMC,mM,108,-1
Ratio,/uM/s,108,-1
Total iron output,ug kg-1,108,1
TPE,hr,107,0
Safety index,,107,0
Conversion rate,%,107,1
Body weight,,107,0
IC10,uM,107,-1
Expression,%,107,1
Secretion,%,107,1
Time constant,ms,107,0
IVP,,107,-1
Activity index,,106,0
Ratio,nM,106,0
Kcat/Km,10'4/M/s,106,1
No. of rosettes/100 Jurkat T cells,,106,1
Kcat/Km,10'5/M/s,106,1
Flu intensity,a.u.,106,1
LAD,mg kg-1,106,1
Sensitivity,,106,-1
Activity,mg/g,106,1
Cell viability,,106,-1
Total radioactivity,%,106,1
A50,uM,106,-1
INH,mg kg-1,105,1
ED,ug ml-1,105,0
Stability,min,105,0
K,10'4/M,105,-1
Estrogenic potency,,105,-1
Inhibitory index,,105,-1
Kiuc,uM,105,-1
kOX,M-1 min-1,105,1
Activity,disintegrations/minute,104,1
Concentration,ng g-1,104,0
C50,nM,104,-1
k3/Ki,1/Ms,104,-1
Ct,ug/g,104,0
Activity,uEq,104,1
MIC95,uM/ml,104,-1
Antifertility potency,,104,-1
LC50,microg/cm3,104,-1
Activity,uM.hr,104,0
T/C x100,,104,1
Ratio pKb,,104,-1
Wet weight of tissue,nM g-1,104,0
deltalogIC50,,104,-1
MTD,mg/kg/day,103,1
ED50,ug injection-1,103,-1
Log I50,,103,-1
AD50,ug/kg,103,1
K app,10e-7/M,103,-1
Ki,ng/ml,103,-1
log(ratioKi),,103,-1
Kcat/Km,10'4/s/M,103,-1
Activity,uM/L,103,-1
IR,%,103,1
MBP,mmHg,103,1
LC100,uM,103,-1
Papp,cm/s,103,1
MFC,10'-3micromol/ml,102,-1
Tm,Â°C,102,-1
Beta2 duration,min,102,1
Dose,ug ml-1,102,0
Ka,10'4/M,102,1
IS,,102,0
PBI,,102,0
Protein-DNA complex formation,%,102,1
Kapp,10^6L/mol,102,-1
permeability,nM/s,102,0
Increase in blood pressure,mmHg,102,1
pI50,mM,102,-1
Activity,hr,102,-1
Fluorescence intensity,,101,1
LD10,M kg-1,101,-1
Serum Ca2+,mg dl-1,101,1
HR,,101,-1
pI50,uM pupa-1,101,-1
TPE,,101,0
ID50 ratio,,101,-1
Accumulation,,101,1
ED90,,101,-1
P50c,mmHg,101,0
Estrogenic effect,%,100,1
Fm,,100,0
ED50,ng ml-1,100,-1
Cures/no. of animals,,100,0
Specific binding,%ID/g,100,1
No. of cells,%,100,1
Paw swelling,%,100,1
No. of sensitive,,100,0
Dose,,100,1
pKi,uM,100,-1
Inhibition zone,,100,1
MEC,,100,-1
K,/M/min,99,-1
Relative binding affinity,%,99,1
Change in response,%,99,1
Adhesion,%,99,1
permeability,cm/s,99,1
Ki,%,99,0
RE,,99,0
behavior,,99,0
kinact,min-1,99,-1
C0,ug ml-1,99,0
MITC95,uM,99,-1
IP,uM,98,-1
Antagonist activity,,98,-1
Average dose per organ,%,98,1
pXC50,M,98,-1
K,min-1,98,-1
APDc,,98,-1
Amount of TNF-alpha,%,98,1
BPR,%,98,1
Agonism,%,98,1
Delta MAP,%,98,1
Hydrolysis,,98,0
Activity,mol%,98,1
ED50,10'-4 ug/ml,98,-1
Increase in IC50,,98,1
Hammett constant,,98,0
K,10'-3/min,97,-1
CL,L/min,97,-1
PCMA antagonism,,97,-1
Activity,pmol/mg,97,1
Log10 cfu,,97,-1
Urine volume,ml 4hr-1,97,1
Benzidine positive cells,%,97,1
log(1/IC50),uM,97,-1
IP,%,97,1
MTD,,97,1
MES,mg kg-1,97,-1
MIC,10^2umol/ml,96,-1
Activity,uMequiv,96,1
MBC,10'-2microM,96,-1
Transfection efficiency,RLU (ug of protein)-1,96,0
XI50,mole fraction,96,-1
Stability,uM,96,0
SD90,mg kg-1 day-1,96,1
Serosal/Mucosal Ca,,96,0
K,10'-4/s,96,-1
Metabolite level,,96,0
TI50,,96,-1
MFC,10'-2microM,96,-1
Rate constant,M-1 min-1,96,-1
Residual insulin release,,96,-1
Max reversal,%,96,1
MBC,10^2umol/ml,96,-1
Taste,,95,0
Activity,mA,95,0
Body weight change,%,95,1
kinact,hr-1,95,-1
3 log kill,,95,-1
ED50,mg,95,1
K,10'6/M/s,95,1
ED1.5,,95,-1
Log K',,95,0
Fold induction,,95,1
SVT,%,95,0
AUC,ug ml-1,95,0
Sleeping time,min,95,1
pka,,95,0
DA release,%,95,1
Estrogenic effect,,95,1
Inhibition,mM,94,-1
Cytotoxicity,ug ml-1,94,0
ED20,gAi/ha,94,1
LD50,ppm,94,1
Free,%,94,1
Plaque reduction,%,94,1
log(1/BC),,94,-1
APTT,uM,94,-1
Log 1/D40,,94,-1
CCID50,uM,94,-1
H2O2 prot,,94,-1
Delta SBP,mmHg,94,-1
IC20,ug ml-1,94,-1
Average survival (days),,93,1
Drug metabolism,ug/g,93,0
EH,,93,-1
D,,93,0
MED=>50,mg kg-1,93,1
MHC,uM,93,-1
Ratio LD50/IC50,,93,-1
Ki,nM l-1 hr-1,93,-1
Radiation prot,,93,-1
Diuretic activity,m equiv kg-1,93,1
Drug recovery,,93,0
IC25,nM,93,-1
Lactone,%,93,1
Max_Delta_Tm,uM,92,-1
AUC/dose,ng.hr/ml/mg/kg,92,1
APD,-60mV,92,0
AbsAC50,uM,92,-1
MGM,uM,92,-1
Induction,,92,1
Mean,,92,0
ED100,mg kg-1,92,1
Differentiation,%,92,1
Ratio LD50/EC50,,92,-1
MIC95,,92,-1
Toxic dose,mg kg-1,92,1
Increase in ear thickness,1/100mm,92,1
NO release,%,92,1
Blood flow,100ml g-1 min-1,92,1
Max fall in blood pressure,,92,-1
Mean aortic blood pressure,mmHg,92,0
Delta G,,92,0
pI50,,91,-1
Papp,10'-5cm/s,91,0
K inact,,91,-1
Excretion Na+,m equiv,91,0
beta t1/2,,91,0
Relative resistance,,91,1
ID50,ug,91,-1
Excretion K+,m equiv,91,0
C20,uM,91,-1
ED50,ug mouse-1,91,-1
ED2,mg kg-1,91,1
V,ml,91,1
Excretion Cl-,m equiv,91,0
Antagonism,,91,-1
Production,%,90,1
Mean excretion of Cl-,m equiv,90,0
Biliary excretion,%,90,1
logKA,,90,-1
Drug metabolism,microL/min/mg,90,1
Diameter of inhibition zone,,90,1
LD50,g/Kg,90,-1
Am,%,90,1
Biodistribution,% dose organ-1 ,90,0
Mean urine volume,ml,90,0
A10,mg l-1,90,1
MIC,microg/cm3,90,-1
Average consumed,g,90,1
INH,mM,90,-1
ED50,micromol/kg/min,90,-1
Excretion,m equiv,90,1
Increase in life-span,%,90,1
Activity,Kg,90,1
ISA,%,90,1
Mean excretion of Na+,m equiv,90,0
Mean excretion of K+,m equiv,90,0
p[A]50,,89,-1
Fluorescence,nM,89,0
ED25,mg kg-1 day-1,89,1
IC50,equiv,89,-1
Activity,% dose (g of tissue)-1,89,1
Vmax,umol/min/mg,89,1
REC,,89,-1
Kapp,uM,89,-1
Cmax,ug/g,89,0
Temperature,degrees C,88,1
Nuclear cataract,%,88,1
MFC,mM,88,-1
mean log D,,88,0
Metabolism,%,88,1
Activity,deltalog10CFU/ml,88,-1
BWD,,88,-1
CCTD50,uM,88,-1
V0,microM/min,88,1
Kinetic constant,,88,-1
ED20,ug kg-1,88,1
ID50,ng min-1 rat-1,88,-1
PDK,,88,-1
Tmax,,88,0
K inact/Ki,M-1 s-1,88,-1
Drug uptake,nmol/min,88,1
pK1,,88,0
Kr,/mM/min,87,1
AbsAC90,uM,87,-1
% inhibition,nM,87,1
Inhibition,ng ml-1,87,-1
RAC,,87,1
-Delta G,,87,-1
Ovulating rats,,87,0
Inhibitory zone,mM,87,0
Esc loss,%,87,1
Judgments,,87,0
Diuretic activity,ml,87,1
EC200,ug ml-1,87,1
fCmax,ng/ml,87,1
Decrease in AP,%,87,1
MIC=>90,mg/L,87,-1
Relative uterus weight,,87,-1
Kd,10'-2/s,87,-1
Glucose transport,%,87,1
% of residual activity,%,87,1
Activity,10'3/mm3,87,1
BK,%,87,1
Ke,uM,87,-1
Ct,,87,0
Protective index,,86,1
EC50,ug,86,0
No. of rats ovulated,,86,0
Weight difference,,86,1
Cell viability,%,86,1
T-C,,86,0
Therapeutic ratio,,86,1
HC50,mg/L,86,-1
Analgesic activity,,86,0
Systolic blood pressure,mmHg,86,1
Metabolism,uM min-1mg-1,86,-1
Cytotoxicity,U,86,0
pIC50(app),,86,-1
Mean blood pressure,mmHg,86,1
Result,,86,0
Delta APD95,%,86,1
pCC50,uM,86,-1
Ratio pA2,,86,1
Metabolism,,86,0
Activity,ug/mg,86,1
CLH(app),uL/min,86,-1
CL,ug ml-1,86,0
Revertants/plate,,86,1
log KOW,,85,0
Stability,uL/min.mg,85,-1
LC90,ug ml-1,85,-1
AD50,ug kg-1,85,-1
Concentration,nM (10e6*cells)-1,85,-1
MEC,mg/L,85,-1
TdeltaS,kcal/mol,85,0
Latency,s,85,-1
Injected dose/g tissue,%,85,1
Contraction,%,85,1
fEC50,nM,85,-1
Antibacterial activity,,85,-1
Protection index,,85,1
Decrease in blood pressure,mmHg,84,-1
Relative protection,,84,1
Stability,uL/min,84,1
IC50 relative,,84,-1
Binding affinity,nM,84,-1
pA10,,84,-1
Change in blood pressure,mmHg,84,0
LLR score,,84,1
IC100,ug ml-1,84,-1
Drugexcretion,mg,84,0
S,,84,0
DRF,,84,1
ov. rat/total,,84,1
logKb,,84,-1
Change in weight,%,84,1
LDH,MU,84,-1
EC100,ppm,84,1
MPE50,mg kg-1,84,1
Inhibition ratio,,84,1
MD,,84,-1
Decrease in blood glucose,%,84,1
Plasma content,nM ml-1,84,1
EII50,,84,-1
Loss,%,84,1
Brain content,nM ml-1,84,1
k,min-1,83,-1
logKcat,,83,-1
Average weight change,%,83,1
Concentration,nM,83,-1
Kb,10'7/M,83,-1
EC15,nM,83,-1
Drug metabolism,nmol/g,83,0
Vmax,pmol/min/mg,83,1
Relative JC-1 accumulation,,83,-1
2x APTT,uM,83,-1
Rmax,,83,1
Survival days,,83,1
Survival ratio,,83,0
PD50,,82,-1
EH,none,82,0
pIC100,,82,-1
Fibril formation,%,82,1
p(1/MIC),,82,-1
EC15,uM,82,-1
Activity,nmol/mg/min,82,-1
BP decrease,mmHg,82,-1
LTC,,82,1
Vmax,micromol/min,82,-1
Kd,10'-1/s,82,-1
ki/Ki,M-1 min-1,82,-1
K,10'4/M/s,82,1
Activity,total picomoles,82,1
RP,,82,-1
Level,%,82,1
Drug metabolism,umol/L,82,0
No. of Colony forming Units,,82,0
Relative EC30,nM,81,-1
Fmax,%,81,1
Relative activation,%,81,1
Extracted,%,81,1
EC50,microg/cm2,81,-1
Activity,L/mol/s,81,1
MTC,,81,-1
logBB,,81,0
CL free,,81,0
Activity,pmol/hr,81,1
Biodistribution,%Dose/g,80,0
Lipid level,mg dl-1,80,0
Contraction,,80,1
MABP,,80,0
Mycelial growth,cm,80,1
ALP activity,,80,-1
Activity,milli optical density/minute,80,1
Plasma level,ug ml-1,80,0
Ki'',uM,80,-1
Emax,nM,80,1
CMP,,80,0
K,10^4/M/s,80,1
Log Ki,mM,80,-1
Relative amount,%,80,1
IAr,,80,1
LC50,ugAi/ml,80,-1
logRA,,80,-1
-log(RatioIC50),,80,-1
EC30,nM,79,-1
ED50,umol/L,79,-1
LD90,uM,79,-1
Mean weight,mg,79,1
Activity,pM,79,-1
logMIC,,79,-1
ECS ratio,,79,-1
RU,,79,0
AUC/dose,uM.hr.Kg/mg,79,0
Mutagenicity,,78,0
MBC50,mg/L,78,-1
Baseline systolic BP,%,78,1
DOM,%,78,1
Activity,/uL,78,1
MBC90,mg/L,78,-1
Kinact,mM,78,0
Concentration,pg ml-1,78,0
AA,,78,0
Duration of action,hr,78,1
TCS50,nM,78,-1
IF,,78,-1
log10CCID50,,78,-1
SVT,,78,1
Activity,fmol,78,1
LD90,ug/g,78,1
I50,ppm,77,-1
Affinity constant,uM,77,-1
RUmax,,77,1
Binding intensity,,77,0
P,cm s-1,77,0
Peak rhGH,ng ml-1,77,1
Drug metabolism,pmol/min/mg,77,1
Ki/Km,,77,-1
MNTD,ug ml-1,77,0
MFC100,ug ml-1,76,-1
IC200,uM,76,-1
Activity,10'3CFU/ml,76,1
Kapp,10'6/M,76,1
Inhibitory response,%,76,1
DIZ,mm/mg,76,1
Max decrease in heart rate,%,76,1
Cytotoxicity,ng ml-1,76,-1
Range,ug ml-1,76,0
D50,mg kg-1 day-1,76,1
pKa4,,76,0
IC16,uM,76,-1
K,10'3/M/s,76,1
Activity,IU,76,1
EC,,76,-1
Kel,/min,76,-1
TG100,uM,76,-1
Sleeping time,s,76,1
IP,,76,1
Activity,p.p.m.,76,1
Decrease in CR,%,76,1
TI rating,,76,0
Oral diuretic activity,m equiv [Na+] 5hr-1kg-1,76,1
GS,,76,-1
Fold resistance,,76,0
K 0.5,nM,76,-1
Krel,,76,0
Antibiotic activity,,76,-1
Log Kmemb,,76,0
Ratio GI50/EC50,,76,-1
increase in mean survival time,day,75,1
scMet,,75,0
Activity,mU,75,1
HSAI,,75,0
DeltaTC,%,75,1
Degradation,%,75,1
Slope,,75,0
2-DG uptake stimulation,,75,1
Ratio,/uM/min,75,-1
Log potency ratio,,75,-1
Relative affinity,%,75,1
Duration,,75,0
CyD50,ug ml-1,75,-1
Reversal activity,%,75,1
Zone of inhibition,,74,1
Cured/treated,,74,1
dTm,K,74,-1
ED10,ug kg-1,74,1
Rate,,74,0
Activity,nmol/hr,74,1
ED50,%,74,1
T50,min,74,-1
K,10'6/M,74,-1
Log Ki,uM,74,-1
logS0,,74,0
Growth zone,mM,74,0
MGC,uM,74,-1
AUC/dose,nM.hr.kg/mg,74,0
Cell Proliferation IC50,uM,74,-1
Activity,nM/s,73,1
XI50,,73,-1
FR,,73,-1
Drug uptake,nmol/Kg,73,1
K,10'-2/min,73,1
Remaining activity,%,73,1
EC40,uM,73,-1
AUC,ng/g.hr,73,1
No. of rabbits convulsed,,73,0
Activity,pg/mg,73,1
Rblood_plasma,,73,0
Drug discrimination effect,%,73,1
Bioreduction,%,73,1
PB,pmol,73,0
Bmax,pmol,73,0
Log [MrI],,73,0
TGIR,%,73,1
Hill coefficient (n50),,73,0
CL,ml/hr,73,-1
Excretion rate,,72,1
Sweetness potency,0-15 scale,72,1
TBPS shift,,72,-1
log(Tau/KA),,72,1
MBC>99.9,umol/L,72,-1
Serum concentration,,72,0
Diuretic activity,ml kg-1,72,1
Blockage activity,,72,-1
Compound_Concentrati,uM,72,-1
Ratio,U,72,0
Ka,10'5/M/s,72,1
Biodistribution,nM (g of tissue)-1,72,0
pK2,,72,-1
Saluretic activity,m equiv 6hr-1 kg-1,72,1
K,10^-3/min,72,1
log(1/MED),,72,-1
Shift,,71,-1
k2,min-1,71,-1
Stabilty,min,71,0
Death,%,71,1
logPF,,71,-1
Relative uterus weight,mg,71,0
Inflection point,nM,71,0
log%Abs,,71,1
Lw/Bw,,71,0
Concentration,% kg dose g-1,71,1
Mouse behavior activity,,71,0
Blood sugar lowering,%,71,1
Inhibitor level,,71,0
Selectivity index,SI,71,0
Plasmaconcentration,ug ml-1,71,0
Log CR,,71,1
Ka,10^5/M,71,1
Cr,mg dl-1,71,0
GHI,,70,-1
ED50,g/Kg,70,1
Cells,%,70,1
LogD6.5,,70,0
Papp,uL/hr/cm2,70,1
Log cell kill,,70,1
Stability,nm,70,0
Affinity,nM,70,-1
Binding affinity,%,70,1
Ka',,70,-1
C20 APD95,uM,70,-1
UD50,mg kg-1,70,-1
Biodistribution,% g-1,70,1
ED30,uM kg-1,70,-1
Ulcerogenic index,,70,0
Glyceamia evolution,%,70,1
KB app,uM,70,-1
Methemoglobin,,70,-1
No. of cures,day,70,1
AUC,uM.hr/ml,70,0
Resistance,%,70,1
AUC/dose,min.kg/L,70,1
ND,,70,0
IC50,% conc,70,0
SS,%,69,1
EC30,,69,-1
Survivors / animals tested,,69,0
I0.5,uM,69,-1
Drug uptake(free),uM,69,0
Ratio,10'3/M/s,69,1
AOA,,69,-1
Mortality,day,69,1
LS,%,69,1
Latency,,69,0
Diuretic effects,,69,1
MIC,microg,69,-1
Log A,,69,1
Activity,/M/s,69,1
Kapp,10^3/M,69,1
ED50,mM l-1,69,-1
MFC,mg/L,69,-1
Inhibitory potency,,69,-1
Change in reaction time,%,69,1
UN,mg dl-1,69,0
Log BB,,69,0
Delta,%,69,1
AUC/dose,kg.hr/L,69,0
Activity,ml/kg,68,1
Change TC,%,68,1
Activity,10'6/ml,68,-1
Ka,/uM,68,-1
Kinact,/mM/min,68,-1
Displacement,,68,-1
Temperature change,degrees C,68,-1
Log relative k',,68,0
Potency,mg kg-1 day-1,68,1
Activity,nmol/L,68,1
PCA,,68,-1
% absorbed,%,68,1
Activity,% ID/g,68,1
AR,,68,-1
CT10,uM h,68,-1
ID50,umol,68,-1
-Delta G,kCal mol-1,68,-1
MBEC,,68,-1
Drug uptake,ng/mg,68,0
Vasorelaxant effect,,68,-1
MID,,68,-1
ED200,uM,68,-1
Convulsion,%,68,1
Activity,log10CFU/g,68,-1
pC1,,68,-1
MBC,ug,68,-1
Delta G,kCal,68,-1
ED150,mg kg-1,67,1
Bmax,fM mg-1,67,1
Activity,mmol/Kg,67,0
Activity,M,67,0
No. of chicks,,67,1
Average change in body weight,%,67,0
EC100,nM,67,-1
Hypothermic effect,,67,1
Stability,ml/min,67,0
[3H] concentration,% kg dose g-1,67,1
Turnover,ng ml-1,67,0
Activity,Da,67,0
Uterine weight,mg,67,1
SP,mmHg,67,0
Occ,,67,-1
MHC,ug,67,-1
Mean peak APTT,,67,0
Activity,uIU/ml,67,1
TC,mg dl-1,67,0
No. of emetic episodes,,67,0
MFC99.9,,67,-1
-Log ID50,,66,-1
Ratio_Papp,,66,0
CD100,uM,66,-1
Ki 0.5,nM,66,-1
log1/Ki,,66,-1
K obs,,66,-1
Edema variation,%,66,1
log Pe,cm/s,66,0
Activity,mol/min,66,1
Parasite_Clearance,%,66,1
Urinary recovery,%,66,1
Ratio,M-1 min-1,66,1
Growth delay,day,66,-1
EC50,%,66,1
Ratio,/s/M,66,-1
AUC,ug.hr/g,66,1
EC2x,uM,66,1
Activity,/M/cm,66,0
P50d,mmHg,66,1
EC20,nM,66,-1
NOAEL,mg/kg/day,66,1
Iron output,,66,1
delta Log P,,66,0
Delta Vmax,%,66,1
MBC90,uM,66,-1
Drug uptake,ugequiv,66,0
Weight loss,g,66,1
PFC,,66,1
BWLmax,%,66,1
% recovery,,66,1
Serum Ca2+,,65,1
Biological activity,%,65,1
Pc,cm s-1,65,0
Kdiss,/min,65,-1
Kd,min-1,65,-1
K2,min-1,65,1
C1.6,mM,65,-1
Selectivity,zone unit,65,0
No. of deaths,,65,1
Ulcer incidence,number/group,65,1
Max reduction,%,65,1
Kieq,nM,65,-1
Body weight change,g,65,1
ED50,mg ml-1,65,1
Log kw,,65,0
CC25,ug ml-1,65,0
K,10'3/M/min,65,-1
MDD,,65,-1
logGI50,,65,-1
Activity,RLU,65,1
Potency_Clk4_uM,uM,65,-1
LD10,mg kg-1 day-1,65,1
Activity,m,65,1
Activity,nmol/sec,65,1
pKd,,65,-1
Serum level,mg dl-1,65,1
Specific binding,%,65,1
CC,,64,0
-TdeltaS,kJ/mol,64,-1
ED100,,64,-1
eLog D,,64,0
MCC50,uM,64,-1
Radius of inhibition zone,mM,64,1
Kbapp,nM,64,-1
deltaRm,,64,0
Toxicity,uM kg-1,64,-1
p24,pg ml-1,64,1
Inhibition Zone,cm,64,1
Delta HDL,%,64,1
Rotarod toxicity,,64,0
Discrimination ratio,,64,0
Stability,ml/min/mg,64,1
Behavioral score,,64,1
Log Pe,cm s-1,64,0
log(1/SD90),,64,-1
Binding affinity,uM,64,-1
AC3,uM,64,1
Tm,,64,-1
Change in weight,,64,0
Activity,10^2 mm,64,1
Relative EC30,,64,0
Net cell kill,log10,64,-1
LD20,,64,1
Activity,/cm3,64,1
Systolic blood pressure,,64,1
Tracer,%,64,1
Residual insulin secretion,%,64,1
CL_renal,L/hr,64,1
Papp,10'-5 cm/s,64,0
LD100,mg kg-1,64,1
Fraction ionised,,64,0
Stability,pmol/min/mg,63,-1
Papp,10^6cm/s,63,1
Inhibition uptake,%,63,1
Activity,molar ratio,63,0
No. of cells,,63,0
RUmax,10'2/Da,63,0
EC1.5,,63,-1
Metabolic stability,%,63,1
APD75,%,63,1
-Log KD,,63,-1
Imax,mmHg,63,1
ED85,g/ha,63,1
Relative velocity,,63,1
K ass,l uM-1,63,1
BA,%,63,1
I ABC,,63,0
Activity ratio,,63,0
Activity,10'-3/M/s,63,1
pLC50,,63,-1
Ratio IC50,uM,63,-1
K,M-1 s-1,63,-1
Log activity,,63,-1
Agonist activity,,63,-1
Bmax,fmol/mg,63,1
Cl - current change,,63,-1
log(IA),,62,-1
Max non-toxic dose,ug ml-1,62,1
Hydrolysis rate,,62,1
permeability,10'-5 cm/s,62,0
GR50,kg/ha,62,1
pA50,,62,-1
log(1/LD50),,62,-1
cAMP accumulation,%,62,1
Uterotrophic effect,,62,0
K,10'5/M.s,62,1
Ulcerogenic activity,%,62,1
ED99,ug ml-1,62,-1
Activity,10'9/L,62,1
ED50,mg mouse-1,62,1
Activity,log10FFU/ml,62,-1
TC,%,62,1
Activity,m equiv kg-1,62,1
Kdiss,uM,62,-1
Activity,pmol/g,62,0
Relative velocity,%,62,1
Log RAI,,62,0
Delta MAP,,62,-1
Deaths,,62,-1
PI turnover,,62,1
PHA,,62,-1
CPA,%,62,1
MIC=<50,uM,62,-1
Concentration,mg ml-1,62,0
Kin,hr-1,61,0
Cmin,mg/L,61,1
Stability,uL/min/kg,61,1
Ka,10^6/M,61,1
Alpha E,,61,0
Lowering,,61,-1
Drug metabolism,ug ml-1,61,0
Delta MAP,mmHg,61,1
Potency_Clk2_uM,uM,61,-1
Tumor weight,g,61,0
Organ distribution,%,61,1
ISA,,61,-1
Activity,10^-7/M,61,1
AUC,%,61,0
ED20,,61,-1
Inactivation,%,61,1
Papp,nM/s,61,1
Significance,,61,0
KD/Ki,nM,61,-1
LD50,microgAi/g,61,-1
Effect,mg 100g-1,61,0
Dead cells,%,61,1
ED95,mg kg-1,61,1
Log ED50,uM kg-1,61,-1
T/C,day,61,1
Bmax,fM (mg of protein)-1,60,1
Ratio_ATPase activity,,60,0
Vmax,nM min-1,60,1
PCA shift,,60,-1
Median day of death,,60,1
No. of animals protected,,60,1
[I],uM,60,-1
Weight,%,60,1
Change in heart rate,beats min-1,60,-1
ED50,nM mouse-1,60,-1
HYPO,,60,-1
IFN,ml,60,-1
SF,,60,-1
Sensory evaluation,,60,0
Latency time,s,60,1
Activity,10'-3cpm,60,-1
DAR,,60,0
MG MID,uM,60,-1
Drug release,,60,0
% maximum response,%,60,1
K,10^5/M/min,60,1
Anticoccidial Activity,%,60,1
-Log ED50,,60,-1
Activity,ugequiv/ml,60,1
Level,uM,60,-1
% remaining,%,60,1
A0.5,uM,60,-1
Chemotherapeutic index,,60,0
CC30,uM,60,-1
Potency_Dyrk1a_uM,uM,60,-1
Activity,10'7mol/J,60,1
pID50,,60,-1
Activity,mg/mg/day,60,-1
Cytotoxicity,nM,60,-1
MIC=>50,ug ml-1,60,-1
%AUCextra,%,60,1
Absorbance,nm,60,1
CD,,59,-1
Other,,59,0
RHT,,59,0
kon,nM^-1 min^-1,59,1
Relative hydrolysis,,59,0
Total cholesterol,mg dl-1,59,0
ED30,,59,1
Half duration,min,59,1
CFU,/ml,59,-1
Average weight,,59,0
Change of tumor area,%,59,1
Dose ratio,,59,-1
Activity,microg/ml,59,1
log(Kinetic_solubility),,59,0
Relative uterine weight,,59,0
LC90,uM,59,-1
Fold activation,,59,1
Inhibitory diameter,,59,1
ED99,mg kg-1,59,1
Erythroid induction,%,59,1
Effective dose,mg kg-1,59,1
koff,min^-1,59,-1
MLC,uM,58,-1
LD50,mg/L,58,1
dP/dt20,mg kg-1,58,1
ED50,g/ha,58,1
Glycaemia evolution,%,58,1
Log GI50,,58,-1
Potency_Dyrk1b_uM,uM,58,-1
EC5X,uM,58,-1
Stabilty,ml/min.kg,58,1
ACT,%,58,1
Inhibition ratio,%,58,1
Estrogenic effect,nM,58,-1
AWC,g,58,0
Cmax,nmol/g,58,0
Cmax/dose,uM,58,0
Specific activity,uM min-1 (mg of protein)-1,58,-1
AE Score,%,58,1
Reduction factor,,58,1
UR,%,58,1
KI_MICROM,um,58,-1
MED,uM kg-1,58,-1
Tp control,%,58,1
Level,pM g-1,58,0
Collapse time,min,58,1
Relative growth,,58,-1
Activity,fL,58,0
ECmax,,58,1
Relative salidiuretic activity,,58,0
IE50,uM/L,58,-1
Neuroprotection,%,58,1
Body weight loss,%,58,1
Activity,10'-7M,58,-1
AUC,uM.hr/mg.kg,58,0
TCID50,uM,57,-1
Anti-pent effect,,57,-1
SI,uM,57,0
Uterine activity,%,57,1
LD0,mg kg-1,57,1
Max increase,%,57,1
AUC cytotoxicity,,57,1
AUC Ratio,,57,0
K,10'-5/s,57,1
PC,,57,0
EC80,ug ml-1,57,-1
Onset,s,57,1
Total radioactivity,ug equiv g-1,57,0
pKi,nM,57,-1
ED50,microg/cm2,57,-1
Polyamine level,,57,0
Ratio,ug ml-1,57,0
Antiovulatory activity,%,57,1
Max PI,%,57,1
Activity,mmHg/s,57,1
LBF,%,57,1
Ct,% dose/g,57,1
ED25,uM kg-1,57,-1
RPP,%,57,1
Surviving fraction,,57,-1
Mean uterine weight,mg,57,1
ID90,uM,57,-1
CL,L/Kg,57,0
T99.9%,hr,56,1
pRA2,,56,-1
Relative stability,%,56,1
Kr,/min,56,-1
T/C,min,56,0
Kb,M-1,56,-1
Activity,umolequiv/g,56,1
Therapeutic index 99,,56,0
ITP,%,56,1
MDD50,mg kg-1,56,-1
ZImax/KZI,mm microL/micromol,56,1
Lipid-soluble radioactivity,,56,0
Modification,%,56,1
pRA1,,56,-1
Stimulation,,56,1
IC,uM,56,-1
Vmax,nM/s,56,1
% Inhibition of Control Values (Mean n=2),%,56,1
IZ,mm/mg,56,1
Log k,,56,0
Uterine weight,,56,1
Growth of cells,,56,-1
Activity,10'6CFU,56,0
EC30,ug ml-1,56,-1
pTCD50,,56,-1
Deuterium retention,%,56,1
Recovery,,55,0
Metabolism,pM min-1 mg-1,55,-1
pC,,55,-1
Log 1/EDMES(2.5),,55,-1
Removal of microfilariae,%,55,1
pA2,nM,55,-1
Activity,pA/pF,55,-1
AUC/dose,microg.hr/mL,55,0
Activity,uM kg-1,55,-1
D50,,55,-1
EDMES(2.5),mg kg-1,55,-1
logKa,,55,-1
ED100,ug,55,1
Saluretic score,,55,0
MTD,ug ml-1,55,-1
Supression,%,55,1
ED50,ug ear-1,55,1
Activity,kcal/mol,55,0
ID75,uM kg-1,55,-1
-log(inh/100-inh),,55,1
K inact,s-1,55,-1
TAC,mmol/L,55,1
K,10'3/s,55,-1
Serum total triglycerides,mg dl-1,55,1
NOHA,%,55,1
log(1/D40),,55,-1
STY seizure,mg kg-1,55,-1
Clearance,L/h/Kg,55,0
Log 10 LC50,,55,-1
Antidiuretic activity,mg,55,0
CD,nM,55,-1
Log AP,,55,-1
Clearance,ul min-1,55,0
Kinact,/M/min,55,-1
GC50,,55,-1
PO2,%,55,1
Reactors/Test group,,55,0
permeability,10'-4 cm/s,55,0
NO formation,%,55,1
ED300,ug kg-1,54,-1
Activity,mmol/g,54,1
Kcat/Km,microM/s,54,-1
Total dose,mg kg-1,54,1
No. of falls,,54,1
Protected mice,%,54,1
No. of lung colonies,,54,1
pKm,,54,-1
Growth Inhibition,mm,54,1
CC25,,54,-1
Log D50,,54,-1
Biodistribution,dose/organ %,54,0
Binding energy,kCal M-1,54,-1
Maximal effect,%,54,1
Median survival day,,54,1
CD50,nM mouse-1,54,-1
Concentration,ng (g of tissue)-1,54,0
Receptor occupancy,%,54,1
nHill,,54,-1
Drug metabolism,ng/g,54,0
Polyamine content,nM g-1,54,0
Rel Max FI,,54,1
Relative ID50,,54,-1
AUBC,log10CFU/ml.hr,54,1
Relative inhibition,%,54,1
Length,mM,54,0
AUC,microM.hr/mg/kg,54,0
log(10'6/IC50),,54,-1
log(1/ED30),,54,-1
Rotation number,,54,0
Drug uptake,pmol/mg,54,1
Drug uptake,ppm,54,1
alphaKi,uM,54,-1
SUVmax,,54,1
MBEC50,ug ml-1,54,-1
Papp,10^-8cm/s,54,0
Ct,ug ml-1,54,0
Activity,umol/g,54,-1
Vmax,uM min-1mg-1,54,1
Ka,L/mol,54,1
Initial activity,%,54,1
CLH,uL/mg/min,54,-1
Injection dose/g,%,54,1
Punch weight/MPO activity,,53,-1
Normalized abundances for compound,,53,1
DOPA accumulation,,53,-1
IC50,10^2 uM,53,-1
Anti-fighting behaviour,,53,0
Normalized abundances for DMSO,,53,0
CLz/F,L/hr/kg,53,-1
k cat,,53,-1
K,10'6/M/min,53,1
Vmax(app),/s,53,1
Drug uptake,%ID/ml,53,1
ED90,gAi,53,0
Drug metabolism,umol,53,0
Relative agonistic activity,%,53,1
Life span,day,53,1
Methemoglobin,%,53,1
Maximal activation,%,53,1
Turns,,53,0
Max increase,,53,1
Behavioral effect,,53,0
Binding,,53,-1
Drug degradation,mol%,53,-1
Ki',uM,53,-1
CS index,,53,0
Delta HR50,%,53,1
Ki,ug ml-1,53,0
Delta HR50,beats min-1,53,1
Blood glucose,mg dl-1,53,1
K,/uM/s,53,-1
Inhibitory diameter,mM,53,1
Clined screen test,,53,0
KSV,10'4/M,53,-1
LogFC,,53,1
EC95,ug ml-1,53,-1
MED=>50,,53,-1
Activity,10^3 /uL,53,-1
LD10,,53,-1
MLD,ug ml-1,53,-1
MBC=>99.9,uM,53,-1
Transactivation,%,52,1
Saldiuretic activity,m equiv 6hr-1 kg-1,52,1
Rhodamine-123 accumulation,arbitrary units,52,0
Kdiss,/s,52,-1
Vmax,uM,52,-1
K,10^-3/s,52,-1
Activity,million/mm3,52,0
CD,ug ml-1,52,0
Ratio,10'4/M/s,52,1
Vmax,pM min-1 mg-1,52,1
Protective effect,%,52,1
Zone diameter,mM,52,1
pKp,,52,-1
ECmax,uM,52,-1
Eye toxicity,,52,0
Max/average,,52,0
EC50,nmol/cm2,52,-1
Fraction experiencing seizures,,52,1
Ks,nM,52,-1
TWI,%,52,1
Inhibition potency,,52,-1
Activity,degree,52,1
Kinetic_solubility,Ug/ml,52,0
Distribution coefficient,,52,0
Vmax/Km,uL/min,52,1
-Log Kdiss,,52,-1
SER,,52,-1
IC90,uM well-1,52,-1
IC90,ppm,52,-1
GM-MIC,ug ml-1,52,-1
Stool output,g (350g of rat weight)-1,52,1
K,10'-5/M,52,-1
Delta p,%,52,1
IC50,uM well-1,52,-1
Incorporation,c.p.m.,52,-1
Aneuploidy activty,,51,-1
K2,uM,51,-1
MIC=>50,uM,51,-1
Kis,,51,-1
UI,mm,51,1
IC50,p.p.m.,51,-1
IC90 mutant/IC90 WT,,51,-1
% Inhibition of Control Agonist Response (Mean n=2),%,51,1
Max Achievable Bioavailability,%,51,1
Competition factor,,51,-1
Activity,kCounts,51,0
pIC90,,51,-1
CLH(app),,51,-1
ED50,pM mouse-1,51,-1
Acceptor activity,,51,-1
cAMP activity index,,51,-1
ascites volume,ml mouse-1,51,1
Challenge time,min,51,0
packed cell volume,%,51,1
Zone of stimulation,mM,51,1
EC,mM,51,-1
Vmax,mM/min,51,1
Responding,%,51,1
Activity of control,%,51,1
CLH,nmol/min/mg,51,-1
Weight loss,%,51,1
Antihypertensive score,,51,0
Drug uptake,cpm,51,0
Log ESA,,51,0
Increase in CBF,ml min-1,51,1
Kcat/Km,10'7/M/s,51,1
Papp,10'-4 cm/s,51,1
MOT,min,51,1
% of Control Agonist Response (Mean n=2),%,51,1
Relative inotropic potency,,51,1
Efficacy ratio,,50,0
Total excretion,%,50,0
Tissue distribution,ug g-1,50,0
Rate of O2 consumption,nM min-1,50,-1
Log K1,,50,-1
Max T/C,,50,1
pKi,mM,50,-1
Blood pressure,%,50,1
Log 1/ratio,,50,-1
Beta-lactamase induction,,50,0
Max,mmHg,50,1
GT fold stimulation,,50,1
Locomotor activity,mg kg-1,50,1
BP,%,50,1
mequiv of Na+/kg,0-5h,50,1
BDW,g,50,0
Modulation factor,,50,-1
Avg IC90,uM,50,-1
C20,ug kg-1,50,1
logCL,,50,-1
MPC,,50,-1
GDP ED50,mg kg-1,50,-1
LED,mg kg-1,50,1
Max delta APD95,%,50,1
Days,,50,0
Reversion activity,%,50,1
S0.5,mM,50,-1
Increase in concentration,uM,50,1
LC95,mg/L,50,-1
Papp,10^7cm/s,50,1
FT mean score,,50,1
XI50,uM,50,-1
CL,uL/ml/kg,50,-1
FBP mean score,,50,1
AbsAC30,uM,50,-1
Delta pH,,50,1
Activity,nmol/mg.min,50,1
Activity,ng/mg,50,0
Initial blood pressure,mmHg,50,1
Virucidal,nM,50,-1
Survival rate,number of mice,50,0
Cp(f),%,50,1
K,10'-8M,50,-1
Kcat/Km,10'3/M/s,50,1
Systemic effect,%,50,1
T>MIC,hr,50,1
K,10'4/M.s,50,1
Uptake,nM (mg of protein)-1,50,0
Ka,10'6/M/s,50,1
K,10'7/M,50,-1
Ka,10'3/M,50,1
Ka,10'-4L/mol,50,1
MTL,uM,49,0
Accumulated counts,,49,1
Mean body weight,g mouse-1,49,0
FA,%,49,1
Median life span,day,49,1
Activity,um/hr,49,1
Ks/i,uM,49,-1
Control Uptake,%,49,1
RIC50,,49,-1
ka,min-1,49,-1
Antiviral effect,,49,-1
N,,49,0
Arterial pressure,mmHg,49,1
-Log C,,49,-1
APTT,IU mg-1,49,-1
ID50,uM hr-1 kg-1,49,-1
ADI,,49,0
BWC,g,49,1
Recovered,%,49,1
Bmax,%,49,1
pEC100,,49,-1
Turnover,,49,0
KSV,10'4L/mol,49,-1
Efficacy,nM,49,-1
ED2,,49,-1
Delta TAO,,49,-1
K,hr-1,49,-1
pTI,,49,-1
Activity,/ml,49,0
Cmin,uM,48,0
RH,%,48,1
Diameter,mM,48,0
Broncho selectivity,,48,0
Radioactivity,c.p.m.,48,0
Potentiation,,48,1
Drug concentration,uM,48,0
Binding constant,M-1,48,-1
Behavior score,,48,1
Baseline,%,48,1
CD50,,48,-1
MABP change,mmHg,48,0
Pmax,mM,48,0
Drug recovery,%ID,48,1
Reversal,,48,-1
Drug uptake,umol/Kg,48,1
LD50,M,48,-1
PWT,g,48,0
Skin tests intensity,,48,1
Specific activity,nM min-1,48,-1
Kic,nM,48,-1
Stability,mg/ml,48,0
EC75,uM,48,-1
IA50,%,48,1
CLH,min/ml/kg,48,1
EC99,ug ml-1,48,-1
ECI,%,48,1
Survival range,,48,1
ED10,mg kg-1,48,1
MED,ug ml-1,48,0
P ABC,,48,0
ED25,,48,-1
Ka,nM,48,-1
Activity,fmol/min,48,1
ED40,,48,-1
Ka,10'7/M/s,48,1
Cytoprotective effect,,48,0
Optimal concentration,mM,48,0
KSV,10'3/M,48,-1
Activity,CFU/g,48,-1
ED50,uM l-1,48,-1
Tm shift,degrees C,48,-1
Total activity,uM min-1,48,-1
No. protected/tested,,48,0
K inact,M-1 s-1,48,-1
K bind,nM,48,-1
K Bind,uM,48,-1
MI0.5,nM,48,-1
Efficacy index,,48,0
Urine volume,ml min-1,48,1
Irritation,arbitrary units,48,1
Inhibitory concentration,ug ml-1,48,-1
Vmax / Km,,48,-1
FI5,nM,48,-1
MID,uL/L,48,0
Increase in footpad thickness,mM,48,1
AUC/dose,ng/hr/ml,48,0
fold selectivity,fold selectivity,48,1
MNTD,mg kg-1,48,1
log10FFU,,48,-1
logPm,,48,0
Concentration,uM g-1,48,-1
GTP shift,,48,0
Glucose rise,mg dl-1,48,1
MTD50,mg kg-1,48,-1
Cp,%,47,1
LMA,,47,0
Reactivation,%,47,1
Log Ko,,47,0
Contragestational activity,mg kg-1,47,1
MIC70,ug.mL-1,47,-1
cAMP,%,47,1
Response rate,,47,0
Vc/F,l,47,0
solubility,10^-6 cm/s,47,0
[35S] TBPS shift,,47,0
Mean latency,s,47,1
Survival rate,,47,0
Body weight,%,47,1
Activity,mmolequiv/L,47,1
Activity,/mm3,47,0
Permeability,cm s-1,47,0
Compound remaining,%,47,1
K0.5,uM,47,-1
Alphax10E,,47,0
CBF Ratio,,47,1
Rectal temperature,degrees C,47,0
CL,L/Kg.hr,47,-1
Activity,uL,47,1
Pgp AbA/analogue ratio,,47,-1
MAC,ug ml-1,47,-1
LD10,mg/kg/day,47,1
Growth,,47,0
ID50,nM ml-1,47,-1
Stability,pmol,47,0
FBF Ratio,,47,-1
Log Pn,,47,0
Mean IC50,,47,-1
Positive cells,%,47,1
Relative Ki,,47,-1
Activity,IU mg-1,47,1
Relative ET-A IC50,,46,-1
C175,uM,46,1
Log M50,,46,-1
Dose excreted,%,46,1
Duration of action,,46,0
MI50,ug ml-1,46,-1
Log TGI,,46,-1
permeability,%/hr,46,1
Pm,,46,0
MED20,mg kg-1,46,1
Activity,10'-3mg/ml,46,1
Log SOSIP,,46,-1
Log 1/I50,1/M,46,-1
Average lesion score,,46,0
Lethal dose,mg kg-1,46,-1
Delta APD90,,46,1
Relative uptake,,46,0
Ataxia,%,46,1
Variation/Control,%,46,1
Active/total cultures,%,46,1
LM,uL/min/mg protein,46,-1
Vigour_index,,46,1
Activity,nM/mg,46,-1
Log ILS max,,46,1
Activity,nM/mg*min,46,1
MNCC,mM,46,0
MDR ratio,,46,1
kin,hr-1,46,-1
PFU/ml,,46,1
Ki,ug nM-1,46,-1
Cytotoxic activity,,46,-1
KB app,,46,-1
Blood sugar lowering,,46,-1
PKa,,46,0
Drug uptake,mM,46,0
Cell number,,46,-1
RD50,mg kg-1,46,-1
Activity,10'6/mm3,46,1
Fold-induction,,46,1
IC15,uM,46,-1
REP,%,46,1
Reaction time,s,46,1
EC20,%,46,1
No. of animals with liver necrosis,,45,0
Alpha,,45,0
Relative Kd,,45,-1
Relative F%,,45,0
Foci/dish,,45,0
Drug metabolism,micromol/min,45,1
Weight,,45,0
Tubulin binding,%,45,1
Acute electroshock activity,,45,0
Blood level,ug ml-1,45,0
ka/Ki,uM-1 min-1,45,-1
NC,,45,0
Vz/F,l,45,0
Ka,10'-5/M,45,1
AUEC,A% min-1,45,1
OD(540nm),,45,1
CAC,uM,45,0
rIC50,,45,-1
RAC app,,45,-1
log(1/CON),,45,-1
Delta MABP,mmHg,45,-1
LV FRP,%,45,1
ED100,ug kg-1,45,1
Apparent enzyme activity,,45,0
Hepatic Extraction ratio,,45,0
Kcat,10'5/s,45,-1
logK(lung),,45,0
Level,mg dl-1,45,0
Kb,10^4/M,45,-1
Delta G,kCal mol-1,45,-1
Antiviral activity,mM,45,1
Drug uptake,ng/ml/g,45,0
Possible response,%,45,1
Change in body temperature,degrees C,45,-1
ED50,10'3nM,45,-1
Activity,ng dl-1,45,1
Activity,cm/s,45,1
LC90,mg/L,45,-1
Papp,10^-7 cm/s,45,0
pEC170,,45,-1
logK(blood),,44,0
GSH-Px activity,,44,0
CC25,uM,44,-1
Drug degradation,/hr,44,0
No. of mice survived,,44,0
Activity,10'-6M,44,1
Kcat/Km,10'6/s/M,44,1
ECmax,%,44,1
Virus yield,log pfu ml-1,44,-1
Ki ss,nM,44,-1
CPP,mmHg,44,0
Activity,ug/L,44,1
Inhibition constant,,44,-1
CL,ug/min,44,-1
Cells killed,%,44,1
Mean blood pressure,%,44,1
IC20,,44,-1
HD50,ug ml-1,44,-1
Administered dose,%,44,0
LD,uM,44,-1
MBEC50,uM,44,-1
Alpha max,%,44,1
Delta TM,c,44,-1
-logKa,,44,-1
Immobility time,s,44,-1
Reversal type,,44,0
Change in blood pressure,delta mmHg,44,-1
Fraction cured,,44,0
Antitumor activity,%,44,1
Decrease in MABP,%,44,1
Change in response rate,%,44,1
Decrease in QA interval,,44,-1
LVP,mmHg,44,0
log1/CLD50,,44,-1
ED50,10'-5 ug/ml,44,-1
Level,U l-1,44,1
Average weight change,,44,0
Liver weight,mg (g of body weight)-1,44,1
GR,%,44,1
Ka,10'7/M,44,-1
pA2/pKB,,44,-1
Diuretic activity,ml kg-1 6hr-1,43,1
TP,%,43,1
EPMR,,43,-1
Max inhibition,,43,-1
fCmax,ug ml-1,43,0
"% Enzyme Activity (relative to DMSO controls, average n=2)",%,43,1
Cmax/dose,ng/ml,43,1
Drug metabolism,nmol/mg/hr,43,1
Sleeping time,,43,1
EC5,nM,43,-1
Inhibition over time,%,43,1
RSA,%,43,1
pEC90,,43,-1
KiH,nM,43,-1
Activity,pg/g,43,1
ILS30,,43,1
LT50,ppm,43,1
Active dose,mg kg-1,43,1
kr,min-1,43,-1
Behavior,,43,0
GR80,gAi/ha,43,1
MNEC,uM,43,-1
Activity,/mM/min,43,1
Activity,10'3 /uL,43,1
Recovery time,min,43,1
No. of entries,,43,0
log1/CED90,,43,-1
MED,mM kg-1,43,1
Median survival time,day,43,1
Potential,,43,0
Activity,micromol/m2/s,43,1
Deoxyribose degradation,uM of MDA mM-1,43,-1
ED50,mg ear-1,43,1
CL_renal,ml/min,43,1
RL,%,43,1
pD,M,43,-1
TCID50,ug ml-1,43,0
Log Kw,,43,0
Unchanged,%,43,1
Influx,nM mg-1,43,-1
SP,%,43,1
REA,,43,1
DR10,mg kg-1,43,1
Ka,10^5/M/s,43,1
AUClast,hr.ng/g,43,0
Competition,%,43,1
R,,43,0
Net log cell kill,,43,-1
Control compound IC50,uM,43,-1
LD5,uM,43,-1
deltaS,kJ/mol,43,0
Radioactivity,nM equiv (mg of tissue)-1,42,0
Capacity,,42,0
Clast,ng/ml,42,0
P (Ei),,42,1
Bmax,pmol/mg,42,1
Rise HR,,42,1
PCY,,42,-1
Daq,10'-6cm2/s,42,0
Csat/Co,,42,0
Decrease in SBP,mmHg,42,-1
ED90,mg l-1,42,1
K+ excretion,,42,0
Cell protein,ug dish-1,42,0
Distribution,% dose g-1,42,1
RD500,mg kg-1,42,-1
ID40,mg kg-1,42,1
ED35,mg kg-1,42,1
MLD50,uM,42,-1
Tremorolytic dose,uM kg-1,42,-1
Loss of righting reflex,,42,-1
Max change in blood pressure,mmHg,42,1
IT50,min,42,-1
k cat/Km,10e4 M-1 s-1,42,1
Compound recovery,10^-9M,42,0
Antihypertensive activity,,42,-1
MED>50,mg kg-1,42,1
APD60,,42,-1
ED80,mg kg-1,42,1
Diuretic activity,m equiv,42,-1
NBT positive cells,%,42,1
Uterine weight,g,42,1
EC80,ppm,42,1
Ka,/M/s,42,1
Activity,ng/g,42,1
No. of shocks,,42,1
MED,M kg-1,42,-1
Vdu,ml,42,0
Lethality,dead/total,42,-1
Inhibition,delta A min-1,42,-1
AUC,ng/ml,42,0
No. of cured,,42,0
Separation,,42,0
Co,g dl-1,42,0
AUC,ng.hr/ml/mg/kg,42,0
K,10^-4/s,42,1
K,/M,42,-1
Na+ excretion,,42,0
Csat,g dl-1,42,1
Urinary volume,,42,0
Range,day,42,0
No. of dead mice,,42,1
Emax,pM,42,-1
Cell death,%,41,1
ED50,M l-1,41,-1
Activity,U mg-1,41,1
K,10^5/M/s,41,1
ED125,uM kg-1,41,-1
Survival rate,%,41,1
Vmax,nM min-1 mg-1,41,1
Smax,uM min-1 kg-1,41,1
DNA crosslinking,,41,0
Kr,M,41,-1
WBC,%,41,1
AUClast,,41,0
Index,%,41,1
Fmut,,41,-1
Antagonistic activity,,41,-1
Pigment binding,%,41,1
MNTD90,uM,41,-1
GI,mM,41,-1
Relative rate of hydrolysis,%,41,1
Relative rate,,41,0
Concentration,ug/g tissue,41,0
Migration index,,41,0
ID50,mg,41,-1
MfI,,41,-1
AC200,uM,41,-1
Log C,,41,0
pK50,,41,-1
CAR,,41,1
-Log IC25,,41,-1
Delta ERPc,%,40,1
IC70,nM,40,-1
Activity,U/min,40,1
Luciferase activity,RLU 10s-1,40,1
Reactivity,,40,-1
pKa_B2,,40,0
Log 1/ID75 (uM L-1),,40,-1
ID50,M l-1,40,-1
Dose,ug,40,-1
Recovery time,%,40,0
Dose,uM,40,-1
ID50,mM l-1,40,-1
GR,,40,0
ID50,ng/ml,40,-1
K,mM,40,0
CFU,10'8/ml,40,-1
ASF,p.p.m.,40,-1
ID90,mg kg-1,40,1
Mean no. of revertants,,40,1
MP,%,40,1
IC50,g/ha,40,0
log(1/MIC>90),,40,-1
Aspirin formed,%,40,1
Arthritic score,,40,1
Drug uptake,nmol/mg.min,40,1
Fold activation,%,40,1
Body weight reduction,%,40,1
In vivo duration,Minutes,40,0
Drug uptake,pmol/min,40,1
LD50,g/ha,40,1
Fluorescence Intensity,,40,1
Change in BP,,40,1
Change in BP,%,40,1
LD20,mg kg-1,40,1
RU,pg/mm2,40,1
Max inhibitory effect,%,40,1
Zone diameter,,40,1
KSV,10^4L/mol,40,-1
RTV,,40,0
Papp,10^-5cm/s,40,1
EC12,uM,40,-1
Serum cholesterol,mg dl-1,40,1
EC25,,40,1
ED50,umol/cm2,40,-1
Tissue concentration,% injected dose g-1,40,1
"Kpot A,B",,40,-1
MIC=<80,ug ml-1,40,-1
Activity,uM min-1 (mg of protein)-1,40,1
Activity,Bq,40,0
Kii,nM,40,-1
RPF,pM nM-1,40,-1
AZT formation,,40,1
ED99.9,mg kg-1,40,1
Ki/KI,M-1 s-1,40,-1
DD,uM of MDA mM-1,40,-1
EC90,pM,40,-1
ECmax,nM,40,-1
ED50,mg l-1,40,-1
MIC100,microg/ml,40,-1
MES ED50,mg kg-1,40,-1
Cytokine induction,,40,1
Biodistribution,ug of B g-1,40,0
ED90,ug ml-1,40,-1
Positive control,%,40,1
Quantity,mg,40,0
Suppression,,39,-1
I 90,,39,-1
log Kp,cm/s,39,0
k2,,39,-1
k cat/Km,mM-1 min-1,39,1
k,s-1,39,-1
delta(V1/2),mV,39,-1
Vmax,nM/mg*min,39,1
Vmax,microM/min/mg,39,1
Activation,,39,1
Vd,ml,39,0
V,ml 6hr-1 (kg of body weight)-1,39,0
Toxic level,M,39,1
Topical potency,,39,1
Activity,Hz,39,1
TBMIC,ug ml-1,39,-1
Activity,nM (mg of protein)-1,39,-1
Activity,ug (mg of protein)-1,39,0
Analgesia duration,,39,1
Relative susceptibility,,39,0
Average dose,ug kg-1,39,1
BCM serum Ca,mg 100ml-1,39,1
BWC,%,39,1
Ratio AUC,%,39,0
Rate of phosphorylation,,39,0
RSA,,39,1
P24 concentration,ng ml-1,39,1
CLint,uL/min/1E6 cells,39,-1
Oral diuretic activity,u equiv of [Na+] kg-1 hr-1,39,1
Na,m equiv 6hr-1 kg-1 (body weight)-1,39,1
Change in body weight,g mouse-1,39,1
Mean arterial blood pressure,,39,0
Max temperature decrease,,39,1
Cp,ng/g,39,0
MIC,10'-3uM/ml,39,-1
D150,mg kg-1,39,-1
Dead,,39,-1
Decrease in CR,,39,-1
MAP,,39,0
Delta pCa50,,39,-1
Lesion length,mm mice-1,39,1
E,,39,0
EC170,uM,39,-1
Kq,10'12/M/s,39,-1
Kp,ucm/s,39,0
Kp,10^-6 cm/s,39,0
Kdiss,10'-3/s,39,-1
Ka,10'4/M/s,39,1
K,10^-2/uM/min,39,-1
FI,,39,1
Infectedmosquitoes,%,39,1
Flea,p.p.m.,39,1
IS/AAR,%,39,1
ID50,10'-4M,39,-1
pMIC,,38,-1
RIA,,38,-1
Log PR,,38,-1
LD0,mg,38,0
Vertebral blood flow,,38,0
Binding,(ng of DNA) dish-1,38,0
ED50,mg/day,38,1
Inhibition,ug kg-1,38,1
Onset,hr,38,1
I90,ppm,38,1
% NO2-,M/M,38,0
Binding ratio,,38,0
Dose/g of tissue,%,38,1
IC80,,38,-1
IC50,mMequiv,38,-1
Dose,mg kg-1 day-1,38,1
Affinity ratio,,38,-1
Apoptotic Activity,%,38,1
Activity,kilobase,38,1
D50,10'-5M,38,-1
CLH,ml/hr,38,-1
Relative luciferase response,,38,1
x fold,uM,38,0
Change in heart rate,,38,0
PDH active/PDH total,%,38,1
PL,%,38,1
x fold,,38,1
Activity,log10PFU/ml,38,-1
AUCt,,38,0
Histone_modification,,38,-1
Lipophilicity,=,38,0
BMF,,38,0
Activity,/g,38,1
No. of animals survived,,38,0
DNA binding,degrees C,38,0
Partition ratio,,38,0
Activity,nM min-1 mg-1,38,-1
CIC,nM,38,-1
Acute toxicity,,38,0
Ct,pmol/g,38,0
LogPapp,,38,0
K aps,l M-1,38,1
MLC,%,38,1
Stability,day,38,0
MLS,day,38,1
pKapp,,38,0
A1 selectivity,,37,0
No. of animals exhibiting toxicity / Number of animals tested,,37,0
H ABC,,37,0
Max delta MAP,mmHg,37,1
Hyperglycemic activity,,37,1
Kreact,s-1,37,-1
BP change,%,37,1
BSI,,37,1
Alpha max,uM,37,-1
Agonist,%,37,1
Vmax,deltaOD/min,37,-1
AUC/dose,hr.kg.ng/ml/mg,37,1
Activity,PSL/mm2,37,1
Kobs,/min,37,-1
Hmax,,37,1
Dose-modifying factor,,37,-1
Inihibition,%,37,1
FaFg,,37,0
Fu,uM,37,0
Stability,% ID/g,37,0
INH,mm,37,1
C20,uM l-1,37,1
QH,,37,0
G30,,37,1
Time,nanoseconds,37,0
Presynaptic antagonism,,37,-1
Delta T,degrees C,37,1
AUC,ng.hr/Kg,37,0
Delta HR,beats min-1,37,1
Postsynaptic antagonist,,37,-1
Delta BG,,37,1
log(10'3/IC50),,37,-1
Vasoconstriction effect,,37,1
Drug uptake,mg/L,37,0
Kdiss,10'-4/s,37,-1
Max delta HR,beats min-1,37,1
EC10,nM,37,-1
Mu/kappa ratio,,37,0
GMMIC,ug ml-1,37,-1
Papp,%,37,1
DNA cleavage,ug ml-1,37,0
MED,mg kg-1 5day-1,37,1
P50e/P50c,,37,0
AD50,uM kg-1,37,-1
Change in Tm,,37,-1
CT10 ratio,,37,-1
Tension,%,37,1
MTD,mg kg-1 5day-1,37,1
No. of mouse protected,,37,1
Glucose level,mg dl-1,37,1
Test/control survival,,37,0
NSB,,37,-1
MIC100,umol/ml,37,-1
Optimal dose,mg,36,1
Tubulin polymerization ratio,,36,-1
Pressure,mmHg,36,1
Intrinsic Toxicity,,36,0
Enzyme level,U l-1,36,1
pEC0.5,,36,-1
Activity,umol/hr,36,1
K2,nM,36,-1
Relative toxicity,,36,0
CMR,,36,0
Ki,10^2 uM,36,-1
Activity,nmol/g tissue,36,1
Activity,Counts,36,0
IG,%,36,1
36Cl- uptake,,36,-1
Amax,pmoles,36,1
Polyamine,pM g-1,36,-1
Degradation rate constant,hr-1,36,-1
Change of body weight,%,36,1
log1/activity,,36,-1
Plasma GH release,ng ml-1,36,1
Inhibition,pM of cAMP min-1 mg-1,36,-1
Sensitized animals,,36,1
Decrease in AP,,36,-1
Kb,10^5/M,36,-1
Activity,g%,36,1
logLD50,,36,-1
SI,beats min-1,36,1
Survival increase,,36,1
Pc,nm s-1,36,0
Uptake at C50,,36,-1
Inhibition_index,,36,-1
% Inhibition of Control Values,%,36,1
MSD,,36,-1
30 day survival / total,,36,1
CL,nmol/mg.min,36,-1
nNOS activity,%,36,1
MBIC50,,36,-1
Ct,% ID/g,36,1
Activity,10'-5/ml,36,1
AUC/dose,nM.hr/mg/kg,36,0
BNa,%,36,1
K,mM/min,36,1
SC50,ug ml-1,36,-1
ID50,mg/day,36,-1
Activity,/mmol/min,36,1
Thymidine shift,,36,-1
MEC,mg l-1,36,0
Relative inhibitory potency,,36,0
Formation of NO2-,nM,36,-1
Incorporation rate,c.p.m. hr-1,36,1
ED95,p.p.m. in feed,36,1
Dose,rd mCi-1,36,0
fpIC50,,36,-1
k,,36,-1
Initial rates,,36,0
Reversal ability,,36,-1
Rate,%,36,1
Exp Inhib Constant,,36,-1
AUC/dose,ug.hr/mL/mg/kg,36,0
RVR,,36,0
Log M,,36,0
fCmax,mg/L,36,1
Log 1/LD50,,36,-1
-log(1/EC50),,36,-1
EC1000,nM,36,-1
IC,ug ml-1,36,-1
Vmax,pmol/mg/min,36,1
K,10^-2/s,36,-1
Maximal non-toxic dose 50,ug ml-1,36,1
C,uM,36,-1
Vmax,mAU/min,36,1
Log k'w,,36,0
Delta/kappa,,36,0
RBA ratio,,36,0
Delta pKi,,36,-1
MIC50/MIC90,,36,-1
IC25,umol/L,36,-1
Log 1/ED50,,36,-1
G index,,36,1
Delta cpm x10e-3,,36,-1
TI,uM,36,0
Cross linking,%,36,1
SD,min,36,1
ED90,p.p.m.,36,1
koff,1-s,36,-1
SBP,mmHg,35,0
LD50,microg/cm2,35,-1
Seizure score,,35,0
Weight gain,%,35,1
Agonist activity,%,35,1
TMP.decrease,degrees F,35,1
ED50,M kg-1,35,1
ED50,10'-6 ug/ml,35,-1
MPC4,ug ml-1,35,0
Motor activity,,35,0
Activity,beats min-1,35,1
McPhail index,,35,-1
Cmin,umol/L,35,-1
Change from Control (LV dp/dt),%,35,1
Cellular reversion,%,35,1
ED40,ug kg-1,35,1
2x aPTT,uM,35,1
pKHB,,35,-1
Minimal dose,ug ml-1,35,-1
Tumor response,%,35,1
MIC,U ml-1,35,-1
Cholesterol,mg 100ml-1,35,0
CT50,uM,35,-1
MF,%,35,1
Activity,mg ml-1,35,0
ID50,10'-5M,35,-1
Activity,/nmol,35,0
pAlpha,,35,0
Kcat/Km,/uM/min,35,-1
AFI,,35,1
CLH,10^-6uL/min,35,-1
MD,mg kg-1,35,-1
p alphaKa,,35,-1
ED50,mg 4kg-1,35,1
Decrease in IC50,,35,-1
Plasma glucose,mg dl-1,35,0
Loss of righting reflex,%,35,1
AUC,ng.hr.kg/mg/ml,35,0
Protected,,35,1
MTD50,ug ml-1,35,-1
Log TCID50,,35,-1
IT100,min,35,1
k cat/Km,mM-1 s-1,35,-1
MTD,umol/Kg,35,1
Ratio,/mM/min,35,-1
Ratio,1/Ms,35,-1
Log ED50,,35,-1
fT>MIC,hr,35,-1
ERP,%,35,1
Exhibiting turning,%,35,1
Log 1/ED40,,35,-1
AbsAC0.39_uM,uM,35,-1
Drug metabolism,nmol/mg/min,35,-1
Average turns,,35,0
Average tumor volume,mm**3,35,1
IA50,equiv,35,-1
Activity,RFU min-1,35,-1
ED50,umol,35,-1
LOAEL,uM,35,-1
Drug uptake,fmol,35,0
LED,mgP kg-1,35,1
LC50,microg/cm2,35,-1
solubility,ml,35,0
LD90,ppm,35,1
FSC recovery,%,35,1
Vmax/Km,microL/min/mg,35,-1
Volume,l hr-1,35,0
Mean survival time,,35,-1
TMED50,mg kg-1,34,0
Agonistic activity,,34,-1
T50,hr,34,1
Activity,10'7No_unit,34,1
K cat,1/sec,34,1
TAR,,34,0
Delta Gsolv,kCal mol-1,34,0
Retention_index,,34,0
C0,uM,34,-1
Activity A,uM kg-1,34,-1
% of selectivity,%,34,1
Loss of cells,%,34,1
KOX,M-1 min-1,34,1
Survival median,,34,0
E 1/2,,34,0
Parent compound,%,34,1
Caco-2 Papp,cm s-1,34,1
Cell cycle analysis,,34,0
AUC/dose,nmol.hr/L,34,1
CL,ml/mg/kg,34,0
Flu intensity,%,34,1
Log KAT,,34,-1
Activity,10'5U/mL,34,1
K,10'7/M/min,34,1
AUCt,ng/g.hr,34,0
Stabilty,ml/min.Kg,34,1
Ka,10'3/M/s,34,1
Ki low,nM,34,-1
Jump latency time,s,34,1
TN,uM min-1,34,-1
IC75,uM,34,-1
K,1/s,34,-1
Ea,kJ/mol,34,0
PI metabolism,%,34,1
CTS,,34,1
No. of retches,,34,1
SH level,uM g-1,34,0
Kill at C50,%,34,1
Phosphorylation rate,uM,34,0
Synergy,fold,34,1
Incidence,,34,0
Control current,%,34,1
dP/dt max,,34,-1
Duration,s,34,1
Rolipram activity,%,34,1
Rate constant,min-1,34,0
MED,mg,34,1
dP/dt,mmHg s-1,34,0
Selectivity ratio S3/1,,34,0
ER,,34,-1
rf50,,34,-1
Serum level,,34,0
Log k' w,,34,0
K,10'4L/mol,34,-1
Cardio selectivity,,34,-1
Range of survival days,,34,1
Cytotoxic concentration,M,34,-1
Cells in metaphase,%,34,1
Currents,%,34,1
Death,,34,-1
MFC,ug,34,-1
OD,ug kg-1,34,1
Bapp,,34,0
RC50,uM,34,-1
BA,,34,0
Delta Fmax,%,34,1
Change of SBP,%,33,1
Plasma insulin,ml,33,0
Pm,10^-5 cm/min,33,0
Drug uptake,nmol/ml,33,0
Polyamine level,nM,33,0
SRR,,33,0
Cmax/dose,nM.kg/mg,33,0
BP decrease,%,33,1
Activity,umol/mg/min,33,1
TdeltaS,kJ/mol,33,-1
No of monkeys,,33,0
-Log 1/Kb,,33,-1
Stereotypy score,,33,0
Total score,,33,0
cGMP content,pmol/mg protein,33,0
No. positive cases/tested,,33,0
Ka,10^4/M,33,-1
HVA control,%,33,1
Functional profile,,33,0
RBF,,33,0
KT,,33,-1
Specific index,,33,0
permeability,10^-7 cm/s,33,0
ED30,uM,33,-1
Cytokinetic response,,33,-1
TG,mg dl-1,33,0
Selectivity coefficient,,33,0
K1,nM,33,-1
Clearance,,33,0
Cytotoxiciy,,33,-1
inhibition of control,%,33,1
LC50,ug,33,-1
dP/dt,max,33,1
Vmax,U/mg,33,1
SC50,,33,-1
CLH,umol/min/mg,33,-1
K ass,l mol-1,33,-1
L/CE,%,33,1
Edema,,33,0
PDD50,ug ml-1,33,-1
Activity,uV,33,1
Saluretic potency,u equiv min-1,33,1
IM,,33,0
Tm shift,Â°C,33,1
Duration of action,min,33,1
Symptoms,,33,0
Ratio,1/uM*sec,33,-1
RT50,min,33,-1
MUD,mg kg-1,33,-1
Activity in animals,%,33,1
Inotropic effect,,33,0
ED80,ug/kg,33,1
K,/nM/min,33,-1
ED Arec,mg kg-1,33,1
Ratio,/uM,33,-1
DNA cleavage,,33,-1
Relative inhibition index,,33,0
Change in systolic pressure,mmHg,33,-1
Efficacy,uM,33,-1
AUC,nmol.hr/g,33,1
Ks,M,33,-1
IW,,33,0
Maximum test concentration that did not exhibit cytotoxicity,uM,33,1
tR,min,33,0
GI90,nM,33,-1
Tlag,hr,33,0
CL,hr.Kg/L,33,-1
Change of CF,%,33,1
Accumulation coefficient,,33,0
Change of CO,%,33,1
Change of DBP,%,33,1
Kapp,10^-6/M,33,-1
Phospholipidosis as % of positive control,%,33,1
permeability,uM,33,0
AC50,%,33,1
MI100,ug kg-1,33,1
Change of HR,%,33,1
Treated cells,,32,0
pGC50,,32,-1
KiL,nM,32,-1
IC30,nM,32,-1
No. of positive animals,,32,0
Vdss/F,L.kg-1,32,0
Max drop,%,32,1
Activity,10^-10.mol/mg/min,32,1
RLU/well,,32,1
Cell no/dish,,32,0
RBA1,,32,-1
DA response,%,32,1
pkB,,32,-1
Activation time,%,32,1
AUC N,mM hr dose-1,32,1
log10 TCID50,,32,-1
Temperature,,32,0
ED50,molar ratio,32,-1
MEC,mM,32,-1
Activity scale,,32,0
GI90,uM,32,-1
Relative rate of hydrolysis,,32,0
Drug uptake,umol/L,32,1
DD,uM,32,-1
EC95,nM,32,-1
Drug degradation,uM,32,0
Ratio,10'3/M/min,32,1
Cp,ng.Eq/ml,32,0
Permeability,cm hr-1,32,0
No. of platelets,%,32,1
CC25,umol/L,32,-1
IC5,nM,32,-1
Activity,nmol/umol,32,1
HC20,uM,32,-1
CI,ml min-1 kg-1,32,-1
Ionotropic activity,mg,32,0
Activity,/day,32,1
logKd,,32,-1
Anticonvulsant Activity,,32,1
%,,32,1
Plasma GH,ng ml-1,32,0
Survivors / treated,,32,0
EC10x,mM,32,1
Licking latency,,32,-1
pIC50(calc),,32,-1
Drug recovery,ngequiv/g,32,0
Recovery,mg,32,0
Stability,nmol/min/mg,32,-1
RLU,%,32,1
Ka,10^7/M,32,-1
MLD,,32,-1
Log 1/IC50,mM,32,-1
Active dose range,mg kg-1,32,-1
Activity,mAU,32,0
Kq,10'12L/mol/s,32,-1
TAC,U,32,0
TD50,nM,32,-1
Ka,10^6/M/s,32,1
Log B/F,,32,0
Kin x10e3,hr-1,32,1
Cmax,ng/mg,32,0
Activity,umol/L/min,32,1
1/IC50,,32,-1
Plasma lipids,mg dl-1,32,0
OD,nm,32,-1
Cell viability,uM,32,-1
AUC,nM,32,0
MIC=>95,ug ml-1,32,-1
MRF,,32,1
Weight change at nadir,,32,0
Dry weight,%,32,1
Occ50,uM,32,-1
RC10,uM,32,-1
Activity,pmol/ml,32,1
MRT,,32,0
CL,ml.min/kg,32,-1
KA,nM,32,-1
Vmax,/min,32,1
Cytostatic activity,%,32,1
UI,%,32,1
RBA2,,32,-1
Cp,nmol/ml,32,-1
dP/dt,%,32,1
EC0.01,uM/A unit/min,32,1
Oral diuretic activity,u equiv of [Na+]  kg-1,32,-1
CD50,nM,32,-1
Organ weight,mg,32,1
Kcat,10'6/s,32,1
SPF,,32,1
ED25,ug kg-1,32,1
HDL-C,mg dl-1,32,1
Repression,%,32,1
SRR,%,32,1
No. of circlings,,32,0
CIC95,,32,-1
Reverse transcriptase activity,,32,-1
K ass,M-1,32,1
Activity,pmol/L,32,1
Activity,cm3,32,1
Viscosity,,32,0
Max collateral index,,31,0
Cleavage,ug ml-1,31,0
C50,,31,-1
EC0.25,,31,-1
Delta ERP,%,31,1
-Log IC50,,31,-1
Relative PT,,31,0
Activity,uM g-1,31,0
Analgesic activity,%,31,1
Locomotor activity,uM kg-1,31,0
Spont activity,Counts 10min-1,31,-1
UVAPF,,31,1
Survivors at day 9,,31,1
LD90,ug ml-1,31,1
Potentiation,nM mg-1,31,-1
Hypothermic effect,degrees C,31,1
MTC50,ug ml-1,31,-1
K,m equiv 6hr-1 kg-1 (body weight)-1,31,1
Change from control,%,31,1
Kcat,10^5/s,31,1
MIC50,%,31,0
Dissociation constant,,31,0
Metabolic stability,,31,0
LD90,J cm**-2,31,1
Kcat/Km,uM/hr,31,-1
FSC,,31,0
MFC,mg/ml,31,-1
K1/2,uM,31,-1
Max hypotension,%,31,1
ID50,umol/L,31,-1
SSC,,31,0
EFTPC,nM,31,1
Tail vein toxicity,,31,1
Vd,ml/cm3,31,0
Binding stoichiometry,,31,0
FL-1,,31,0
MIC100,nM,31,-1
MLC,,31,-1
Tail flick latency,s,31,-1
Volume,,31,0
Binding site preference,,31,0
Ka,min-1,31,-1
Ca2+ transport,,31,-1
LogD5.0,,31,0
Treatment period,,31,0
Cl-,m equiv 6hr-1 kg-1 (body weight)-1,31,1
Delta G,%,31,1
Uterine wet weight,,31,1
K,10^-2/min,31,-1
Accumulation,nM (mg of protein)-1,31,0
LC95,mgAi/L,31,-1
Urinary output,ml,31,1
Collateral index,,31,0
Fluorescence activity ratio,,31,0
-Log activity,,31,-1
SOD activity,mM,31,1
NG ratio,,31,0
Cured animals,,31,1
K,%,31,1
MIC+/MIC-,,31,-1
Time above IC50,hr,31,1
EC100,ug ml-1,31,1
Drug metabolism,nmol,31,1
RBF,ml min-1,31,0
Max possible effect,%,31,1
Delta FC,%,31,1
AUC/dose,ug.hr/ml,31,0
Crel,,31,1
G30,%,31,1
MLD50,ug ml-1,31,-1
Activity,10'3CFU,31,0
Log 1/MIC (mM L-1),,31,-1
pEC15,,31,-1
solubility,mg,31,0
permeability,pmol/s,31,1
DHP-I susceptibility,,31,0
Vmax,nmol/mg.min,31,1
VT50,min,31,-1
No. of nonpregnant/treated,,31,1
log1/S,,31,-1
Cardiac force,,30,0
KSV,,30,-1
Brain level,nM g-1,30,0
Activity,IU ml-1,30,1
Speed of induction,,30,1
Log CFU,,30,-1
Activity,u equiv min-1,30,1
Activity,uL/ml,30,0
Log KA,,30,1
TC25,uM,30,-1
Effect,mg dl-1,30,0
TD50,mmol/Kg,30,1
TC,,30,0
K,10'3/M,30,-1
Cp,mg/L,30,0
2aPTT,,30,-1
K,10'5/Ms,30,-1
Non-HDL-C,,30,0
ID (per g of organ),%,30,1
Max decrease,,30,1
T/V,,30,-1
Efflux ratio,,30,-1
Change in Tm,degrees C,30,1
MSIC,ug ml-1,30,-1
Efflux ratio plus inhibitor,,30,0
Tumor size,,30,1
T/C 1,,30,1
Activity,cps,30,0
MIC>90,10'-4M,30,-1
Residual secretion,%,30,1
T-cell inhibition,,30,-1
Residual activity,,30,-1
Electrolyte excretion,uM sample-1,30,0
Kcat(app),/min,30,1
ED30,nM,30,-1
Activity,10'1AU.min,30,1
Activity,c.p.m. min-1 mg-1,30,1
Max decrease,%,30,1
LAD,M l-1,30,-1
PD50,nM,30,-1
EC100,mg/L,30,1
Assembly,%,30,1
-Log K,,30,-1
Least dose,mg kg-1,30,-1
K rel,,30,-1
A2 selectivity,,30,-1
DLS Concentration,uM,30,0
PTZ protection,%,30,1
Cell cycle,nM,30,-1
VAR,,30,0
Max CF response,%,30,1
GM,,30,0
Papp A to B plus inhibitor (mean),10E-6 cm/s,30,1
Papp B to A (mean),10E-6 cm/s,30,1
Papp B to A plus inhibitor (mean),10E-6 cm/s,30,1
Relative binding,%,30,1
permeability,10'-9meter/s,30,0
VERP,ms,30,-1
Max delta FRP,%,30,1
ED30,ug,30,-1
pIC50,uM,30,-1
Dec,%,30,1
Phorbol displacement,uM,30,-1
Phototoxic effect,,30,1
Ke,/min,30,-1
LC50,microg/mL2,30,-1
MPE,,30,0
LD50,10'-3 mol/L,30,-1
Drug uptake(free),,30,0
-Log KB,%,30,0
log(M50),,30,-1
In/Fi,,30,0
BP increase,mmHg,30,1
No. of counts,uM kg-1,30,0
Recovery time,,30,0
Recovery B to A plus inhibitor (mean),%,30,1
FICI80,,30,-1
CC75,uM,30,-1
Recovery B to A (mean),%,30,1
Recovery A to B plus inhibitor (mean),%,30,1
KD',M,30,-1
Mean no. of shocks,,30,1
Basal inhibition,%,30,1
Max stimulation,,30,1
CC10,ug ml-1,30,0
ED85,mg kg-1,30,1
Mean day of death,,30,1
Vmax,abs/min,30,-1
Skin reaction,,30,0
Log sweet/bitter,,30,1
Stability,nM,30,0
Immobility,%,30,1
Ki/KI,,30,-1
pGI50,M,30,-1
Drugexcretion,umol/min/kg,30,1
Ki50,uM,30,-1
Activity,ug/min,30,1
HDL-C,,30,0
KF,,30,0
Differential,,30,-1
Peff,10'-7 cm/s,29,0
Relative change,%,29,1
Ka,10^-6/M,29,-1
MI,,29,0
Activity,10'8CFU,29,0
Lethality,,29,-1
Average peak Concn.,ug ml-1,29,1
MBP,ug kg-1,29,1
ED 50,mg kg-1,29,1
NT,mg kg-1,29,-1
ED ratio,,29,0
Contractility,%,29,1
Glucose normalisation,,29,1
PGE2 Level,ng ml-1,29,1
Mutagenicity,revertants plate-1,29,1
Stability,nmol/min/kg,29,-1
Vz,l,29,0
Total cholesterol,mg 100ml-1,29,1
Rate constant,,29,-1
LambdaZ,hr,29,0
Maximal efficacy,%,29,1
Antibody stimulation,,29,1
Log Ki,D4,29,-1
RHR,,29,0
pKi ratio,,29,-1
Top1 cleavage activity,,29,-1
Delta mV,,29,1
fEC50,uM,29,-1
Increase in concentration,pmol/mg prot.,29,1
RIA,%,29,1
CLH,uM/ml,29,0
Body weight gain,g day-1,29,-1
RV,%,29,1
Feed efficiency,,29,0
Feed consumption,g day-1,29,1
Viable cells,*10e-5,29,-1
Max dose,mg kg-1,29,1
CLIP,,29,0
Activity,kDa,29,1
Activity,mgequiv/mmol,29,1
-Log K0.5,,29,-1
pC3,uM,29,-1
KA,M-1,29,1
NCC,%,29,1
pMIC,M l-1,29,-1
Cmin,,29,-1
ED15,ug kg-1,29,1
Net log kill,,29,-1
RM,,29,0
K cat,s-1,29,0
pLADY,,29,0
T/C min,%,29,1
No. of errors,,29,1
Mean enhancement of binding,,29,1
Nr/N,,29,1
IC50,10^-9mol/L,29,-1
Antimalarial activity,,29,0
EC200,nM,29,-1
BPR,ml/g,29,0
Toxicity zone,mM,29,1
Activity,pmol/mg/min,29,1
Ka,10'3/M/min,29,1
CFU,10'5/ml,29,0
Reversible,%,29,1
Enhancement,,29,0
SubMIC,uM,29,-1
Cp,pmol/ml,29,0
Max contraction,%,29,1
Vmax,nmol/mg/min,29,1
Compound recovery,ng/g,29,0
Activity,%ID,29,1
BFU,,29,-1
Concentration in serum,ug ml-1,29,0
EC>90,uM,29,-1
Cell growth,,29,0
Heart rate,min-1,28,0
No. of cultures active/total,,28,0
Grip score,,28,0
Adjusted Ki,nM,28,-1
Cat score,,28,0
A-selectivity,,28,0
Kapp,/M/s,28,-1
MIC,g,28,-1
No. of rats,,28,0
CTL activity,,28,1
pED50,uM kg-1,28,-1
Effect,day,28,1
No. of tumours,,28,0
Kb,10^6/M,28,-1
ICmax,ug ml-1,28,0
Cure,,28,0
Cure rate,%,28,1
Optical density,,28,0
MET,,28,-1
Optimal dosage,mg kg-1 dose-1 day-1,28,1
T/C,survivors/total,28,1
LC100,ug ml-1,28,-1
Organ weight ratio,,28,0
P50e / P50c,,28,-1
Synergy,,28,0
TdeltaS,J/mol,28,1
CLH,uL/ml,28,-1
Mydriasis,%,28,1
FSC,%,28,1
CL/F,ml/min,28,0
CL/F,mL/min,28,1
IC30,,28,-1
Content,ug (g of tissue)-1,28,0
VCR accumulation,,28,0
Max effect,mmHg,28,1
IC30,ug ml-1,28,-1
CL,ml/kg.min,28,-1
n50e,,28,0
APD50,ms,28,-1
Tumor-free,survivors/total,28,0
Activity,nanoampere,28,1
Inverse relative potency,,28,-1
Plasma glucose,mg 100ml-1,28,1
EC90,mg/L,28,1
Kel,hr-1,28,0
Ki,10'3/M/min,28,-1
solubility,10'-3mol/dm3,28,0
Active dose range,mg kg-1 day-1,28,1
Lowest effective dose,mg kg-1,28,-1
LogK-IAMex,,28,0
Tumors with CR,%,28,1
Edema ratio,,28,0
Delta P50,,28,-1
Ep,mV,28,0
K2,M-1 min-1,28,1
LC50,ng/cm2,28,-1
EC50,mol%,28,-1
RFU,%,28,1
RI,%,28,1
ISC,%,28,1
k cat/Km,,28,-1
Mean log concentration ratio,,28,-1
Blood level,Counts min-1 0.2ml-1,28,0
Anti-uterotrophic effect,,28,0
AUC N,uM hr dose-1,28,1
Ratio,Io/Eo,28,0
Blockade,%,28,1
FICI,nM,28,-1
LD,mg kg-1,28,-1
Drug metabolism,mmol/L,28,0
Aggregates,%,28,1
Drug metabolism,uM/L,28,0
Worm reduction,%,28,1
Saldiuretic activity,,28,0
deltaH,J/mol,28,-1
Ae,%,28,1
Relative inhibition,,28,1
MTD,mg Kg-1,28,1
TN,M min-1 M-1,28,1
deltaG,J/mol,28,0
Ataxia,mg kg-1,28,0
Arrhythmias times,,28,-1
Antiviral index,,28,-1
Actvity,mmHg,28,1
LC100,ppm,28,1
LC50,umol/dm3,28,-1
Ka,10^4L/mol,28,-1
Activity,10'3/M/s,28,1
TDI,/min,28,-1
pLADM,,28,-1
pKred,,28,0
AUC/dose,pmol.hr/ml,27,1
CF C20,uM,27,-1
Log Kobs,,27,1
MPO release,ug ml-1,27,1
kinact,M-1 s-1,27,-1
No. of animals responding/animals receiving drug,,27,0
MCT,s,27,1
LD90,,27,-1
Activity,micrometer/day,27,1
DD,,27,0
p nMED,,27,-1
MABP,delta mmHg,27,-1
Analgesic efficacy,%,27,1
Ka,1/Ms,27,1
ED50,mmol/L,27,-1
AUC/dose,ng.hr/ml.mg,27,1
Amount of cross-linked protein,(ug of cross-linked protein) (mg of protein)-1,27,1
LD50,umol/L,27,1
solubility,ppm,27,0
Activity,pM (10e6*cells)-1,27,1
Monoamine level,pg mg-1,27,0
log1/GI50,,27,-1
Kact,nM,27,-1
CLH,microM/min,27,-1
Myoblasts with parasites,%,27,1
Pm,nm/s,27,0
Ka,10^3/M,27,1
Ki,/M/s,27,-1
Weight gain,,27,-1
Tox50,uM,27,-1
PD2,,27,-1
Vd,,27,0
Plasma selectivity,,27,0
Activity,microM/min/mg,27,1
AdoMetDC,%,27,1
TG100,,27,0
Plasma level,nM,27,0
MED,ug,27,-1
Plasma level,mg ml-1,27,1
ID84,M,27,1
EC150,nM,27,-1
Zone of inhibition,uM,27,0
SSAT,%,27,1
Activity,nmol/hr/mL,27,1
MED50,,27,-1
T-C/C,%,27,1
pNF,,27,-1
Kcat,10'3/s,27,1
Weight loss,,27,1
ascrit,,27,0
Cardiotoxicity,,27,0
Differentiated cells,%,27,1
Reversibility ratio,,27,0
FRP C20,uM,27,1
Max delta,%,27,1
ID16,M,27,0
Log 1/EC50,uM,27,-1
CC100,uM,27,-1
VF,%,27,1
2PT,,27,-1
No. of pos rxns,,27,1
Survival after 10 days,,27,1
Change,mmHg,27,0
Kq,10'13L/mol/s,27,-1
pCF,,27,-1
MTD,uM day-1 kg-1,27,1
Delta G,kCal M-1,27,-1
ODC,%,27,1
IC50,uL,27,0
ID (per g of tissue),%,27,1
AUC,ug.hr/kg,27,0
Activity,nM (10e6*cells)-1,27,1
dp/dt,mmHg s-1,27,1
Vmax,M s-1,27,1
Cave,uM,27,-1
T>IC50,hr,27,1
NOEC,uM,27,0
K ass,10e6 l M-1,27,1
Na+ excretion,m equiv kg-1,27,-1
% activity remaining,%,27,1
Parasitaemia,,27,-1
Na,,27,0
Kd,10^-1/s,27,-1
E1/2,,27,-1
Log K2,,27,-1
Delta IC,%,27,1
Average survival days,,27,1
Activity,USP-U/mg,27,1
AUC/dose,pmol.hr/g,27,1
Rate of hydrolysis,nM min-1 mg-1,27,-1
Volume of ascrit fluid,,27,0
Muscarinic agonist index,,27,-1
Specific activity,nM min-1 mg-1,27,-1
Vmax,/s,27,1
Kb,10'-4L/mol,27,-1
Long-term survivors,,27,0
Mitotic index,,27,0
IC50,10^3nM,27,-1
Toxicity Survivors,,27,1
Ratio,10'5/M/s,27,-1
ED25,M,27,1
Saline control,%,27,1
Total turnings,,27,1
pKi1-pKi2,,27,-1
K inact/Ki,M-1 min-1,27,-1
Kinact,10'-3/s,27,-1
Delta BP,%,27,1
KSV,/M,27,-1
V,,26,0
Residual peptide,%,26,1
Kb,10'3/M,26,-1
Bmax,pM (mg of protein)-1,26,-1
Total cells,ml,26,0
K1,min-1,26,-1
Triglycerides,M,26,0
KSV,10'5L/mol,26,-1
K inact/Ki,,26,-1
Activity,uM (g of spores)-1,26,-1
Ratio,/min/microM,26,-1
Antibiotic resistance,,26,0
Km,/s/microM,26,0
Diuretic activity,ml g-1,26,1
Rate constant (k),Ie3 M-1 s-1,26,1
No effect dose,mg kg-1,26,-1
Body temp change,degrees C,26,1
Rate,mg of protein,26,0
Radiolabel recovery,ngequiv/ml,26,0
Sp St,%,26,1
Radioactivity,,26,0
Speed of performance,,26,0
Etopic beats,%,26,1
Activity,pmol/min/mg,26,1
Activity,ug/kg,26,1
Kif,nM,26,-1
RHA,%,26,1
Ventricular rate,beats min-1,26,0
Log beta3,,26,0
R.I,,26,-1
Transcriptional activation,,26,1
Stability,ml/min/g,26,0
Stability,months,26,0
Toxic dose,uM,26,-1
V,%,26,1
Mitotic index,uM,26,-1
Unaltered compound,%,26,1
Potency_Clk3_uM,uM,26,-1
Improvement,,26,0
K aff,,26,-1
Alloste ic enhan er (AE),,26,1
Staining potential,,26,1
Potency,uM kg-1,26,-1
f(Cave),nM,26,-1
Sinus beats,%,26,1
ED50,10'-7 ug/ml,26,-1
Activity,um/min,26,1
Inhibitory activity,nM,26,-1
Potency,IU mg-1,26,1
Alpha-adrenolytic activity,,26,-1
log(1/ED80),,26,-1
EC68,uM,26,-1
Ki,M-1,26,-1
CCCT,uM,26,-1
Alpha-cholesterol,%,26,0
LD100,,26,1
TT,uM,26,-1
Lowest effective concentration,p.p.m.,26,-1
Triglycerides,mg 100ml-1,26,1
MA,%,26,1
Vmax,milli optical density/minute,26,-1
log(PB),,26,0
Liver weight,g,26,0
Fm,%,26,1
Ca2+ antagonism,,26,-1
Pleural fluid,ml,26,0
Plaque accum,,26,-1
ID80,mg kg-1,26,1
MTD,mM kg-1,26,1
Activity,nM/min,26,-1
Serum Mg2+ level,,26,0
tox/total,,26,0
Phorbol displacement,,26,-1
Day of first positve reaction,,26,0
EC125,uM,26,-1
AP50,ng ml-1,26,-1
Drug metabolism,ug/kg,26,0
Activity,mole fraction,26,0
Ka,10'8/M/s,26,1
Fabs,,26,0
MNTD50,ug ml-1,26,-1
HYPO,mg kg-1,26,1
Kd,10'-4/s,26,-1
Kapp,/M,26,-1
DNA relaxation,,26,-1
Papp,10'-6/cm,26,0
Surviving factor,%,26,1
HDL cholesterol,mg 100ml-1,26,1
LDL cholesterol,mg 100ml-1,26,-1
Activity,V/s,26,1
Kaliuretic activity,uM g-1,26,0
PTD50,mg kg-1,26,-1
KH,nM,26,-1
CLH,mL.min/g,26,-1
AUClast,%,26,0
AFC50,mg/ml,26,-1
CLH,microL/min/g,26,-1
Lactone production,,26,1
DC50,mg/L,26,-1
Selectivity,Ratio,26,0
AE activity,%,26,1
DAP,%,26,1
pAI50,,26,-1
MED,g,26,0
PC100,uM,26,-1
LT50,hr,26,-1
Heart rate,delta beats min-1,26,0
cAMP production,pM min-1 well-1,26,-1
Activity,mg/day,26,0
HC10,ug.mL-1,26,0
ID50,10'-7M,26,-1
Optimal dose,ug kg-1,26,1
Antitumor activity,,26,-1
Cp,umol/L,26,0
Residual contractile activity,%,26,1
Change in cholesterol,%,26,1
Natriuretic activity,uM g-1,26,0
Min lytic concentration,uM,26,-1
LD50,mg kg-1 i.p.,26,1
Catalepsy,%,26,1
GT rate,nM min-1 (mg of protein)-1,26,-1
Occupancy,%,26,1
K,10'-7/s,26,1
Activity,g/m,26,1
IC50,10^-5 uM,26,-1
Coronary flow,,26,0
ICD,,26,0
Count/h,,25,1
Tumor number,,25,0
Tumor mass,g,25,0
Activity,10^6 /uL,25,1
ED99,,25,-1
Total tumors,,25,0
K ass,M-1 s-1,25,1
permeability,10^6cm/s,25,1
Activity,10'6PFU/ml,25,1
K aff,M-1,25,-1
% recovery,%,25,0
IC50,/uM,25,-1
Change in WBC,%,25,1
MIC75,uM,25,-1
pKa_A2,,25,0
Cardiotoxicity,nM,25,-1
Calcium release,,25,1
MI0.5,uM,25,-1
CTE,uM,25,-1
CPM,,25,0
Occ50,nM,25,-1
CMC,mmol/L,25,0
MET,umol/min/mg,25,1
GSH,%,25,1
GR50,ppm,25,-1
pAFC50,,25,-1
MDL50,uM,25,-1
PTZ seizure,mg kg-1,25,-1
Papp,nm s-1,25,0
GI99,ug ml-1,25,-1
Peff,10'-5cm/s,25,1
APTT,,25,-1
log1/S0,,25,0
MAC,,25,1
CD90,mg/kg/day,25,0
CD50,mg/kg/day,25,1
Potency,nM kg-1,25,-1
Protected/Tested,,25,0
Delta blood pressure,mM,25,0
QH,ml/min.kg,25,0
Mean graph mid point,,25,-1
k2/Ki,M-1 s-1,25,-1
Mean life extension,,25,1
Log K-1,,25,-1
Rate response,min-1,25,1
solubility,g,25,0
Food intake,g mouse-1 day-1,25,1
Ileal activity,uM,25,-1
Ratio,mg dl-1,25,0
Biological evaluation,,25,0
Biodistribution,ug equiv/g,25,0
Binding selectivity,,25,0
Binding activity,c.p.m.,25,0
Fold selective,,25,1
deltaH,,25,-1
Relative enzyme activity,,25,1
Drug response,%,25,1
Relative maximum,,25,1
Relative tumor growth,,25,0
Increase in dP/dTmax,%,25,1
AUCt,ng.hr/g,25,0
Drug uptake(free),%,25,1
LC90,mgAi/L,25,-1
Inhibition (% of control),%,25,1
E2 response,%,25,1
EC150,,25,-1
HSF,ml,25,0
Kis,mM,25,-1
Injected (dose/g),%,25,1
Excess zone radius,mM,25,1
Velocity,%,25,1
Activation (% of control),%,25,1
Erythema,,25,0
Epileptogenicity,,25,0
Clast,ug ml-1,25,0
Ki,min-1,25,-1
Survival,months,25,1
K,10'-2/hr,25,-1
Activity,/mm2,25,1
T inh,s,25,1
Kcat,10^-3/s,25,1
Kcat,%,25,0
T/C untreated,,25,1
ED20,uM kg-1,25,-1
Min oral dose,mg kg-1,25,1
Activity,log10IU/ml,25,1
Uptake/Binding ratio,,25,0
ED30,ug/kg,25,-1
ED5,mg kg-1,25,1
K,10'7/M/s,25,-1
KSV,10^4/M,25,-1
Activity,10'12/L,24,0
Kd,/uM,24,-1
P50,%,24,1
Ka,10'8/M,24,1
P50,Torr,24,-1
K'a,,24,-1
Rm,%,24,1
ERP,ms,24,0
Frequency,,24,1
Verapamil index,,24,0
kOH,M-1 min-1,24,1
INH,ug,24,0
pED40,,24,-1
Aggregation response,,24,-1
VDR affinity,%,24,1
MLC,umol/ml,24,-1
Log TA98,,24,-1
Delyse,%,24,1
Activity,mol/L.sec,24,1
Selectivity ratio S3/2,,24,-1
Femoral blood flow,,24,0
No. toxicity/tested,,24,0
Transport inhibition,%,24,1
Activity,Miller_unit,24,1
Net accumulation,,24,0
AUC/dose,micromol.hr/L,24,1
Drug uptake,pmol/L,24,0
IC10,mM,24,-1
Activity,pg/L,24,1
ED75,mg kg-1,24,1
Relaxation,,24,0
Edema,ml,24,1
New tumors,,24,1
PTD50,mg,24,-1
MIC=>80,mg/L,24,1
apE,,24,-1
Astrocyte reversal,%,24,1
Change systolic BP,%,24,1
BWL,%,24,1
Time,hr/ha,24,1
Ref I oncostatic index,,24,1
Mean % growth (n = 2) for 1.0 ÂµM probe concentration,%,24,1
Kd,10^-2/s,24,-1
FI,%,24,1
Mean score,,24,0
No. of axonal points,,24,0
Precursor inhibition,%,24,1
Vmax,uM s-1,24,1
T/C 41,,24,1
EC50 iGC,nM,24,-1
Tritium release,%,24,1
pKact,,24,-1
fAUClast,hr.ng/ml,24,1
Enzyme inhibition,%,24,1
Activity,10^4/M/cm,24,1
K,10^6/M/s,24,1
Drug transport,pmol/cm2/hr,24,1
Beats/min,,24,-1
Cmax/dose,uM.kg/mg,24,0
CC90,ug ml-1,24,-1
Schizont size,,24,0
Occ90,nM,24,-1
% turnover,%,24,1
Cardiac depression,%,24,1
Delta C urate / delta C insulin,,24,0
Intrinsic activity,pmol,24,0
Oncostatic index,,24,0
Rel max,,24,1
LD50,M kg-1,24,-1
Lysis diameter,mm,24,1
Reduction in RBS,%,24,1
Cmax,ng g-1,24,1
Vss/F,l,24,0
Activity,EU/ml,24,1
MTC,M,24,0
EC90,mM,24,-1
Cage leaving,,24,0
pC60,uM kg-1,24,1
ED50,10'-8M,24,-1
Decrease in Systolic blood pressure,,24,-1
Substrate activity,c.p.m.,24,0
No. of mice receovered,,24,0
Level,pM min-1,24,1
Substrate specificity,uM min-1mg-1,24,1
Suppression ratio,%,24,1
TC50,M,24,-1
Urinary glucose excretion,,24,0
LD50,ng,24,-1
Mean % growth (n = 2) for 10.0 ÂµM probe concentration,%,24,1
EC37,uM,24,-1
% nucleotide present,%,24,1
Biodistribution ratio,,24,0
Ca2+ current,mV,24,0
Kapp,10^-7/M,24,1
Antiinflammatory Activity,%,24,1
Mean % growth (n = 2) for 100.0 ÂµM probe concentration,%,24,1
Ratio,l s-1 M-1,24,-1
Phototoxicity,,24,-1
LC20,uM,24,-1
No. of sensitive animals,,24,0
AUC,%ID/g/hr,24,1
Kapp,mM,24,1
fVdss,L/Kg,24,0
Cumulative dose,,24,0
Vmax,10'-3uM/min,24,-1
Sweetness potency,,24,1
AUCt/dose,hr.ng/ml.mg,24,1
Mean no. colonies,10e4*cells,24,1
Others,%,24,1
BIC,ug ml-1,24,0
Ratio,/min.mg,24,0
Actvity,ngAoxigen/min/mg of RLM,24,1
deltapKi,,24,-1
MBIC90,ug ml-1,24,-1
AIDH activity,nM min-1,24,-1
Formation of erythema,,24,1
ED,uM,24,-1
Activity,c.p.m.,24,0
Activity,cells ml-1,24,1
Mean % growth (n = 2) for 0.01 ÂµM probe concentration,%,24,1
pA2 - pA10,,24,-1
Number,millions,24,0
NADPH oxidation,nM min-1 (mg of protein)-1,24,-1
MED,mg Kg-1,24,1
Ae,a.u.,24,0
k obs / 1,M-1,24,1
-log(1/MED),,24,-1
Mean % growth (n = 2) for 0.1 ÂµM probe concentration,%,24,1
Tissue distribution,%,24,0
T/C-CQ,,24,1
KSV,10'-4L/mol,24,1
MG-MID,uM,24,-1
Kinact,10'-4/s,24,-1
-log(1/MKC),,24,-1
Activity,/nl,24,-1
Antilipid peroxidation,%,23,1
S.I,,23,-1
Activity,nM min-1 (mg of protein)-1,23,1
Drug uptake,umol,23,0
No. of transfers,,23,1
Gated current,,23,-1
"median survival time, days",,23,1
ED200,mg kg-1,23,1
CL,min/ml/kg,23,-1
SD90,mg kg-1,23,1
Papp,10e-6 cm s-1,23,1
FPT,,23,0
Palpha,,23,-1
ED,,23,-1
CL free,uL/min,23,-1
KA,10'6/M,23,-1
K,/mM/s,23,-1
MCC50,,23,-1
"pEC0.5,diss",,23,-1
Emax,meter/s,23,0
AI,,23,0
Optimal dose,mg kg-1 day-1,23,1
PMA,%,23,1
Organ weight,g,23,1
DHP-I stability,,23,0
MED25,mg kg-1,23,1
PGI,,23,-1
Log,,23,0
EC,mg kg-1,23,-1
ED50,mg kg-1 5day-1,23,1
CLT50,uM,23,-1
Kcat/Km,/min/mM,23,-1
Activity,10^12/L,23,1
pC2A,uM,23,-1
Increase in volume,ml min-1,23,1
Tumor volume,,23,0
ED50 Ratio,,23,-1
AbsAC0.54_uM,uM,23,-1
ED90,uM kg-1,23,1
Drug metabolism,%ID,23,0
HSF release,ug ml-1,23,1
Acute toxicity,%,23,1
LD50,mg/kg/day,23,-1
Ratio Ki,uM,23,0
FBP,,23,0
ED80,uM/g,23,-1
Activity,ugequiv,23,1
Vmax,uM min-1 (mg of protein)-1,23,1
Imax,uM,23,-1
EC40,nM,23,-1
Log EC50,nM,23,-1
Dose interval,hr,23,1
Blood level,uM ml-1,23,0
Ratio,/min/M,23,-1
Fapp,%,23,1
ED90,mg kg-1 5day-1,23,1
Change of body temperature,degrees C,23,0
Activity,uM/g,23,0
TOX,,23,0
Hydrogen peroxide degradation,,23,-1
Dopamine release,%,23,1
LC50,ug/g,23,-1
Kinact,10^-4/s,23,-1
AUCmet/AUCp,%,23,1
Distribution,,23,0
AUC,ug hr uM-1,23,0
Mean hemagglutination titers,,23,1
IC50,10^-7mol/L,23,-1
Change MAP,%,23,1
LC50,umol/g,23,-1
Ka,10'9/M,23,1
kOH-,M-1 s-1,23,-1
RD500,,23,-1
MIC>99,,23,-1
ka,/hr,23,1
MIC>98,,23,-1
Cell survived,day,23,1
Q50,uM,23,-1
INH,10'4L/mol/s,23,-1
MTD50,,23,-1
Log10ED50,,23,-1
Insulin release,,23,0
Influx Ki,uM,23,-1
2x PT,uM,23,1
Intinsic activity,,23,0
Delta RM,,23,0
No. of crosses,,23,1
Delta HR,,23,-1
Ki,Ratio,23,0
EC60,uM,23,-1
Caspase induction,,23,1
Activity,nmol.hr/g,23,1
Ki,10'5/M/min,23,-1
MIC,ug disk-1,23,-1
Intrinsic_solubility,,23,0
Plasma-E2 concentration,pg ml-1,23,1
Plasma concentration,,23,0
AZT formation,%,23,1
KSV,10'5/M,23,-1
AC10,uM,23,-1
"Emax,diss",%,23,1
E/Emax,%,22,1
LD50,uM/L,22,-1
bwc,g,22,1
LD90,ug/kg,22,1
c30,uM,22,0
c90,uM,22,0
Mean vesicle score,,22,1
Vmax/Km,/min,22,1
LC50,g/m2,22,-1
Increase in plasma amylase,IU ml-1,22,1
LED100,mg kg-1,22,1
EC10,uM,22,-1
Remaining,,22,-1
FA,,22,0
solubility,mg/g,22,0
Incidence,N,22,0
BEI,%,22,1
deltaS,cal/mol.K,22,-1
Life span,,22,1
Recovery time,mg kg-1,22,0
Log 1/D125 (L1210) (mM kg-1),,22,-1
BW loss,%,22,1
HIA,%,22,1
Absorption,,22,0
fEC50,mM,22,-1
Log 1/conc (mM min-1 L-1),,22,-1
Log APA,,22,-1
Excretion,ml,22,1
Solubility,%,22,1
Accumulation counts,,22,1
Rate of decomposition,(nM of drug) min-1 ml-1,22,-1
Bmax,,22,1
Kinact,10'3/s,22,1
k0,M-1,22,1
EC50,g/m2,22,0
ED50,uM/L,22,-1
RBA,g,22,0
Log potency,,22,-1
Median T/C,day,22,0
kn,M-1 min-1,22,1
Intestinal toxicity,,22,0
Median T/C,,22,0
Ep,V,22,0
kon,10e3* M-1 s-1,22,1
permeability,uL/hr/cm2,22,1
IG50,,22,-1
Ki,M-1 s-1,22,-1
log(1/LC50),,22,-1
Platelet aggregation,uM,22,-1
Ke ratio,,22,-1
Decrease in QA interval,ms,22,-1
GI20,uM,22,-1
AUC,AU.min,22,1
Physical dependence capacity,,22,0
Cmax/dose,kg/L,22,0
Activity,M g-1,22,1
Permeability coefficient,cm s-1,22,0
Max intensity,turns min-1,22,1
GI80,uM,22,-1
logSI,,22,-1
VERP,,22,-1
ECmax,ug ml-1,22,1
Mean activity counts,,22,1
AI50,,22,-1
DNA,ug,22,0
PR,,22,1
K,10^-4/min,22,-1
Thymidine uptake,c.p.m. (mg of protein)-1,22,0
DC50,pM,22,-1
PDE inhibition,,22,-1
T decrease,degrees C,22,-1
IC2x,uM,22,-1
Optimal dose,,22,1
Cytocidal activity,%,22,1
Observed log APA,,22,-1
T>MIC,%,22,1
No. resp animals / Total,/ 7,22,1
CT10,uM hr-1,22,-1
Gastric toxicity,,22,0
pEC200,,22,-1
CTL activity,M,22,0
CV dose,mg kg-1,22,0
pI50,M l-1,22,-1
Minimal bacteriostatic concentration,,22,-1
TC50,umol/L,22,-1
Max IOP reduction,mmHg,22,1
Activity,kC/sec,22,1
Cp(f),ng/ml,22,0
Activity,10'3No_unit,22,0
Cell number,%,22,1
No effect dose,mg,22,1
Ulcer score,,22,0
Covalent binding,,22,-1
IC50,milliequivalent,22,-1
TFS,%,22,1
MITC95,nM,22,-1
IC50,10^-8mol/L,22,-1
Mutagenicity,%,22,1
TGI correlation coefficient,,22,0
Toxicity,ug ml-1,22,0
K,uM-1,22,-1
ED90,nM,22,-1
K,10^-6/s,22,-1
ED75,uM kg-1,22,-1
Ka,/M,22,1
SI,%,22,1
Amount,ml,22,0
X1(50),,22,-1
SD50,mg kg-1 day-1,22,-1
Vrel,,22,0
Mean time to seizure,s,22,1
Anesthesia duration,min,22,1
Thrombus weight,mg,21,1
BUN,mg 100ml-1,21,0
Paw weight increase,%,21,1
Cmax/SS,uM,21,0
Deaths/total,,21,1
EC99,,21,-1
Testes weight,mg,21,1
CT50,ug ml-1,21,-1
logCC50,,21,-1
logC50,,21,-1
Picoequivalents of amine/10e6 cells,,21,0
Serum lipoprotein cholesterol,,21,0
CV,%,21,0
Log 1/D125 (mM kg-1),,21,-1
MIC,%,21,0
Supression,,21,1
Decrease in MABP,mmHg,21,-1
Vc,l,21,0
AUC,hr,21,1
ED25,ug,21,1
BT,,21,0
Creatinine,mg 100ml-1,21,0
Kapp,10'4/M,21,1
CI,uM,21,-1
Metabolic stability,mg ml-1,21,0
Platelet aggregation,%,21,1
-Log IC50,uM,21,-1
SI,ug ml-1,21,0
Pmax,%,21,1
CD90,mg kg-1,21,1
Activity,umol/ml,21,1
Reflex,mg kg-1,21,0
No. of escape failures,,21,1
Weight,mg dl-1,21,0
Postjunctional agonist potency,,21,-1
Retention ratio,,21,0
Postjunctional antagonist potency,,21,-1
Potency index,,21,0
LogIC50,,21,-1
LED,,21,-1
pKb,nM,21,-1
Prejunctional agonist potency,,21,-1
Cell cycle,,21,0
Prejunctional antagonist potency,,21,-1
koff,,21,-1
No. effective,,21,1
d tox,,21,0
Protected/tested,,21,0
Hill slope,,21,0
Activity,10'5/ml,21,1
C20 FRP,uM,21,-1
Treated,,21,0
Relapses,,21,1
Incidence of RBC decrease,,21,0
INH,Miller_unit,21,1
Delta pEC50,,21,-1
Animal death,%,21,1
Log delta (1/T2),,21,0
Na,u equiv kg-1,21,1
Ka,10^4/M/s,21,1
ED50,mg/ml,21,-1
Mean number of parasites,,21,0
Change HDL -C,%,21,1
Log TA100,,21,1
kOH,M-1 s-1,21,-1
Log MBC,,21,-1
MTD,mg,21,1
RTW,%,21,1
Ka,10'8/M/min,21,1
TG,%,21,1
RTW,,21,0
NEA,,21,0
Distribution,pM mg-1,21,0
Range of death,day,21,1
Rate,pM,21,0
Activity,turns hr-1,21,1
AUC,ugequiv/l.hr,21,1
Log K3,,21,0
TGD,day,21,1
Log K' IAM,,21,0
Change in entry latency,s,21,0
Bmax,nM,21,0
Final average tumor weight,mg,21,1
Ka,10'4L/mol,21,1
HTD,mg kg-1,21,1
Average,%,21,1
HD100,uM,21,-1
Solubility,g,21,0
MPE50,,21,-1
Initial average tumor weight,mg,21,0
ED99,mg Kg-1,21,1
Toxicity,mg kg-1,21,1
Ataxia,,21,0
Activity,10'6dpm,21,-1
Apoptosis,,21,-1
IC100,,21,-1
Edema inhibition,%,21,1
Drug degradation,nmol/min,21,-1
Mean survival days,,21,1
Activity,um2,21,1
Log 1/ID50,,21,-1
Vmax,uM min-1,21,1
Activity,um3/um2,21,1
pC25,,21,-1
MED,mg/kg/day,21,1
MED,mg kg-1 day-1,21,1
Symptom initiation,%,21,1
DIZ,mm3,21,1
Kcat/Km,10'5/s/M,21,1
POT,nM,21,-1
V0,/s,21,1
Absolute turn angular/3 min,,21,1
Optimal dose,uM kg-1,21,1
Kcat,10'-3/s,21,1
Eggs,%,21,1
pC60,,21,-1
Metabolism,pM min-1,21,-1
ID/g tissue,%,21,1
Total turns,,21,1
-Log KA,,21,-1
AI recovery time,min,21,1
ED delta5,nM kg-1,21,-1
ID/brain,%,21,1
ED delta20,nM kg-1,21,-1
LH level,ng ml-1,21,1
K,/min/microM,21,-1
MST increase,,21,1
Activity,/cm2,21,0
Survivor increase,,21,1
Gain,%,21,1
CL,nmol/min/mg,21,-1
Kd,10^2 uM,21,-1
K,10'-7M,21,-1
ICmax,uM,21,-1
Activity,10'4Meq,21,0
IC99,ug.mL-1,21,-1
K calc,M-1 s-1,21,-1
CT10,mM hr,21,-1
GII50,,21,-1
K,u equiv kg-1,21,1
Total lysis,uM,21,0
Passivity,mg kg-1,21,0
Modification of hemoglobin,%,21,1
Kp,10'-6 cm/s,20,0
Mean HR,beats min-1,20,1
Mean LAF,ml min-1,20,0
Mean RBF,ml min-1,20,1
Complex formation,,20,0
Complex_formation,deltaA.10^4nmol-1,20,0
MTD,uM/g,20,0
Min effective dose,,20,-1
Concentration ratio,,20,0
Mortality inhibition,%,20,1
Change non HDL-C,%,20,1
MMC,uM,20,-1
Control,ug kg-1,20,0
Change in cAMP,%,20,1
MLD,umol,20,-1
NSR,,20,0
MIC=>90,,20,-1
Hemodynamic change,%,20,1
Cardiac frequency,beats min-1,20,1
No. of mice effected/No. of treated,,20,1
Ca2+ transport S/M,,20,-1
CTF,%,20,1
CS50,uM,20,-1
CQ,uM,20,-1
I/C,,20,-1
CLH,ug/min/mg,20,-1
CLH,uL/ml.millig,20,-1
CLH,ml/mg/kg,20,1
MDL50,,20,-1
PI hydrolysis,%,20,1
CL,uL/ml.millig,20,-1
Papp,10'-8cm/s,20,0
DP,%,20,1
MBC90,,20,-1
Dead/total,,20,1
CL,/uM/min,20,-1
Photo-cross-linking of DNA,,20,0
CI,l hr-1 kg-1,20,0
MAPD90,ms,20,1
I50,molar excess,20,-1
Degree of resistance,,20,0
Pw,,20,0
Delta latency time,s,20,0
QTc interval,ms,20,1
RC50,ug ml-1,20,-1
Log Y,,20,0
RCI,,20,0
Diameter,nm,20,1
Brain concentration,ng g-1,20,0
Distribution,fM mg-1,20,0
Rate of formation,pM min-1 (mg of protein)-1,20,-1
Log K delta,,20,0
Log II50,,20,-1
Ratio,1/sM,20,-1
Log AC50,uM,20,-1
Recovered radioactivity,%,20,1
Drug metabolism,% ID/g,20,1
Lipid peroxidation,%,20,1
BHIA50,,20,-1
Average onset,min,20,0
Average No. of metastasis,%,20,1
Average,,20,-1
Removal,%,20,1
Residual binding,%,20,1
Respiratory frequency,r.p.m.,20,1
LD50,p.p.m.,20,-1
Drug uptake,pmol/g,20,0
S50,mM,20,-1
Analgesic effect,%,20,1
Selectivity,A1/A2A,20,0
Selectivity,nM,20,0
Actual duraction,min,20,0
Serum HDL-cholesterol,%,20,1
Serum LDL-cholesterol,%,20,1
Serum cholesterol,%,20,1
Kr,,20,1
Serum concentration,hr,20,0
Activity,umolequiv/L,20,1
Km,ug ml-1,20,0
Activity,pmol/mg/hr,20,1
Activity,pg ml-1,20,1
Stabilty,microL/min/mg,20,1
Activity,nmol/ml.min,20,1
Ki,10'4/M/min,20,-1
Ki,/M/min,20,-1
Activity,ng/hr,20,1
Activity,nM ml-1,20,1
Activity,nM mg-1,20,0
Activity,mmol/ml,20,1
ED (1mV),ug kg-1,20,1
Survivors alive/total,,20,0
Survivors at day 8,%,20,1
ED10,mM,20,-1
Kcat/Km,/s/mM,20,-1
T max,nM,20,0
ED15,mg kg-1,20,1
ED15,ug,20,1
Kb,ug kg-1,20,1
TBPS IC50,uM,20,-1
Kb,10'4L/mol,20,-1
ED25,mM,20,-1
Kapp,10'5/M,20,1
ED3,mg kg-1,20,1
Activity,g/m2,20,1
Activity,day of onset,20,0
Ka,10'7/M/min,20,1
Ka,/hr,20,1
Activity,K/uL,20,1
K50,M,20,-1
Time constant T1,ms,20,0
Time constant T2,ms,20,0
Total counts,,20,0
Toxic level,mg kg-1,20,1
K,10^4/M,20,-1
Tumor weight,mg,20,1
Turns/first hour,,20,1
K,10'6L/mol,20,-1
Effective molarity,M l-1,20,-1
Urinary Na+,m equiv,20,0
Urine volume,ml kg-1,20,1
Activity,10'-2/hr,20,-1
Activity,/s/microM,20,-1
Vc,ml,20,0
Ip,,20,0
Intrinsic efficacy,,20,0
Epidermal thickness,,20,1
Vmax,cm-1,20,0
Vmax,nM/min,20,1
Vmax,pmol/hr,20,1
Vmax(app),pmol/min,20,-1
Water consumption,ml,20,1
AUCt/dose,ng/mL.hr,20,1
FPG correction,%,20,1
Increased life span,%,20,1
dTagg,K,20,0
deltaG,,20,-1
Flow rate,ml min-1 100g-1,20,1
increase in RFU,%,20,1
k2',min-1,20,-1
k2'',min-1,20,-1
AUC,mg hr-1 kg-1,20,1
ID99,ug ml-1,20,1
APD90,ms,20,-1
AFC50,ug ml-1,20,-1
HVA level,%,20,1
-Log EC20,,20,-1
IC50,ug/g,20,-1
pLADm,,20,-1
IC50,kJ m**-2,20,0
2DG uptake,uM,20,0
p[BH+50],,20,-1
IC50,10^-4microM,20,-1
-ln K,,20,-1
-TdeltaS,,20,-1
HD50,,20,-1
Highest active dose,mg kg-1,20,1
Level,ng ml-1,19,1
Average seizure score,,19,0
Horizontal activity,Counts min-1,19,1
Cmax/dose,nM/mg/kg,19,0
Average inhibition,,19,1
Relative protection,%,19,1
Concentration,ug (g of wet tissue)-1,19,0
Relative stability,,19,0
ActiveConcentrationI,uM,19,-1
Na+ ion content,,19,0
Approx. lethal dose,,19,1
Corr,%,19,1
pLADy,,19,-1
pKinc,,19,0
Cmax_[GH],ng ml-1,19,1
LED100,,19,-1
Drug uptake,microM,19,0
Antagonist effect,,19,0
Analgesic efficacy,,19,0
[EOP']infinity/[EOH]infinity,,19,0
IC12,nM,19,-1
Change in weight,g,19,1
LD50,10'-3M,19,-1
Change in systolic BP,%,19,1
TVI,%,19,1
Ki high,nM,19,-1
Cation influx,,19,0
Vdss,L/hr/kg,19,0
Catalase rate,uM of O2 min-1,19,1
Cp(T),uM,19,0
FOC,,19,-1
IC50/IC50,,19,-1
MIC,ug/disk,19,-1
MNTC,uM,19,-1
Drugabsorption,,19,0
No. of metastases,,19,1
EC50,mol/g,19,-1
ED50,nM min-1 kg-1,19,-1
LC99.9,mg/L,19,-1
MTD,ug/kg,19,1
Inhibition activity,uM,19,-1
Viability,,19,0
Selectivity factor,,19,0
CT2,uM,19,-1
CT1,,19,0
HI,%,19,1
Kr,uM,19,-1
Kinact,10^5nM,19,-1
Kq,10^12/M/s,19,-1
Number,%,19,1
Skin uptake,uM,19,0
Kinetic,,19,0
ERP1,,19,-1
GTP-gammaS index,,19,1
Smax,ul min-1 kg-1,19,1
Activity,g/cm2,19,0
ERP3,,19,-1
Occ50,mg kg-1,19,-1
ClT,ml min-1,19,0
TT,,19,-1
K+/Na+ ratio,,19,0
Max effect,,19,1
Activity,N,19,1
Treated cells,%,19,1
Urine osmolality,mOsmol kg-1,19,1
Kapp,10'7/M,19,-1
CMC,ug ml-1,19,0
Cytotoxic endpoint,uM,19,-1
PFU,,19,-1
Tumor uptake,uM,19,0
ED25,microg/cm3,19,-1
PG,%,19,1
PKC,uM,19,-1
PT,,19,-1
Decrease,degrees C,19,-1
Decrease in RFU,%,19,1
Activity,log10ng/ml,19,-1
CFU,10^4/ml,19,-1
AUC,mg/dl,19,1
CFC20,uM,19,-1
Activity,mU/mg,19,1
AUC,mmHg hr-1,19,1
permeability,10'-8cm/s,19,1
permeability,10'-6/cm,19,0
log Pe,10^-3cm/min,19,0
log KOA,,19,0
kon,M-1-s-1,19,1
Tested/Control,,19,0
ILS30,mg kg-1,19,1
Prolongation,%,19,1
ILSmax,mg kg-1,19,1
ke,hr-1,19,0
permeability,10'-5cm/s,19,1
Activity,millimeter/min,19,1
Max aggregation response,,19,1
ED0,gAi/ha,19,1
Activity,min-1,19,1
Activity,ml min-1,19,1
C100,uM,19,-1
Combination_index,,19,0
Max hemorrhage,,19,1
Survivors at day 15,%,19,1
Disease control,,19,0
Change in body weight,%,19,1
Log ED50,mM kg-1,19,-1
Ratio,10'6/M/s,19,1
Max,(fM of GTP-gammaS bound) (mg of protein)-1,19,1
increase in mean survival time,,19,1
Log CDQR,,19,-1
1/kobsd-ka,min,19,-1
Log CDGH,,19,0
Kdiss,,19,-1
Binding competition,mean counts,19,0
Improvement,%,19,1
fCmax/MIC,,19,-1
Basal,(fM of GTP-gammaS bound) (mg of protein)-1,19,1
Incidence,%,19,1
K+ Ion content,,19,0
MID,ug,19,-1
deltaS,J/mol.K,19,0
ED100,microg/cm3,18,1
KD app,uM,18,-1
Activity,HAU/ml,18,1
Metabolic turnover,%,18,1
ED50,microg/cm3,18,-1
ERP observations,,18,1
TT,ug ml-1,18,1
ED50,2mg kg-1,18,1
Activity,U (mg of protein)-1,18,1
TGI ratio,uM,18,0
Ka,10'5L/mol,18,1
Activity,delta mV,18,1
Activity,delta mmHg,18,1
TD90,ug ml-1,18,1
Activity,fold,18,1
Uncut DNA,%,18,1
Med tumor weight,mg,18,1
TCID50,/ml,18,-1
Histamine level,,18,0
Efficacy,mg kg-1,18,1
Urinary excretion,ml kg-1,18,1
ED25,uM,18,-1
Efficacy,pM,18,-1
Uterine activity,mg,18,0
Activity,mg%,18,1
V0,RFU/s,18,1
ED10,gAi/ha,18,1
Activity,/millimeter,18,1
Survival treated,,18,0
Kd,l M-1,18,-1
Kdiss,10^5/M/s,18,1
Iron excretion,mg kg-1,18,1
Iron excretion,%,18,1
Activity,ng/uL,18,0
Stomach,%,18,1
Activity,nm/s,18,1
EC80,%,18,1
Intrinsic activity,nM,18,-1
Vd/F,L,18,0
Stability,weeks,18,0
Mean survival in days,,18,1
Stability,pmol/mg/hr,18,-1
Intact,%,18,1
Insulin secretion,,18,0
Activity,pM of drug (10e6*cells)-1,18,1
EC50,uM kg-1,18,-1
Stability,nmol/mg/min,18,-1
Stability,ml/min.Kg,18,1
Activity,pixel,18,0
Stability,cpm,18,0
Kinact,/hr,18,-1
Ex-vivo screening,,18,0
Initial_rate,deltaA.10^4nmol-1.min-1,18,1
Initial rate ratio,,18,0
Vmax,(nM of H202) min-1 (ug of protein)-1,18,1
Kiuc,,18,-1
EC5,ug ml-1,18,-1
Slow binding,,18,-1
Vmax,10^-8mol/s,18,0
Kn,M-1 min-1,18,1
Acc. counts,,18,0
Vmax,V s-1,18,-1
Kobs,/hr,18,-1
Kon,s-1,18,1
Kp,s-1,18,1
permeability,mN/meter,18,0
Vmax,mM s-1,18,1
EC20,,18,-1
Extremes treated,,18,0
Serum corticosterone,ug ml-1,18,1
Activity B,uM kg-1,18,-1
EC100,,18,-1
FBF,,18,1
Selective toxicity,,18,0
LC50 ratio,uM,18,-1
Affinity constant,,18,-1
Duration of block,min,18,1
Aggregation,mg kg-1,18,0
Hemolytic activity,%,18,1
FIC50,nM,18,-1
LD10,mg m**-2,18,1
LD100,%,18,1
LD50,10'-5M,18,-1
LD50,J/cm2,18,1
SD90,mg/kg/day,18,1
permeability,ng/cm2/min,18,1
Drug uptake,pmol/min/mg,18,0
[GSH],nM (10e6*cells)-1,18,-1
Anticonvulsant dose,mg kg-1,18,1
Response,mmHg,18,1
Antiemetic activity,%,18,1
Antimalarial activity,%,18,1
AUClast,ng.hr/g,18,0
Mean no. of lung colonies,,18,1
dP/dt,nM,18,-1
Relative molar potency,,18,-1
Mean day appearance of lesions,,18,1
deltaH,cal/mol,18,-1
Drug metabolism,uM/min.mg,18,-1
Relative ODN uptake,,18,0
Drug metabolism,pmol/min/ug,18,1
Drug metabolism,ng,18,0
Inactivation,,18,0
Locomotor activity,Counts,18,1
Drug level,ug ml-1,18,0
fAUC/dose,uM.min,18,0
Log 1/LD50 (mM kg-1),,18,-1
Binding,pM 30min-1 (mg of DNA)-1,18,-1
fCmin,mg/L,18,1
Binding activity,,18,-1
Ratio Cmax,,18,1
Fold_activity,,18,1
Imbalance,,18,-1
fIC50,uM,18,-1
Ratio,[Na+]/[K+],18,0
AUC metabolite/AUC radiolabel,%,18,1
Blockade,,18,-1
Ratio,Ratio,18,0
Rate of oxidation,,18,0
Bmax,pM mg-1,18,1
Dmax,,18,1
AUC,ugequiv.hr/g,18,1
AUC,ug/hr.kg,18,0
Rate of decrease,%,18,1
Rate,nM,18,-1
AUC,ug.hr/mL/mg/kg,18,0
Dissociation ratio,,18,-1
Log LD50,,18,-1
k1,s-1,18,-1
Log Pc18,,18,0
Brain level,pM g-1,18,0
Differential affinity,,18,0
INH,ppm,18,-1
C24,ug ml-1,18,0
Q1/2,mM,18,-1
G2/M,%,18,1
Delta Vmax,,18,1
C50,umol/L,18,-1
Prodrug reduction,%,18,1
krel,,18,0
CC,ug ml-1,18,-1
CC50,10^2 uM,18,-1
AUC,nM hr ml,18,1
CE logK',,18,0
CE37,uM,18,-1
AUC,min.g.nM/mg,18,0
GHmax,ng ml-1,18,1
Polyamine pools,%,18,1
IE,%,18,0
Decrease in MAP,%,18,1
Phagocytosis,,18,0
MBC50,mg/ml,18,-1
GI50 ratio,uM,18,-1
Colony formation,%,18,1
MBC90,mg/ml,18,-1
max Delta Vmax,,18,1
Partial remission,%,18,1
GID75,mg m**-2,18,1
MBC99.99,ug ml-1,18,-1
DT,hr,18,-1
ALD50,g/Kg,18,1
CL,nl/min,18,1
GOF,,18,0
Max lowering,%,18,1
GR50,g/ha,18,1
CLH(app),uL/min/mL,18,-1
MED,ug kg-1,18,1
P,M l-1,18,0
MTS,day,18,1
GSH level (mg),%,18,1
Optimal dose,mg uM kg-1,18,1
Onset of action,min,18,0
Cured/Infected,,18,0
MFED,mg kg-1,18,-1
CT3,,18,0
CT5,uM,18,-1
pED50,ug,18,1
MI20,nmol/L,18,-1
permeability,um/s,18,0
IC85,uM,18,-1
Glucose correction,%,18,1
Cpss,ng/ml,18,1
pK1a,,18,-1
No. of lung metastasis,,18,0
pK1b,,18,-1
pK1d,,18,-1
A/B ratio,,18,0
Cp,ug/L,18,0
Cave,nM,18,-1
No. of counts,,18,0
Cell no,,18,0
Cell size,,18,0
Net dry weight,mg,18,-1
Nature,,18,0
Macrophage cytotoxicity,%,18,1
pMED,,18,-1
Na+ excretion,ml kg-1,18,1
Conversion dose,mg kg-1,18,1
2*APTT,uM,18,1
Controls,%,18,1
1/IC50,/uM,18,-1
Control response,%,18,1
IC50,10'-5g/L,18,-1
Change in conflict,%,18,1
,,18,0
Mydriasis,,18,1
Muscarinic receptor affinity,,18,-1
Mortality,day of death,18,1
MRP,,18,0
Chemotactic index,,18,1
Cholesterol,mM l-1,18,0
Min effective dose,mg kg-1,18,-1
permeability,10^-5 cm/min,18,1
Min antiviral concentration,ug ml-1,18,-1
K app,1/min,18,1
Activity,10'6CFU/g,18,-1
K eff,M-1 min-1,18,1
Activity,10^-9No_unit,18,0
Transport rate,M hr-1,18,1
Time constant,s,18,0
Triglycerides,mM l-1,18,0
K,M,18,-1
Thymolysis,,18,0
Tt,k,18,0
K,10'2/min,17,-1
Pigment induction,,17,1
Mean response/min,,17,0
Kinact,10'6nM,17,-1
MLC50,uM,17,-1
Gastric emptying,%,17,1
Vmax,nmol/sec,17,1
Cp,% ID/g,17,1
Decrease in Bmax,,17,-1
Toxicity,hr,17,0
ED50,10'-12 ug/ml,17,-1
Deaths/total,%,17,0
Activity remaining,%,17,1
30 days survivors,,17,0
NR,,17,0
AQ,,17,0
Permeability,nM hr-1 cm**-2,17,0
LC50,mg kg-1,17,-1
Vmax / Kmax100,,17,1
GABA current,%,17,1
Hypnosis duration,min,17,1
EA,,17,-1
APD95,ms,17,0
GI50/EC50,,17,-1
Synergy,nM,17,-1
Mean IC70,ug ml-1,17,-1
ID50,ug min-1 kg-1,17,1
Max T/C,%,17,1
Day 9-RTV,%,17,1
AUMC,hr.hr.ng/ml,17,0
Day 22-T/C,%,17,1
Time,microsec,17,0
No. of animals protected / no animals tested,,17,1
Synergy EC50,nM,17,-1
Uptake,nM g-1,17,-1
Activity,nM/min/mg,17,1
Rats blocked,%,17,1
KDs,uM,17,-1
KD50,ug/g,17,0
Agonism,IU mg-1,17,1
Ct,ng/mg,17,0
K,10^3/M/s,17,1
Kcat/Km,10'8/M/s,17,-1
Ka,/s/microM,17,-1
MHC,,17,0
Parasites,%,17,1
influx_CL,ml/min.Kg,17,1
kHOX,,17,0
Drug uptake(free),ug ml-1,17,0
GDP ED50,,17,-1
Ratio,uL/min,17,-1
Worm movement inhibition,%,17,1
ToxD/Surv,,17,1
Activity,pA,17,-1
K,10^6/M,17,1
DNA cleavage activity,,17,-1
DNA,%,17,1
Thromboxane B2 (TxB2),pg 0.1ml-1 500x10^3,17,-1
Drug uptake,umol/g,17,0
TC lowering,%,17,1
Efficiency,,17,0
Concentration,g dl-1,17,-1
ID50,mg/ml,17,-1
EC50,ug/kg,17,-1
"Log Pe,max",,17,0
EC50,umol/Kg,17,-1
ED50,uL,17,0
Time,%,17,1
FS-SIF,mg ml-1,17,0
GR20,ppm,17,1
Activity,mg/cm3,17,1
K,10'9/M/s,17,1
MDR,,17,1
Clearance,ml hr-1,17,0
Log Po,,17,0
PD50,ug ml-1,17,-1
Cr release,%,17,1
MEC,ug/g,17,1
LD99,,17,-1
CLH,ug/ml/min,17,-1
Toxicity day survivors,,17,1
Fraction of accumulated 86Rb remaining.,,17,-1
Antiovulatory activity,,17,0
LDL oxidation,%,17,1
Sterilized,%,17,1
Delta F75,M l-1,17,1
Antipapilloma activity,%,17,1
Drug uptake,mg/ml,17,1
Ki,10'6/M/min,17,-1
CL_renal,mL/min,17,1
Remains,%,17,1
P2 uptake,,17,-1
Increase in dP/dt max,%,17,1
KR,uM,17,-1
ED50,10'-8 ug/ml,17,-1
LTS,%,17,1
Effective concentration,uM,17,-1
Ccellular,ug of B (g of cells)-1,17,1
Intrinsic activity,uM,17,-1
GSH level,,17,0
C,nM g-1,17,0
Mean log GI50,M,17,-1
Cytotoxicity,mM l-1,17,-1
ED50,mg/kg.day,17,1
TFS,,17,0
Optimal dose,mg kg-1 injection-1,17,1
Relative lipophilicity,,17,0
Drug responding,%,17,1
Kiuc,mM,17,-1
kOX,,17,1
Km,/s,17,-1
ED90,mg kg-1 day-1,17,1
MABP,%,17,1
pCD,,17,-1
Emax,mg kg-1,17,1
Tlag,min,17,0
Relative daunomycin accumulation,,17,0
Time constant T3,ms,17,0
Activity,ug/dl,17,1
KmH,uM,17,-1
CMC,,17,0
Swimming activity,,17,0
TC25,,17,-1
IC10,ug ml-1,17,-1
Activity,g/Kg,17,1
CPE50,uM,17,-1
Hydrophobicity index,,17,0
KA,10'6L/mol,17,-1
Dose,nM,17,-1
Liver cholesterol,mg g-1,17,0
Cmax/dose,ug/mL/mg/kg,17,1
Cp max,ng ml-1,17,1
No. of deaths/mice injected,,17,0
deltapIC50,,17,-1
Load,%,17,1
G-protein activation,,17,1
Drug metabolism,mg kg-1,17,0
ED50,(mg/kg)/day,17,-1
efflux_CL,ml/min.Kg,17,1
permeability,10^-5 cm/s,17,0
Survival,min,17,1
AUC,ug hr-1 g-1,17,0
Activity,(fM of O6-MeG removed) (mg of protein)-1,17,-1
EDmin,,16,-1
LC90,,16,-1
LC95,uL/L,16,-1
Spreading,%,16,1
Cholesterol Concentration,mg dl-1,16,-1
KiAH,nM,16,-1
Amount delivered,pg ml-1,16,0
Insulin release,ng/islet/h,16,1
Amount excreted,,16,0
Stability,pmol/min,16,-1
CTS increase,,16,1
Cmax,Î¼g/mL,16,0
Amount of Acotine used,,16,0
Hematotoxicity,%,16,1
SC200,,16,-1
Analgesic,%,16,1
[Ca2+] variation,,16,0
Inflamed,mmHg,16,0
Infarct,%,16,1
Rs,uM min-1 kg-1,16,-1
EC50rel,uM,16,-1
Retention_time,,16,0
Tumor growth,10e3mm,16,1
Ca2+ reduction,,16,-1
MIC,ng,16,-1
Response,min,16,0
Resistance reversal,,16,-1
AB50,,16,-1
Carbohydrate,ug,16,0
LED,mM,16,-1
Apoptosis index,,16,0
Increase in dP/dtmax,%,16,1
Apoptotic activity,,16,0
Remaining ratio,%,16,1
Remaining rate,%,16,1
Unbound,%,16,1
Relative value,,16,0
HF ratio,,16,-1
Stretches,,16,0
A50,nmol,16,-1
Ionization,%,16,0
Activity,ng (g of tissue)-1,16,0
Relative intrinsic activity,,16,1
Average score,,16,0
Activity,nanoseconds,16,0
Relative esterase susceptibility,,16,-1
Suppressive dose,mg kg-1,16,0
ED90,mg Kg-1,16,1
Drug metabolism,umol/ml,16,0
Incidence_count,,16,0
B,ug (g of abscess)-1,16,1
Tp,min,16,1
Fluorescence,nm,16,0
Drug metabolism,uM/Gy,16,0
Maximal relaxation,%,16,1
ED90,(mg/kg)/day,16,-1
Drug metabolism,uL/min,16,1
Fluorescence intensity,a.u.,16,0
Activity,equiv/uM,16,1
EC90/MIC,,16,-1
Inactivation time,min,16,0
Reduction in virus titer,%,16,1
pK3,,16,-1
IC50/[E],,16,-1
BUN,mg dl-1,16,1
Drug metabolism,%/min/pmol,16,1
fAUC,,16,0
K,10'5L/mol,16,-1
A0,,16,0
EC95,mg/L,16,1
A,ug (g of abscess)-1,16,1
Ke,/M,16,0
Ulcerative index,,16,1
Effect on polyamine pools,,16,0
Concentration,mg kg-1,16,0
Binding inhibition,%,16,1
ED80,,16,-1
Cave,ng/ml,16,0
Dose/ml,%,16,1
HT50,%,16,1
Cmax,min,16,0
Survival median,day,16,1
Toxic level,,16,0
Kd,10^3nM,16,-1
Activity,mmHg/min,16,1
IZ,U,16,1
k,se-1,16,-1
Rate of hydrolysis,,16,0
No. of canine,,16,0
Cell kill,%,16,1
Activity,FU/min,16,1
Log KH,,16,0
No. deaths/treated,,16,0
Log KL,,16,0
Rate constant,k hr-1,16,0
Cell protein in untreated control,%,16,1
Radioactive constituents,%,16,1
Toxic dose,,16,-1
k',min-1,16,-1
Survivors / total,,16,1
RTP,%,16,1
k1,M-1 s-1,16,1
MIC>80,ug ml-1,16,1
Survivors at day 30,,16,1
MTT reduction,%,16,1
Fu,ng/ml,16,0
Median survival,day,16,1
KB,uM kg-1,16,-1
Difference,%,16,1
AUC,uM h kg/mg,16,0
Dependency,,16,0
C24,ng ml-1,16,0
Log t1/2,,16,0
K2,,16,-1
Activity,/mmol,16,1
Activity,10'6 /uL,16,1
MIC>99,ug ml-1,16,-1
AUC,nmol/g.hr,16,1
AUC,nmol.min.g-1,16,1
Probability,,16,0
Pressor activity,mg,16,1
Potentiation,uM kg-1,16,-1
K,10'-4/nM/min,16,-1
ED50,10'-7M,16,-1
Cleavage rate,nM min-1 mg-1,16,-1
Total binding,%,16,1
ILB,,16,0
CC50/EC50,,16,-1
Delta Gm,,16,0
K obs / 1,uM-1 s-1,16,-1
Activity,10^3/mm3,16,1
Kcat,10'-3/min,16,1
Control value,g dl-1,16,0
Transport rate,nM min-1 mg-1,16,-1
Activity,mU/L,16,1
Activity,mMequiv/mg,16,1
HC10,,16,-1
Colony_count,,16,-1
CFU,10^3/ml,16,-1
ED20,nM kg-1,16,-1
Decrease in the QA interval,ms,16,-1
MAT,hr,16,0
Plasma cholesterol,mg dl-1,16,0
CI50,,16,-1
Heart weight,g,16,0
MBC,umol,16,-1
Activity,log10PFU,16,-1
TI,%,16,1
Change in IC50,fold,16,-1
NM,,16,0
HR,mmHg,16,0
Peak deltaMAP,mmHg,16,1
Peak deltaHR,beats min-1,16,1
Tissue/Blood ratio,,16,0
Ka,1/M.sec,16,-1
ID50,nmol/ml,16,-1
MBEC90,uM,16,-1
MNCC,nM,16,-1
Max cAMP,%,16,1
Papp,10'-6nanometer/s,16,0
K,10'8/M,16,1
CL,ug/min/mg,16,-1
MDD50,,16,-1
CLH,l/min/mg,16,-1
Time to max. inhibition,hr,16,0
CLH,mg/min/mL,16,-1
Activity,U/g,16,1
ER max,mM,16,0
Original amplitude,%,16,1
Organ weight,,16,0
Tensile strength,g cm**-2,16,1
MNTD,umol/L,16,-1
Activity,10'-4/min,16,1
MET,%,16,1
Specific Displacement,%,16,1
Efficacy,ug ml-1,16,-1
Activity,ug/100mg of tissue,16,0
Specific activity,Ci mM-1,16,-1
ED2sec,mg kg-1,16,1
Serum triglyceride,mg dl-1,16,1
ED300,uM kg-1,16,-1
Normal,mmHg,16,0
Serum metabolite,mg dl-1,16,1
EC50,10'8pM,16,-1
Kr,10^-3/min,16,1
AD,mM l-1,16,1
Non-HDL-C,%,16,1
Vmax,nM s-1,16,1
Activity (mg),%,16,0
Vmax,optical density/minute,16,1
Vmax,pM min-1,16,1
Virus rating,VR,16,0
No. total,,16,0
Inhibition of damage,%,16,1
LC10,ug ml-1,16,-1
CT-luci TAR,T/C,16,0
Activity,pmol/ug,16,1
Acute tolerability,,16,0
Viability,mM,16,-1
Selectivity,%,16,1
E/Eref,,16,1
Vmax/Km,ml/min,16,-1
LC50,uL/L,16,-1
FC50,uM,16,-1
E max,%,16,1
E,mV,16,0
Uptake,,16,1
LC60,mgAi/L,16,1
IC,nM,16,-1
ACT,,16,-1
Kin,/s,16,1
Cp(f),,15,0
-Log I50,,15,-1
-Log concentration,M l-1,15,-1
2x APTT,,15,-1
3H-TdR incorpolation,c.p.m.,15,-1
AERP,,15,0
AP,,15,-1
AUC/dose,ng/mL.hr/(mg/kg),15,1
AUCt,ng.min/g,15,1
Accumulated counts/30 min,,15,1
Activity,/10'2cm3,15,1
Activity,Angstrom,15,0
Activity,FU,15,1
Activity,M-1 s-1,15,1
Activity,RLU/mg,15,1
Activity,mJ/m2,15,1
Activity,mMequiv,15,1
Activity,mS/cm,15,1
Activity,mmolequiv,15,1
Activity,uA.cm^-2,15,1
Activity,uM of MDA (mM of deoxyribose)-1,15,-1
Activity,ug disk-1,15,1
Ae,%ID,15,1
Alkylation,%,15,1
Amount bound,M g-1,15,0
Analgesia duration,min,15,1
Animals cured,%,15,1
Antidiuretic activity,,15,-1
Average change in weight,%,15,1
Average survival time,day,15,1
Average tumor volume,,15,1
B50,M,15,-1
Blood glucose level,,15,1
Body weight change,BWC,15,1
C10,mM hr,15,0
C8h,uM,15,0
CF,%,15,1
CGI,nM,15,-1
CHI,%,15,1
CL free,%,15,1
CLH,mg/min/microL,15,-1
CL_renal,ml/hr,15,0
CLogD7.4,,15,0
CMC,umol/L,15,0
CR,,15,0
Cell proliferation,%,15,1
Change in rat blood sugar,%,15,1
Cholesterol,ug,15,0
Clp,ml.min-1,15,1
Cmax,ng.hr/ml,15,1
Co,uM,15,0
Communicating cells,,15,0
Cp,mg/ml,15,0
Cp(f),ug ml-1,15,0
Crop_yield,kg/ha,15,1
Cures,survivors/total,15,1
Cytotoxicity,mM,15,-1
Decrease RVR,%,15,1
Decrease in fighting,%,15,1
Delta HDL-C,%,15,1
Dose,mg ml-1,15,0
Drug metabolism,ml/min.kg,15,0
Drug recovery,umol,15,0
Drug uptake,ug/L,15,0
E50,uM,15,-1
EC25,ug ml-1,15,-1
EC40,mM,15,-1
EC95,uM,15,-1
ED40,nM kg-1,15,-1
ED80,uM kg-1,15,-1
ED85,ng ml-1,15,-1
Effectiveness,%,15,1
Efficacy,picometer,15,1
Extent of skin lesions,cm**2,15,1
FE,,15,-1
Food intake,g,15,1
Fresh weight,ng g-1,15,0
GI,nM,15,-1
GI25,nM,15,-1
GTP-gamma35S bound,%,15,1
Gastric concentration,ug g-1,15,0
HC30,mg/ml,15,-1
Hemispheres reduction,,15,1
Hx shift,,15,0
Hypoglycemic activity,mg kg-1,15,1
I50,ppb,15,-1
IC100,nM,15,-1
IC50,M ml-1,15,-1
ID50,umol/kg/hr,15,-1
INH,10'-3M,15,-1
Inhibitory effect,,15,-1
Insulin-sensitizing activity,%,15,1
K,1/Maa,15,1
K app,nM,15,-1
Ka,10'2/M,15,-1
Kact,uM,15,-1
Kapp,10'-5/M,15,-1
Kcat,10'-4/s,15,-1
Kcat/Km,10'2/M/s,15,1
Kcat/Km,10^6/M/s,15,1
Kcat/Km,L/mmol/s,15,-1
Kinact,10'4/M/s,15,1
Kq,10^12L/mol/s,15,-1
Kq,10^13L/mol.s,15,-1
LD95,mg kg-1,15,1
Log 1/B+1,,15,-1
Log 1/B+100,,15,1
Log 1/B.5,,15,-1
Log 1/Th+200,,15,1
Log K'W,,15,0
Log concentration,,15,-1
Log2,,15,0
MAC,mg/kg/day,15,1
MOT,,15,-1
MPE,mmHg,15,-1
MTX equivalent,mg kg-1,15,1
Max agonist response,%,15,1
Metabolite levels,ug,15,0
Metabolite levels,,15,0
Mineral apposition rate,mm day-1,15,1
NBT positivity,%,15,1
No. of cells,ml,15,0
No. of entries,%,15,1
No. of living cells,,15,0
No. of suncus vomited,,15,0
Optimal dose,mg uM kg day-1,15,0
P50d/P50c,,15,-1
PD50,mg Kg-1,15,1
Plasma concentration,nM,15,0
Preventive_index,,15,1
Proliferation,,15,-1
RBI,,15,1
RMP,mV,15,0
RVR ED15,ug kg-1,15,1
Rate constant,M-1 s-1,15,1
Ratio,10^3/M/s,15,-1
Ratio,10^5/M/s,15,-1
Ratio CC50/IC50,10'4No_unit,15,1
Reduction in movement,%,15,1
Relative differentiating activity,,15,0
Remaining compound,%,15,1
Rmax,RU,15,1
Root_galling_index,%,15,1
S,Dilution factor,15,0
Scavenging activity,%,15,1
Spent time,hr,15,1
Stability,%/hr,15,1
Stability,yr,15,0
Succeeded/tested,s,15,0
Survival,weeks,15,1
T/C (ratio of treated to control),%,15,1
T/C 1.2,,15,1
T/C survival days,,15,1
T50,nM,15,-1
TI,Ratio,15,0
Tonic seizures,%,15,1
Total number of entries,,15,0
Triglyceride correction,%,15,1
Tumor volume,cm*3,15,1
VCT,,15,0
Vd/F,l,15,0
Vm/Km,,15,-1
Vmax,RFU/min,15,1
Vz,,15,0
WLC PRA,,15,1
Weight change,g mouse-1 on day 8,15,1
Weight changes,g,15,1
cpm,,15,0
deltaOD,/min,15,1
fIC50,,15,-1
k obs / 1,1/M 1/s,15,-1
p alpha,,15,0
pAD,,15,-1
pAH50,,15,-1
pD2,M,15,-1
pEC50 diss,,15,-1
Relative level,,14,0
LD50,mg/ml,14,-1
log10PFU/ml,,14,-1
Stain index,,14,0
Max MBP,mmHg,14,1
PB,pmolequiv,14,0
Rate max,beats min-1,14,1
Subcut score,,14,-1
Decrease in Bmax,%,14,1
ID50,ng,14,-1
ED15,uM kg-1,14,-1
Rate of inhibition,s-1,14,0
C/P,,14,0
ALP Level,U l-1,14,1
GOT Level,U l-1,14,0
Activity,nM g-1,14,-1
Net grain counts,,14,0
Average body weight change,%,14,1
Activity,ml/min.Kg,14,0
Drug metabolism,pmol/hr,14,-1
Survivors at 24 h,,14,0
Lipid peroxidation,,14,0
Experimental DPM,,14,0
Log rate constant,M-1 s-1,14,-1
C20 APD95,,14,1
Relative t1/2,,14,0
Kidney weight,,14,0
Liver TG,mg g-1,14,0
LD50,10'-6M,14,-1
Parasites no. per 100 Myoblasts,,14,1
Max increase in coronary flow,%,14,1
T/C corr,%,14,1
Kid,uM,14,-1
ID50,nmol,14,-1
ED33,mg kg-1,14,1
MBC=>99,ug ml-1,14,-1
Inhibitory activity,uM,14,-1
TC50,umol,14,-1
TC90,umol,14,-1
TCID50,ml-1,14,-1
CAR,MPK,14,0
Relaxed DNA,%,14,1
CT10,mM-hr,14,0
MI50,uM,14,-1
Cmax,hr.fmol,14,0
No. protected/ No.dosed,,14,1
Peak time,min,14,0
Hypotensive activity,mmHg,14,1
Ka,10'-6/M,14,1
GSTCP activity,,14,-1
ED50,10'-7mol/cm2,14,-1
Inhibition potency T/II,,14,-1
AI50,nM,14,-1
IC60,nM,14,-1
TPO,%,14,1
Potentation,,14,-1
EC10,ug ml-1,14,-1
Blood urea nitrogen,mg 100ml-1,14,1
No. of writhings,,14,1
Mean decrease,%,14,1
AUC p,,14,1
Pcaco2,cm s-1,14,0
Delta TC,,14,-1
Duration of reversal,min,14,0
AUC,nM.hr.kg/mg,14,0
Activity,L/s,14,1
k,M-1 min-1,14,-1
pXI50,,14,-1
Activity,IU/dl,14,0
Infectious virus,ffu ml-1,14,1
Antimicrobial activity,,14,0
DNA cleavage,%,14,1
EC100,mg ml-1,14,1
deltaA,nm,14,1
HVA level,ug g-1,14,0
PEI,%,14,1
LD10,mM,14,-1
Therapeutic effect,%,14,1
MCCD,mg kg-1,14,0
Growth delay (T-C/C),%,14,1
Vmax / Km,nM min-1 mg-1 mM-1,14,-1
Ki,10'6/M,14,-1
Histopathology,,14,0
Therapeutic index,ug ml-1,14,0
KI',uM,14,-1
5-HT syndrome,,14,0
Ouabain,ug kg-1,14,-1
Increase in DPM,(mg of protein)-1,14,1
Thermodynamic solubility,ugA/ml,14,0
fCmax,,14,1
Myoblast with parasites,%,14,1
Ct,hr.fmol,14,0
MIC,umol/uL,14,-1
KDMPC,M-1,14,-1
Increase over control,%,14,1
GI,square millimeter,14,1
Time,10'3s,14,1
CCh,,14,-1
Positive,%,14,1
Increase in plasma lipase,IU ml-1,14,1
Lysis area,mm.mm,14,1
Complete remission,%,14,1
Kt,uM,14,-1
No. of scratches,,14,1
kc,10e-3 1/s,14,1
deltaTm,hr,14,0
Max relaxation,%,14,1
LD0,,14,-1
Blood glucose,mM (l of whole blood)-1,14,1
Tonic-clonic seizure,,14,-1
NADH oxidation,uM min-1mg-1,14,1
ED50,uM site-1,14,-1
-Log Sw,,14,-1
Amount,nM (mg of protein)-1,14,-1
MIC,ug m/L,14,-1
Increase in blood pressure (P/R),%,14,1
dose BP/BP,,14,-1
Body weight change,g (100g of body weight)-1,14,0
Activity,10'7/ml,14,1
Toxicity related death,,14,-1
LWI,%,14,1
No. of plaques,,14,1
Radiation equivalent,,14,0
K obs,uM,14,-1
gammaCMC,mN/meter,14,0
Max tolerated dose,mg kg-1,14,0
ED6,mg kg-1,14,1
Agonistic activity,%,14,1
Tumor burden,mg,14,1
Tumor growth delay,day,14,1
Bilurubin Level,mg %,14,1
Vmax(app),pmol/mg.min,14,1
K,10'-1/min,14,1
PD50,mg/kg/day,14,-1
Reactivity,%,14,1
Emax,mM,14,1
G0/G1,%,14,1
No. of mice dead/day died,,14,1
k3,s-1,14,-1
Tumor weight,%,14,1
Kdiss,10'-2/s,14,-1
LD50,ug/mg,14,-1
UD,mg kg-1,14,1
K app,min-1,14,-1
POT vigilance,,14,0
No. of males mated,,14,1
Ratio,10^4/M/s,14,-1
Cl,mg ml-1 kg-1,14,0
No. of males fertile,,14,1
No. of males cohabited,,14,1
Kdapp,nM,14,-1
K NBP,s-1,14,1
Kd1,nM,14,-1
K H,s-1,14,1
Activity,10'-5OD/s,14,1
Ko,min-1,14,-1
Emax,mV,14,1
EDmin,uM kg-1,14,-1
Activity,10'-10mol/min,14,1
ECLT,min,14,0
MID log LC50,M,14,-1
C1.3,uM,14,-1
EI,,14,1
K,10^6/M/min,14,1
VM,pM min-1,14,1
k2,10e-3 1/s,14,-1
RT,min,14,0
No. of dogs used,,14,0
Equilibrium OD340,,14,-1
Adjuvant effect,,14,0
Change in blood flow,,14,0
Fungicidal,ug ml-1,14,-1
k-2,10e-3 1/s,14,-1
K,10^3/M/min,14,1
No. of dogs reverted,,14,0
Concentration,M l-1,14,-1
K,10'-4/min,14,1
Reduction,hr,14,-1
Drug uptake,ug base equiv/g,14,0
Vdss,ml,14,0
I75,gAi/ha,14,1
Reduction,mg,14,0
Edema density,,14,0
Reduction,mg kg-1,14,-1
IC,mM,14,-1
NLCK,,14,-1
Log Pmic,,14,0
Vmax,uM min-1 mg-1,14,1
K,10'-6/M,14,-1
MFC,mg l-1,14,-1
Of control,%,14,1
Control relaxation,%,14,1
Ratio,10^6/M/s,14,-1
Serum stability,,14,1
Serum triglyceride,%,14,1
Drug uptake,ml/min/mg,14,1
K,10'3/uM/s,14,-1
Vmax,nM hr-1 (10e6*cells)-1,14,1
Vmax,nM hr-1 mg-1,14,1
Maximum response,%,14,1
Erythema induction,,14,0
IC20,nM,14,-1
Abdominal fat,g,14,1
Change,uM,14,-1
Vmax,nmol/min/mg protein,14,1
Activity,ul min-1,14,1
Plasma histamine,ng ml-1,14,0
Log change,,14,-1
Free complex,%,14,1
Nitric oxide,%,14,1
Kd,1/s,14,-1
Activity,uS,14,0
Dissociation rate constant,1/S,14,0
Activity,uM/day,14,0
AUC c,,14,0
Sp Max,%,14,1
AUC,mg kg-1,14,1
Lethal dose,p.p.m.,14,1
Bullatacin index,,14,-1
APA,mV,14,0
Activity,uM min-1,14,1
B(DPB),%,14,1
Net turns/min,,14,1
Plasma ALT at 24 h,mU ml-1,14,1
Kr,10'-3/min,14,1
Kinact,10^-3/s,14,1
Prolactin treatment,ng ml-1,14,0
Activity,pmol/min/ug,14,1
Activity,pmol/min.mg,14,1
Prolactin control,ng ml-1,14,-1
Dose range,mg kg-1,14,0
Pigmentation capacity,,14,0
Max decrease in blood pressure,mmHg,14,-1
Stability,nmol,14,0
Kcat/Km,10'-3/microM/s,14,-1
GPT Level,U l-1,14,0
fAUC/MIC,hr,14,-1
30 day survivors,,14,1
Photosensitization,,14,0
AUCt,nM/ml.hr,14,1
Hypocotyl length,cm,14,1
AUMCt,hr.hr.ng/ml,13,0
Cmax,uM-1 kg-1,13,0
K,10'-4/M/s,13,1
increase in response,%,13,1
NOAEL,ng/ml,13,0
K,/min/nM,13,-1
HC5,ug ml-1,13,0
Ratio,mg/L,13,0
Emax,ms,13,1
Kr,mmol/min,13,1
MST,%,13,0
Ip score,,13,-1
Hepatic necrosis in survivors,,13,0
Cures,%,13,1
IC20,10'-5M,13,-1
Enhancement ratio,,13,1
Negation,%,13,1
Equilibrium,ug/ml,13,0
AUCt/dose,nM.hr,13,0
Weight change on day 5,%,13,1
fAUC/dose,nM.hr/mg/kg,13,0
Inotropic potency,nM kg-1,13,-1
Necrosis response,%,13,1
Wet weight,mg,13,1
Fmax,,13,0
Excreted,%,13,1
Differentiation activity ratio,,13,0
Exploratory activity,,13,0
MRD,V s-1,13,-1
deltaA,%,13,1
PDI,%,13,1
Induction,fM,13,1
Cmax,mg kg-1,13,0
Increase in HR,%,13,1
Kq,10'11/M/s,13,1
Behavioral response,,13,0
LC90,ugAi/L,13,-1
Basal,%,13,1
Km/Kcat,,13,0
EC40,,13,-1
RHA,,13,0
Protective Index,,13,0
Radioactivity level,ml,13,0
Reduction in virus yield,pfu/ml,13,-1
Log cfu/g,,13,-1
Regression response,%,13,1
BMD,mg/cm3,13,1
BEI,kDa-1,13,0
B/P,,13,0
Relative bioavailability,,13,0
Average weight change,mg kg-1,13,0
Body weight loss at nadir,%,13,1
Relative florescence,,13,1
Average tumor volume,T/C,13,1
EC50,Ke nM-1,13,-1
log10LT50,,13,-1
Relative stimulatory activity,%,13,1
Relativity,,13,0
Log tumor cell kill,,13,1
IC>80,,13,-1
Ki/(Km/Kcat),,13,-1
P value,,13,0
Drug deaths,,13,1
Radioligand bound,%,13,1
RBP,%,13,1
AD50,nmol,13,-1
Ki',mM,13,-1
Ki int,uM,13,-1
Ki,s-1,13,-1
Logit_p(conc),,13,-1
Ki,10^5/M,13,-1
Root_galling_index,,13,1
S,%,13,1
Delta ED50,mg kg-1,13,-1
p10 MIC,nM,13,-1
SB,%,13,1
Drug uptake(free),ng/g,13,0
Amine formed,ug,13,1
LVEDP,mmHg,13,-1
Optimal dose,mg uM kg-1 day-1,13,1
Alpha Ki,M,13,-1
ST,s,13,1
Duration time,hr,13,0
Kdiss,10^-3/s,13,-1
Agonism,,13,-1
EC99.9,uM,13,-1
LC50,ugAi/L,13,-1
AUC,hr/mL,13,1
Kd,s-1,13,-1
CL,ml/min.g,13,-1
CL,ml/kg.hr,13,1
E100,M,13,0
AERP,ms,13,0
LD50,mg,13,1
CMI,mg l-1,13,-1
Rate,delta OD340 min-1,13,1
Kd,10^-3/s,13,-1
Serum level,ug ml-1,13,0
Kd,10^-12M,13,-1
LD50,mg kg-1 day-1,13,1
Shutdown time,min,13,1
Length,mm rat-1,13,1
CL,ml.Kg/min,13,-1
MAP,%,13,1
Lesion_Clearance,%,13,1
Rate,nM min-1 (10e6*cells)-1,13,-1
Chlorine uptake,,13,-1
Activity,pmolequiv/mg,13,1
Parasitemia,,13,-1
Spontaneous motor activity,,13,0
Max SBP,mmHg,13,1
Rate constant,hr-1,13,0
Kcat/Km,10'2/s/M,13,1
Kcat/Km,/min/microM,13,-1
LD50,mg/m2,13,1
Photolysis,,13,0
ED100,nM,13,-1
Occ50,ng/ml,13,-1
Max delta BP,mM,13,0
LBF,ml/min,13,0
Peroxidase rate,uM of ABTS min-1,13,1
ED2,ug kg-1,13,1
Survivals,%,13,1
T,min,13,0
Activity,mg/g DW,13,0
Activity,mg.min/dL,13,1
Max enhancement,,13,1
Log 1/IC90,,13,-1
Activity,mg l-1,13,0
LBF,L/min,13,0
MBC>99.9,,13,-1
MTX ratio,,13,-1
Activity,degreeC.hr,13,1
Hill coefficient,nH,13,0
Peff,10'-4 cm/s,13,0
MBIC=>90,ug ml-1,13,-1
TO,min,13,-1
Ka,10'-4/M,13,1
Ratio,/min,13,0
TPI,%,13,1
DNA fragmentation,,13,-1
C120/ED50,,13,-1
Ka,/mM,13,-1
MNTD,mg/kg/day,13,1
TT,min,13,-1
ED50,M mouse-1,13,-1
ED50,gAi/ha,13,1
ED50,kg/ha,13,1
ID50,uM ml-1,13,-1
AUC,nM/ml,13,0
RFU,a.u.,13,0
ED50,m equiv [H+] l-1,13,-1
ID50,umol/cm2,13,-1
Kup,ml/min/g,13,1
ln Kt,,13,-1
ln Kp,,13,0
Change in temparature,degrees C,13,1
QT interval,ms,13,0
KDNB,,13,0
Kt,,13,0
MIC,umol/cm3,13,-1
ID95,nM,13,-1
ED50,mpk/d,13,0
KB app,nM,13,-1
Tissue levels,ug ml-1,13,0
MEC,%w/v,13,0
Migration,%,13,1
Activity,10'9CFU/g,13,1
Hormonal activity,,13,0
kR,uM,13,-1
IC25,,13,-1
Transcriptional activity,%,13,1
ILS (T/C),%,13,1
Ks,mM,13,-1
Change in cholesterol,,13,0
Caco-2 permeability,,13,0
Ratio,10^4/M/min,13,-1
Tumor inhibition ratio,%,13,1
ED70,mg kg-1,13,1
K bind,,13,-1
I50,gAi/ha,13,0
K OX,M-1 min-1,13,1
K HOX,,13,0
ED90,mg/kg.day,13,1
Urine/bile,,13,0
K,10^8/M,13,1
MTD,mg/m2,13,1
VOLSYN,,13,1
Vagal response,,13,0
Activity,(ng of PGE2) (mg of protein)-1,13,1
K,10^-5/s,13,-1
Cmax,ug g-1,13,1
MIC,U/ml,13,-1
Cell Proliferation AC50,nM,13,-1
Vm,10'-4m3/mol,13,0
k'',s-1,13,-1
AUC,SUV.min,13,1
D,10'-10m2/s,13,0
MED10,mg kg-1,13,1
Effective concentration,,13,-1
Vmax,c.p.m.,13,1
Effective dose,uM kg-1,13,1
Absorbance,,13,0
Effectiveness,,13,0
MED50,mg,13,1
MED98,mg kg-1,13,1
Blockade duration,min,13,1
Cell permeation,nm s-1,13,1
Vmax,pmol,13,1
RSA tR,min,13,0
Activity,mg m-1,12,0
LD20,mg/ml,12,-1
C0,mg/L,12,0
Log K,M-1,12,-1
Dose (urinary recovery),%,12,0
RAP,,12,-1
Quantity,pM mg-1,12,0
QTc delta,%,12,1
LD50,uM/ml,12,-1
QT,ms,12,-1
Cp,nmol/L,12,0
QH,L/hr/kg,12,0
LD80,ug/mg,12,1
Protonated,%,12,1
LD90,ng/ml,12,-1
Protective activity,%,12,1
C5a max,%,12,1
Progressed tumors,%,12,1
log10PFU,g,12,-1
LH concentration,mU ml-1,12,1
CC10,mg/L,12,1
Potencymean,ng g-1,12,1
Potency vs EKC,,12,-1
Drug uptake,PSL/mm2,12,1
LV dP/dTmax(delta),%,12,1
AUC,g.hr,12,0
AUC,hr.sec,12,1
Platelet aggregation,,12,-1
AUC,hÂ·fmol/million cells,12,1
Latency,min,12,0
CFU,10^8/ml,12,-1
CFU,10^9/ml,12,-1
Plasma lipid level,mg dl-1,12,0
Plasma levels,ug ml-1,12,0
Lesion length,mm rat-1,12,1
Plasma corticosterone,ng ml-1,12,1
Mortality range,day,12,0
Drug metabolism,%molar,12,0
CITH,,12,-1
Drug metabolism,ug/L,12,1
GPI,nM,12,-1
Phosphorolysis,,12,0
GPGB tension,g,12,1
Drug metabolism,pmol/ml,12,0
Peff,10^-7 cm/s,12,0
CL,mg/ml/kg,12,0
Peak current,%,12,0
Peak concentration,ug ml-1,12,1
Log 1/E100,,12,-1
MIC80,%v/v,12,0
log S,M/m3,12,0
Cp,ug base equiv/g,12,0
HbS solubilized,%,12,1
Mean relative surviving fraction,,12,1
lesions,,12,0
kinact/Ki,M-1 s-1,12,-1
AUC,pM ml-1,12,1
Myristoylpeptide,%,12,1
N/T,,12,0
MNTD70,uM,12,-1
IC50H,nM,12,-1
INCC50,uM,12,-1
INH,%/min,12,-1
Change in cell number,%,12,1
Clp,,12,-1
k cat/Kuncat,,12,-1
IC10,umol/L,12,-1
Change in MST,,12,1
k,10e-3 min-1,12,-1
hSlo current,%,12,1
Crop_yield,%,12,1
Formaldehyde,nM (mg of protein)-1,12,0
AUC normalised,((ug.h.ml-1)/(mg/kg),12,1
Ibuprofen,%,12,1
Cmax,hr,12,0
NRD,mg/kg/day,12,1
AUC/dose,hr.microg/ml,12,0
HR(delta),%,12,1
Change,hr,12,0
Fecal recovery,%,12,1
Fe removed,%,12,1
Falling,%,12,1
deltaS,J/mol/K,12,0
Infarct volume,mm**3,12,1
Mean duration,min,12,1
Na+ excretion,m equiv 5hr-1 kg-1,12,1
MHC,mg/ml,12,0
FIC index,,12,-1
cAMP content,pmol/mg protein,12,0
Mean day of death for total dead,,12,1
av,,12,1
Ct,nmol/g,12,-1
Control growth,,12,-1
[3H] TdR uptake,c.p.m.,12,-1
Extraction,%,12,0
MFI,,12,1
Ct,pmol/ml,12,-1
Excretion,mg kg-1,12,0
Excretion,m equiv 4hr-1,12,1
Cholestrol levels,g l-1,12,1
Excretion,% of dose,12,1
Weight gain or loss,%,12,1
Metabolic rate,pM min-1 (mg of protein)-1,12,-1
AUDPC,,12,0
Intensity of erythemia,,12,1
Neostigmine reversal,,12,0
Iron excretion,ug kg-1,12,1
Emesis,,12,0
MIC>90,,12,-1
Volume,ml,12,0
Vmax/Km,uL/min.mg,12,-1
Vmax/Km,uL/mg/min,12,1
Mean,pM mg-1,12,-1
Vmax/Km,pl/min,12,1
Vmax(app),%,12,1
Vmax / Km,10^-9 L min-1,12,1
Cmax,pmol/g,12,0
Concentration,nM min-1 (mg of protein)-1,12,-1
MES/TEST,,12,1
Vmax,pM hr-1,12,-1
No. of animals alive,,12,1
Cell cycle fraction,%,12,1
No. of animals protected/number of animals tested,,12,1
Absorption,ng ml-1,12,0
Effect,pM (10e6*cells)-1,12,-1
MTD,(mg of CPT) kg-1,12,1
Effect,mmHg,12,1
Vmax,10'-4deltaA/s,12,0
Acetaldehyde,nM (mg of protein)-1,12,0
No. of animals with damage,,12,0
Viscosity,%,12,1
Acid output,u equiv of [H+] 2hr-1,12,-1
ERP (delta),%,12,1
Catalyptic action,,12,0
Concentration,% dose g-1,12,0
Conc_plasma,uM,12,0
Vaginal activity,,12,0
Activity,(ng of TXB2) (mg of protein)-1,12,1
VI30,%,12,1
D50,uM,12,-1
V0,microM/s,12,-1
Activity,10'-2k/min,12,1
Counts/30 min,,12,1
Urine volume,,12,0
Urine Na+,m equiv,12,0
Urine K+,m equiv,12,0
Urine,ml,12,0
Urinary volume,ml kg-1 5hr-1,12,1
Urinary level,mg,12,0
K 0.5,uM,12,-1
K L,,12,-1
Max. activation,%,12,1
Unchanged tracer,%,12,1
Activity,10'-8M,12,-1
UR,,12,0
Activity,10'-9PFU/ml,12,1
UB,,12,0
DAP,,12,0
K app x10e-7,M-1,12,-1
IC50,ug well-1,12,-1
Tumor/liver ratio,,12,0
Tumor/blood ratio,,12,0
ED70,,12,-1
Activity,10'3/cm2,12,1
K diss,s-1,12,0
No. of mice protected/tested,,12,1
Tumor cure,%,12,1
Tubulin polymerization,%,12,1
Activity,10'5/cm'3,12,1
K obs / 1 1/Ms,,12,-1
No. of pits,,12,1
Transacylation rate,,12,-1
K+ excretion,m equiv 5hr-1 kg-1,12,1
K-1 decrease,%,12,1
Cmax normalised,(ug/ml)/(mg/kg),12,0
ME increase,nM min-1 mg-1,12,1
Max release,%,12,1
Total acid output,%,12,1
Total,%,12,1
Tmin,hr,12,1
Tissue concentration,uM,12,0
MDL,day,12,-1
Complete spontaneous reversal,,12,0
Time in flight,%,12,1
Activity,10^6/ml,12,1
Thyroid status,nM l-1,12,0
Activity,10e-4 K s-1,12,1
DIZ,cm2,12,1
Threshold active dose,mg kg-1,12,1
Activity,AUC units,12,1
HV interval,,12,-1
Activity,KA,12,0
KSV,L/mol,12,-1
TVR,mmHg ml-1 min-1 g-1,12,0
Activity,M min-1 (M of enzyme)-1,12,1
Cmax(app),uM,12,0
TOX/TEST,,12,1
Mean value,,12,0
TOC ED50,M,12,-1
DNA photo-crosslinking,,12,-1
DNA single strand breaks,rad equiv,12,0
TLm,ug ml-1,12,1
Activity,Torr,12,1
TI,TD50/MIC50,12,-1
Activity,cm s-1,12,1
Ka,10'4/Ms,12,1
Activity,cm/min,12,1
IC35,nM,12,-1
TDI,uM,12,-1
Max intensity,,12,1
Activity,fmol/g,12,1
CQ,,12,0
Activity,log CFU,12,-1
AC,,12,0
TAC,%,12,1
Macrophage activation,,12,0
T1/2 increase,%,12,1
Cmax/dose,kg.ng/ml/mg,12,0
O2 production,%,12,1
T/C,mg kg-1 injection-1,12,1
T/A,,12,-1
OD,/hr,12,1
Kapp,10'-7/M,12,1
Min concentration,ug ml-1,12,-1
%R,%,12,1
T free,ns,12,0
T bound,ns,12,0
ED25,mM kg-1,12,1
Activity,micrometer,12,1
Activity,micromol/s,12,1
ED25,10'-5M,12,-1
Kapp,,12,-1
Kb,10'3L/mol,12,-1
OSAV,%,12,1
Mean tumor volume,cm*3,12,1
Kb app,uM,12,-1
Activity,nM stent-1,12,-1
Observed at,ug ml-1,12,0
Kcat,10'-1/s,12,1
Static tumors,%,12,1
Activity,no. of living cells (10E3) /mL,12,-1
Cmax_unbound,nM,12,-1
IC50,pmol/L,12,-1
Stability,ng/ml,12,0
Stability,%ID,12,0
Activity,pmol/s,12,1
Spermatogenic index,,12,0
Kcat/Km,10^4/M/s,12,-1
Specific activity,dpm,12,1
Activity,uM min-1 mg-1,12,-1
ED,ug/kg,12,1
Activity,ucat/L,12,1
Slope of Schild plot,,12,-1
MAO deamination,%,12,1
Serum TG,mg dl-1,12,0
Activity remaning,%,12,1
Degranulating activity,,12,-1
Adduct formation,,12,1
Adjuvant activity,,12,0
Ae,umol,12,0
Kd2,nM,12,-1
Age,d,12,0
AH interval,ms,12,0
Optimal dose,%,12,1
M50,%,12,1
AH interval,,12,-1
Amount of Ouabain used,,12,0
SC,mg dl-1,12,1
SBP decrease,%,12,1
Kel,L/hr,12,-1
Osmolality,mOsmol kg-1,12,0
Analgesic response,,12,0
-log(1/AD50),,12,-1
CLp,L.h-1.m-2,12,1
Ki,10'-4/M,12,-1
Rise HR,%,12,1
Anticoagulant activity,uM,12,-1
IC90,ug well-1,12,-1
Ki,M-1 min-1,12,-1
Response,RU,12,0
Logit bioavailability,,12,0
Residual contractile activity,,12,1
CL_renal,,12,0
Relativity,c.p.m. mg-1,12,0
pSI,,12,-1
Kic,,12,-1
ALAT levels,IU/l,12,1
Average No. of metastasis,,12,1
Average activity,,12,0
Average colony count,,12,0
Relative intensity,,12,0
Relative inhibitor potency,,12,-1
Relative growth,%,12,1
Log k'o,,12,-1
Relative effect,,12,0
PC50,,12,-1
Relative binding potency,,12,-1
mBP(delta),%,12,1
Relative Bioavailability,,12,0
Regiospecificity,,12,0
Log [-8],,12,-1
logt1/2,,12,-1
EC5,uM,12,-1
Reducing activity,%,12,1
Log [-7],,12,-1
Log [-6],,12,-1
Log [-5],,12,-1
EC30,mgAi/L,12,-1
GT rate,,12,0
EC30,M,12,-1
Baseline,,12,0
PDC,,12,0
Ratio IC50/EC50,uM,12,-1
Kq,10'5/M,12,1
Ratio CC50/IC50,10'5No_unit,12,1
MIC98,uM,12,-1
EC20,ng ml-1,12,-1
Log Pmw,,12,0
logPc,,12,0
Log Phep,,12,0
L-T3,%,12,1
Ratio,/s/microM,12,-1
LAD,,12,-1
Bmax,fM assay-1,12,0
Log PI,,12,-1
EC,uM 15min-1 mg-1,12,-1
ASAT levels,IU/l,12,1
Rate of decomposition,,12,0
LC30,ug ml-1,12,-1
Rate,ka/Ks,12,0
Rate,beats min-1,12,-1
CLH,/hr,12,-1
LC50,mg/cm2,12,-1
LC50,ng,12,-1
Log Ka,,12,0
pKapy,,12,0
logK-IAMex,,12,0
LC90,ug,12,-1
Diuretic activity,m equiv [Na+] 5hr-1kg-1,12,1
PL-017 shift,,12,-1
RVmax,,12,0
Dopamine level,ng mg-1,12,1
RPP,mmHg beats min-1,12,0
Brain penetration index,%,12,1
Bronchoalveolar lavages,,12,0
BsI,%,12,1
RH/RL,,12,0
pKabz,,12,0
Delta mmHg,,11,1
Count,,11,0
Ratio Ki,10^-4No_unit,11,0
Bmax,cpm,11,0
Response,min-1,11,1
General activity,,11,0
T-cell binding,%,11,1
AUMC,ug/ml.hr^2,11,0
AUCt,ug/g.min,11,0
Mean tumor volume,,11,0
Rating,beats min-1,11,1
AHV,%,11,1
Low,%,11,1
CPE50,ug ml-1,11,-1
G Index,,11,0
Exclusion parameter,,11,0
fAUC/dose,microg.hr/mL,11,1
Others,,11,0
Glucose,%,11,1
Rotorod,,11,0
No. of implants/pregnancy,,11,1
Kn,M-1,11,-1
S/T,,11,-1
Activity,millimeter/sec,11,1
MIC,pug ml-1,11,-1
ClC95,nM,11,-1
Delta Ca,mM,11,-1
%T>MIC,%,11,1
Activity,mm3/day,11,1
CD90,,11,0
SBP change,%,11,1
LC50,ppb,11,-1
ED20,nM,11,-1
Diuresis,ml kg-1,11,1
Max delta BP,mmHg,11,-1
Kb,L/mol,11,-1
ED20,gAi,11,0
SC200,nM,11,-1
KmL,uM,11,-1
Drug metabolism,ppm,11,0
Substrate specificity,,11,0
Phosphor,%,11,1
ABBC,log10CFU/ml/hr,11,-1
Distribution ratio,,11,0
Max CF response,,11,1
Phosphorolysis,%,11,1
CLu/F,L/hr/kg,11,0
K,microM/min,11,-1
SF50,uM,11,-1
Kcat,10^6/s,11,1
Ke,/hr,11,1
Activity,10'-3M,11,1
Fluoroscence,%,11,1
Kcat(app),/s,11,1
%hepatic blood flow,%,11,1
Alkylating activity,,11,0
ED100,mg/kg/day,11,1
Kcat/Km,/min/M,11,-1
ID50,nM (mg SR protein)-1,11,-1
Stability,uL/mg/min,11,0
Vmax,pmol/uM/min,11,-1
Binding affinity,spec bound mg-1,11,-1
Activity,pM of citrulline min-1 (mg of protein)-1,11,1
Decrease in heart rate,beats min-1,11,-1
Log 1/ISA,,11,-1
Log 1/Kd,,11,-1
Drug period,hr,11,0
"pKa,2",,11,0
Log P',,11,0
Kdiss,10^-2/s,11,-1
MED,%,11,1
Agonist effect,%,11,1
E2,%,11,1
Kdiss,10'-5/s,11,-1
Fluorescence intensity,%,11,1
AUC,microM/L.hr,11,0
Activity,uA.cm'-2,11,1
Platelet count,ul,11,0
Extent,,11,0
AbsAC0.47_uM,uM,11,-1
Activity,uM/micrometer/s,11,-1
log1/CMC,,11,-1
Minimum Tmax,h,11,0
[A],uM,11,-1
MAC,mg/L,11,1
"pKa,1",,11,0
Log 1/delta/Ca,,11,-1
Lesion frequency,%,11,1
Selective index,,11,0
HAR,,11,1
Degradation ratio,,11,0
CGI,,11,-1
Serum level,ug dl-1,11,0
Plasma level,pg ml-1,11,0
Max.stimulation,%,11,1
IC10,ng ml-1,11,-1
[EA],uM,11,-1
Untreated control,%,11,1
2aPTT,nM,11,-1
AUClast/dose,nM.hr,11,1
Activity,10'-6mg/kg,11,1
Ulceration,%,11,1
Change of size,%,11,1
CLH,ml/(min.mg),11,-1
INH,/M/s,11,-1
Vmax,deltaA/min,11,1
Mice with lesions,,11,0
K,10'-5/M/s,11,-1
LD90,g/ha,11,1
Inhibition activity,,11,-1
Psychotropic Effect,,11,0
rK,,11,0
amount in urine,%,11,0
ED80,mg,11,1
Kq,10^13L/mol/s,11,-1
ND,mg kg-1,11,0
Binding site fraction,,11,0
No. of mice alive,,11,0
Hgb levels,g dl-1,11,0
cAMP,pM well-1,11,-1
Clp,ml min-1,11,-1
K cat,1/S,11,1
cAMP production,pM min-1 mg-1,11,1
ED60,mg kg-1,11,1
Control period,,11,0
IC10,nM,11,-1
AD50,nM mouse-1,11,-1
Tumor cure,,11,0
Change in No. of trophozoites x 10E-5,,11,1
Cells arrested,%,11,1
Ileal activity,,11,-1
Tubulin polymerization,,11,-1
Drugexcretion,ug,11,0
dP/dt,,11,0
IC50,umol/Kg,11,-1
FR10 control,,11,0
FR10 treated,,11,0
AUCED90,ug.hr/ml/day,11,1
Counts,min-1,11,1
kHO,M-1 s-1,11,1
Inflammation units,,11,0
Vp/F,l,11,0
Ca2+ flux,,11,1
AUC/dose,hr.ng/ml,11,1
Translation,,11,0
Ratio_EC50,,11,-1
AUC,uM hr l-1,11,0
K',abs/time,11,1
Max suppression,%,11,1
K''IAM,,11,0
Vmax / Km,mM-1 min-1,11,1
ED50,ug min-1 kg-1,11,1
AUC,uM h/mpk,11,0
Vmax,AU/min,11,1
Vmax,10^4M,11,1
Ca2+ elevation,nM,11,-1
K-1,min-1,11,-1
AUC/dose,ng.hr/ml/mg,11,1
IC50,ug/mol,11,-1
Activity,10'7log10CFU/ml,11,-1
deltaS,cal/mol/deg,11,0
f(Cave),uM,11,-1
K1,10e-3 min-1,11,1
Ca2+ binding protein,ug (100mg of duodenum)-1,11,0
Med tumor area,mm**2,11,1
Tox50,ug ml-1,11,-1
2x TT,uM,11,-1
Mean rate constant,,11,1
Ca2+,mM l-1,11,0
Maximum Tmax,h,11,0
Change of predose,%,11,1
Km,10^4M,11,0
Papp,10'-6cm/min,11,1
No. of rats with 5-HT syndrome,,11,1
Ca2+,%,11,1
BGL,%,11,1
Tolerance,,11,0
EC15,,11,-1
Tmax,uM,11,0
KA,10'7/M,11,-1
Tlast,min,11,1
Prolonged ARP,%,11,1
LD90,mg/L,11,1
Relative agonist activity,,11,1
Vss,,11,0
Blood AcH,uM,11,0
Relative agonistic activity,,11,1
Log geometric mean,pfu mg-1,11,-1
log10cfu,/ml,11,-1
Average weight gain,g,11,1
Relative concentration,,11,-1
Cell Proliferation EC70,uM,11,-1
Enhancement,uM,11,0
AUC,ngequiv.hr/g,11,0
Relative cytotoxicity,,11,0
Vz,ml,11,0
CT10 ratio,air/N2,11,0
Mean volume of hind paws,,11,0
KIs,M,11,-1
AUC,ng.hr/ml/mg,11,0
Brain/Plasma,,11,0
K,10^-4/M,11,-1
Relative inhibitory activity,,11,0
KPCB,M-1,11,-1
CLH,nmol/min,11,1
Activity,IU/g,11,1
K,10^-5/M,11,-1
CT10,,11,-1
NOEL,mg kg-1,11,0
No. of vomiting episodes,,11,0
Active dose range,mg uM  kg-1 day-1,11,1
Relative phosphorylation,,11,0
LC90,mg/ml,11,-1
Activity,KgAi/ha,11,1
Protein interaction energy,kCal M-1,11,-1
Log Pion,,11,0
AUC,mmHg.hr,11,1
pFe3,,11,-1
Pe,10e-6 cm s-1,11,0
IPA,,11,1
Ks,,11,-1
Relative rate metabolism,,11,0
Cells,,11,0
ICL50,uM,11,-1
CL,microM/min/mg,11,-1
No. of dead animals,,11,1
TI50,uM,11,-1
Vbeta,l,11,0
TI,hr-1,11,0
MI50,,11,-1
Log,%,11,1
Kii,mM,11,-1
Atttacks,%,11,1
Arthritis scores,,11,1
Papp,10-6 cm/s,11,1
Hind-paw lick latency time,s,11,1
TG,,11,1
Vasodilatory rate,%,11,1
Aberrant cells,%,11,1
Vascular relaxation,%,11,1
Collapse time,s,11,1
MED99,MKP,11,-1
10E2 k1,min-1,11,1
KiL,uM,11,-1
CT,,11,-1
pI50,M,11,-1
EC50,ng/g,11,-1
TD100,uM,11,-1
KiA,uM,11,-1
Drug metabolism,10'-5/s,11,1
K,1/Ms,11,-1
Release,,11,0
MED90,MKP,11,0
Apoptotic index,,11,0
7-day weight change,%,11,1
Ki',,11,-1
Ki slope,uM,11,-1
K,1/M.sec,11,-1
% of effect,%,11,1
T1/29,min,11,0
A2,nM,11,-1
EC50,ug.cm'-2,11,-1
D/P,,11,0
CLH,microM/min/mg,11,-1
ED30,nmol/Kg,11,-1
Resorbing implants,%,11,1
EC25,mM,11,-1
Papp,10'-2 cm/s,11,1
VFT,mA,11,1
EC50,10^3nM,10,-1
CPM x1000,,10,0
cAMP increase,%,10,1
Cellular uptake,uCi ml-1,10,1
Mean increased life span,%,10,1
ED50,U ml-1,10,1
cKi,nM,10,-1
ID50,quanta,10,0
Tumor half growth,,10,-1
clogP-logP,,10,0
D,10^-7cm2/sec,10,0
TCID50,,10,-1
kA-,M-1 s-1,10,1
Kp,10^-3cm/min,10,1
VRT,hr2,10,0
CLH,ng/ml,10,0
ACT,uM,10,0
Cell toxicity,uM,10,-1
kAH,M-1 s-1,10,-1
% bound,none,10,1
Max tolerated dose,mg kg-1 day-1,10,1
Concentration,pmol/10E6 cells,10,0
EC50,M 50ul-1,10,-1
Frel,,10,0
Delta coronary flow,,10,1
TTO,min,10,-1
MED,umol/Kg,10,1
MEC,mg/ml,10,0
Function,,10,0
Iron mobilization,%,10,1
CLblood,mL/min/kg,10,0
Vmax,U/ms,10,1
Triglyceride level,mg dl-1,10,1
Inflection point,,10,0
Liver weight,mg 10g-1,10,0
Log 1/E50,,10,-1
Brain concentration,nM kg-1,10,0
Activity,mU m l-1,10,1
R%,,10,1
Emesis_Cmax,uM,10,0
Catalepsy score,,10,1
O2 consumption,%,10,1
rb,,10,0
CL,nmol/mg/min,10,-1
CA activity,%,10,1
NTD,mg kg-1,10,1
Clonazepam,%,10,0
Vmax/Km,10'6/min,10,1
RD1000,mg kg-1,10,1
Active/total,,10,0
Drug uptake,pmol/mg/min,10,0
Heart weight,mg 10g-1,10,1
Vmax,nmol/mg,10,1
Vmax,IU mg-1,10,1
Transactivation,fold,10,1
Transacetylation rate,nM/mg*min,10,1
Infected erythrocytes,%,10,1
EC50,ug/g,10,-1
TC50,10'4nM,10,-1
ED5,ug,10,1
TOC ED50,,10,-1
Activity,10'6No_unit,10,1
k'/k'+1,,10,0
Mean effect,mg,10,0
Induction number,,10,0
FT50,hr,10,-1
HD50,umol/L,10,-1
Log 1/GI50,,10,-1
Tp,,10,0
Induction,%,10,1
LC80,,10,-1
Induced convulsion,number convulsed,10,-1
FaFg,%,10,1
Ctt2,uM,10,-1
Drug metabolism,ml/min/g,10,-1
Vmax,10'5mmol/min/mg,10,1
Log,k,10,0
MED,nM,10,-1
ED50,ug day-1 kg-1,10,1
log2(ratio),,10,-1
Antiviral activity,nM,10,-1
TMSW,%,10,1
AUC/dose,nM.hr/mg,10,0
Maximal decrease in IOP,,10,1
pC30,,10,-1
% of growth rate,%,10,1
MIC,ug m1 l-1,10,-1
Relative seminal vesicle weight,,10,0
APTT,ug ml-1,10,1
I50,ug,10,-1
Ka,10^3/M/s,10,1
Drug uptake,a.u.,10,0
K12,hr-1,10,0
K13+K23,hr-1,10,1
Max fall in IOP,mmHg,10,1
MBC99.5,,10,-1
Average,uM,10,-1
TC25,ug ml-1,10,-1
Concentration_Plasma,nM ml-1,10,0
NOAEL,,10,1
MNCC,,10,-1
Response unit,umol/L,10,1
R50,uM,10,-1
Bmax,disintegrations/minute,10,0
Vmax,pmol.min.mg-1,10,1
Rating,hr,10,0
Dose/g tissue,%,10,1
Km,10'5mM,10,0
Oxygen uptake,nM min-1,10,-1
Ki,10^3nM,10,-1
K,10^4/Ms,10,-1
pH1/2,,10,0
LD99,mg/ml,10,1
A50,ug,10,0
ED25,nM,10,-1
Rice stem length,cm,10,1
permeability,ng/uL,10,0
K21,hr-1,10,1
LC50,ug/sq.cm,10,-1
K,10^7/M/s,10,1
K,10'8/M/s,10,1
C20,,10,-1
Kapp,10^5/M,10,1
Writhes,,10,0
EC80,nM,10,-1
Gastric lesion score,mM,10,0
PKa2,,10,0
V0,pmol/min,10,-1
Rel potency,,10,1
K,10'3/mol,10,-1
Kb,/M,10,-1
Initial mean arterial pressure,mmHg,10,0
Max delta HR,%,10,1
Ki,10'1/M,10,-1
TGI50,mg kg-1,10,-1
Body weight In. / Fi.,g,10,1
Post drug blood pressure,mmHg,10,-1
BK,,10,-1
Min lethal dose,mg kg-1,10,1
Drugabsorption,nM,10,-1
DNA unwinding concentration,uM,10,-1
BBC50,uM,10,-1
Post Antibiotic Effe,hr,10,0
Parasitemia clearance after treatment,%,10,1
Accumulation,ug ml-1,10,1
Vmax,uM min-1 g-1,10,1
Fold shift,,10,1
Survivors / total,%,10,1
GMS activity,,10,0
Analgesic efficacy compared to morphine,%,10,1
PCR cure rate,%,10,1
-Log alpha,,10,-1
DeltaTC,,10,1
Analgesic efficacy compared to epibatidine,%,10,1
HV interval,ms,10,0
CT10,uM,10,-1
BAT weight,g,10,1
D50,quanta*10e-18,10,0
Tissue/Plasma Ratio,,10,0
Mice,,10,0
Max reduction in mean arterial pressure,mmHg,10,-1
pC25,uM kg-1,10,-1
Uterotropic activity,,10,-1
MyristoylCoA,%,10,1
Cellular uptake,pCi cell-1,10,0
Log P16,,10,0
Relative ability,,10,0
Drug uptake,10^-2microM,10,1
Activity,nM min-1 ml-1,10,1
Activity,10'-2/min,10,-1
K,M/s,10,1
Kbapp,mM,10,-1
CL/F,L/min,10,1
Concentration,nM ml-1,10,-1
Binding activity,uM,10,-1
Activity,nM.min,10,0
Survival,hr,10,1
Amount of metabolite,nM ml-1,10,1
permeability,10'-6cm/min,10,0
Suppression of parasitemia,%,10,1
Relative activity,c.p.m.,10,0
MFC>99,ug ml-1,10,-1
A50,,10,-1
k2 / Ki,M-1 s-1,10,-1
Ratio,M/s,10,-1
Kcat,10'-2/s,10,-1
Radioactivity level,%,10,1
CTP,mg/L.hr,10,0
Substrate metabolized at 1hr,%,10,1
MTT,s,10,0
Substrate,uM,10,-1
ED99,mg/kg/day,10,1
Horizontal screen,number passed,10,1
Vss,L.m-2,10,0
Phosphorylating activity,pM min-1 assay-1,10,-1
Dose per organ,%,10,0
permeability,ml/min,10,1
M-agonist index,,10,-1
PTZ,,10,-1
Residual activity,c.p.m.,10,0
Kcat,10^-4/s,10,1
Amount,pM (10e6*cells)-1,10,-1
Z,%,10,1
Cytotoxicity index,,10,-1
P50d/P50c,mmHg,10,-1
Level,ug of tissue,10,0
Mice,%,10,1
M.A.D,ug kg-1,10,-1
Rate max,,10,1
MFC99.5,,10,-1
Occ50,ng/g,10,-1
Amount,%,10,1
Time constant T4,,10,0
Alpha-lipoprotein cholesterol,mg dl-1,10,0
Kdiss,10^3/M/s,10,-1
Intrinsic actvity,,10,0
pI,,10,0
C/I,,10,-1
CMpH,,10,0
Drug uptake,nmol/hr,10,1
ED100,mg kg-1 day-1,10,1
B,%,10,1
kinact,s-1,10,-1
Stability,ppm,10,0
Fold activation,uM,10,0
MTD,mM,10,1
Activity,pM of cGMP (min)-1 (mg of protein)-1,10,1
Log k GSH (s-1),,10,-1
PKa1,,10,0
MA,,10,-1
Ka,10'5/s/M,10,1
A50,mg kg-1,10,1
Decrease in mean arterial pressure,%,10,1
Cytoplasmic vacuolization,,10,0
IAR,,10,1
Stability,nM/min,10,-1
Stability,mmol/min,10,-1
ST,min,10,1
Efflux Ki,min-1,10,-1
Pka,,10,0
k cat/Km,uM-1 s-1,10,-1
CL,ml/min/m2,10,1
Kcat/Km,10'3/s/M,10,-1
Delta RBF,%,10,1
Emax,log10CFU/ml,10,-1
ED37,uM,10,-1
Activity,AU.min,10,0
permeability,day,10,0
60-day survivors,,10,1
Parasitemia clearance after immunosuppression,%,10,1
KD1,uM,10,-1
Change in body weight,g,10,-1
Activity,pmol/uL,10,1
Spleen weight,mg,10,1
Spleen weight,g,10,0
KD2,uM,10,-1
ED50,mg/m2,10,1
k'o,M-1 s-1,10,1
Log sensitivity,,10,-1
CI,mg/kg uM h,10,0
Inhibitory potential,,10,-1
Kq,10'4/M,10,-1
Specific binding,fM mg-1,10,-1
T>MIC90,hr,10,-1
Mean inhibition,%,10,1
EC>90,nM,10,-1
Kd2,uM,10,-1
k2',M-1 min-1,10,-1
Mean graft survival,day,10,1
IC50,mmol/Kg,10,-1
Distribution percent,,10,0
rIC50,nM,10,-1
HA release,,10,-1
C10 N2,uM,10,-1
Kd1,uM,10,-1
Parasite suppression,%,10,1
Acid output,u equiv hr-1,10,1
ED 50,uM,10,-1
METD,%,10,1
Delta MABP,%,10,1
Concentration,nM min ml-1,10,0
Arterial pressure,% mmHg min,10,1
Emax,fmol/mg,10,1
Ae,,10,0
CA,%,10,1
Delta LV,,10,0
CL/F,,10,0
DNA alkylation,%,10,1
LD50,10'-4M,10,-1
Uptake selectivity,,10,-1
MNTD,ug,10,0
Activity,ug mouse-1,10,1
Free,,10,0
Kp,cm hr-1,10,1
lnK,,10,0
Max protection,%,10,1
MAC reduction,%,10,1
K Bapp,uM,10,-1
Sigmap,,10,0
Si,,10,-1
Serum cholesterol,mg %,10,1
Activity,um2/s,10,1
Onset,min,10,0
Cp(T),ng/ml,10,0
Activity,fM ml-1,10,1
Serum total cholesterol,mg dl-1,10,0
A50,nM,10,-1
Relative influx,,10,0
A/Ad,,10,-1
Inhibition type,,10,-1
K,10'-9M,10,-1
DNA alkylation,,10,1
Log TCID50/mg,,10,-1
Carboxylase activity,dpm,10,0
GTPase Activity,,10,0
AUC,ug.ml-1,10,1
INH,10'-5 mol/L,10,-1
Cp,ngequiv/ml,10,0
TD50,ng/ml,10,-1
Liver weight,g 100g-1,10,0
Concentration,uCi ml-1,10,0
Delta heart rate,,10,1
Inhibition effect,,10,-1
R/S ratio,,10,0
INH,10'-4 mol/L,10,-1
k/K,M-1 s-1,10,-1
[I] for Km',uM,10,-1
INH,ng/ml,10,0
K,10'4No_unit,10,0
Relative ionotropic activity,,10,0
HMGR activity,,10,-1
No. of tumors/mouse,,10,1
Average latency,%,10,0
Max vasoconstriction,,10,1
k2c,min-1,10,-1
k3,min-1,10,-1
Activity,Counts 30min-1,10,1
Intensity,%,10,1
PB,pmolequiv/mg,10,-1
FC,10'5No_unit,10,0
Aqueous solubility,,10,0
alphaKi,nM,10,-1
logCMC,,10,0
Mice In. / Fi.,,10,0
Km',uM,10,-1
Recovery,min,10,0
INH,mole fraction,10,0
Tumor weight,,10,-1
Growth rate,%,10,1
Jss,nM hr-1 cm**-2,10,1
Gellar cook activity,,10,0
K ass,,10,-1
CL_Ratio,%,10,1
Activity,KA Units,10,1
No. of untreated cells,%,10,1
Km x10e3,hr-1,10,0
AUC,uM min l-1,10,0
k3/k1,M-1 s-1,10,1
Vmax,uM/min,9,1
Eicosanoid production,pM 2hr-1,9,-1
Vmax,uM hr-1 mg-1,9,1
Reaction time,hr,9,1
PD50,mg kg-1 day-1,9,-1
Cytotoxic concentration,,9,-1
Cytotoxicity,M dm-3,9,-1
K,10'2/M/s,9,1
Abrasion score,,9,0
No. of animals,%,9,0
MIC,10^3nM,9,-1
k cat/Ki,M-1 min-1,9,-1
K,10'3L/mol,9,-1
MTC50,mg kg-1,9,-1
Reaction,%,9,1
MTC50,uM,9,-1
MED100,mg kg-1,9,1
K,10'5/s,9,1
K,10'6/uM/s,9,1
Derived trabecular thickness,uM,9,0
K,10'8/M/min,9,1
Glucuronidation,nmol/min/mg,9,1
Acetylcholine level,uM,9,0
Median,day,9,1
Acid secretion,,9,-1
Vehicle control,%,9,1
Vdss/dose,L/Kg,9,0
K,10^-6/M/s,9,-1
ERH,min,9,0
Binding Decrease,%,9,1
Active dose range,,9,0
Papp,10'-6cm/s,9,0
Binding activity,%,9,1
Vd,kg-1,9,0
Creatinine_CL,ml min-1 kg-1,9,0
Vasodilation,,9,1
Vascular accumulation ratio,,9,0
Maximal binding,,9,1
Maxi-K current,,9,-1
INH,IU/mg,9,0
k0,s-1,9,-1
K,10^5/M.s,9,-1
k2,10e3 s-1,9,1
INH,10'5L/mol/s,9,-1
No. of ferrets,,9,0
EC25,%,9,1
K,L/mol/s,9,-1
INH,10'-8M,9,-1
Urine output,ml kg-1,9,0
ED97,mg kg-1,9,1
PDD50,,9,-1
Binding competition,%,9,1
LD50,10'-1 ug/ml,9,1
K A,M-1,9,1
I50,10'6mol/L,9,-1
Unwinding,,9,0
Chronic TI,,9,0
logPi,,9,0
k2/KI,nM-1 min-1,9,-1
CLH,ml/kg,9,1
INH,10'-4/min,9,1
Activity,10'-8mol/L,9,1
DA utilization,,9,0
Kq,10^12/M,9,-1
ED80,umol/Kg,9,1
PDR,,9,0
RD500,ug rat-1,9,-1
Kq,10^4/M,9,-1
Tumor free survivors,,9,0
No. of mice surviving >6 months,,9,1
Pt,cm s-1,9,0
ED6,,9,1
Connectivity density,mm**-3,9,0
Activity,10'4log10CFU/ml,9,-1
MNTD,,9,-1
AC30,uM,9,-1
K obs,M-1 s-1,9,1
Cmax,ugequiv/g,9,0
Ca2+ serum,,9,1
Activity,10'5log10CFU/ml,9,-1
DC,,9,0
K x10e-5,M-1,9,-1
ED50,ug/Kg/min,9,-1
Bleeding time,min,9,-1
ID50,10'-6 mol/L,9,-1
AUC,uM L,9,0
K+ output,uM kg-1,9,0
Cp/dose,nM,9,0
Toxic/total,,9,-1
K2,1/M*s,9,-1
Total peripheral resistance,mmHg ml-1 min-1,9,0
Activity,10^-6No_unit,9,0
Total activity,,9,0
NADH oxidation,nM min-1,9,1
KA,10^3/M,9,-1
Tissue area,mM,9,0
Ratio,L/min/umol,9,0
khydr,min-1,9,-1
MDH Reactivation,%,9,1
DD,uM mM-1,9,-1
Time constant T4,ms,9,0
MDD,mean day of death,9,1
2x aPPT,uM,9,-1
Activity,A570 min-1,9,1
solubility,mg kg-1,9,0
kobs,/min,9,1
Threshold concentration,uM,9,-1
No. of strains,,9,0
CT50,mM,9,-1
Mutation frequency,,9,1
Activity,Amax nM-1,9,1
KL,uM,9,-1
Therapeutic index,%,9,0
Therapeutic efficacy,,9,0
Mu/delta ratio,,9,0
Tetramer,%,9,1
Motor activity,Counts,9,1
KSV,10'3L/mol,9,-1
DNA damage,10e7 exchanged dCps (ng of DNA),9,0
ED50,fmol,9,-1
Cmax normalised,nM.kg/mg,9,1
Min ED,mg kg-1,9,-1
TW,,9,0
LD50,ug fly-1,9,-1
AUC,nM.hr/L,9,0
KT4,M-1,9,-1
Activity,M kg-1,9,1
MTS50,ug ml-1,9,-1
Peak effect,,9,0
Pc,,9,0
No. partial,,9,1
EC1000,uM,9,-1
ED50,10'-9 ug/ml,9,-1
ED50,10'-8mol/cm2,9,-1
Dose,mg,9,-1
Content of cell cycle,%,9,1
Drug uptake,pg,9,0
CL,ul.min.nmol-1,9,1
Ka,10'10/M,9,-1
No. pregnant/mated,,9,1
Ka,10'3/M.s,9,-1
Ratio,10'-4No_unit,9,0
DOM,,9,-1
AUC,micromol.hr/L/mg/kg,9,0
TE50,,9,-1
TDI,10'-4/min,9,1
MBIC,mg/ml,9,-1
TD50,micromol/kg,9,-1
Activity,gAi/ha,9,1
CL,mL/min,9,1
TC50,uM/ml,9,-1
NonRGS-EC50 (uM),uM,9,-1
Activity,log10/ml,9,1
Ka,10^4/Ms,9,-1
ED40,10^-5 mol/L,9,-1
TAI,,9,0
Ratio,/min/mM,9,-1
DSB,,9,0
logMEC,,9,-1
Ka,10^8/M,9,-1
T1/2,%,9,1
A50,mM kg-1,9,-1
IC50,uM tube-1,9,-1
ED300,nM,9,-1
Cmax/dose,ng/mL/(mg/kg),9,0
RF,delta beats min-1,9,-1
ED30,mM,9,-1
Activity,mg.equiv,9,0
Marrow area,mM,9,0
Periosteal mineralizing surface,%,9,1
PRL,ng ml-1,9,1
Kapp,10^-3/hr,9,-1
Directly measured thickness,uM,9,0
Activity,microM/s,9,1
Activity,microg/cm2,9,1
Activity,microg/cm2/h,9,1
LC100,ng/ml,9,-1
Rate of rotation,,9,1
OD max,mg,9,1
Activity,millimeter/mg/ml,9,1
ODC activity,(nM of CO2) hr-1 (mg of protein)-1,9,-1
ABC,mmHg hr-1,9,1
ED200,nM,9,-1
permeability,mole fraction,9,0
Permeability coefficient,,9,0
Permeated,%,9,1
Activity,nM min-1 (10e-6*cells)-1,9,1
ID25,mg kg-1,9,0
Decay-time constant,ms,9,0
PT extension,nM,9,-1
Kbapp,,9,-1
Kbb,,9,0
Summation MABP,,9,1
Rate of death,%,9,1
Kcat,10'-5/s,9,1
SubG0,%,9,1
COF,c.p.m. (mg of protein)-1,9,-1
Occ50,mg Kg-1,9,-1
Activity,nmol/mg/hr,9,1
Log GTI,,9,-1
C0,nM,9,0
Activity,pM min-1 (mg of protein)-1,9,1
Max delta,uM,9,-1
Activity,pmol/mg.min,9,1
Clonic seizures,,9,0
C10 air,uM,9,0
Kcat/Km,10^-6 microM/s,9,-1
Decrease in pressure,mmHg,9,-1
Activity,uL/min,9,1
Rate,nM min-1 (nM of cytochrome P450)-1,9,-1
AD50,nmol/kg,9,-1
MIC90,%v/v,9,0
Social interaction,,9,0
Control tumor volume,,9,0
Smax,nM min-1 kg-1,9,1
Contractility,,9,0
Max change,%,9,1
Simulation,%,9,1
Latency time,%,9,1
Sensitisation,,9,0
Distribution,l kg-1,9,0
Acute TI,,9,0
Acute toxicity,M dm-3,9,-1
Body temperature,%,9,1
Ae,% ID/g,9,1
ECAUC0.2,,9,1
Secondary response,,9,1
Onset seizure,,9,-1
Max binding,%,9,1
Max blood pressure fall,%,9,1
AFC50,ppm,9,-1
Scavenging Activity,%,9,1
IC50,min,9,-1
Range of survival,,9,1
Degree of activation,fold,9,1
Onset time,min,9,0
Lag time,min,9,1
pA2,%,9,0
RBA,h/min,9,0
SUV,g/ml,9,0
CLz/F,ml/min.kg,9,-1
STY seizure,,9,-1
ST/CB ratio,,9,0
Delta,,9,0
LD10,mg/m2,9,1
IC50,10'-4nM,9,-1
Minimum single dose,mg kg-1,9,1
SEC50,M,9,-1
Range of deaths,day,9,1
Amplitude,mV,9,0
Amylase stimulation,max,9,0
Chelator,%,9,1
SC50,mM,9,-1
AT1 affinity,nM l-1,9,-1
Oral duration,hr,9,1
Kel,,9,-1
Keq,,9,1
AHA,delta mmHg,9,1
Lung weight,g,9,1
PKB,,9,0
EC80,uM,9,-1
E,-V,9,0
Rs,ul min-1 kg-1,9,0
Rs,nM min-1 kg-1,9,-1
E,%,9,1
Postdrug,ug kg-1,9,1
Animals dead,,9,0
Geometric mean,M,9,-1
Antiamnesic activity,,9,0
Duration time,,9,0
Anticonflict activity,,9,0
Ki,10e2 M-1 s-1,9,1
Resting potential,mV,9,0
Ki,app,9,-1
Responders,,9,-1
Potency,MU,9,0
Gastriculcer index,,9,0
LogD5.5,,9,0
tz,hr,9,1
CC50,%,9,1
IC>80,uM,9,-1
Predrug,ug kg-1,9,0
Pregnant,%,9,1
Approx. pKa,,9,0
Mortality number,,9,0
IC50,mol,9,-1
Body weight gain,mg,9,1
Area,mm**2,9,1
Relative thymus weight,mg 100g-1,9,1
Log ratio,,9,0
Primary response,,9,1
EC50,M kg-1,9,-1
Production,ng 2hr-1,9,1
Drug uptake,mg/g,9,1
pMLD,,9,-1
Cp,ng/mg,9,0
Pa,,9,0
Average weekly weight change,%,9,1
AP,mV,9,0
IC50,10^-10mol/L,9,-1
Kinase activity,pM min-1*ml-1,9,1
Drug uptake,micromol/min,9,1
Relative adrenal weight,mg 100g-1,9,1
pKa5,,9,-1
Mean survival,time day-1,9,1
Propioaldehyde generated,uM,9,-1
Reduction of heart rate,%,9,1
DeltaTm,,9,0
HR,delta beats min-1,9,-1
selectivity,,9,0
Increase in concentration,,9,1
AUC/dose,ng.hr/g/mg/kg,9,0
deltaS,cal/mol,9,0
Na,uM,9,0
logI50,,9,-1
Increase in CBF,,9,1
Clast,ng/g,9,0
deltaG,cal/mol,9,-1
MPR,%,9,1
Infection score,,9,-1
FRE,,9,1
dP/dt max,mmHg s-1,9,1
C50,ug ml-1,9,-1
Inhibition,(nM of H202) min-1 (ug of protein)-1,9,-1
EC37,ug ml-1,9,-1
Inhibition,c.p.m./Abs,9,0
First adverse effect,,9,0
Concentration,ug ml-1 ml-1,9,0
Na+ inactivation,,9,-1
Inhibition (at concentration M),%,9,1
[LDH]max,UI l-1,9,1
Hemolysis,,9,-1
Na+ output,uM kg-1,9,0
Flaking score,,9,0
F/dose,%,9,1
Na+ restoration,%,9,1
[ALP]max,UI l-1,9,1
APD70,ms,9,0
HHP,mg,9,0
Mean change,mM,9,0
pEC99,,9,-1
AUCt,hr/ng.ml,9,1
Hypotension,%,9,1
PD50,mM kg-1,9,-1
Inhibitory rate,%,9,1
AUCt,ng/ml,9,0
Corpora lutea,,9,0
Fold reduction,,9,-1
Implants,,9,1
Weight change at nadir,%,9,1
Change TC,,9,1
Immobility time,%,9,1
Cmax,ng/kg,9,0
Contractility,mmHg s-1,9,0
Vz/F,ml,9,0
t1/2lambda,hr,9,0
EC30,M kg-1,9,1
AUG,ng ml-1 hr-1,9,0
AUC(app),uM.hr,9,0
Endosteal mineralizing surface,%,9,1
Endosteal eroded surface,%,9,1
Fold_reduction,,9,-1
Ionotropic activity,,9,-1
Cells sickled,%,9,1
Volume of urine,ml,9,0
Recovered in urine,%,9,1
fIC20,nM,9,-1
fIC30,nM,9,-1
Emax,ug,9,1
I / E100,,9,-1
Cutaneous toxicology score,,9,0
VmaxH,pmol/min,9,1
Control death day,,9,0
Formation,,9,0
K,/ms,9,-1
K,/nM/s,9,-1
MPC/MIC,,9,-1
K,1/M,9,-1
Emax,hr,9,0
K,10'-1/s,9,-1
fT>MIC,,9,-1
Vmax(app),mM/min,9,1
Vmax(app),M/min,9,1
Vmax,umol/mg/min,9,1
Clast,uM,9,0
T,uM,8,-1
Diazepam antagonism,,8,-1
K,10^4No_unit,8,0
CC50%,ug ml-1,8,1
T,,8,0
Restoration,%,8,1
Hyperactivity,%,8,1
Microsomal stability,pg min-1 (mg of protein)-1,8,-1
Delta I/I,mV,8,0
DW,,8,0
Drug metabolism,nmol/ml,8,-1
Lipoprotein level,%,8,1
Max fall,mmHg,8,1
ED30,MPK,8,-1
Max fall in MAP,mmHg,8,-1
Drugexcretion,ug/g,8,0
Ki,kcat/Km,8,0
k-1,s-1,8,0
Ki,mg/ml,8,0
Cholesterol level,mg dl-1,8,0
IC40,nM,8,-1
R+V,90 min,8,0
Delta K,,8,-1
Antilipid peroxidation,,8,0
Activity,%Idose,8,1
CL,ng/ml,8,1
permeability,pmol/min/cm2,8,1
T/C max,%,8,1
Activity,mM-1,8,-1
DT50,day,8,-1
ITI activity,,8,0
Brain level,ug weight-1,8,0
RBI,%,8,1
TAD,%,8,1
Antitumour activity,,8,0
Antiuterotrophic activity,,8,-1
LT50,min,8,-1
EC50,ucm,8,-1
Cleavage,M,8,-1
HDL-C change,%,8,1
Log PTA,,8,0
tRNA peak exclusion,%,8,1
Drug uptake,cpm/uL,8,0
LSD,%,8,1
Weight at term,g,8,1
CC30,nM,8,-1
Log K'w,,8,0
Ka,10^3/M.s,8,1
Reserpine hypothermia,,8,-1
EC50,ppb,8,-1
Ki(1.8x10e-11),M,8,-1
GR50,nM,8,-1
Vd,L,8,0
Drug uptake,nmol.hr/g,8,1
Ki.c,,8,-1
Drug metabolism,nmol.min,8,0
Normal weight gain,%,8,1
EC50,pmol/L,8,-1
Apparent binding constant,M-1,8,-1
K,10^-6M,8,-1
Cavg,pg/mL,8,0
Cocaine,%,8,1
TC90,uM,8,-1
AUC,0-24hr,8,1
Mean response,,8,0
CAT activity,,8,-1
CT,ms,8,0
Ka,10'9/M/min,8,1
Active culture,%,8,1
Activity,g/ml,8,0
MBEC90,ug ml-1,8,-1
KiH,uM,8,-1
CL,nmol/min,8,1
I/IC50,,8,-1
Quenching,%,8,1
Interferon response,ml,8,0
WBC x10e-3,ul-1,8,0
Arrhythmia score,,8,0
LD app,mM kg-1,8,-1
pBBB,10'-6 cm/s,8,1
Dose elevation,mg kg-1,8,1
AUBC,log10CFU/ml,8,-1
Drug metabolism,mol,8,0
Diffusion analysis,,8,1
LH,,8,0
ED50,10'-3mmol/kg,8,-1
Atherogenic index,,8,0
QT interval,,8,1
Drug metabolism,mmol/L/hr,8,1
Relative to DA,%,8,1
Hypermotility,,8,0
ED50,10'-5M,8,-1
Kii,,8,-1
AUEC,%,8,1
HDL cholesterol,mg kg-1,8,1
TGI50,ug kg-1,8,1
Diffusion,%,8,1
CAC,mM,8,1
Ka,10'2/M/s,8,1
APTT,nM,8,-1
Delta logS,,8,0
Ka,10'-5/M/s,8,1
pEMR,,8,-1
Cp,nmol,8,0
Ka,10'-2/M,8,1
Delta mean blood pressure,,8,-1
Blood glucose,mM l-1,8,0
Max lowering MABP,mmHg,8,1
Activity,OD/mm2,8,1
Dose modification,,8,-1
Activity,Kcal/kg/day,8,1
Kina,min-1,8,1
Koff,M-1,8,-1
Vz/F,(mg/kg)/(ug/ml),8,0
Tc,uM,8,-1
HD10,ug ml-1,8,1
Brain level,pM forebrain-1,8,0
ID50,uL/L,8,-1
CL,uL/min/pmol,8,-1
GID75,mg/m2,8,1
molecular ellipticity,deg.cm2/dmol,8,1
Frequency,beats min-1,8,0
Relative metabolic rate,,8,0
AUC,nM.hr/mg/kg,8,0
Frequency,%,8,1
LDL-C,%,8,1
log Pe,cm2/sec,8,1
Binding,dpm mg-1,8,0
ED50,mg kg-1 (day in diet)-1,8,1
Blood clearance,ug ml-1,8,0
Average proportion,,8,1
PC50,ug,8,-1
Therapeutic index,mg kg-1,8,0
Kinact,10'5/M/s,8,1
max inhibition,%,8,1
Progesterone production,ng 2hr-1 (10e5*cells)-1,8,1
Drug uptake,nmolequiv/g,8,1
AAL,,8,0
LDL cholesterol,mg kg-1,8,0
LD100,uM,8,-1
Highest nontoxic dose,mg kg-1 (day in diet)-1,8,1
I/E,,8,-1
Du,,8,0
LD50,umol,8,-1
KDss,M,8,-1
ED50,mg/kg/hr,8,-1
DFMBMD,mg/Ecm,8,0
Ratio,10^5/s/M,8,-1
MDA content,uM (g of tissue)-1,8,0
ED50,mpk day-1,8,1
Kinact,10^6nM,8,-1
DeltaCp,kcal/mol/K,8,-1
Tidal volume,%,8,1
PC95,ug,8,1
Cytotoxity,%,8,1
Tidal volume,ul,8,0
Log effect,,8,-1
ID95,uL/L,8,0
No. of axonal branch points/cell,,8,1
AUC,pM kg-1,8,0
Basal control,%,8,1
Krelative,,8,0
Ratio of depolarizing activity,,8,0
Cumulative amount,ug,8,0
Mean reaction,,8,0
ED50,ng,8,-1
Activity,10^5/ml,8,1
Tissue level,ug ml-1,8,0
KA,M,8,1
Activity,10^3No_unit,8,1
ED50,nmol/mouse,8,-1
Relative Potency Ratio,,8,1
ka,L/hr,8,1
K6,s-1,8,-1
HSA shift,,8,0
Prolonged VRP,%,8,1
K6,1/min,8,1
DC50,ug ml-1,8,-1
LD50,umol/ml,8,-1
Log cfu/g of tissue,,8,1
K5,1/min,8,1
Property,,8,0
2TT,ug ml-1,8,-1
Binding,M of drug (M of BSA)-1,8,-1
Morphology,,8,0
K,10'-5/nM/min,8,1
Vm,%,8,0
Enantiomeric composition,%,8,0
Proportion of survivors,,8,0
Km,/uM,8,-1
Reduction in TG,%,8,1
ED50,pg/ml,8,-1
Protection,nM,8,-1
Total cholesterol,mg kg-1,8,1
Dose normalized clearance,ml/min.kg,8,0
Cmax normalised,(umol/L)/(mg/kg),8,0
Density,mg/cm3,8,0
K2,10e-3 min-1,8,1
Increase in blood pressure,%,8,1
dp/dt(max),%,8,1
IC0,ug ml-1,8,-1
Change in LV dp/dt,%,8,1
Vss,l hr-1 kg-1,8,0
Fever response,degrees C,8,1
K1,M-1 min-1,8,1
Cmax,ug,8,1
No. of protected/tested,,8,1
AUC/dose,ng.hr.kg/ml.mg,8,0
Change,beats min-1,8,1
LC95,ug ml-1,8,-1
Boron concentration,ug g-1,8,0
fCmin,nM,8,1
ED50,ug ear-1 dose-1,8,1
Cmax normalised,(ng/mL)/(mg/kg/day),8,1
NADH oxidized,nM min-1,8,1
Vmax,nmol,8,-1
Dobs,,8,0
Increase in LD50,%,8,1
MED,ug/kg,8,1
Fg,%,8,1
Edema,ul,8,0
fAUC,nM.hr.kg/mg,8,1
Vmax,nmol/hr/microg,8,1
MID,mg kg-1,8,1
K-2,min-1,8,-1
MHC,umol/L,8,0
ID40,,8,1
Concentration,ug/10e6 cells,8,-1
GDPactivity,nM min-1 mg-1,8,-1
Vmax,M min-1 mg-1,8,1
Ca2+ elevation,,8,0
IC27,uM,8,-1
IC50/[E],nM milliunit-1,8,-1
Median retension latency,,8,-1
Glucuronidation rate,nM min-1 mg-1,8,-1
Reduced BP,%,8,1
AUC normalised,(umol.h/L)/(mg/kg),8,1
No. of pits/slice,,8,1
Ratio,uL/min/pmol,8,0
Change in MABP,%,8,1
Activity,10'6/M,8,1
Increase (Emax),%,8,1
2x APTT,nM,8,-1
delta logP,,8,0
Activity,10'5No_unit,8,1
Vmax,M-1 s-1,8,0
K m,uM,8,-1
Human potency,MU,8,1
Triglyceride level,,8,0
ID50,10'-6M,8,-1
ADD,s,8,-1
MTD,%,8,1
LD90,p.p.m.,8,-1
k x10e-3,min-1,8,-1
Tt,,8,0
Ct,ng,8,0
MIC,10^-3mM,8,-1
Volume of air,ml,8,1
Tumor area,mm**2,8,1
Mean pit size,um2,8,0
cholesterol level,mg dl-1,8,1
HPB,,8,0
k3/ki,M-1 s-1,8,1
Ac,uM,8,-1
FICI90,,8,-1
FICI50,,8,-1
Activity,10'4 /uL,8,0
BPR,10'-3/hr,8,1
Emesis,vomiting/tested,8,1
Max uterine weight,mg,8,1
cAMP production,N,8,0
Tumor response,,8,1
Calculated Ratio,,8,0
LC99,ug ml-1,8,-1
ED70,uM,8,-1
Tumor uptake,uM kg-1,8,0
AUMC,ng.hr/ml,8,0
rT3 Production,pM tube-1,8,0
Turnover,%,8,1
Cellular uptake,pM ul-1,8,1
k obs / concentration,,8,-1
Activity,10'1/mm2,8,1
K app ratio,,8,0
alkaline phosphatase activity,U l-1,8,0
Carbonyl group,,8,0
Ct,nmol/Kg,8,0
aPTT,uM,8,0
LD50,%,8,0
Jmax,pmol/min,8,1
K alkyl,s-1,8,-1
Max weight loss,%,8,1
Ratio CIC95/IC50,,8,-1
IC05,ug ml-1,8,-1
Control of P-450 marker,%,8,1
Vmax,cpm,8,0
AUClast/dose,ng.hr/ml/mg/kg,8,1
AUClast/dose,uM.hr,8,0
Effective dose,mg,8,1
AUC normalised,((ng/mL).hours)/(mg/kg/day),8,1
K DMPG,M-1,8,-1
Plasma level,,8,0
Latency to step through,s,8,-1
Drug degradation,pmol/min,8,-1
Activity,um3,8,0
Of non-HDL-C,%,8,1
Oligo modified,%,8,1
Serum concentration,nM l-1 hr-1,8,0
Latency time,,8,1
CMT,uM,8,-1
Severity,,8,0
Kd,10^-5/s,8,-1
CGI,uM,8,-1
permeability,10'-7nmol/cm2/min,8,1
Kd,10^-6/s,8,-1
ROR,%,8,1
Kd,10^1 uM,8,-1
Activity MABP,%,8,1
Km(unbound),uM,8,-1
CL(app),uL/min,8,0
[Ca2+] increase,,8,1
Skin response,,8,0
AUC,ug.min/g,8,0
Papp e-6,cm s-1,8,0
Selectivity rating,,8,0
K DMPC,M-1,8,-1
Kd,10^5/s,8,-1
IC12,ug,8,-1
MAC,mg/ml,8,0
Skin scaling,,8,0
Urinary excretion,ug,8,1
Selectivity,uM s-1,8,-1
pD2,uM,8,-1
Receptor occupied,%,8,1
LD50,mg kg-1 (day in diet)-1,8,1
RP,mV,8,0
C10,nM,8,-1
Rate,nM min-1,8,-1
Onset of block,min,8,1
GR10,gAi/ha,8,1
Contractility (LV dP/dt),,8,-1
Free C,nM,8,-1
Drug uptake,ng/kg,8,0
Ct,pmol,8,0
Plasma half life,min,8,0
Log TCI,,8,0
Smax,,8,1
Activity,uM ml-1,8,1
Affinity,M-1,8,-1
Plasma concentration,uM l-1,8,0
Of HDL-C,%,8,1
Scavenging Activity,,8,-1
NSVT,mg kg-1,8,0
MPD,ug kg-1,8,1
Ratio I/P,,8,0
pA2,mg,8,0
Km/Ki,,8,-1
MST,hr,8,1
Inhibitory concentration,mM,8,-1
CLH,g/ml/min,8,-1
Kdiss,1/s,8,-1
Extension,%,8,1
AUMC,hr2.ng/ml,8,1
Specific activity,ukat kg-1,8,1
No. of killed or paralyzed,,8,0
MBBC,ug ml-1,8,1
Platelets x10e-3,ul-1,8,0
permeability,a.u.,8,0
K,/day,8,1
Mean time to seizure,,8,1
Emax,pg/ml,8,1
Vocalization time,s,8,1
NSR survival rate,,8,1
K,s-1,8,-1
Level,mequiv/L,8,0
Stability,%Idose,8,0
Activity,pmol/million cells,8,1
Activity,pg/ml/hr,8,1
Bmax1,%,8,1
Deiodination,%,8,1
Kcat/Km,10'-2/microM/s,8,-1
Cysteine reaction,min-1,8,0
Drug metabolism,ug,8,0
K,pM,8,-1
Level,ug ml-1,8,0
Pm,10'-5 cm/min,8,0
M/T,,8,0
CFU,10^6/ml,8,-1
permeability,microg/cm2/h,8,1
CFU,10^2/ml,8,-1
Stabilty,hr,8,0
CFU,10'4/ml,8,-1
Kcat,pmol/min,8,-1
Activity,nmol/mg.hr,8,1
Log P/(100-P),,8,0
Level,units/mL,8,1
Activity,10'-3dpm,8,-1
Cholesterol,%,8,1
Activity,ng/mL.hr,8,0
K,min,8,0
Activity,ng/dl,8,1
EDmax,uM kg-1,8,1
Amount incorporated,M (M of tubulin)-1,8,1
XL50,uM,8,-1
HCMV yield,pfu/ml,8,1
Supressive effect,ug ml-1,8,1
Activity,nM/hr,8,1
log10CFU/ml/day,,8,-1
Ke naloxone,nM,8,-1
Delta APD90,%,8,1
Vmax(app),pmol/min.mg,8,1
Uterotonic activity,IU mg-1,8,1
Uterotrophic activity,,8,0
BW,%,8,1
Survival extension,,8,1
Activity,mutants (10e4*survivors)-1,8,1
Mean total resorption,um2,8,0
Survival ratio,%,8,1
Drug uptake,uL,8,0
AUCt,ngequiv.hr/g,8,1
Kel,h-1,8,1
Ct,ug,8,0
Max delta FC,%,8,1
ID50,ng/kg,8,-1
V/K,,8,-1
Papp,cm min-1,8,0
Activity,mmHg.hr,8,1
ITP,,8,-1
Activity,/uM,8,-1
Survivors,N/total,8,1
E/Emax,,8,1
GTP-gammaS Index,,8,-1
Max delta FRP,,8,-1
Khydrol,s-1,8,-1
RRI,,8,-1
Counts/30,min,8,0
-ln (MIC),,8,-1
Hypocalcemic activity,IU mg-1,8,-1
ABC,,8,0
HD10,uM,8,-1
Rate of reduction,uM min-1mg-1,8,-1
fAUC/dose,microM.hr/mg/kg,8,0
k2,min-1 M-1,8,-1
V0,,8,-1
Wet weight,g,8,1
Damage score,,8,0
LD40,uM,8,-1
Rotations/10 h,,8,1
K,10^7/M,8,-1
Max delta MABP,mmHg,8,1
PT,nM,8,-1
ED25,10'-8M,8,-1
D-2,%,8,1
ED25,mg/kg/day,8,-1
Activity,microL/min/kg,8,1
MBC99,uM,8,-1
Drug uptake,RFU,8,0
Revertant colonies per plate,,8,1
Eudismic ratio,,8,0
Reversion,,8,0
Delta F,%,8,1
Cmax_metabolite,ng/ml,8,0
Delta FFA,,8,1
Permeability,*10e6,8,0
Papp,10'-6cm/s2,8,0
ABBC,log10CFU/ml.hr,8,-1
Oxidation rate,,8,0
RBC x 10e 3,ul-1,8,0
Melanotropic activity,,7,-1
ClM,ml min-1,7,0
Clast,nM,7,0
Median life span,,7,0
Concentration of max response,,7,-1
Cmax,%,7,0
MPC,uM,7,-1
MPE,mg kg-1,7,1
Concentration,ug rat-1 hr-1,7,1
Concentration,ug of B g-1,7,0
pCB50,,7,-1
Mean aortic flow,ml min-1,7,0
Cmax,ngequiv/g,7,0
IC60,uM,7,-1
Glucose uptake,nM hr-1 (mg of worm),7,-1
MTD,mpk,7,1
Max rev,%,7,1
Cmax normalised,microM/mg/kg,7,0
Max lowering,,7,1
Max intensity,rotations min-1,7,1
Max efficacy,%,7,1
AE activity,,7,0
Max delta BP,,7,1
Cmedia,ug of B/ml,7,0
Max Uosm,mOsmol kg-1,7,1
pA2-pA10,,7,-1
Max contractile force,,7,1
ATP content,pM (mg of protein)-1,7,0
ID30,uM,7,-1
logD IAM,,7,0
AUC,cm2,7,0
AUC,microM/hr/mg,7,0
GID75,mg/me2,7,0
AUC,min,7,0
AUC,ml/min.kg,7,1
AUC,ng.min/g,7,1
ID50 mg/kg,,7,-1
IE1,eV,7,0
AUC,s,7,0
kH,s-1,7,0
AUC,uM hr-1 ml-1,7,0
"kC,U",hr-1,7,0
ILS40,mg kg-1 day-1,7,1
GABA agonism,,7,-1
G1,%,7,1
permeability,umol/cm2/hr,7,1
INH,10'-6 mol/L,7,-1
k2,m M-1 hr-1,7,-1
k1,min-1,7,-1
I50,%,7,1
k',s-1,7,-1
Fu,ng/g,7,0
k cat,-1/min,7,-1
Free radical scavenging,%,7,1
k act,M-1 s-1,7,-1
fIC90,uM,7,-1
AUC ratio,,7,0
Incidence of occlusion,,7,0
AUC/dose,hr.nM,7,0
fAUC,ng.hr/g,7,1
Fh,%,7,1
AUC/dose,min.uM,7,0
AUC/dose,min.ug/ml/(mg/kg),7,0
Increased life span,,7,1
AUC/dose,uM.hr.mg/kg,7,0
Induced frequency,,7,0
HR,delta %,7,1
Infarct volume,mM,7,0
IC100,umol/L,7,-1
AUC/dose,uM.min.kg/mg,7,0
AUClast,hr.nmol/ml,7,1
cell kill activity,,7,-1
FLT,%,7,1
AUClast,ng.min/g,7,1
cAMP,,7,-1
[Ca2+] variation,nM,7,0
Zone of stimulation,,7,1
AUCt,nmol.hr/g,7,0
Writhing number,,7,0
Erythema intensity,,7,1
AUCt/dose,nM.hr/mg,7,0
Hypnosis potentiation,%,7,1
WBC,10e3 ul-1,7,0
Intrinsic vasorelaxation,M,7,-1
Vss,L,7,0
Iron clearence,ug kg-1,7,1
Vomiting frequency,,7,0
Iron mobilized,%,7,1
Irreversible binding,,7,-1
Jss,ug/cm2.hr,7,0
Volume,ml 4hr-1,7,1
Volume,ml 2hr-1,7,0
Emax,uM kg-1,7,-1
Vmax/Km,uL/min/U,7,1
K,/uM/min,7,-1
Vmax/Km,uL,7,1
Vmax,ug/min.kg,7,1
AUMC,ug/ml.hr'2,7,0
Vmax,uM min-1 unit-1,7,1
Vmax,rel,7,0
Vmax,pmol/s,7,1
Vmax,pM s-1 mg-1,7,1
Vmax,nM min-1 (mg of protein)-1,7,1
Efficacy,number ul-1,7,1
Absolute ratio,,7,0
K,10'4/M/min,7,-1
Vmax,U/min,7,-1
Acceleration,,7,1
K,10'6/s/M,7,-1
Vmax,1/min,7,1
Vm,uM min-1 (mg of protein)-1,7,1
Virus yield reduction,,7,-1
Viral titer,PFU.mL-1,7,-1
K,10^-5/M/s,7,1
Vd/F,,7,0
K,10^-8M,7,-1
Activity,%.min,7,1
Activity,%/mmol,7,1
Vbeta,L/hr,7,0
Vagus,delta %,7,1
K,10^4/M/min,7,1
K,10^7/M/min,7,1
Hydrolysis,nM min-1 mg-1,7,1
Uterotropic effect,,7,0
Activity,10'-3 mol/L,7,-1
K Bind,nM,7,-1
Unreacted drug,%,7,1
Ulcer index,,7,1
K app,M-1 s-1,7,1
Activity,10'3log10CFU/ml,7,-1
Activity,10'4/M/s,7,-1
ED50 mg/kg,,7,-1
Activity,10'5/mm3,7,1
Activity,10'5AU/sec,7,1
K',,7,0
ED50,ug embryo-1,7,1
Activity,10'7CFU/g,7,1
Activity,10'8CFU/ml,7,1
IC30,10'-6M,7,-1
Activity,10^-3/min/uM,7,1
ED50,uM g kg-1,7,-1
K3,min-1,7,0
Activity,10^3/ml,7,1
Tissue swelling,ul g-1,7,0
Time to onset,min,7,0
Time to offset,min,7,0
KH,uM,7,-1
KII,M,7,-1
KSV,10^3/M,7,-1
KSV,10^5/M,7,-1
Ka,/mM/s,7,1
Ka,/s,7,-1
ED50,10'-9M,7,-1
Ka,1/M*1/S,7,1
ED50,10'-4M,7,-1
TDI,/min/M,7,-1
TD50/ED50,,7,-1
Activity,fg,7,0
ED5,ug ml-1,7,0
Ka,10^1/Ms,7,-1
Activity,m/3h,7,1
T>EC99,hr,7,1
Ka,M,7,-1
T/C (survival),%,7,1
Ka(T4),%,7,0
Ka1,,7,-1
T.I.,,7,0
ED250,,7,1
Kapp,/hr,7,-1
Kapp,/s,7,1
Kapp,10'-2/s,7,1
T max,,7,0
ED25,ug/kg,7,1
Activity,mgequiv/g,7,1
ED25,10'-7M,7,-1
Activity,millimeter/hr,7,1
Kb,10'4No_unit,7,-1
Kb,10'8/M,7,-1
HCMV yield reduction,pfu/ml,7,-1
ED20,ng,7,1
Kb,10^6L/mol,7,-1
Activity,mmol/min/mg,7,1
Activity,ng/kg/day,7,1
Kcat,10'4/s,7,1
Stroke volume,ul,7,0
Activity,nmol/hr/L,7,1
Activity,omegacm2,7,0
Kcat/Km,10'-5/M/s,7,1
Stability,microM/min,7,1
Spread,%,7,1
Spontaneous activity,,7,0
Kcat/Km,10^-5/nM/s,7,-1
Kcat/Km,10^7/M/s,7,-1
Activity,uU/ml,7,1
Kd,1/Ms,7,-1
-Log KD50,,7,-1
ED,mg,7,1
Selectivity ratio,%,7,0
ECAUC0.2,uM,7,-1
"Kd,app",nM,7,-1
KdH,uM,7,-1
KdL,uM,7,-1
Saq,,7,0
Saftey margin,,7,0
Agonist,,7,1
SF50,nM,7,-1
Amount formed,pM,7,-1
EC90,ng/ml,7,-1
S50,umol/L,7,-1
S50,uM,7,-1
Rn,,7,0
Antagonist activity,ug min-1 kg-1,7,1
Anti-infectious effect,,7,-1
Retention,,7,0
Antidiuretic,mg,7,0
Resowing,%,7,1
EC50,umol/g,7,-1
Ki 0.5,,7,-1
Antiuterotropic effect,,7,0
EC50,uL/L,7,-1
Repolarization time,,7,0
Repellency,,7,-1
Apparent_pKa,,7,0
Kii,uM kg-1,7,-1
Relative substrate velocity,%,7,1
Kin,10^-4ml/g/s,7,0
Relative rate of decomposition,(nM of drug) min-1 ml-1,7,-1
Relative potency,M,7,0
Kinact,1/min,7,-1
Relative liver weight,%,7,0
Average survived,day,7,1
Avoidance time,s,7,1
pM,,7,-1
IC50,10^-2microM,7,-1
BPI,%,7,0
Km(app),,7,0
2aPTT,10'-3M,7,-1
Ba,%,7,1
HC50,10'-5M,7,-1
Receptor binding,,7,-1
EC30,10'-7M,7,-1
Kq,10'5L/mol,7,-1
Binding intensity,%,7,1
Ratio CC50/EC50,10'3No_unit,7,1
Block time,ms,7,1
Ratio,10'6/M,7,1
Kun,s-1,7,-1
Ratio,10'2/s.M,7,-1
LAL test,,7,0
Rate of reduction,nM min-1 mg-1,7,-1
LC20,ug ml-1,7,-1
E0,,7,0
LC50,umol/dm'2,7,-1
Duration of immobility,,7,1
Radiolabel recovery,ug ml-1,7,0
Radiolabel recovery,ng/g,7,0
Boron incorporation,ug/10e6,7,0
LD,uM kg-1,7,-1
LD10,mg/me2,7,1
Brain/Blood concentration,,7,0
Drugabsorption,ug/g,7,0
C/T,,7,1
C0,,7,0
Drug uptake,nmol/mg/min,7,1
Drug uptake,nmol/L,7,0
Pyrogenic effect,,7,1
Pupil size,mM,7,0
LD84,mg kg-1,7,-1
LD90,mg/ml,7,1
LD95,microg/cm2,7,-1
Drug uptake,mmol/Kg,7,1
LDH release,%,7,1
Profile,,7,0
Production,,7,1
Proconvulsant action,,7,1
LLR msad,mg kg-1,7,-1
CBF-ID75,ug kg-1,7,1
CFU,10'3/ml,7,-1
CFU,10^5/ml,7,-1
CFU,10^7/g,7,-1
Lactate produced,nM hr-1 (mg of worm),7,0
Lambda-em,nm,7,0
Lambda-ex,nm,7,0
CFU,10^7/ml,7,-1
Platelet,10e6 ul-1,7,0
Lesion index,mM,7,1
Drug responding,,7,0
Plasma glucose level,mg dl-1,7,1
Lethal toxicity,,7,1
Lethality,mg kg-1,7,-1
Drug recovery,g,7,0
CIC IC50,nM,7,-1
CIC90,,7,-1
Level,ug g-1,7,0
Phospholipidosis_MEC,,7,-1
Perturbations,,7,1
Light transmission,%,7,1
Permeability coefficient,nm s-1,7,0
Drug metabolism,pmol/mg.hr,7,1
Drug metabolism,nmol/J,7,0
Drug metabolism,nanomol/min,7,-1
Drug metabolism,mol%,7,0
CL,mg min-1 kg-1,7,-1
Log 1/ED30,uM kg-1,7,-1
CL,mg/min/kg,7,-1
Drug metabolism,/min,7,-1
Papps,cm s-1,7,0
Drug degradation,nmol/J,7,0
Papp,10^-5 cm/s,7,1
Log Dmax,,7,0
Log IC50,%,7,0
PTZ seizure,,7,-1
Log Ki,%,7,0
A50,umol/Kg,7,1
CLH,L/hr,7,1
PFC/spleen,,7,1
CLH,micromol/min,7,-1
Depression,%,7,1
Log net cell kill,,7,1
Log rate,,7,0
Delta heart rate,beats min-1,7,0
CL_renal,ml min-1,7,0
CL_renal,ml s-1,7,0
CLb,%,7,1
rel ko,,7,0
IC50,nM/unit,7,-1
Delta MA,hr,7,0
CLint,uL min-1 mg-1,7,-1
Delta I,%,7,1
Oxygen consumed,nM min-1,7,1
Delta HR,min-1 hr-1,7,1
pIC30,,7,-1
CLtotal,ml s-1,7,0
Offset time,min,7,1
MAP,delta %,7,1
CMV yield,pfu/ml,7,0
CNS activity,,7,0
Decrease in No. of avoidence responses,%,7,1
CO,mM,7,0
Group toxicity,,7,-1
IC50,ppm g dm**-3,7,-1
Decrease,mM,7,-1
Dead/treated,,7,1
ODC Activity,(nM of CO2) 30min-1 (mg of protein)-1,7,-1
Damaged area,%,7,1
CPI,mN/meter,7,0
DTT inhibition,,7,-1
MBEC99.9,ug ml-1,7,-1
MBIC80,ug ml-1,7,-1
DNA peak exclusion,%,7,1
DNA binding,M-1,7,1
MCD,mg/kg/day,7,1
MEC,mg ml-1,7,1
DBP-20,ug kg-1,7,1
MED,(mg of base) 20g-1,7,-1
D2 duration,min,7,1
MED,mpk,7,1
Catalepsy,,7,0
MED,uM.kg/diet,7,1
Cell saturation,pM (10e5*cells)-1,7,-1
Cure,%,7,1
Nephrotoxicity,ng ml-1,7,0
Nephrotoxicity,mg dl-1,7,0
NTD50,mg kg-1,7,-1
Change,mg kg-1,7,0
NOAEL,ug/L,7,0
pEC20,,7,-1
NO2- (mol/mol),%,7,1
Creatinine_CL,ml/min,7,-1
sigmaL,%,7,1
Change in dP/dt,%,7,1
AD50,MPK,7,0
Change in mean aortic flow,%,7,1
Change in respiratory frequency,%,7,1
Mutation frequency,10e6 F,7,0
Change in respiratory frequency,beats min-1,7,0
Cp(f),mg/ml,7,0
Change in stroke volume,%,7,1
Change in tidal volume,%,7,1
Change in tidal volume,ul,7,0
IC50 reduction,%,7,1
Cp,pmol,7,0
Modification of adsorbed drug,%,7,1
Mitogenic effect,,7,0
sigmaH,%,7,1
ClB,ml min-1,7,0
Melanotropic potency,,7,-1
Radioactivity,nM equiv (ml of urine)-1,6,0
Radioactivity,nM equiv mg-1,6,0
Druguptake/dose,nM/mg/kg,6,0
Duration of plateau,min,6,1
E max,,6,1
PIC seizure,mg kg-1,6,-1
MIC70,uM,6,-1
CL/F,ml/hr,6,0
Body temperature drop,degrees C,6,-1
E1/2,mV,6,0
Rat fertility,%,6,1
CL/F,uM.hr,6,0
Distribution of excreted Fe,%,6,1
Rat turning,%,6,1
EAUC50,hr.ng/ml,6,-1
LC50,mg,6,-1
Median tumoral volume,cm*3,6,1
Distribution,% dpm,6,0
Distribution,% dose organ-1 ,6,0
Body temp drop,degrees C,6,-1
CLH,10'-6uL/min,6,-1
AUC,ng.eq.h.ml-1,6,0
Rate,pM min-1 (g dry weight)-1,6,-1
log(1/C50),,6,-1
Log MrI,,6,-1
Bmax2,%,6,1
Bmax,uM,6,0
CLH,microL/ml/min,6,-1
Rate of hydride transfer,s-1,6,0
Rate of turbidity change,,6,0
Bmax,fM g-1,6,1
Bmax,MFU,6,0
Blood/Plasma ratio,,6,0
Log Palk,,6,0
IC50,nA,6,-1
Blood pressure,,6,-1
Cp,ug,6,0
Kw,min-1,6,1
Blood loss,mg kg-1,6,1
Ratio,10'-5/M,6,0
Ratio,10'3/M.s,6,-1
EC1000,umol/L,6,-1
Block,,6,1
Ratio,ng/mg,6,1
Bitter taste intensity,0-15 scale,6,1
Kq,,6,-1
Kq,10^13/M/sec,6,-1
Ratio CC50/IC50,10'3No_unit,6,1
Binding constant,,6,-1
Binding constant,l M-1,6,1
Ratio IC50,10'4No_unit,6,-1
Kq,10'13/M/sec,6,1
Kq,10'11L/mol/s,6,-1
Ratio Ki,10^-5No_unit,6,0
Developed tension,%,6,1
Binding,fM uterus-1,6,-1
pKinact,,6,-1
Ratio_[3H]:tubulin,,6,-1
Bathochromic shift,nm,6,1
Derived trabecular number,mM,6,0
Basis motility,,6,1
AUC,nM.hr/g,6,0
Reaction rate,,6,0
BUN_CHANGE_BY,%,6,1
Recovery rate,%,6,1
BPI,,6,0
Km,nmol/mg,6,0
Km,mg/ml,6,0
PCoct,,6,0
Depletion,%,6,1
Reduction,beats min-1,6,1
Log beta,,6,1
Denaturation rate constant,min-1,6,-1
Reduction of IOP,mmHg,6,1
BP,mM,6,0
Kiuc,nM,6,-1
Relative Fluorescent Unit,,6,1
Relative Km,,6,0
Log d50,nM,6,-1
Relative Selectivity,,6,0
Relative amplitude,,6,1
Relative analgesic potency,,6,0
PCP activity,cysts g-1,6,1
CLH,uM/min.mg,6,-1
Log k,hr-1,6,-1
PC95,ug ml-1,6,-1
Relative binding,,6,-1
Avoidance response,,6,0
Kinact,M/s,6,-1
Relative dissociation rate,,6,0
Average turns/first 15 min,,6,1
PC50,ug ml-1,6,-1
Kinact,10^-2/min,6,1
Average ratio,,6,1
Relative metabolic stability,,6,0
Average for skin reaction,,6,0
Kinact,/ms,6,-1
pD2 app,,6,-1
Relative permiability,,6,0
Kin,uL/g.min,6,0
Relative response,%,6,1
Change in tumor area,%,6,1
Average,c.p.m.,6,-1
Relative threshold dose,,6,-1
Relative uterotrophic activity,,6,1
EC50,mh/kg,6,1
Area,AU mm-1,6,1
log(activity),/ml,6,-1
Relaxivity,mM-1 s-1,6,1
AUC,mM.min,6,-1
1/krel,,6,0
ID50,mg ml-1,6,-1
1/MIC,L/mg,6,-1
Control cell number,%,6,1
ID50,fmol,6,-1
Approximate colony formation unit,(g kidney)-1,6,0
Remaining at 40 min,%,6,1
Residual RR activity,%,6,1
EC50,uM.hr,6,-1
P ratio,,6,0
Mortality,number of descendants/number of tested,6,-1
Antitumor activity,g,6,1
Antiproliferative effect,uM,6,-1
GRI,,6,0
Antinociception,%,6,1
Antigen p24 content,ng ml-1,6,1
Change of hemoconcentration,,6,0
Respiratory system resistance,,6,-1
Response,mg kg-1,6,1
Resting potential,-mV,6,-1
GSH,uM g-1,6,-1
Anticonulsant activity,%,6,1
logD,pH7.4,6,0
Antibody titer,,6,1
Retraction time,s,6,-1
logED50,,6,-1
Loss of inactivation,%,6,1
ID/organ,,6,0
Anti-fXa activity,%,6,1
Reverse potential,,6,0
CLm,l hr-1,6,0
Reversibility,,6,-1
Antagonism effects,,6,-1
Rmax,mM,6,1
-log(1/HC50),,6,-1
Khydrol,,6,-1
permeability,10'-4 cm/min,6,0
-TdeltaS,cal/mol,6,-1
"S20,w",Svedberg,6,-1
IC50,nmol/mg,6,-1
EC90,mg kg-1,6,1
SC50,%,6,1
SD50,mg kg-1,6,-1
Amount of [3H]thymidine,c.p.m.,6,1
GST activity,nM min-1 (mg of protein)-1,6,-1
Ke,10'7/M,6,1
Ke,10'6/M,6,1
Amount,pM,6,0
CLup,ml/min,6,1
SMT,,6,1
SNA,%,6,1
CLz/F,ml/hr/kg,6,0
M2/M1 index,,6,0
Alpha 50,molar fraction,6,-1
SR,,6,0
Agonistic effect,%,6,1
SSAT,pM min-1 mg-1,6,-1
Agonist index,,6,1
Agonist activity,IU mg-1,6,1
Kdiss,10'-1/s,6,-1
Aggregation,,6,-1
MABP change,,6,-1
Score,%,6,1
Kd,ug ml-1,6,0
Secretion,uM hr-1 kg-1,6,-1
Adduct formation,%,6,1
Selectivity ratio,nM,6,-1
Onset for sleep,min,6,1
Activity_index,mg/g,6,0
Activity regained,%,6,1
Activity (umol/g.of liver 75.min),%,6,1
IC50,10'-4g/L,6,-1
Activity,units/assay,6,0
Activity,umol/mol,6,0
ID/g femur,%,6,1
Serum glucose,mg dl-1,6,0
Activity,um3/um2/day,6,1
Slope,g dl-1M-1,6,0
Slope,mutants ug-1,6,-1
MAP,beats min-1,6,0
APD75,ms,6,0
Kcat/Km,10^5/M/s,6,-1
Decrease of SBP,mmHg,6,-1
Decrease in tone,,6,-1
Specificity,%,6,1
Spermidine concentration,nM (10e6*cells)-1,6,0
Occlusions,,6,0
Kcat/Km,10'-4/uM/s,6,-1
mequiv of HCl,,6,0
Growth Index,,6,0
Stability,nmol/g,6,0
Stability,pmol/ml,6,0
Occ80,mg kg-1,6,0
Occ50,,6,-1
Activity,pM (2*10e6*cells)-1,6,1
Kcat/Km,/M/min,6,-1
ED100,ppm,6,1
Molar primaquine Index,,6,-1
Static remission,%,6,1
Modification of hemoglobin,,6,0
MLD,pmol,6,0
Gastric score,,6,0
Activity,nm s-1,6,1
Kcat,10'-2/min,6,1
p24,ng ml-1,6,1
Mitotic index,nM,6,-1
Survival,number,6,1
t,ns,6,0
Activity,million,6,1
Kb,10'5L/mol,6,-1
Death dose,mg kg-1,6,1
Control of growth,%,6,1
Kb,10'4mol/L,6,-1
OMNI med,mg kg-1,6,0
Susceptibility,nmol/mg protein/h,6,-1
ODC activity,(nM of CO2) 30min-1 (mg of protein)-1,6,-1
pA1,,6,-1
scMet,mg kg-1,6,1
Kb,10'-5L/mol,6,-1
COI,%,6,1
Kb,10'-4/M,6,-1
Kapp,10'6/M/s,6,-1
Synergy with methicillin,,6,1
T-C,days (optimal dose)-1,6,-1
IC50(app),,6,-1
Kapp,/min,6,-1
ED250,umol/Kg,6,1
Max dV/dt,V s-1,6,1
Activity,mV/ms,6,1
t1/2,%,6,0
ED300,ug ml-1,6,-1
Ka,10^9/M,6,-1
Ka,10^6/Ms,6,1
T>EC50,hr,6,1
T>fEC50,hr,6,-1
Activity,m equiv l-1,6,1
Ka,10^2/Ms,6,-1
TC50,10'5nM,6,-1
CR,%,6,1
Activity,kU,6,1
%PFU,%,6,1
MBEC2,uM,6,-1
Non-HDL-C,mg dl-1,6,0
TCT,s,6,-1
TD50,mg,6,-1
ED50,(ug of misoprostol) kg-1,6,-1
ED50,10'-10M,6,-1
Cmin,fmol,6,0
Activity,eggs/g,6,1
Ka,10'5/Ms,6,1
Activity,cmH2O/ms,6,1
MBIC,,6,-1
Ka,10'4/M.s,6,1
Activity,W,6,1
Activity,U/uM,6,1
Activity,U l-1,6,1
Activity,Ratio,6,0
Max delta APD95,,6,1
Activity,RFU/min,6,1
Membrane integrity,%,6,1
Ka,10'-6/M/s,6,1
Ka,/uM/s,6,-1
TPO(max),%,6,1
Activity,Momega,6,0
No. of writhes,,6,1
Activity,Kb M-1,6,-1
Activity,KA/dl,6,0
Activity,J,6,1
Temperature decrease,degrees F,6,1
Testosterone,ng ml-1,6,1
Testosterone,,6,0
AE,%,6,1
KNBP,min-1,6,1
ED50,mg kg-1 4day-1,6,1
Therm_solubility,g,6,0
Min effective dose,ug kg-1,6,1
DMF,,6,0
Activity,AU/mm,6,1
Thr uptake,,6,-1
High,%,6,1
Threshold current,nA,6,-1
IC50,ucm,6,-1
No. of spikes,,6,1
Thymidylate shift,,6,0
Thyroid status,ng ml-1,6,0
"KCS, APP",uM,6,-1
ED50,nM day-1 kg-1,6,-1
No. of shocks accepted/5 min,,6,1
Time of licking,s,6,1
Time over 100ng/ml,hr,6,1
KA,,6,-1
Time to peak tension,min,6,0
KA,nm,6,-1
Topoisomerase-I activity,,6,-1
Total DPM,,6,0
No. of relapses,,6,1
Activity,10^2CFU,6,-1
Total binding,pCi mg-1,6,0
K2,s-1,6,-1
Total radioactivity,,6,0
K1,uM,6,-1
K1,M-1 s-1,6,1
Toxic level,mg ml-1,6,0
Trabecular no.,mM-1,6,0
Trabecular thickness,nm,6,0
ED50,ug mg-1 kg-1,6,1
Trans,%,6,1
Transcriptional activation,%,6,1
K obs x10e2,min-1,6,-1
Activity,10'6/100microL,6,0
Transport rate,uM min-1 g-1,6,0
Cminss,nmol/g,6,0
K inact/Ki,uM-1 min-1,6,-1
Triglycerides,mg dl-1,6,1
Cmax/dose,,6,0
K inact,10e-3 s-1,6,-1
Tumor growth delay,,6,-1
Tumor growth inhibition,%,6,1
Tumor size,mM,6,0
K bind,uM,6,-1
No. of mice dead,,6,1
Tumor volume,%,6,1
Activity,10'2/M,6,1
U osm,mOsmol kg-1,6,1
K app,uM-1,6,-1
K app,1/M,6,-1
K alkyl,,6,-1
K aff,nM,6,-1
Ulcer index,mM,6,0
K H,,6,-1
ED90,mg/kg,6,1
Hydrolysis,nM min-1,6,-1
Max platelet response,,6,1
MED,(mg of base) kg-1,6,1
No. of infected cells,%,6,0
V0,10^-8M/s,6,1
No. of foci per dish,,6,1
Activity,/10'3mm'-3,6,0
Hexobarb ST,min,6,-1
VLDL,ug mg-1,6,0
Cardiac output,ml min-1,6,1
D2 selectivity,,6,-1
Max respose,,6,1
K,10^5/Ms,6,1
VRT(t),hr2,6,0
EMax,,6,1
VT50,,6,-1
K,10^3/M,6,-1
K,10^2/M/s,6,-1
Midpoint dose,mg kg-1,6,-1
Vd,%,6,0
Cmax,umol/Kg,6,0
K,10^-7M,6,-1
Active dose range,mg uM kg-1 day-1,6,1
Caverage,uM,6,0
K,10^-5/nM/s,6,-1
Vdss,L/hr,6,0
Cmax,ug/kg,6,0
Cdyn,%,6,1
Cell,%,6,1
Virus titer,pfu/ml,6,1
Virus yield,ffu ml-1,6,1
Ear thickness,uM,6,0
Acetylation,%,6,1
MED,ug/L,6,-1
Accumulation counts,Counts,6,0
Effect,pM g-1,6,-1
K,10'6/M.s,6,1
Vmax,amol/cell.min,6,-1
Cell aggregates,,6,0
Vmax,delta A/min,6,1
Vmax,mM min-1,6,1
Hepatocyte stability,uL/min/10e6 cells,6,0
Absorbance,%,6,1
Vmax,mmol/min/mg,6,1
Cz,ng/ml,6,0
Cell growth,number of cells ml-1,6,0
HDT,mg kg-1,6,1
Cell no./dish x10E3,,6,1
Vmax,nM min-1 g-1,6,1
Abortion,%,6,1
MED90,mg monkey-1 day-1,6,1
Cell no./dish x10E5,,6,1
Efflux,uM,6,-1
Aberrant cells,,6,1
Vmax,nmol/min/U,6,1
Vmax,pM,6,1
Egg reduction,%,6,1
No. cured/total,,6,1
K,10'-7/hr,6,1
Cmax,ug/hr,6,0
Nitrite,uM,6,0
K,10'-6M,6,-1
K,10'-6/s,6,1
Vmax,pmol/min/pmol,6,1
Vmax,ug/ml/min,6,1
Nitrate,uM,6,0
Vmax rel,,6,1
Cytochrome loss,,6,0
Cell survival,,6,-1
Vmax/Km,10'3ml/min,6,1
Vmax/Km,U/mg/uM,6,-1
K,10'-1/hr,6,-1
VmaxH,pmol/min/g,6,1
Neurite bearing cells/total cells,%,6,1
Volume,ml min-1,6,1
Volume,uM,6,0
IC20,10'-7M,6,-1
Irritation of eyes,arbitrary units,6,1
Cells positive,%,6,1
Iron binding,m equiv kg-1,6,1
IogP,,6,0
pC20,,6,-1
Net Swelling,,6,1
Nephrotoxicity,,6,0
Concentration,mg dl-1,6,0
Cmax,pmol.hr/g,6,1
Intrinsic efficacy,%,6,1
Vz,uL/g,6,0
Ep2/2,mV,6,0
Culture negative,%,6,1
WBC_CHANGE,%,6,-1
Weight,(mg of prostate) (100g of body weight)-1,6,0
AUCt/dose,min.kg/L,6,0
Ctau,ng/ml,6,0
AUCt/dose,microM.hr/mg/kg,6,1
Cellular content,pM (10e6*cells)-1,6,0
Cellular growth,%,6,1
Hypochromic shift,%,6,1
Excretion,mg dl-1,6,0
Xi50,,6,-1
MFC>99,,6,-1
Exploration motility,,6,0
Ext AUC,%,6,1
Inhibitory activity ratio,,6,-1
Zone size,,6,1
Inhibition tumor index,%,6,1
Na+ ratio,,6,-1
[I],mM,6,-1
FACO Activity,%,6,1
AUClast/dose,mg.hr/ml,6,1
AUClast/dose,hr.ng/ml,6,1
AUClast,nmol/hr/L,6,1
Inhibition,uM kg-1,6,-1
cpm/million cells,,6,0
d50,nM,6,-1
Cellular uptake of boron at 16h,ug of B (g of cells)-1,6,1
FPTase activity,fM ug-1 min-1,6,1
deltaG,degrees C,6,0
AUC/dose,ng/mL.hr,6,0
Fallen/treated,,6,0
deltaS,cal/mol/K,6,0
MHPG_SO4,ug g-1,6,0
deltaT,,6,-1
Mean ED50,mg kg-1,6,-1
Increase contractility,%,6,1
Fibers/preparations,,6,0
Final plasma concentration,nM,6,0
Concentration,pM (10e6*cells)-1,6,-1
Css,ng/ml,6,1
Flu intensity,RU,6,1
Incorporated,%,6,1
Fluorescence,a.u,6,0
fAUC/dose,nM.hr,6,0
I,M,6,-1
Immunosupressive activity,%,6,1
fAUClast,hr.nM,6,0
Change in FVR,%,6,1
AUC/dose,Kg.mg.hr/L.mg,6,0
AUC units,,6,1
I,uM,6,-1
Crop_yield,g,6,1
Cmax,ng/mL.hr,6,0
Crop_yield,Kg,6,1
Formation,pM/10e9,6,0
fKi,nM,6,-1
AD99,mg kg-1,6,1
graft survival,day,6,1
MIC,10'-6mmol/L,6,-1
Change in MAP,%,6,1
AUC 1/T1,s-1 min-1,6,1
Free fraction,%,6,0
MSC,ug ml-1,6,-1
NO release,,6,1
k cat,M-1,6,-1
k obs / concentration,M-1 s-1,6,-1
Change in TC,%,6,1
k x10e3,min-1,6,1
k+2,s-1,6,0
MRTlast,min,6,0
MIC,mg,6,-1
k+2/k,M-1 s-1,6,-1
k-1 app,hr-1,6,-1
Change in TPR,%,6,1
Fungicidal concentration,uM,6,-1
NED,mg kg-1,6,1
Cr secretion,%,6,1
k2,M-1,6,-1
k2,s-1,6,1
AUC,uM.h. kg/mg,6,0
k3,min-1 M-1,6,-1
GABA enhancement,,6,1
Concentration,uM 100ml-1,6,-1
Mean arterial blood pressure,%,6,1
ILC,%,6,1
k_elim,hr-1,6,0
Concentration,ul,6,0
AUC,u-1 hr-1 ml-1,6,1
GFR,ml min-1 kg-1,6,0
GH AUC 0-180,ug min l-1,6,1
ka,/min,6,0
IFN,,6,0
Change in hematology,,6,0
GH peak,ug l-1,6,1
AUC,pmol.hr/g,6,0
AUC,pM hr-1 g-1,6,-1
AUC,nmol.hr,6,0
Cmax,mg Kg-1,6,0
ks,min-1,6,-1
AD50,pM,6,-1
GI25,uM,6,-1
Convulsion threshold,mg kg-1,6,1
Glycine antagonism,,6,-1
Conversion rate,,6,0
Peak inhibition,%,6,1
Change in sensitivity,,6,0
% of inhibition or stimulation,%,6,1
rate constant app,min-1,6,0
Peak radioactivity in blood,% injected dose cm**-3,6,1
A50,M,6,-1
CL,mL/min/m2,6,0
Drug metabolism,nmol/L,6,0
Periosteal mineral apposition rate,mm day-1,6,1
pKH,,6,0
Permeability,Papp* 10E6 cm/s,6,1
Drug metabolism,10'-2/hr,6,1
Level,ng g-1,6,0
Clp,ug hr ml-1,6,0
CI95,,6,-1
Drug mol/base pair,,6,0
Plaque inhibition result,,6,0
CI75,,6,-1
Plasma,ug ml-1,6,0
Parasite_Clearance_time,hr,6,1
Growth rate,uM,6,0
Plasma insulin,pM l-1,6,-1
GI50,%,6,1
CFU/g,,6,-1
Latency to exit,,6,-1
Latency,ms,6,0
permeability,umol cm2/hr,6,0
pKL,,6,-1
CFU,10^8/g,6,-1
LambdaZ,/hr,6,1
Lag time,s,6,0
Drug degradation,10'-8mol/min,6,-1
Log 10 cell kill,,6,1
Papp,umol/L/s,6,0
Papp,ucm,6,0
LZ,/min,6,-1
CCID50,mM,6,-1
CC90,,6,-1
CC50,ppm,6,-1
Drug uptake,cpm/mm2,6,0
CBF increasing activity,%,6,1
Drug uptake,kBq/cm3,6,0
Cp(T),nM,6,-1
CAI activity,,6,-1
Drug uptake,mg,6,0
CL,uL/mg/min,6,-1
Drug uptake,microL/min/mg,6,1
LDL,ug mg-1,6,0
CL,uL/ml,6,-1
LDH release,MU,6,0
AUC,ng.hr.kg/ml/mg,6,1
Prolongation effect,,6,-1
rapp,,6,0
Protein content,%,6,1
C50,M,6,-1
C24,,6,0
QT,,6,-1
Drug uptake,pg/mg,6,0
LD50,pmol/g,6,-1
C10 air/C10 N2,,6,0
50% naproxen formed,%,6,1
Mean log GI50,,6,-1
RC50,umol/ml,6,-1
RC50,,6,-1
Pancreatic response,,6,0
CL free,L/hr,6,1
RCI,%,6,1
Cleavage rate,uM min-1 g-1,6,-1
CL free,uL/min/nmol,6,-1
RD100,mg kg-1,6,1
LD50,10'-2 ug/ml,6,-1
C,ug ml-1,6,0
ROI,,6,0
LD0,uM kg-1,6,1
RRT,mean,6,0
3D PSA,,6,0
RRT,,6,0
PRCF,,6,-1
PPB,pmolequiv/mg,6,0
LD,ppm,6,1
LD,Gy,6,1
RT activity,%,6,1
Boron in media at 0h,ug of B/ml,6,1
Radioactivity,nM equiv (ml of blood)-1,6,0
Cross reaction,%,5,1
HTS data,,5,0
HD100,ug ml-1,5,1
IC50,liposomes ml-1,5,-1
Gated current,%,5,1
ICA,,5,0
ID50,10'-8M,5,-1
ID50,mg ear-1,5,-1
GI50,10^4M,5,-1
IG50,ug ml-1,5,-1
IL-1 production,pg ml-1,5,1
INCC50,nM,5,-1
INH,10'-5M,5,-1
INH,10'-7M,5,-1
INH,pM,5,-1
INH,umol/Kg,5,-1
IOP lowering,mmHg,5,-1
IP+SC score,,5,0
IP3-sensitive Ca2+ stores,%,5,1
IPol,nM,5,-1
ISC,,5,0
Fraction Recovered in urine,%,5,1
Food intake,,5,0
Food intake,%,5,1
Impaired,%,5,1
Flu intensity,10^9/s/cm2,5,1
Increase in [Ca+2],nM,5,0
FRS50,uM,5,-1
Infected,%,5,1
Inhibition,mg kg-1,5,1
Inhibition at 5nM,%,5,1
Inhibition of increase in weight,%,5,1
Exudate volume,ml,5,1
Inhibitory activity,%,5,1
Extent of DNA binding,,5,0
% release of nitric oxide,uM uM-1,5,0
Inhibitory ratio,%,5,1
Initial heart rate,bts min-1,5,0
Excreted,,5,0
Epoxide formation,nM,5,0
Epinephrine level,,5,1
Enantioselectivity coefficient,,5,0
Emin,,5,1
Isometric contraction,%,5,1
K,10'-6/M/s,5,1
K,10'10/M/s,5,1
Efficiency,uM-1 s-1,5,1
K,10'4/Ms,5,-1
K,10'4/s,5,-1
K,10^-4/M/s,5,-1
K,10^6/Ms,5,-1
K,10^8/M/min,5,1
K,nmol/min,5,-1
K beta,nM,5,-1
K inact/Km,M-1 s-1,5,-1
K+ excretion,ml 6hr-1 100g-1,5,1
K+2,min-1,5,-1
K+2/Ki,uM min-1,5,-1
K0.5,10'-5M,5,-1
ED50,uM.hr,5,-1
KA,uM kg-1,5,-1
ED50,mg/L,5,-1
KH,s-1,5,0
ED50,mg kg-1 dose-1,5,1
KNBP,s-1,5,-1
ED50,Ug/ml,5,-1
ED50,10'-4umol/ml,5,-1
Ka,10'5/M.s,5,1
Ka,10'5/uL,5,1
Ka,10^10/M,5,-1
Ka,l mol-1,5,-1
ED30,mg/kg/day,5,-1
Kapp,10'3/M/s,5,-1
Kapp,10'8/M,5,1
ED200,,5,1
Kb,10'9/M,5,-1
Kb,10^4L/mol,5,-1
Kb,mg kg-1,5,1
Kcat,10'-3/hr,5,1
ED100,ug ml-1,5,1
Kcat/Km,/M/hr,5,-1
ED100,nM kg-1,5,-1
ED10,M,5,-1
ED delta,mg kg-1,5,1
ED,ug,5,1
Kd,10'-8/s,5,-1
Kd,10^-4/s,5,-1
Ke,10'5/M,5,-1
EC95,ppm,5,1
EC90,ppb,5,1
Keq,uM,5,-1
Kh,min-1,5,1
Khd,,5,0
EC80,,5,-1
Ki,/nM,5,-1
Ki,1/M.s,5,-1
EC50,uL/ml,5,-1
Ki1,uM,5,-1
Ki2,uM,5,-1
Ki_app,nM,5,-1
Kic,mM,5,-1
EC50,10^2 uM,5,-1
EC50,10'11PFU,5,-1
Kinetic_solubility,10'-4mg/ml,5,0
Kinetic_solubility,10'-5mg/ml,5,0
Kix,mM,5,-1
Km/Kcat,uM s-1,5,0
Kobs,/ms,5,-1
Kobs,,5,0
Kpol,s-1,5,-1
EC20,M,5,-1
Kr,s-1,5,0
Ks,10'5/M,5,-1
LC50,%,5,0
LC90,mg,5,1
LD,g/Kg,5,1
LD/ED80,,5,-1
LD100,ppm,5,1
LD100,ug ml-1,5,1
LD50,10'-3 ug/ml,5,-1
Drug uptake(free),ng/ml,5,0
Drug uptake,ug/kg,5,0
Drug uptake,uM.hr,5,0
LDH,,5,-1
LMA,%,5,1
Drug uptake,%Idose/kg,5,1
Lambda-z,L.h-1,5,0
LambdaZ,min,5,0
Drug uptake,%ID.m^-2,5,1
Lesion score,,5,0
Liver CH levels,,5,0
Liver TG,,5,0
Liver cholesterol,mg (g of tissue)-1,5,1
Liver weight,g (100g of body weight)-1,5,0
Drug metabolism,microM/min/mg,5,-1
Log 1/I50,,5,-1
Log 1/KL,,5,-1
Drug degradation,pmol/min/mg,5,-1
Drug degradation,a.u.,5,1
Log AC50,,5,-1
Log DSF,,5,0
Log IC50,log(1/M),5,-1
Log Ko/w,,5,0
Dilation,,5,0
Log Pcyc,,5,0
Log Pe,,5,0
Delta weight,,5,1
Delta S-H,ms,5,0
Loss of affinity,,5,-1
Delta H-V,ms,5,0
Delta CPP,mmHg,5,-1
Lysis time,min,5,0
Decrease in hypothalamus norepinephrine,%,5,1
Decrease in heart norepinephrine,%,5,1
Decrease in CVR,%,5,1
Decrease,mmHg,5,-1
MBC100,,5,-1
MBC50,uM,5,-1
DTH,mM,5,1
DR20,ug kg-1,5,1
MBEC80,ug ml-1,5,-1
MD,%,5,1
DFM,mg/cm2,5,0
ME,%,5,1
DBP/UP ratio,,5,0
MEC,ug,5,1
MED99.9,mg kg-1,5,-1
MFC90,mg/L,5,-1
MFED,,5,-1
MHC10,,5,-1
MI0.5,,5,0
MIC,10'-4/M,5,-1
MIC,mg kg-1,5,-1
MIC,ug l-1,5,-1
Cp(f),umol/L,5,0
Cp,ug.hr/ml,5,0
Cp,uM.hr,5,0
Cp,pmol/g,5,0
Cp,pg/mg,5,0
MIC99.9,,5,-1
MIC=<90,,5,-1
Cp,microM,5,0
Covalent binding,%,5,1
Correlation coefficient,,5,0
MLC,mg kg-1,5,1
MNTD>75,uM,5,-1
s-GOT level,Karmen units,5,-1
Concentration,ug kg-1,5,-1
MRTV,,5,1
Concentration,pmol/E109 cells,5,0
Concentration,pmol/10E9 cells,5,-1
Concentration,ng day-1,5,1
Concentration,ml,5,0
Concentration,dpm,5,0
MTD,mg/day,5,1
Compound recovery,hr,5,0
s-GPT level,Karmen units,5,0
Max APD90 (delta),%,5,1
Max Achievable Bioavailability,,5,1
Max activation,%,5,1
Max agonist activity,%,5,1
Max fall in IOP,,5,1
Cmax/dose,umol/L,5,0
Max potentiation,%,5,1
Max protection,,5,1
Max protective effect,%,5,1
Max score,,5,1
Max tolerated dose,uM kg-1,5,0
Max. potentiation,%,5,1
Maximal activation,,5,1
Maximal change,%,5,1
MeAIB uptake,,5,-1
Mean blood pressure,mM,5,0
Mean log LC50,,5,-1
Mean no. of days post-infection to death,,5,1
Clonic seizures,%,5,1
Cl,ml mg-1 kg-1,5,0
Mitotic figures,,5,0
Molar potency,,5,-1
Change of weight,%,5,1
Morbidity,%,5,1
Change in blood flow,%,5,1
Change in TC,,5,1
Challenge dose,,5,1
Na+ excretion,ml 6hr-1 100g-1,5,1
Necrosis,,5,0
Negative chronotropic activity,%,5,1
Negative ionotropic activity,%,5,1
No. of avoidance,,5,1
No. of escape failure,,5,0
No. of guinea pigs protected,,5,0
No. of invaded cells,,5,0
No. of lung lesions,,5,1
Carbonyl group,nM mg-1,5,0
Carbamoylating activity,,5,0
No. of mice without tumors,,5,1
No. of new tumors,,5,1
No. of openarm entries,,5,1
Ca2+ antagonistic activity,%,5,1
No. of rats displaying DA syndrome,,5,0
No. of survivors/total,,5,1
No. of virus free mice,,5,1
No. survived,,5,0
CS50,ug ml-1,5,-1
Observed [pt],mM (mg of protein)-1,5,0
Observed relaxivity,mM-1 s-1,5,1
Of dose excreted,%,5,1
Oligo shifted,%,5,1
CLu/F,ml/min.kg,5,1
Oxytocic activity,U mg-1,5,1
PD200,umol/Kg,5,-1
% of activity remaining,%,5,1
PD50,umol/Kg,5,-1
CLH,mg/min/g,5,-1
CL/F,ug/ml.hr,5,0
PI turnover,%,5,1
CL/F,mg kg-1,5,0
PPM,,5,1
CL/F,(mg)/(ug/ml)/hr,5,1
CL,nL/pmol/min,5,-1
CL,ml/mm/kg,5,0
CL,ml/min.mg,5,-1
Papp,um/s,5,1
CL,ml/hr/mg,5,-1
Partition coefficient,min,5,0
Peff,10'-3cm/min,5,1
Peff,10^-6nanometer/s,5,0
Peripheral restriction index,,5,0
Phospholipidosis,uM,5,-1
Phospholipidosis_index,,5,0
Phosphorylation,%,5,1
Plasma MIC,ug ml-1,5,-1
CI,%,5,1
Plasma total cholesterol,mg dl-1,5,1
Plasmaconcentration,nM,5,0
Platelet count/ul,,5,0
CFU,10'6/ml,5,-1
CFR rating,,5,0
Positive paws,%,5,0
CC100,,5,-1
Pressor response,%,5,1
Prodrug remains,%,5,1
Progressed remission,%,5,1
C8h,,5,0
Protection,day,5,0
C20 FRP,,5,-1
QH,L/hr.Kg,5,1
C2,ug g-1,5,0
C10APD90,uM,5,-1
RBC,10e6 ul-1,5,0
C0,ug/L,5,0
C0,ng/L,5,0
C 8 h,uM,5,0
C,mg ml-1,5,0
Brain concentration,,5,0
Brain concentration,nM,5,0
Brain concentration,mM,5,0
Rate,nM-1 min-1 (mg of protein)-1,5,-1
Rate of formation,nM (mg of protein)-1,5,1
Rate of formation,pM min-1,5,1
Bmax,disintegrations/min,5,1
Ratio,/s/mM,5,-1
Blood urea nitrogen,,5,0
Ratio,1/M.sec,5,-1
Blood level,,5,0
Ratio,10'-7No_unit,5,0
Ratio,10'2/M/s,5,0
Ratio,10'5/M/min,5,-1
Ratio,10^2/M/s,5,-1
Ratio,10^6/M/min,5,-1
Ratio,min-1,5,0
Ratio,ml/g,5,0
Ratio AUC,ml/g,5,0
Ratio EC50,microM,5,-1
Binding affinity,M-1,5,-1
Ratio IC50/EC50,10'5No_unit,5,-1
Bicarbonate level,,5,0
Behavioral syndrome,,5,0
BUI,,5,0
Reduction in AUC,,5,1
BP decrease,,5,-1
solubility,mg/uL,5,0
Reduction in respiratory volume,ml,5,1
BC,uM,5,-1
BAV,%,5,1
B-A/A-B,,5,0
Relative antitumor activity,,5,1
Relative loss of potency,,5,-1
Relative rate,%,5,1
Average 14-day MGR,mm**3 day-1 ,5,1
Remission,%,5,1
Rescued neurons,%,5,1
Residual amine (ee),%,5,1
Antifungal activity,%,5,1
Responding,,5,1
Retention time,,5,1
Animals with palpable tumor,,5,0
Animals affected,,5,0
Animals affected,%,5,1
Anesthetic effect,%,5,1
S-phase,%,5,1
SDL,,5,-1
Amount Recovered in urine,mg,5,1
SGOT activity,units/mL,5,1
SGPT activity,units/mL,5,1
Ambulation score,,5,0
Agonist response,,5,1
SWo,,5,0
Adrenal uptake,,5,0
Actual duraction,,5,0
Serum T4,ug dl-1,5,0
Sleep ratio,,5,1
Specific radioactivity,Ci/M,5,0
Activity,pmol/Kg,5,1
Activity,pmol/(s.cm2),5,1
Activity,pM hr-1 mg-1,5,1
Activity,pM 10min-1,5,-1
Stability,pmolequiv/mg,5,0
Sterility,%,5,1
Substrate efficiency,%,5,1
Activity,nanometer2/sec,5,0
Surface involvement,%,5,1
Activity,ml/cm3/min,5,1
Activity,ml/cm3,5,0
T inh,,5,-1
Activity,meter/s,5,1
T1/2 h,,5,0
T2,hr,5,0
T3,%,5,1
Activity,mM hr-1,5,1
Activity,mJ,5,1
t1/2,ml/min.kg,5,0
Activity,mAU ml-1,5,1
Activity,log10RLU,5,-1
TC,uM,5,-1
TC50/IC50,,5,-1
Activity,g/mm,5,1
TD,uM,5,-1
Activity,dyn/cm,5,0
Activity,deltalog10pfu/g,5,-1
TED,nM kg-1,5,-1
TG 2X lag,uM,5,-1
Activity,Pmol,5,1
TPE,toxicity,5,0
Activity,N/mm,5,1
Therm_solubility,%,5,1
Thy-1 expression,,5,0
Activity,10^6No_unit,5,1
Activity,10^6/mm3,5,0
Time constant T3,,5,0
Activity,10^5No_unit,5,1
Tm,K,5,-1
Total binding inhibited,%,5,1
Activity,10^-8No_unit,5,1
Activity,10^-7No_unit,5,1
Toxic effect,,5,0
Transport,pM min-1 (mg of protein)-1,5,-1
Ts,degrees C,5,0
Tubulin,,5,-1
Activity,10'3/ml,5,1
UD50,,5,-1
Ulcer index,mm,5,1
Uptake,fM cell-1,5,-1
Uptake rate,nM min-1 cm**-2,5,0
Uterus effect,,5,0
Activity,/cm,5,1
Vd,ml/min.kg,5,0
Vdss,Not_given,5,0
Vdss,ml/min.kg,5,0
Acquisition time,,5,1
Virucidal,,5,-1
Virus inactivation,%,5,1
Vm,uM min-1mg-1,5,1
Vm rel,%,5,1
Accumulation,nM g-1,5,0
Vmax,M min-1,5,1
Vmax,area/min/mg,5,1
Absolute,%,5,1
AV block,,5,-1
AUMCt,ng.hr/ml,5,0
Vmax,pmol/min/ug,5,-1
Vmax,umol,5,1
Vmax / K,,5,-1
Vmax(app),microM/s,5,-1
Vmax/Km,ml/min/mg,5,-1
AUMC,microM.hr^2,5,0
VmaxL,pmol/min/g,5,1
Vr,ml,5,0
Vz/F,(mg/kg)/(uM),5,0
AUCt/dose,ug.hr/mL/mg/kg,5,1
Weight difference,T-C,5,-1
X,min,5,-1
AUCt,pmol.hr,5,1
[I] 0.5,uM,5,-1
aPTT,,5,0
AUClast,pmol.hr/g,5,1
damage reduction,%,5,1
AUCED90,uM.hr/day,5,0
AUC/dose,umol/l.hr,5,1
AUC/dose,uM.hr/mg,5,0
AUC/dose,ng.hr.kg/mg/ml,5,1
AUC/dose,nM/hr,5,1
fAUC,nmol/g/min,5,1
AUC/dose,hr.kg.ug/ml/mg,5,0
AUC/dose,M.hr.kg/mg,5,1
fCmax,nmol/g,5,0
fEC50,ng/ml,5,-1
fNOAEL,uM,5,1
AUC ED50,mg kg-1,5,-1
AUC 100,mg kg-1,5,1
AUC,umol.hr/kg,5,1
k cat/Km,uM-1 min-1,5,-1
AUC,ug h/g,5,0
AUC,uM min uM-1,5,0
AUC,uM hr ml-1,5,0
ka,/uM/min,5,-1
AUC,nmol/g/min,5,1
AUC,nmol/g.min,5,1
kinact,,5,-1
kn,,5,1
lambda-z,L.h-1,5,0
log(1/MEC),,5,-1
AUC,min.sec,5,1
AUC,hr.kg.ng/ml/mg,5,1
AUC,/hr,5,1
max Delta Vmax,%,5,1
AOC,,5,-1
AOC,mmHg.hr,5,1
mortality,day,5,1
p value,,5,0
pEC5,,5,-1
ABD50,mg kg-1,5,-1
pIC35,,5,-1
AAC,deltalog10CFU/ml.hr,5,-1
pK4,,5,0
A2,10'-8M,5,-1
pKR+,,5,-1
88Y-serum,%,5,1
2X PT,uM,5,-1
2PT,10'-3M,5,-1
2 x APTT,uM,5,-1
1/n,,5,1
1/Vmax,deltaA/s,5,-1
Hepatic triglyceride,mg g-1,5,1
Hepatic cholesterol,mg g-1,5,0
Hypoglycemic activity,,5,-1
I,mM,5,-1
I,,5,-1
Helicity,%,5,1
I40,uM,5,-1
I50 M,,5,-1
I80,mM,5,-1
Fold stimulation,,4,1
Kinact,10^3nM,4,-1
Ratio,10'2No_unit,4,0
Activity,inches,4,1
Ksolv,hr-1,4,0
Activity,(nM of CO2) hr-1 mg-1,4,1
Vasodilation,%,4,1
Drug uptake,10'-8mol,4,0
NAD+ level,%,4,1
fCmax,ug/g,4,0
CL/F,g/min,4,0
Food,g rat-1 day-1,4,-1
RC10,,4,-1
Kinact,min,4,0
Vasodilatory rate,,4,0
Ks app,uM,4,-1
Axonal regeneration rate,,4,0
EC50,10'-7mol,4,-1
MED50,ug ml-1,4,1
Vasopressor activity,U mg-1,4,1
2aPTT,mM,4,-1
ED50 / ED50 (taxol),,4,-1
Relative activity of AChE,,4,0
fEC50,,4,-1
IC50,mg.min/m3,4,-1
C24h,uM,4,0
ED50 mg/animal/day,,4,-1
TCI,%,4,1
Food intake,g kg-1,4,1
fIC50,ug ml-1,4,-1
Formation of NO3-,nM,4,-1
Relative TS,%,4,1
fIC90,nM,4,-1
CL/F,mg/(ng/ml)/min,4,0
fIC90,ug ml-1,4,-1
Formation of compound,nM,4,0
Ratio,10'6/M/min,4,-1
No. of WDS/60 min,,4,1
Cp,cps,4,0
Log10CCID50/g,,4,-1
Cholesterol level,mg g-1,4,0
CL/F,ml.min-1,4,-1
EC50,10'-2ppm,4,-1
Cortex_Clearance,ml s-1 (10e4*g)-1,4,1
Cooperative effect,,4,0
Ratio,10'7/M/s,4,1
Convulsions,%,4,1
Control vomits,,4,1
fc max/MIC,,4,-1
Cytotoxicity IC50,uM,4,-1
Control retches,,4,-1
CT10,uM hr,4,-1
MLC50,%,4,1
MLD,g/Kg,4,1
AUC glu,mM min,4,1
BG,mM,4,0
K,10^3(1/Ms),4,-1
ft1/2,,4,-1
BG reduction,%,4,1
Ratio,10^-3/min/uM,4,-1
Fraction,,4,0
Median day of survival,,4,1
PHOSLPD_CHANGE,,4,1
IVR,beats min-1,4,-1
Fraction change,%,4,1
Relative Bioavailability,%,4,1
Vbeta,,4,0
Relative,g %,4,1
Ratio,10^-4/uM/min,4,-1
IUP,,4,-1
increase in temperature,,4,0
Cleavage rate,nM U-1 hr-1,4,-1
Kkmax,/hr,4,1
Vc,kg-1,4,0
Reflex,,4,0
DNA on filter,,4,0
MND,14-21 day,4,0
Clones,%,4,1
Pm,10e-5*cm/min,4,1
DNA fraction,,4,0
Displacement of DP,,4,0
Consumption,%,4,1
Fraction of Liver Blood Flow,%,4,1
Mean paw diameter,mM,4,0
IR,,4,0
PG,,4,1
Log10 reduction,,4,-1
Activity,kcps,4,1
Concentration_urine,ug ml-1,4,1
LD50,10'-7M,4,-1
k cat,ms-1,4,1
Vc/F,,4,0
Reduction in prostate weight,%,4,1
PFC/splleen,,4,-1
Drug uptake(free),nmol/L,4,0
k cat/Km,%,4,0
Concentration in Brain,nM,4,-1
Reduction in EOS count,,4,-1
AUC,ug/g.hr,4,0
k cat/Km,m M-1 min-1,4,1
Mean body weight,%,4,1
Cmax,nM l-1 hr-1,4,0
Mean axonal area,,4,0
Haptoglobin,g l-1,4,0
Mean activity,uM,4,-1
Cmax,ng/hr,4,1
MRTinf,hr,4,0
Cmax,ng/ml/mg,4,0
k eff,M-1 min-1,4,1
k eff (rel),,4,0
TC50,mg/m3,4,0
Cmax,pmol/10^6cells,4,1
Concentration,ng mg-1,4,0
Ks,10^5/M,4,-1
INH,ugequiv,4,-1
Ks,10^4/M,4,-1
Mean,nM hr-1 mg-1,4,-1
LD50,10'-4M/ml,4,-1
Mean,%,4,1
Fu,ug ml-1,4,0
Heart weight absolute,g,4,0
DTH,,4,0
MTA,,4,1
TC50,10^3uM,4,1
Concentration,nM (g of tissue)-1,4,-1
Cmax,uM.hr,4,0
Ks,10'6/M,4,-1
Cmax,uM.kg/mg,4,0
Functional selectivity,,4,0
Ka,10^3(1/Ms),4,1
Maximal decrease in IOP,mmHg,4,1
Delta latency time,,4,0
AC50,ug ml-1,4,-1
Activity,l kg-1,4,0
pKx,,4,-1
Conc_plasma,ng ml-1,4,0
Cmax,ug/10^6 cells,4,0
AUC,ug .h/g,4,1
CLH,min/mL,4,-1
Max uterotonic response,%,4,1
Activity,%/hr,4,1
k2,10e-3 s-1,4,-1
Drug uptake(free),nmol/g,4,1
MTD,ug/kg/day,4,1
MTD ratio,,4,0
Occ90,nmol/g,4,0
Ks,/hr,4,-1
k2,mM-1 min-1,4,-1
MTD/ TGI50,,4,-1
Drug uptake,microg/g,4,0
KA,10'5/M,4,-1
Max response,uV,4,1
Competitive protection,,4,-1
pEC50,nM,4,-1
Activity,10'5/M/s,4,1
Km app,,4,0
2PT,ug ml-1,4,-1
ED5,nM kg-1,4,-1
k2/Ki,nM-1 min-1,4,1
Kr/kmax,M-min,4,1
MTT,min,4,0
Cmax/Tmax,,4,0
Cmax/dose,kg.mg/L.mL,4,0
Tm(app),degrees C,4,-1
NOAEL,mgAi/L,4,1
PAE,day,4,1
k3',L (M min)-1,4,-1
Cmax/dose,microM/mg/kg,4,0
RD50,uM,4,-1
IMPDH activity,(nM of XMP formed) hr-1 (mg of protein)-1,4,-1
Recovery,dpm ml-1,4,0
Mass index,%,4,0
Lactose production,uM mg-1,4,0
Tm,hr,4,0
Ka,10^5L/mol,4,-1
K,10^-7/s,4,-1
Drug uptake,%Idose,4,1
ILS days,%,4,1
Mass index,mg/10g body weight,4,1
ILS (mg/kg),%,4,1
MFC50,,4,-1
Activity,mIU/L,4,1
GDP activity,nM min-1 mg-1,4,-1
Cmin_PBMC,pmol/10^6cells,4,1
Max effect,Counts 10min-1,4,1
Ka,10^6/M.s,4,1
AUC,uM h/(mg/kg),4,0
Max dose,mM kg-1,4,1
Activity,mIU/ml,4,-1
Cmax_tumor,uM,4,0
IC50,nM kg-1,4,-1
No. of uptake sites,,4,0
Decrease in mean arterial pressure,,4,1
Basal GH,ng ml-1,4,0
T3/4,,4,0
Drug uptake,mgequiv/ml,4,0
IH50,uM,4,-1
Receptor state,,4,0
Cmin(84hr),pg/mL,4,1
Basal binding,%,4,1
Cmin,mg/dl,4,0
Max contractility,%,4,1
Cytochrome loss,%,4,1
Vdss,L/m2,4,0
Cmin,ng,4,0
DNA damage,,4,0
IC50,10^2 nM,4,-1
T2,,4,0
CT50,day,4,-1
ka/kr,,4,0
kaKr/kr,M,4,0
kb,M-1 min-1,4,-1
PD50,uM kg-1,4,-1
IC50,umol/dm3,4,-1
permeability,10^-5cm/s,4,0
AD50,%,4,1
Ratio,ml/min/uL,4,0
ID95,uM,4,-1
ki/Ki,M-1 s-1,4,-1
IC37,uM,4,-1
Kp,nM,4,-1
Active,,4,0
kinact,1/min,4,-1
Prodrug remains,,4,1
K app x10e6,M-1,4,-1
I/M ratio,,4,0
DL50,mg kg-1,4,-1
Rats turning,%,4,1
MBC100,ug ml-1,4,-1
AD50,mM kg-1,4,1
kirr,s-1,4,-1
EC30,10'-6M,4,-1
Cp(f)max,nM,4,1
LD16,mg kg-1,4,1
Bleeding time,s,4,1
ko,min-1 s-1,4,1
AD50,ug ml-1,4,-1
Behavior response,,4,0
C70,uM,4,0
AUC,nmol/L.min,4,0
5-HTP accumulation,ug g-1,4,1
Desensitisation,%,4,1
AUC,nmol.hr/kg,4,1
Glucose uptake,uM mg-1,4,0
Ratio,nmol/g/uM,4,-1
IC70,,4,-1
AUC,ng/mL.kg,4,1
Plasma triglyceride,mM,4,-1
kon,,4,-1
ADP formation,%,4,1
pBBB,,4,0
Activity,10'9/s/cm2,4,1
A,%,4,1
UC50,uM,4,-1
Depolarisation,mV,4,1
Ka,L/hr,4,0
ID80,micromol/kg/min,4,1
Biological activity,,4,0
T1,,4,0
pBBB,10'-3cm/min,4,1
IC75,nM,4,-1
Ratio (Ci/Ce),,4,0
pAh,,4,-1
IC50,10^-1microM,4,-1
AUC,ng.hr,4,1
log Kp,ucm/s,4,0
Binding potency,,4,-1
Kq,/M/s,4,-1
Plasma magnesium_CHANGE_BY,%,4,1
NRD,,4,-1
AUC,ng ml-1,4,0
AG80,%,4,1
PB,uM,4,-1
GI90,M,4,-1
pA2,IU mg-1,4,1
Ratio CC50/EC50,10^2No_unit,4,1
C,ng/mL,4,0
Kq,/kM/s,4,-1
Ratio CC50/EC50,10^3No_unit,4,-1
Prodrug reconversion,%,4,1
Ratio CC50/EC50,10^4No_unit,4,1
Activation,fold,4,1
Ratio of stimulation,,4,0
Velocity,uM min-1mg-1,4,-1
Ratio of dose,,4,0
ED300,,4,-1
Glucose,mg day-1,4,1
Cyclase stimulation,%,4,1
Velocity relative to ATP,,4,0
Venom,%,4,1
Kq,10'-12/M/s,4,1
IC95,,4,-1
Ventricular MAPD90,ms,4,0
Of rats turning,%,4,1
ALB_CHANGE,,4,-1
N20 formed,nM,4,0
ALT,U l-1,4,1
UD50,%,4,-1
Binding,nM,4,-1
ALT.,U l-1,4,1
CFU-GEMM,%,4,1
ICmax,%,4,0
AUC,microg.hr/mL.g,4,0
T/C min,,4,1
AMPA effect,%,4,1
Activity,mU ml-1,4,1
Plasma levels,nM,4,0
Binding,ug g-1,4,0
Acid titer,m equiv l-1,4,-1
AUC,mg/L,4,0
Activity,mU.nmol/h,4,1
ED30 DBP,,4,1
Log [-10],,4,-1
Gastric damage,%,4,1
Activity,10'1/M,4,1
MIC,ug/mg,4,-1
Binding activity,fM mg-1,4,-1
Monocation species,%,4,1
Acid output,u equiv 2hr-1,4,1
Log [-9],,4,-1
ID/g,,4,0
T/C (d),%,4,1
Binding affinity,1/M,4,-1
CT50,,4,-1
ID100,ug/kg,4,1
AUC,hr/L.kg,4,1
ARP,m/M,4,-1
ATP content,pM mg-1,4,0
AUC,hr.nmol/ml,4,1
ID30,ug,4,1
2TT,uM,4,-1
UD50,uM kg-1,4,-1
Drug transport,ug/g,4,0
AUC,hr.%ID/ml,4,1
No. of survivors,%,4,1
ID50,%,4,1
Virucidal,uM,4,-1
Change in foot-licking latency,%,4,1
Log inhibition,,4,1
AUC,fmol,4,1
CLH,ug ml-1,4,0
Ratio IC50,10^3No_unit,4,-1
Ratio IC50,10^2No_unit,4,-1
AUC,10^4nM.min,4,1
log10cfu,mg,4,-1
UD50,umol/Kg,4,-1
KA,mM,4,1
T.P.L,ng ml-1,4,0
LD90,ug,4,1
Kapp,10'-3/s,4,1
Drug transport,nmol/hr.cm2,4,1
KA,mM-1,4,-1
Brain uptake,%,4,1
T-cell,nM,4,-1
UI,mm2,4,1
K,10^-1/M/s,4,-1
ED50,ugAi/ml,4,-1
Plasma integral,uCi min ml-1,4,0
Plasma insulin,uUnits ml-1,4,-1
Primary tumor weight,mg,4,1
Lesion,%,4,1
Activity,10'-8mol/kg,4,1
LH,ng ml-1,4,0
Drug uptake,ngequiv/ml,4,0
KA effect,%,4,1
-Log IC50/IC50,,4,-1
Plasma half-life,hr,4,0
CTC50,M,4,-1
Activity,mg/mm3,4,1
Vmax,/RU/s,4,1
Activity,mg/uM,4,1
Change in volume,%,4,1
CHOL_CHANGE,,4,1
Plasma glucose,mM,4,-1
Synaptic site,,4,0
Time of half inactivation,min,4,0
Swimming activity,T/C,4,0
KB,s-1,4,-1
Activity,milliosmole,4,1
Changes in airway resistance,RL,4,1
Critical concentration,ug ml-1,4,0
Ulcer Index,,4,0
Vmax,10'-5 uM/s,4,1
Activity,10'4CFU/ml,4,1
Tubulin content,pM mg-1,4,0
Drug recovery,ug ml-1,4,0
Activity,ml/kg/hr,4,1
Plasma concentration,pg ml-1,4,0
Activity,ml/s/g,4,0
Activity,mmHg hr-1,4,1
MI50,umol/L,4,-1
Time constant T2,,4,0
Drugexcretion,uM,4,0
Vmax,10'4OD/sec,4,1
Activity,10'9uL,4,0
Time constant T1,,4,0
CTE,,4,-1
Activity,mmHg/L.min,4,1
Activity,10'-7mol/L,4,1
Pressor response,mmHg,4,1
Total urine activity,%,4,1
Activity,mmol/m2/s,4,1
Total uptake,,4,0
Pressor response,IU mg-1,4,1
Activity,10'-7 ug/ml,4,1
Kb,10^5L/mol,4,-1
ED50,ug rat-1,4,-1
Survival range,day,4,1
Pressor activity,,4,1
CV,,4,0
Kbapp,10'-8M,4,-1
DC50,nmol/L,4,-1
K,10'6/Ms,4,1
NMDA effect,%,4,1
Effective concentration,nM,4,-1
K,10'5No_unit,4,1
Drug recovery,uM,4,0
RT50,,4,-1
Plasma cholesterol,mM,4,-1
ED15,,4,-1
K,10'5/M/min,4,1
K inact,hr-1,4,-1
Activity,10^-2No_unit,4,1
Growth response,%,4,1
Absorption,u equiv min-1,4,1
% change,%,4,1
Vmax,mAU/min/uM,4,-1
Brain lesion,mm,4,1
Kcat,1/s,4,1
Brain content,nM g-1,4,0
ED15,mg kg-1 i.d.,4,1
Total tritium,%,4,0
Vmax,microM/microg/sec,4,1
Kcat,10'-4/min,4,1
Subcutaneous score,,4,0
CI25,,4,-1
Activity,10'6CFU/ml,4,1
Cholesterol content,,4,0
Drug uptake,mBq,4,1
Total release,%,4,1
K,10'3No_unit,4,0
No. of rats with lesions,,4,0
Activity,ngequiv,4,1
Activity,10^9(p/s)(uW/cm^2),4,0
Vmax,nM hr-1 (mg of protein)-1,4,-1
IC50,10^-6 mol/L,4,-1
Unmetabolized,%,4,1
Total rate,g-1 min-1 ml-1,4,1
K,10'2/s,4,-1
K,10'2/mol/s,4,1
ED50,umol/kg.min,4,1
MDS,,4,-1
KD hydro,mM,4,-1
CREAT_CHANGE_BY,%,4,1
Activity,nmol of MDA/mg of LDL,4,1
Vmax,nM/min/mg,4,1
-Log Ki,,4,-1
Kcat,mM,4,1
% of NO release,,4,1
Vmax,nmol/ mL h,4,1
DC50,mM,4,-1
K inact,1/min,4,-1
Kcat,uM,4,0
Changes in dynamic compliance,Cdyn,4,0
Stability,um,4,0
Activity,10e-6*s cm-1,4,0
Activity,10'-6 cm/s,4,0
Kcat/Km,/nM/s,4,-1
Tumor free/total,,4,0
C12h,ng g-1,4,0
LC99,mgAi/L,4,-1
Vmax,nmol/min/ug,4,1
AUPAP,%,4,1
Drug mobility,,4,0
Drug uptake,ng.hr/ml,4,0
Stability,pmol/mg,4,0
Vmax,pM U-1 min-1,4,1
Activity,pM/mg,4,-1
ED10 HR,,4,1
LC95,ppm,4,-1
Activity,pS,4,1
Thymidine reversal,,4,-1
Stability,ng/ml/hr,4,-1
Vmax,pMl hr-1,4,1
Activity,pfu/ml,4,-1
Thylpositive cells/spleen,%,4,1
Drug metabolism,ug/ml.hr,4,0
Drug uptake,nmol.min,4,0
Thylpositive cells,%,4,1
CL,%ID/cc,4,1
Activity,10'-5AU/sec,4,1
Change of area,%,4,1
AUMCt,hr2.ng/ml,4,0
Ca2+ flux,nM mg-1,4,0
Vmax,pmol/min/10^6cells,4,1
Level of cGMP,pM,4,0
Potentiation inflection point,nM,4,-1
Vmax,pmol/min/g,4,1
Duration,day,4,0
Kcat/Km,10'4/Ms,4,-1
MEC,M,4,-1
AB,%,4,1
KDs,,4,-1
Thermogenesis,,4,1
Activity,uL/L,4,1
Specific activity,pM hr-1 (mg of protein)-1,4,1
qKD,uM,4,-1
Permeability rate,nm s-1,4,0
Urea Nitrogen Concentration,mg dl-1,4,0
CMC,10'-3 mol/L,4,0
Thermogenesis,%,4,1
AUMClast,hr.hr.ng/ml,4,0
Limiting t1/2,min,4,-1
Creatinine_CL,mL/min,4,0
Activity,uM/hr,4,-1
Activity,AU.min/L,4,1
Vmax,uM min-1 ml-1,4,-1
Activity,AU/L,4,1
Activity,uM/kg,4,-1
Solubility,mg kg-1,4,0
Vmax,uM/hr,4,1
Total rate,1/min,4,-1
CL,L/hr/1.73 m2,4,0
K,10'-3M,4,-1
MEC,ng/ml,4,0
IC50,10'-8mg/ml,4,-1
Lipid peroxidation,nM MDA (mg LDL)-1,4,-1
Skin thickness,,4,0
Duration of seizure,min,4,1
Permeability,AB cm/s,4,0
M2/M1 Index,,4,0
Challenge time,,4,0
K diss,uM,4,-1
Kd,10'-5/s,4,-1
Vmax / Km,ml min-1 kg-1,4,1
Permeability,10e4*cm min-1,4,0
M/NTT,,4,0
Drug metabolism,pg/ml/min,4,1
Sign free dose,mg kg-1,4,1
AUMC,ug.hr/g,4,0
Optimal dose,mg.kg/inj,4,1
Emax,bpm,4,1
Drug metabolism,nmol/hr,4,1
Caco-2 permeability,% hr-1,4,1
Kd,10'3/s,4,-1
Severity mean,,4,0
Kd,10'6/M,4,-1
Emax,deltalog10CFU/ml,4,-1
Percent remaining,%,4,0
Body temperature,degrees C,4,1
ED,U mg-1,4,1
Serum prolactin level,mg ml-1,4,1
Penetration,,4,0
HC5,,4,-1
Vmax(app),pmol/min.ml,4,1
Vmax/Km,%,4,1
Serum creatinine conc,mg dl-1,4,0
ED50,mg kg-1 hr-1,4,-1
Serum creatinine,,4,0
Activity,units ml-1,4,0
No. of mice infected /total,,4,1
Change in blood pressure,,4,0
Serum conc,uM,4,0
Activity Factor,,4,1
Urinary recovery,,4,0
Activity Score,,4,0
Activity in animals,,4,0
pH dependence,,4,0
KOH,M-1 s-1,4,1
Liver concentration,nM kg-1,4,0
CC50,10'3ug/ml,4,-1
Hydroxyproline release,ug ml-1,4,-1
Activity,10'-4AU/sec,4,0
DBP change,%,4,1
Activity_index,mg kg-1,4,1
Selectivity ratio,Ratio,4,0
Urine,%,4,1
Actual clearance,ml min-1 kg-1,4,1
ED90,umol/Kg,4,-1
Kd,10^5/M/s,4,-1
Drug uptake,pmol/ml,4,0
Selectivity index,%,4,0
Peff,%,4,1
KSV,/uM,4,-1
Acute lethal toxicity,,4,-1
VmaxL,pmol/min,4,1
IC20,10'-6M,4,-1
Peak striatal uptake,,4,1
Emax,ng ml-1,4,1
C50k,mg/L,4,-1
K,/M/hr,4,1
LC50,10'-3ppm,4,-1
Kd,kcal/mol,4,0
Adrenochrome formation,nM min-1 (mg of protein)-1,4,1
Adrenochrome formation,,4,-1
Peak effect time,min,4,0
Rate,nM min-1 (unit XOD)-1,4,-1
AUMC,hr.hr.ug/ml,4,0
Volume change,%,4,1
DA/NE ratio,,4,1
Irreversibility,%,4,1
Kd',M,4,-1
Test,,4,0
solubility,/mM,4,0
Affinity constant,M-1,4,-1
LD50,mmol/L,4,-1
Vomits,,4,-1
Saluretic activity,,4,-1
ECAR,%,4,1
IC20,10'-4M,4,-1
AUMC,%,4,1
C5a affinity,%,4,1
Activity,10'6uL,4,0
ED50,dp/dt,4,0
KSV,10'5L/M,4,-1
CL,mg/kg/min,4,-1
Drug metabolism,L/mol/min,4,-1
Vss,kg-1,4,0
Vss,l,4,0
Drug uptake,pmol/mm3,4,0
Aggregation ratio,,4,0
LC50,10'-1ppm,4,-1
Activity,Karmen,4,0
Kdiss,10'-5M,4,-1
MEC50,uM,4,-1
Challenge dose,cells mouse-1,4,0
Total protein,mg 100g-1 24hr-1,4,1
K,l mol-1,4,-1
CL,mg/ml/g,4,-1
KSV,10'6/M,4,-1
Passivity,,4,0
Vz/F,(mg/kg)/(ng/ml),4,0
Punishment test msad,mg kg-1,4,-1
Cp,nmol/g,4,0
Vz/F,g,4,0
ST elevation,delta mV,4,0
Intraperitonal score,,4,0
LT99.9,hr,4,-1
Activity,10'7/M/s,4,1
Rate change,%,4,1
DA stim,%,4,1
Intima area,10e3 um2,4,1
Internalisation,%,4,1
Agonistic potency,%,4,1
Decrease in MAP,,4,0
Lysis time,,4,0
Albumin,mg 100g-1 24hr-1,4,1
Activity,10'7CFU,4,1
Occ ED50,mg kg-1,4,1
Alkylating activity,10e3*k,4,0
Water intake,ml 20min-1,4,1
SPAV3,nM,4,-1
CL,min.kg/L,4,-1
SHR,,4,0
AUCt/dose,uM.hr.Kg/mg,4,0
AUCt/dose,uM.hr,4,0
Activity,10'6/M/s,4,1
partition_ratio,,4,0
Oral duration,,4,0
Amnesia reversal,,4,0
AUCt/dose,ng.hr/ml/mg/kg,4,0
KSV,10^5L/mol/s,4,-1
LC30,,4,-1
AUCt/dose,ng.hr/g/mg/kg,4,1
Insulin release,ng/islet/1h,4,1
Insulin release,%,4,1
IC50,10'5mM,4,-1
Carotid Flow Decrease,%,4,1
Activity,10'3kdyun/cm3,4,1
Ke,10'4/M,4,1
Tail flick,%,4,1
Ke,10'8/M,4,1
Erosions,,4,0
MED,mg/L,4,0
Erythema formation,,4,1
AUCt/dose,mg.hr/ml,4,1
Activity,L/min,4,1
CL,ml min-1,4,0
AUCt/dose,hr.kg.ng/ml/mg,4,0
AUCt/dose,hr.Kg/L,4,0
K,L/mol,4,-1
SDS,mg/kg,4,1
ED50,uM mouse-1,4,-1
Drug dissolution,%,4,1
Paraparetic mice,%,4,1
AUCt,ug.hr/g,4,0
Amount of TXB2 formation,ng ml-1,4,1
AUCt,pmol.hr/g,4,1
Drug degradation,ug ml-1,4,0
Drug degradation,nmol/min/mg,4,-1
Activity,M/uL,4,1
CL,ml.min-1,4,1
SA,uM,4,0
IC0.2,uM,4,-1
AUCt,nmol/g.hr,4,1
S/Cereb Ratio,,4,1
TRIG_CHANGE,,4,1
Initial concentration,%,4,0
S/CX Ratio,,4,0
Analogue level,pM (10e6*cells)-1,4,-1
Rotorod index,ROI,4,0
CL,ml/min/hr,4,-1
Log A50,,4,-1
CL,ml/min/nmol,4,-1
Cartilage space,,4,0
Drug uptake,IU/ml,4,0
Post anitbiotic effect,,4,0
C10,air/N2,4,0
Rmax,uM,4,0
2x TG,uM,4,-1
AUCt,min.ng/L,4,0
Ki,10'3/M/s,4,-1
Papp,nM s-1,4,0
K cat,1/min,4,1
Inhibitory binding,%,4,1
Zone reduction,%,4,1
AUCt,hr.ng/g,4,0
External nucleoside,nM g-1,4,0
Tumor size,mg,4,1
Activity,1/s,4,1
Lung weight,mg,4,0
Catalase,mg of protein,4,0
EBD20,mg kg-1,4,1
[3H]-uptake,,4,-1
NB,,4,0
Ring immobility,%,4,1
Antagonist,,4,-1
Antagonist activity,pA2,4,-1
CL,nM/min,4,-1
Ki,10'7/M/min,4,-1
Papp,cm'-6/s,4,1
Delta ERP,ms,4,1
Inhibition rate,,4,1
F1/2,,4,0
Inhibition period,hr,4,0
F3/4,,4,1
CL,ng.hr/ml,4,0
MED,nmol,4,-1
FBA,((mmol/day)/100g),4,1
Antibody response,,4,0
Retention_time,hr,4,0
Papp,10^-6/cm,4,1
Ka,1/M,4,1
Drug Conc (serum),ug ml-1,4,0
HC90,ug ml-1,4,1
pKa6,,4,-1
CL,pmol/min/mg,4,-1
Drug Conc (LDL),ug ml-1,4,0
Ki,10^4/M,4,-1
Retches,,4,-1
Rate of oxidation,nM min-1 ml-1,4,1
Cp,ng.hr/ml,4,0
AUClast,ug.hr/g,4,1
Ki,10e3* M-1 s-1,4,-1
Response value,uM kg-1,4,1
Anticonvulsant,,4,-1
Papp,10'-8m/s,4,1
CL,uL/min.ml,4,-1
Activity,RFU/ug/min,4,1
1/kmax,min,4,-1
K'i,uM,4,-1
c.v,,4,0
FC,log10RLU,4,1
Antidiuretic activity,IU uM-1,4,-1
TMED,mg kg-1,4,1
Tremorolytic dose,,4,1
Change in spermatogenesis,,4,0
Responder,%,4,1
EC5x,uM,4,-1
FC,uM,4,-1
FD,%,4,1
Antidiuretic activity,U mg-1,4,1
Residue fraction,%,4,0
Antihypertensive activity,mmHg hr-1,4,1
AUClast,ng.hr,4,1
K bind,M,4,-1
NADH oxidation,uM min-1,4,1
LV,dP/dtmax,4,0
Ki',nM,4,-1
Ki'',nM,4,-1
MBC,mmol/L,4,-1
Papp,10'-3cm/min,4,0
Inhibition,M,4,-1
Activity,U/dl,4,1
dP/dt,1/Pmax,4,0
dP/dt,1/Pmax s,4,0
Oxidation,uM min-1,4,1
AUClast,min.ng/g,4,0
Dose converted,%,4,1
Antiviral activity,,4,0
Activity,U/g.Hb,4,1
Ki(app),mole fraction,4,0
AUClast,hr.nmol/g,4,1
Drug uptake,ml/min,4,0
Total infarct volume,mm,4,1
Antiviral selectivity,,4,0
Transport,%,4,1
TGI50,,4,1
Renal clearance,ml min-1 kg-1,4,0
Renal clearance,ml min-1,4,0
ED50,10'-6M,4,-1
delta Log P50,,4,-1
Drug uptake,ml/g,4,1
ED50,10'-5umol/ml,4,-1
Ka,10'3L/M,4,-1
Remains,,4,0
CFU,%,4,1
Apoptosis induction,%,4,1
Ki/K'i,,4,-1
CL free,uL/hr/10^6cells,4,-1
TEWL,,4,0
LV dP/dtmax,%,4,1
Infertility activity,,4,-1
LDH release,,4,0
Gross morphology,,4,0
PVCs,number min-1,4,-1
Oxygen consumption rate,nM min-1,4,1
MBIC50,mM,4,-1
Ka,10'6/M.s,4,1
KiH,fM,4,-1
Dose,nM min-1 kg-1,4,-1
Hypokinesia,Counts,4,1
IC50,10'-10 uM,4,-1
Dose,nM kg-1,4,-1
CL(app),L/hr,4,1
Atrial MAPD90,ms,4,0
Ka,10'6/M/min,4,1
Relative to control,%,4,1
EC50,mg,4,0
Augmentation,%,4,1
AUC/dose,nmol.hr,4,1
CLint,,4,-1
Kimut/Kiwt,,4,-1
ED50,10'-14 ug/ml,4,-1
Cell Survival,%,4,1
Dose,mg mouse-1,4,1
Ratio,/min/nM,4,-1
Polyamine,,4,-1
Kin,uL/sec/g,4,0
rel T,,4,0
Increase in life-span,,4,1
Polyamine,nM (mg of protein)-1,4,-1
Average body weight,g,4,0
MED100,,4,-1
Relative phosphorylation rate,,4,0
Dose,M kg-1,4,1
Average latency,,4,1
Cz,ug/L,4,0
Fecal weight,g,4,0
deltaTCID50,,4,-1
Feces,%,4,1
EOS inhibition,%,4,1
L/CE,,4,0
P,uM,4,-1
Average lung weight,mg,4,0
K,10^4L/mol,4,-1
deltalog10CFU,/ml,4,-1
IC12,,4,-1
No. of animals protected / no animals tested,300mg kg-1,4,1
Ferret emesis,,4,0
Average max,%,4,1
AUC/dose,mmol.L/hr,4,1
Relative initial slope,,4,0
Ratio,1/M 1/s,4,1
AUC/dose,min.ug/ml,4,1
Molar content,Molecules (LDL particle)-1,4,0
Relative initial rate,,4,0
%,%,4,1
No. of animals protected / no animals tested,100mg kg-1,4,1
CL/F,(mg/kg)/(ng/ml)/hr,4,-1
Vacuole response,ng ml-1,4,0
EPS,,4,0
Activity,10^1pg/ml,4,-1
f %t > MIC,,4,-1
AUC/dose,mg.hr/ml,4,1
EPS MED,mg kg-1,4,1
Ratio,10'-3umol/min,4,-1
Kinact,10'3/M/s,4,1
Increase in HR,,4,1
CLd,L/hr,4,0
Naproxen produced,uM,4,0
Po/w,,4,0
Fluid,ml rat-1 day-1,4,-1
PP2A Selectivity,,4,0
K0.5,,4,-1
K1,mM,4,-1
CL/F,L.h-1,4,0
Fmax,pg/ml,4,1
2aPTT,ug ml-1,4,-1
Activity,hr-1,4,1
Occ90,mg kg-1,4,1
AUC/dose,hr.kg.L,4,0
Activity,(nM of vector) (ug of DNA)-1,4,1
ED50,pM,4,-1
K inact/Ki,mM-1 min-1,4,-1
Relative efficiency,,4,0
Ka,10E3*1/M,3,1
Activity,10'5CFU,3,0
Protective ratio,,3,1
Protein,mg ml-1,3,0
Day of death,,3,1
K inact,uM,3,-1
Tumor,number,3,-1
Tumor burden,,3,1
Tumor free survival,,3,0
Tumor growth,%,3,1
K diss,10E-2*1/s,3,-1
Day of vaginal opening,,3,1
Tumor incidence,%,3,1
Tumor latency,day,3,1
K cat/Kinact,,3,0
ED60,uM,3,-1
Activity,10'3cm,3,1
Hind-paw lick latency time,,3,1
Activity,10'3/min,3,1
Activity,10'3/M,3,1
MBC50,,3,-1
Tumor weight reduction,%,3,1
Activity,10'2log10CFU/ml,3,-1
K ass,10E3*1/M*1/s,3,1
Tumour_[5-FU],nmol/g,3,0
Activity,10'10CFU,3,0
ED80,mg/ml,3,1
ED80,nM,3,-1
ED85,,3,-1
Activity,10'-9M,3,-1
K amine,M-1 s-1,3,-1
IC50,ml,3,-1
QH,ml/min.Kg,3,1
Histamine release,%,3,1
Ulceration,mg kg-1,3,0
Activity,10'-7No_unit,3,0
Css,mcg/mL,3,1
Activity,10'-6microL,3,0
Unbound plasma,%,3,1
K Tm,,3,0
Drug uptake,pg/ml,3,1
K Tm,M-1,3,-1
K SH,,3,-1
QTc Interval,ms s-1,3,1
Activity,10'-6 ug/ml,3,1
Qmax,%,3,1
Drug uptake,pmol/OD,3,1
Activity,10'-5M,3,1
Activity,10'-4nmol,3,1
C120,uM,3,0
Activity,10'-4/s,3,1
C100,,3,0
K,mol/L/min,3,-1
MIC,10'-1nmol,3,-1
Activity,10'-2nmol,3,1
Uterine weight,mg cm-1,3,0
Uterine weight effect,,3,0
EF200,,3,1
Uterotrophic effect,%,3,1
C10,mM,3,-1
RBA data,,3,-1
C1.6,,3,-1
K,10^8No_unit,3,0
C1,ml min-1 kg-1,3,1
CO,%,3,1
MIC,(ug of base) ml-1,3,-1
Activity,/M,3,-1
VDR affinity,M,3,1
C0/dose,umol/L,3,1
K,10^5L/mol,3,-1
K,10^4/M.s,3,1
Varea,,3,0
Decrease in exit latency,%,3,1
C0,umol/L,3,0
K,10^3/min,3,1
RC50,10'-1mg/ml,3,-1
Vasopressor responses,,3,0
Activity,(mM of AZT) (mg k-carrageenan)-1,3,1
Activity,%/min,3,1
Vd,ml/hr.kg,3,0
RD1000,,3,-1
Vd,ml/min.Kg,3,0
K,10^-8/s,3,-1
Occlusions,ug min-1 kg-1,3,1
Active dose,,3,1
Vdss,g/Kg,3,0
Vdss,mL,3,0
LD20,uM,3,0
Vdss,mg/ng/ml,3,0
Vdss,ml/hr.kg,3,0
C ss,ng/mL,3,0
Homovanillic acid concentration,nM g-1,3,0
Activation Factor,,3,1
MAD,,3,-1
LD100,microg/cm2,3,1
Ventricular relative refractory period,ms,3,1
K,10^-3/M/s,3,-1
K,10^-3/M/min,3,1
IC30,10'-7M,3,-1
IC2x,,3,-1
Acetylcholine release,%,3,1
Brain uptake,nM g-1,3,0
K,10^-1/s,3,-1
Brain levels,,3,0
Vm,uM,3,-1
Hours above EC90,,3,1
RNA fraction,,3,0
Vm,,3,0
HDL,%,3,1
Vmax,10'-3OD/min,3,1
RPE,,3,0
Vmax,10'-4umol/min/U,3,1
Vmax,10'-5deltaA/s,3,0
Oligo shifted,,3,1
Css,nM,3,0
LD,,3,-1
Brain level,uM,3,0
LD,ug/kg,3,-1
Eff,%,3,1
Vmax,FU uM-1,3,1
Decreased_triglyceride,,3,-1
MAC,uM/L,3,-1
K,10'6/s,3,1
MI50,nM,3,-1
Vmax,RFU/s,3,1
MIC50,%v/v,3,0
Vmax,deltaA/s,3,1
Onset of block,,3,0
HDL,ug mg-1,3,0
Vmax,min uM-1,3,-1
Vmax,min-1,3,1
IC50,10^-6 uM,3,-1
K,10'3/M.s,3,1
Efflux,%,3,1
Abolition,,3,0
Ability,%,3,1
Vmax,nM/mgM,3,0
RW,min,3,0
HDL,,3,0
CMC,10'-4M,3,0
AURC,hr,3,1
CMC,10'-4 mol/L,3,0
Radioactivity,nCi g-1,3,1
Druguptake(free)/dose,ng/ml,3,0
Bone mineral density,mg/cubic cm,3,1
Vmax,pmol/OD/min,3,1
Vmax,pmol/h,3,0
Vmax,pmol/mg.min,3,1
Druguptake/dose,nM,3,0
Bone mineral density,mg/cm3,3,1
K,10'-5M,3,0
Duration of anesthesia,min,3,1
Duration of increase in SLA,min,3,1
CMC,10'-2 mol/L,3,0
Degrees Centigrade,degrees C,3,1
Elevation of threshold,%,3,1
Vmax / Km,FU min-1 uM-1,3,-1
E2:E1,,3,0
AUMC,ng/mL.hr'2,3,0
K,10'-13/s,3,-1
Vmax/Km,U/min/nM,3,-1
AUMC,microg.min/mL,3,0
Vmax/Km,nmol/min.uM,3,-1
Vmax/Km,uL/OD/min,3,1
IC20,10'-8M,3,-1
Emax,mg/dl,3,1
Emax,mg/kg/day,3,1
Emax,s,3,1
2x TG,,3,-1
Iron clearence,,3,0
Emin,nM,3,-1
Vss,L.kg-1,3,0
Empty,%,3,1
Vss,L/hr,3,0
Ion enhancement,,3,0
AUIC,%.hr,3,1
Vz,mg kg-1,3,0
Vz,mg/ng/ml,3,0
Eosinophils,%,3,1
Hepatic extraction,,3,0
Vz/F,,3,0
AUEC,%.hr,3,1
Lysozyme release,%,3,1
t1/2ss,hr,3,0
Walking behaviour,%,3,1
LC5,ng/ml,3,-1
CLtot,ml hr-1,3,0
Inotropic potency,,3,-1
Weight difference,%,3,0
Na+ excretion,mg kg-1,3,0
Injected dose,,3,0
Weight reduction,%,3,1
LC25,ng/ml,3,-1
LC20,,3,-1
AUCt,ng.hr2/ml,3,1
AUCt,nM/ml.min,3,1
Zinc finger reactivity,RFU min-1,3,-1
AUCt,hr.nmol/g,3,1
AUCt,g/hr,3,1
Ct,nM/g,3,-1
Bmax,nmol,3,1
CLp,L.h-1,3,1
FC,10'6No_unit,3,0
Lowering activity,%,3,1
Ouabain dose,ug kg-1,3,1
Overt behavoiur,,3,0
Inhibition,units ml-1,3,0
Inhibition,nmol,3,0
FPGS activity,nM hr-1 mg-1,3,-1
EC10,M,3,-1
AUClast,nM.hr/L,3,0
Infusion rate,ug min-1 kg-1,3,0
dP/dt20,,3,-1
dPT,nM,3,-1
AUCED90,,3,0
Inflection point,nm/s,3,0
AUCED90,ug.hr/ml,3,1
Oxidation rate,nM min-1,3,1
permeability,ug,3,0
AUCED90,uM.hr,3,-1
AUCED90,microg.hr/mL,3,1
delta pKa,,3,0
Oxidation rate,uM min-1,3,1
MGDH GI50,,3,-1
Oxygen consumption rate,,3,0
AUC/dose,uM.hr/mg.kg,3,0
Loss,,3,-1
deltaH,10^4cal/mol,3,-1
deltaH1,cal/mol,3,0
AUC/dose,ng/(hr.mL.mg.kg),3,1
Fana,,3,0
Femur weight,%,3,1
deltalog10CCID50,,3,-1
pKic,,3,-1
NaCl concentration,M,3,0
AUC/dose,microg.min/mL,3,1
HC50,10'-4M,3,-1
CLd/F,L/hr,3,0
IC12,uM,3,-1
Delta TG,%,3,1
Ct,umol/L,3,0
IC50,10^-5 mol/L,3,-1
Improved,,3,0
Fold stimulation,%,3,1
Hematocrit,g,3,0
fAUClast,nM.hr,3,1
Fold_increase,,3,1
Blood lactate,mg dl-1,3,1
Blood lactate,mM,3,0
P/D,,3,0
AUC total,,3,0
AUC second treatment,,3,1
Imax,nM,3,-1
I80,uM,3,-1
Food intake,g day-1,3,1
Delta TG,,3,1
Ratio,10'5/s/M,3,1
AUC glu reduction,%,3,1
ft1/2,hr,3,1
AUC first treatment,,3,0
AUC Npo,uM x h/dose,3,0
Fraction cleared renally,%,3,1
I90,g/ha,3,1
Ratio,10^1/M/s,3,-1
k cat,M-1 s-1,3,-1
Helicity,,3,0
AUC,uh ml-1,3,0
Ratio,10^3/s/M,3,-1
% Inhibition of Control Specific Binding,%,3,1
Fu,nmol/g,3,0
Cp(f)/dose,ng/ml,3,0
Ks,10^3/M,3,-1
INH,mg/L,3,1
k0,min-1,3,-1
Ratio,10^7/M/s,3,-1
Negation,,3,1
k2,d se-1,3,-1
Cholesterol,mg dl-1,3,1
P7.4,,3,0
Kreact,,3,0
Kreact,min-1,3,1
Ratio,g/cm,3,1
Ratio,hr,3,0
I.D./g tissue,%,3,0
Ratio,mM-1s-1,3,-1
CL_Ratio,,3,-1
GAG,%,3,1
PAO activity,pM min-1,3,-1
GD200 [d],%,3,1
Heart weight,,3,0
AUC,uM h/dose,3,0
kONOO-,M-1 s-1,3,-1
AUC,uA.cm'-2,3,1
kR,min,3,-1
GFR,ml min-1,3,-1
k_2,s-1,3,-1
MFC50,mg/L,3,-1
PAR,mg kg-1,3,1
Change in myocardial conduction,,3,0
Cumulative urine volume,,3,1
ka,,3,-1
AUC,pmol,3,0
kel,hr-1,3,-1
ki/Ki,,3,-1
ID95,mg/ml,3,1
AUC,nmol/hr,3,1
IC10,,3,-1
ID90,ug ml-1,3,-1
HR/chol,,3,0
AUC,nmol/g,3,0
koff,*10e6/s,3,0
AUC,nmol/100.000â¯cells x h,3,1
AUC,ng/g,3,0
kr,min1 M1,3,-1
kred,M-1 s-1,3,1
AUC,ng/10^6â¯cellsâ¯Ãâ¯hr,3,1
EC200,ng/ml,3,-1
Cellular concentration,nmol,3,0
Delta plasma cholesterol,%,3,1
Ratio CC50/EC50,10'4No_unit,3,1
AUC,ng,3,0
GI90,,3,-1
AUC,nM.hr/ml,3,0
GIC50,uM,3,-1
Kq,10^12L/mol.s,3,-1
log(1/IC50),,3,-1
Cp(f)max,ng/ml,3,0
AUC,mmol/L,3,1
Kq,10^11/M/s,3,-1
ID50,pg,3,-1
Kq,10'6/M,3,1
AUC,microM/mg/kg,3,0
GR activity,mU mg-1,3,1
AUC,microM.hr.kg/umol,3,0
AUC,mg/dl.hr,3,0
AUC,mg.hr/kg,3,0
MIC,ug/sq.cm,3,-1
Delta t,,3,1
ID50,mg/kg/day,3,-1
ID50,mg kg-1 hr-1,3,-1
Ratio EC50,nM,3,-1
Binding constant,1E4/M,3,-1
AUC,hr.fmol,3,0
AUC,g/hr,3,1
GR50,KgAi/ha,3,1
log10cfu/day,,3,-1
GSH,,3,0
Ratio IC50,10'3No_unit,3,-1
GSH reactivity,,3,0
ID30,mg kg-1,3,1
Ratio IC50/EC50,10'4No_unit,3,-1
ID25,mg kg-1 p.o.,3,1
GST activity,mU mg-1,3,-1
CLH,uL/min/pmol,3,-1
APTT,min,3,1
ID/thyroid,%,3,1
Kq,10'13L/mol,3,-1
Net log change in tumor burden,,3,1
PD'2,,3,-1
PD100,mg/kg/day,3,1
max activation,ug ml-1,3,1
Kq,10'11L/mol,3,-1
mean % of control,%,3,1
Binding,pCi mg-1,3,0
n,,3,0
Kq,10'-5L/mol,3,-1
nKa,M/M,3,0
Kq,10'-4L/mol,3,-1
ICL5,uM,3,-1
Binding,dpm,3,0
p24 synthesis,ng ml-1,3,1
Glucose level,g day-1,3,1
Glucose level,g dl-1,3,0
pA2,uM,3,-1
Glucose level,m equiv l-1,3,0
IC80,ng/ml,3,-1
Glucose level,ml d-1,3,0
Ratio plasma concentration/IC50,,3,-1
AE,,3,0
Derived trabecular number,mM-1,3,0
Cyotoxicity,,3,-1
Behavioral observation,,3,1
IC50L,nM,3,-1
Ratio_liver/blood,ng/ml,3,0
Ratio_tumour/plasma,,3,0
Glutathione,nM mg-1,3,0
pD10,,3,-1
Glutathione levels,umol/g tissue,3,0
Neutrophils,%,3,1
Reaction rate,nM hr-1,3,-1
AC_50,uM,3,-1
Graft survival,day,3,1
Max aggregation,,3,1
Max T/C,mg kg-1,3,1
Cmax_unbound,ug ml-1,3,0
Cmin ss,nmol/L,3,1
Min plague Inhibitory,%,3,1
Basal activity,%,3,1
Cmax_unbound,mg/L,3,0
Max displacement,%,3,1
Max effect,s,3,0
Kobs,/M/s,3,-1
ACT,s,3,-1
Margin before onset of tachycardia,,3,-1
Cmax_PTH,pM,3,1
HSF activity x10e2,ml,3,0
Bacterial growth,,3,0
Ko,/M,3,0
Margin before onset of hypokalemia,,3,-1
EC300,uM,3,-1
MUD,,3,-1
MTX equivalent,,3,0
Max jumping rate,%,3,1
Cytotoxic effect,%,3,1
Competition,,3,0
MTD/8,mg kg-1,3,1
MTD/4,mg kg-1,3,1
MTD/2,mg kg-1,3,1
Max response,delta mmHg,3,1
Log Poct C,,3,0
% Inhibition,"%,%",3,1
Conc_brain,uM,3,0
Km,pmol/uL,3,-1
MTD,mmol/Kg,3,1
Reduced_parasitemia,,3,1
Difference in retention time,min,3,0
NAD,%,3,1
MTD,g/Kg,3,1
Maximum inhibition,%,3,1
Km,10^3/M,3,0
MST,months,3,1
Cmax,ng/mg prot.,3,0
Mean AUC,,3,1
PEI,,3,0
Dioxygen uptake rate,uM min-1,3,-1
Reduction in AUC,%,3,1
Cmax,microg.hr/mL,3,0
Cell plating efficiency,%,3,1
Mean free plasma concentration,nM,3,0
2PT,mM,3,-1
Mean increase in survival,day,3,1
Mean index,,3,0
Heart beat,beats min-1,3,0
Concentration_plasma,microM,3,0
NAD content,M (M of enzyme)-1,3,-1
EC5,,3,-1
EC50,%molar,3,-1
Clp,kg-1 hr-1,3,0
Conduction,mm/m/s,3,1
Consumption,g day-1,3,0
Consumption,ml d-1,3,1
Grip strength,g,3,-1
Kkin,M-1,3,1
Mean total plasma concentration,nM,3,0
EC50,(mg/kg)/day,3,1
Mean ulcer index,mM,3,0
Cleavage,,3,-1
BMD,mg cm**-2,3,1
Mechanistic reference,,3,0
Distribution,l,3,0
Clearance,mg kg-1 uM-1 hr-1,3,-1
Kiso,,3,-1
No. cured,,3,1
Kis,uM/L,3,-1
MLC,ppm,3,1
Control survivals/total,,3,1
Cl,,3,0
Conversion,,3,0
Choline uptake,pM (4 min)-1 (mg of protein)-1,3,-1
Coronary flow,%,3,1
Cortical infarct volume,%,3,1
Counts of rotation,turns hr-1,3,0
EC50,10'-3mol%,3,-1
BAT,g,3,0
B/P ratio,,3,0
Kinetic_solubility,uL,3,0
EC50,10'-4 ug/cm2,3,-1
2*APTT,,3,-1
NAD+ content,%,3,1
B incorporation,ug,3,0
Kinact/Ki,mM-1 min-1,3,-1
EC50,10'7pM,3,-1
IC,,3,-1
PL,,3,0
NAD+ content,,3,0
Kinact,10^4/M/min,3,-1
CL/F,L/Kg,3,-1
solubility,min,3,0
Kinact,10^-2/s,3,-1
Kinact,10'5nM,3,-1
Dosage,ug,3,1
CL/F,(mg/kg)/(ug/ml).hr,3,0
Average sample intake,mg kg-1 day-1,3,0
PPB,nM,3,0
PPB,uM,3,0
EC50,10^3 uM,3,1
IC50,mg Kg-1,3,-1
Average food intake,g mouse-1 day-1,3,1
Dose,mM kg-1,3,-1
MED10,,3,-1
Average IOP,mmHg,3,0
PSA,%,3,1
Relative substrate velocity,,3,0
EC50,mM kg-1,3,-1
Dose,mg uM (kg of body weight)-1,3,-1
EC50,mg kg-1 day-1,3,-1
D,10'-6cm2/s,3,0
Relativity,%,3,1
CL(%Q),%,3,1
KiH,,3,-1
KiH,pM,3,-1
EC50,nmol/Kg,3,-1
EC50,p.p.m.,3,-1
EC50,pH,3,0
NADH content,,3,0
Apoptotic cell,%,3,1
Palmitoyl-CoA oxid,uM min-1mg-1,3,0
Residual activity,nM,3,-1
sigmaSH,%,3,1
Ki app (inact),nM,3,-1
Cp(f)ss,uM,3,1
Ki,TS,3,-1
EC60,nM,3,-1
EC70,nM,3,-1
Papp,10-6 cm s-1,3,0
Papp,10^-5 cm/min,3,1
Drug degradation,%molar,3,0
NADH oxidn,uM min-1,3,1
MED,ng,3,0
Reversing activity,,3,-1
No. of dead mice,mg kg-1,3,1
Animals protected,,3,1
Ki,10'4/M/s,3,-1
EC80,ng/ml,3,1
No. of depolarizations,,3,0
IC50,10'5pM,3,-1
Rotational behavior,turns hr-1,3,1
Papp,nmol/sec,3,1
Ki,10'-16M,3,-1
S/N,,3,0
EC90,(mg/kg)/day,3,1
A,,3,0
Kf,s-1,3,1
Keq,M-1,3,0
Kel,min-1,3,0
Log A,s-1,3,0
Drug degradation,hr,3,1
Kel,1/min,3,-1
Analgesia,,3,0
CL,ml/kg,3,-1
Amount of unreacted substrate,,3,-1
Paralysis,min,3,1
SD50,mg/kg/day,3,-1
Ke,L/hr,3,0
Ke,10^-6M,3,-1
CL,ml kg-1,3,0
Carnitine acetyl transferase,mg of protein,3,0
SHR delta blood pressure,dec,3,-1
EC99,nM,3,-1
SI,ml beat-1 kg-1,3,1
I50,(ug of base) ml-1,3,-1
Alpha c,,3,0
Cp/dose,nM/mg/kg,3,0
Cpss,nM,3,0
Kdiss,10^4/M/s,3,-1
Cp,g/ml,3,0
Kdiss,10^-4/s,3,-1
CL,microL/ml/min,3,-1
Paw edema,%,3,1
CL,mg/ng/ml/hr,3,0
Drug metabolism,10^-3L/mol/min,3,1
Kdiss,10'-6M,3,-1
Paw weight,mg,3,1
Aggregate,%,3,1
Log 1/EC50,,3,-1
Affinity state 2,%,3,1
Affinity state 1,%,3,1
Cp,microg/ml,3,0
Affected animals,%,3,1
Mobilization,%,3,1
Kd Error,uM,3,-1
Kd,uL/OD/min,3,0
Cpss,ug ml-1,3,1
MEC1.5,nM,3,-1
Drug metabolism,mg.equiv,3,0
rate constant app,M-1 s-1,3,0
Drug metabolism,ml/min/mg,3,-1
Selectivity index,ug ml-1,3,0
IC50,nmol/Kg,3,-1
Kd,10^5/M,3,-1
Locomotion,cm,3,0
Peff,10'-8cm/s,3,1
CL,mL/mg/kg,3,0
Activity in animals,mg kg-1,3,1
Activity EC50,uM,3,-1
Activity (umol/mg.of protein. min),%,3,0
permeability,10'-5cm/hr,3,0
Serum TSH,ug 100ml-1,3,1
Activity (nmol/mg.of protein. min),%,3,0
ECmax,pM,3,-1
Activity,umol/min/ml,3,1
Activity,um3/um2/yr,3,0
MEC,nmol,3,-1
Kd,10'7/M,3,-1
Kd,10'5/s,3,-1
Periosteal mineral apposition rate,%,3,1
Activity,um/s,3,1
Caco-2 A-B,cm s-1,3,0
Skin Graft Survival,,3,-1
Permeability,cm (10e3*hr)-1,3,1
Activity,ug kg-1,3,1
CL,g/hr/kg,3,0
CL,L/hr/m2,3,0
Smax,uM min-1 g-1,3,-1
Kd,/M/s,3,-1
Activity,uM/min/uL,3,1
Solubility,mg,3,0
Activity,uM J-1,3,0
Kcat/Km,10^6/s/M,3,-1
Specific activity,nM Pi min-1 (mg of protein)-1,3,-1
Activity,uL/g/min,3,1
Specific activity,uM min-1 (ug of protein)-1,3,-1
Kcat/Km,10^3/M/s,3,1
No. of occlusions,,3,0
Perturbations,%,3,1
Specific incorporation,c.p.m. (mg of melanin)-1,3,1
HC50,mM,3,-1
CL,10'-6uL/min,3,0
pKa app,,3,0
Spleen weight,,3,1
ED1/3,,3,1
Activity,pmol/min.ug,3,1
Phospholipidosis_MEC,uM,3,-1
ED10,uM kg-1,3,-1
pKa value,,3,0
Stability,degrees C,3,0
Stability,mg/g,3,0
MEC,10'-6M,3,-1
Activity,pmol adducts/mg DNA,3,1
Activity,pgequiv/ml,3,1
Stability,mmol/min/mg,3,-1
Stability,mol%,3,-1
CL,% ID/g,3,0
Kcat/Km,10'1/s/M,3,1
No. of protected animals/total,,3,1
MEC,10'-5M,3,-1
CIT,ml min-1 kg-1,3,0
Kcat/Km,/s,3,1
Activity,pKi,3,-1
Stability,uL/ml,3,0
Activity,pIC50,3,-1
Activity,pD2,3,-1
Level,mg ml-1,3,0
Kcat,nmol/min,3,-1
ED100,uM,3,-1
Activity,nmol/mg LDL,3,0
Activity,nmol of acetaldehyde(AcH) oxide per minute per mg of protein,3,1
Kcat,10^-2/s,3,1
Stimulations,%,3,1
Stoichiometry,,3,0
Activity,ng/min,3,1
proof of principle,,3,0
IC50,10'-3g/L,3,-1
ED15,nM day-1 kg-1,3,-1
Succeeded/tested,,3,0
ED15,nmol/kg/day,3,1
Superoxide anion,mM,3,0
Activity,ng.hr/ml,3,1
Plasma Insulin,pM l-1,3,0
Plasma TC,mg dl-1,3,1
Kc,nM,3,0
Plasma TG,mg dl-1,3,1
Survival,10'5CFU/ml,3,-1
Kbapp,10'-9M,3,-1
Activity,nM min-1 unit-1,3,1
Survival extension,%,3,1
Mineralizing apposition rate,mm day-1,3,1
Activity,nM (nM of NOS),3,-1
Plasma clearance,ml min-1,3,0
Activity,ms/s1/2,3,0
Survival time,hr,3,0
Survivals / total,,3,1
CI,l kg-1,3,0
Activity,ml/hr,3,1
ED200,ug,3,1
DDT msad,mg kg-1,3,-1
Susceptibilty Ratio (Liver/Intestine),,3,0
Activity,microm2/micrometer/d,3,1
Mortality threshold,mg kg-1,3,1
Kapp,10^4/M,3,-1
Plasma half life,hr,3,0
Lesion coverage,,3,0
Lesion coverage,%,3,1
T max,uM,3,0
Activity,mg.min/L,3,1
Kact,,3,-1
pkb,,3,0
Cp,ng,3,0
Kact,/min,3,1
ED30,nmol/kg/day,3,-1
Learning time,s,3,1
Ka,M/M,3,1
T/C x100,mg kg-1,3,1
Activity,mN/meter,3,1
pIC50(mM),,3,-1
T1/2,min-1,3,-1
Activity,mM kg-1,3,1
Plasma_[5-FU],nmol/mL,3,0
DLBT,mg kg-1,3,-1
Cp,g,3,0
T1/2 regen,s,3,0
T4,ng ml-1,3,0
88Y-serum,,3,0
ED35,uM kg-1,3,-1
Activity,mEq/dL,3,1
T>MIC,min,3,-1
ED37,,3,-1
Drug uptake,%Idose/L,3,1
ED5,mg Kg-1,3,1
([I]/[S]0.5),,3,-1
Lactone,,3,0
permeability,10^6m/s,3,0
TC50,10'3nM,3,-1
Pleural volume,ml,3,1
Activity,kg/ha,3,1
NOAEL,nM,3,0
Drug uptake,10'-2microM,3,-1
Drug uptake,10'-7M,3,0
Activity,kN/m2,3,1
TC90,ug ml-1,3,1
Ka,10^-6/M/s,3,-1
TCS50,,3,-1
Transfection activity,RLU (mg of protein)-1,3,1
Ka,10'9/M/s,3,1
Motor activity,Counts hr-1,3,-1
TD50,microM/Kg,3,-1
ED5,,3,1
TDS ratio,,3,0
TED,microg/cm2/h,3,1
ED50,10'-15 ug/ml,3,-1
Activity,dB,3,1
Activity,cps/nM,3,-1
Activity,cmH2O,3,1
Motor activity,accumulated counts 30min-1,3,1
Activity,bpm.hr,3,1
Activity,a.u.L/mol.cm,3,0
Ka,10'3L/mol,3,1
TGIR,,3,1
ED50,10'-6umol/ml,3,-1
CD90,uM,3,-1
LUI,%,3,1
TMED50,,3,-1
DOPA level,ug g-1,3,0
Post anitbiotic effect,hr,3,-1
permeability,min,3,0
Ka,/min/nM,3,-1
TPR,%,3,1
TPR,mmHg ml-1 min-1 kg-1,3,0
TRAP staining,,3,0
Activity,Mequiv,3,0
TSH/chol,,3,0
DOPAC,,3,0
CC50/IC50,,3,-1
Drug uptake,SUV.min,3,1
LT99.9,min,3,-1
TTO,,3,0
ED50,L/ha,3,1
TWI,,3,1
Potency,mg,3,0
Activity,Kg/hr.m2,3,1
CC50,U/mg,3,-1
CC50,10^4 uM,3,-1
DOPAC concentration,nM g-1,3,0
LS,min,3,0
Activity,EU/mg,3,1
Activity,Counts/minute,3,1
KSV,10'-4/M,3,1
LRR,min,3,0
LPS,min,3,0
KI50,M l-1,3,-1
Therapeutic indices,TI,3,1
IC5,ug ml-1,3,-1
KHOX,M-1 min-1,3,1
Threshold value,mg kg-1,3,1
Thrombin time,s,3,1
Thromboxane B2 level,%,3,1
DR2,ug min-1 kg-1,3,1
LOAEL,mg kg-1,3,1
Thymus weight change,g,3,0
Pregnancy index,,3,1
KD,,3,-1
Drug uptake,g,3,0
CR2,block/treat,3,-1
Time constant,,3,0
permeability,nanometer/sec,3,0
DR2,,3,-1
CAC,,3,1
Time in light,%,3,1
Presumed drug-related deaths,,3,1
KB,10'4/M,3,-1
Nucleic acids,mg mg-1,3,0
Drug uptake,mg Kg-1,3,0
LED,ng/ml,3,0
Production,pM (mg of protein)-1,3,1
Activity,10^3CFU/ml,3,-1
MBC<=99.9,mM,3,-1
Tmax,%,3,0
Activity,10^3CFU/mg,3,-1
Tmax,mg/L,3,0
IC50,10^3 uM,3,-1
ED50,nmol/kg/day,3,-1
KA,10'4/M,3,-1
LDL,%,3,1
Tmin,,3,0
KA,10'3/M,3,-1
K6,,3,-1
Prolactin release rate,ng mg-1 hr-1,3,1
Topical irritation score(0-21),,3,1
K5,,3,-1
ED50,pmg kg-1,3,-1
Total cells,number ul-1,3,-1
Drug uptake,min,3,0
Total coenzyme,%,3,1
Total liver weight,g,3,0
Prolonged VRP,,3,-1
Total no. of turns,,3,1
Activity,10^-4No_unit,3,0
CPCC,,3,0
Drug uptake,nM/g,3,0
Prostaglandin E2 level,%,3,1
K1,pM,3,-1
Activity,10^-10M,3,-1
C90,nM,3,-1
Toxic index,,3,0
Protected mice,,3,1
Activity,10'8CFU/g,3,1
Activity,10'7CFU/ml,3,1
Toxicity (deaths),%,3,1
Activity,10'7/g,3,1
HVA,,3,0
K-1,hr-1,3,-1
Protection ratio,,3,1
Trabecular no.,,3,0
Trabecular thickness,,3,0
ED50,ug hr-1 kg-1,3,1
Traction test,score,3,0
AUC/dose,ng h/ mL,2,1
AUC/dose,ng.hr.kg/ml/mg,2,1
Cell cycle effect,,2,0
deltaS,,2,0
Poct,,2,0
PPB,pmol,2,0
pKiL,,2,-1
Average gross pathology scores+/- SE,,2,0
CFU,10'9/g,2,-1
Kinact,/us,2,-1
EC50,10^2 ug/ml,2,-1
PPB,ug ml-1,2,0
Activity,dyn/mg,2,1
Cp,ug/g,2,0
Relative peroxidation,,2,0
EC50,10^3ug/ml,2,-1
Cp(f),nmol/ml,2,0
CFU,10'7/ml,2,-1
PR,%,2,1
pKiH,,2,-1
EIR,,2,0
Kin x,hr-1,2,-1
CLint,uL/(min.pmol),2,-1
deltaS,KJ/(mol.K),2,0
Activity,dpm (mg of protein)-1,2,0
Kin,uM,2,-1
Ratio,/nM/s,2,-1
Kin,ml/min/g,2,-1
PS,,2,0
CFU,10'7/g,2,-1
Average GI50,,2,-1
VRT(t),hr,2,0
PT,min,2,-1
EC100,10'-5M,2,1
Kin,10'-2/min,2,1
tR,,2,0
Relative stimulation index,%,2,1
MED,ug/Kg/min,2,0
Fabs,/hr,2,0
MBC,mg kg-1,2,-1
deltaH,cal/mol.K,2,0
Dose,mg rat-1,2,0
Activity,dg/ml,2,1
VRT,ha2,2,0
AUC/dose,nmol.hr/g,2,1
AUC/dose,nmol/ml.hr,2,1
Tmax,ug.hr/ml,2,0
Attacks,%,2,1
Oxytocic activity,,2,-1
Kieq,pM,2,-1
Activity,(pM of product) min-1 (mg of protein)-1,2,1
Ct,nmol/mg,2,0
Kidney VDR,fM (mg of protein)-1,2,-1
PTD50,,2,-1
Arterial occlusion,%,2,1
Kic,10'-7M,2,-1
Kiact,min-1,2,-1
AUC/dose,uM.hr.kg,2,0
ODC activity,,2,0
C0(unbound),uM,2,-1
TED,,2,0
NOL,mM,2,0
Fa,hr.ng/ml,2,0
Induction of catalepsy,,2,1
EIC50,uM,2,-1
Dose,nM mouse-1,2,-1
Ratio,/mM.s,2,-1
Loss of activity,%,2,1
TF/P,,2,0
IC,mg kg-1,2,-1
ED80,mg/kg/day,2,1
delta logPoct-dod,,2,0
CL free,nmol/min/mg,2,-1
DTH,10e-3mm,2,1
Apoptotic cells,%,2,1
Remaining rate,,2,0
K second,M-1 s-1,2,-1
FRP,,2,0
LBF,ml/min.kg,2,1
IC50,10'6uM,2,-1
Activity,cpm/min,2,1
Dose,pM kg-1,2,-1
Renal clearance,L.h-1,2,0
delta Log Doct-dod 7.4,,2,0
LC10,mgAi/L,2,-1
AUC_ratio,,2,0
Dose,ug/embryo,2,0
MIC=<50,ug ml-1,2,-1
Infusion rate,uM min-1 kg-1,2,0
Report,,2,0
Inhibition,(ul of blood) (2ml BALF)-1,2,0
AUClast,hr.ug/g,2,0
AUClast,nM/min,2,0
Cp,microg.hr/mL,2,0
D,10'-7cm2/sec,2,0
FPT msad,mg kg-1,2,-1
Ki slope,,2,-1
Dose elevation,,2,0
LV dP/dt,%,2,1
D,10^-10m2/s,2,0
Cdyn,% delta,2,1
Polymorphonuclear cells,,2,0
MED,uM/g,2,-1
CFU,10'2/ml,2,-1
Inhibition,min-1,2,-1
Papp,10'-6cm,2,0
EC50,ug kg-1,2,-1
EC50,ug.hr/ml,2,-1
Ki,nM-1 min-1,2,-1
Inhibition,pmol,2,0
FI50,ppm,2,-1
CFU,/uL,2,-1
Dose normalized clearance,L/hr,2,0
D,10^-20No_unit,2,0
IC50,10'6pM,2,-1
Papp,10'-6m/s,2,0
Antifertility activity,,2,0
Cavg,ng/dL,2,0
Resorption,,2,0
Dose range,uM kg-1,2,1
FE,%,2,1
AUClast,ng/g.hr,2,1
EC,ng/ml,2,1
EC5x,,2,-1
AUClast,nmol.hr/g,2,1
AUClast,pmol.min,2,1
Rate of recovery,s-1,2,0
ED50,10'-3micromol/ml,2,-1
Triglyceride level,%,2,1
Antidiuretic activity,%,2,1
AUClast,pmol.min/mg,2,1
MED,pmol/hr,2,0
MIC,ug cm**-3,2,-1
Bmax,fM mg-1 protein,2,0
Anticonulsant activity,mg kg-1,2,1
Ka,10'4mol/L,2,1
FC,10'7No_unit,2,0
VFT,,2,0
AUClast,uM.min/ml,2,0
Ki,10^8M,2,-1
No. of culturesactive/total,,2,0
alphat1/2(app),hr,2,0
C6h,ug ml-1,2,0
alphat1/2,,2,0
alphaKi,,2,-1
Inhibition (alpha = 0.01),%,2,1
LC15,mg/L,2,-1
Bmax,pM g-1,2,-1
MED,nmol/Kg,2,1
Inhibition at 1uM,%,2,1
K0.5,mM,2,-1
Inhibition concentration,uM,2,-1
Ki,10^2 nM,2,-1
Activity,abs/uL,2,0
Drug degradation,10'-3nmol/min,2,-1
HF2,,2,-1
Anti-emetic,,2,0
FB,,2,0
Tonic,,2,0
Anti-analgesic,,2,0
Ki,10'8/M/min,2,-1
Change in density of uterine gland,,2,0
Anti-Factor Xa activity,mg,2,0
t1/2,uM,2,0
F,ng/ml,2,0
Ki,10'7nM,2,-1
Rate of hydrolysis,nM min-1,2,-1
Rate of hydride transfer,,2,0
"[A]T,L",10'-8 /no of units.cm'3,2,0
"[A]T,L",/mol.dm'3,2,-1
Growth rate,,2,0
Ri,nM,2,-1
K,10^6/M.s,2,1
Exudate,ml,2,1
Extraction ratio,,2,0
Anogenital distance,mM,2,0
Rlung,% delta,2,1
[3H] thymidine cpm/dish,,2,0
K,10^6No_unit,2,0
pKb,M,2,-1
CLr,l/hr,2,0
AUCt,mg.hr/kg,2,1
Inhibitory ratio,,2,-1
Exhalation of 14CO2,% of dose,2,1
VDR affinity,,2,0
No. resp animals / Total,/ 5,2,1
Ya,,2,0
Exhal+B1718ation of 14CO2,%,2,1
Animals,,2,0
Tonic seizures,,2,0
DOPA accumulation,%,2,1
Rotational behavior,,2,0
t1/2,nanoseconds,2,0
XL50,,2,-1
Inhibitory zone,,2,1
Rotorod index,,2,0
Ki,10'-3/min,2,-1
Rs,uM min-1 g-1,2,-1
MED,mg/kg/hr,2,0
C6h,ng ml-1,2,0
Ki,/min/M,2,-1
Papp,uM,2,0
Bmax,pmol/ml,2,0
1/Ki,M-1,2,-1
D,kHz,2,0
Excretion,,2,0
Gross log kill,,2,0
CDOG,,2,1
AUCt,nmol/g.min,2,1
Activity,/M/min,2,1
Kgmax,10'-3 log10CFU/ml/hr,2,-1
Highest nontoxic dose,,2,1
"S20,w",,2,0
LV DRxHR,%,2,1
Kf,M-1,2,1
Activity,10'2CFU/ml,2,-1
SA,%,2,1
HED,mg kg-1,2,1
Activity,U (g of tissue)-1,2,1
Growth inhibition,uM,2,-1
SBP,,2,0
LV,,2,0
Kel,10'-3/hr,2,-1
Activity,/min/M,2,1
reduction in CL_renal,%,2,1
K,10^8/M/s,2,1
TMED,,2,-1
Ke(app),,2,-1
Carotid flow reduction,%,2,1
IC20,10'-3M,2,-1
Ke(app),/M/min,2,-1
Ke selectivity ratio,,2,0
Excreted glucose,mg,2,1
Drug uptake,nM/mg,2,0
SD,,2,0
SD200,uM kg-1,2,1
Worm reduction,,2,0
Protective dose,mg kg-1,2,1
Activity,/min/nM,2,-1
SD80,mg kg-1,2,1
Ke,M,2,-1
AUCt,ug ml-1,2,0
Ka,10'1/M,2,1
Rate of [Ca+2] increase,nM min-1,2,1
V0,mg/ml/hr,2,-1
Excess MST,%,2,1
Weight ratio,,2,0
CLt/F,uL/min,2,-1
Drug excretion,nmol,2,0
Drug uptake,ug.hr/ml,2,0
AUCt/dose,microg.hr/mL,2,1
Drug excretion,pmol,2,0
1-logKi,,2,-1
LC30,ppm,2,-1
tCmax,min,2,1
SF50,,2,-1
Amount,,2,0
Weight change of AP-S,mg,2,0
Ka,10'-5M,2,1
Insulin lowering effect,%,2,1
Kds,nM,2,-1
Drug excretion,uM,2,0
Rate constant,s-1,2,0
Rate constant,mM,2,0
Drug level,,2,0
AUCt/dose,uM.hr.kg/mg,2,0
Ka,10'-5/RU/s,2,1
Activity,10^2pg/ml,2,1
IC50,10'3pM,2,-1
Drug uptake,AU/min,2,0
Activity,PFU/ml,2,0
K,10^9No_unit,2,0
Cardiac output,,2,0
SLI,,2,1
Alpha Ki,uM,2,-1
ED75,uM,2,-1
ED50,10'-9mol/cm2,2,-1
SNGFR,nl min-1,2,0
K0.5,10'-4M,2,-1
Kdiss,10^2/M/s,2,-1
Allodynia score,,2,1
Delta BP,,2,0
IC,nmol/ml,2,-1
SPB,%,2,1
Central selectivity,,2,0
Kdiss,10^-7M,2,-1
Intact,,2,0
Parent remaining at time,%,2,1
Intake,%,2,1
DA level,pg 5ul-1,2,0
HC>=50,ug ml-1,2,1
Kdiss,10^-4M,2,-1
K,L/min.mmol,2,-1
Intinsic activity,%,2,1
AUEC,,2,1
Rate acceleration,,2,0
Drug uptake,Gy/MBq,2,0
Ct,mmol/g,2,0
Total CL,L/hr,2,0
MBC99.9,mg/ml,2,-1
K5,hr-1,2,-1
Paw swelling,,2,1
ABC,mmHg.hr,2,0
TPR,,2,0
LD50,gAe/L,2,-1
Enoyl-CoA hydratase,uM min-1mg-1,2,-1
Vz,L/hr/kg,2,0
Rate,pM min-1 (mg of protein)-1,2,-1
Inverse agonism,%,2,1
Vss,k,2,0
Rate,pM min-1,2,-1
Emesis_ED,,2,1
Saldiuretic activity,pM equiv kg-1 6hr-1,2,-1
CCIC50,,2,-1
K4,min-1,2,-1
Drug metabolism,fmol/mg,2,0
NOAEL,ug/kg,2,1
Utreotropic effect,,2,1
Affinity constant,l M-1,2,1
BmaxH,nmol/mg,2,0
Rate,nl min-1,2,0
Affinity,uM,2,-1
Affinity,M-1 s-1,2,-1
Volume of urine,,2,0
Cardiac contractile force,g,2,0
Group performance time,s,2,1
Drug metabolism,g/mol,2,0
CPM,%,2,1
Affinity,M,2,-1
AUMC,hr.hr.ng/g,2,0
K3,M-1 min-1,2,-1
NOAEL,nmol/Kg,2,0
Uterus to blood ratio,,2,0
Kd,umol/dm3,2,-1
ED75,mg/kg/day,2,1
Sedative dose,mg kg-1,2,1
Treatment,ng ml-1,2,0
Seizure stage,,2,0
Total binding,,2,0
Volume distribution,l,2,0
Volume,mm**3,2,0
Volume,ml min-1 kg-1,2,0
LC50,10'-2ppm,2,-1
TTC,min,2,0
KT4,,2,0
Rate,nM min-1 (mg of protein)-1,2,-1
Log,1/M MIC,2,-1
Kd,M-1,2,-1
VmaxL,pmol/min/mg,2,1
Change in body weight,,2,0
Kd,10^6/M,2,-1
VmaxH,pmol/min/mg,2,1
K,/min/M,2,-1
AUMC,mg.hr/L,2,0
DBP,,2,0
K,/nM.min,2,-1
Tumor volume reduction,%,2,1
ED50,KgAi/ha,2,1
Activity,10^10/M,2,1
Css-4w,pg/mL,2,0
KSV,10^6L/mol,2,-1
Kd,10^4/M/s,2,-1
Rate,nM (mg of protein)-1,2,-1
Cr leakage,,2,0
RBA,M,2,-1
K/10e4,M-1,2,-1
Activity_index,mm,2,1
Peff,10^-5cm/s,2,1
MBC,ng/ml,2,-1
Vmax/Km,pmol/microM,2,-1
K,1/sM,2,-1
BmaxL,nmol/mg,2,0
Vmax/Km,U/mg,2,1
DUR,mg kg-1,2,-1
Optimum T/C,%,2,1
Peff,10^-8cm/s,2,0
CLz/F,L.hr/kg,2,0
CSF levels,uM,2,0
Serum LH level,mg ml-1,2,1
KSV,10^6/M,2,-1
NOAEL,ug/kg/day,2,1
Kd,10^-8mol/L,2,-1
Activity,Kcal/kg/hr,2,1
Kd,10^-6 mol/L,2,-1
Peff,cm/s,2,0
EF90,,2,1
LC50,gAi/L,2,-1
Rate,M-1 s-1,2,1
E50,,2,-1
Vmax/Km,10'-4L/min,2,1
Drug uptake,uM/g,2,0
Vmax/Km,/nM.min,2,-1
Vmax/Km,/M,2,-1
MEC,nmol/Kg,2,-1
Tc,,2,0
AUMC,ng/mL.hr^2,2,0
CL,hr/L/kg,2,0
Activity,umol/min/g,2,1
CC50,mol,2,-1
Kd,10^-10mol/L,2,-1
CLz/F,L/Kg,2,0
K,10'-2/Ms,2,-1
LC50,microg/dm2,2,-1
Occ,ng/ml,2,0
EDP,mmHg,2,0
Vmax(app),abs/min,2,0
Activity,10'-3/s,2,1
Vmax(app),abs/hr,2,1
LD50,ml,2,-1
CLz/F,L/kg/hr,2,-1
Vmax(app),10'-4abs/s,2,1
AUMC,ug.hr/L,2,0
AUMC,ug.hr/ml,2,0
KSV,10'4M,2,-1
"K(p,uu,brain)",nM,2,0
Vmax / Km,uM min-1 (ug of protein)-1,2,1
Transporter deg rate const (k),day-1,2,-1
LC50,pg,2,-1
CLz/F,l/hr.kg,2,-1
Range,%,2,1
Activity,ug/min/cm2,2,1
AUMC,ug/L.hr,2,0
Activity,ug/min.kg,2,1
Elimination,,2,0
Vmax,umol.min,2,1
Sleep time,,2,1
ED50,gAe/L,2,-1
ED,nM,2,-1
permeability,omegacm2,2,0
Hydrolysis rate constant,s-1,2,1
CC50,10^3 uM,2,-1
Activity,ug g-1,2,0
Critical micelle concentration,uM,2,1
I50,10'2mol/L,2,-1
Duration of peak action,min,2,1
DBP15,ug kg-1,2,1
Kd,/uM/s,2,-1
C5 min,nM,2,-1
CL,L.h/kg,2,0
ED 50,mg kg-1 day-1,2,1
CL,L.h-1,2,0
Sni,,2,0
K,mole fraction,2,0
CPD50,mg kg-1,2,-1
Kcat/Km,ug ml-1,2,0
Total glomeruli,,2,0
Elevation,%,2,1
K,10'-4M,2,-1
Body weight gain,g,2,1
Vmax,uM min-1 (ug of protein)-1,2,1
Radiolabel recovery,ugequiv.hr/ml,2,0
Permeability index,Pi,2,0
Kcat/Km,microM/min,2,-1
MEC,mg kg-1,2,1
Bone damage score,,2,1
Non-specific binding,,2,0
% bound fraction,%,2,1
K,ms,2,0
AUMClast,hr.hr.ug/ml,2,0
Urinary volume,ml min-1,2,0
Duration of action,mg kg-1,2,0
Light transmission,,2,0
Radiolabel recovery,hr,2,0
Therapeutic dose,mg kg-1,2,1
Specific activity,uM min-1mg-1,2,-1
DPM,,2,0
Drug metabolism,pmol/mg/min,2,-1
ED90,mg/L,2,1
Drug uptake,cps/ml,2,0
Degree of cross resistance,,2,0
Specific binding per mg of protein,fM mg-1,2,-1
Therapeutic index,14 day,2,0
CL,L (min mg)-1,2,-1
Activity,rat,2,0
K ass app,l uM-1,2,-1
Specific radioactivity,,2,0
Kcat/Km,10^-6/nM/s,2,-1
Activity,ppm/g/hr,2,1
Activity,10'5CFU/ml,2,-1
Activity,pmolequiv,2,0
Change in blood glucose,%,2,1
CL,/s,2,0
Vmax,pmol/min/ml,2,1
Drug uptake,dpm/ml,2,-1
ED delta20,,2,1
pKa_decrease,,2,0
ED delta5,,2,1
Kcat/Km,10'6/Ms,2,-1
ED1/3,M,2,1
Mobilization,,2,0
Activity,10'5PFU,2,1
CL,(mg/kg)/(ng/ml)/hr,2,0
ED10,nmol/Kg,2,-1
KHOX,,2,0
t1/2,ug ml-1,2,0
Drug metabolism,uM.hr,2,0
AUMClast,hr2.ug/g,2,0
IC50,10^4 uM,2,-1
LD80,mM,2,-1
Radioactivity in urine,% of dose,2,1
Therm_solubility,ug,2,0
Vmax,pmol/min.ug,2,1
Stability,mg/dl,2,0
Activity,10'-4M,2,-1
Ca2+ excretion,uM day-1,2,1
AUMCt,mg/L.hr,2,0
K 0.5,,2,-1
Radioactivity in urine,%,2,1
Growth inhibiton,%,2,1
pInhibition,%,2,1
CL,%ID,2,0
Level,pg ml-1,2,0
qKD,nM,2,-1
Vmax,pmol/(min.ug),2,1
Kcat/Km,10'2 uM/s,2,1
Activity,10'-5 ug/ml,2,1
Activity,10'-5/min,2,1
LOAEL,ng/ml,2,1
K,10'-8/s,2,-1
CS50,mA,2,-1
Stability,nM/min/mg,2,-1
Kcat/Km,10'-5/s/uM,2,-1
Efflux,,2,0
AUMCt,ug/L.hr,2,0
Kcat/Km,10'-4/M/s,2,-1
Drugexcretion,umol/hr,2,0
Activity,10'-5/s,2,1
MEC,10'-6 mol/L,2,-1
Vmax,pM assay-1 hr-1,2,-1
KD2,nM,2,-1
Level,nmol ofpHB/min/mgof protein,2,-1
ED100,MPK,2,0
MI,uM,2,0
Tumor inhibition,%,2,1
Creatinine_CL,min/ml/hr,2,0
permeability,10'-6cm/s,2,0
ED100,mg Kg-1,2,1
AUMCt,ug/ml.hr^2,2,0
Activity,10^-5/s,2,1
LC99,ppm,2,-1
Level,ng dl-1,2,1
KD1,nM,2,-1
Creatinine_CL,ml/min.kg,2,-1
C50g,mg/L,2,-1
K2,1/M,2,-1
Activity,pEC50,2,-1
Radioactive absorption,%,2,1
K ACT,M-1 s-1,2,-1
solubility,ugA/ml,2,0
Stability of BSR,%,2,1
Css-48h,pg/mL,2,0
Activity,pA2,2,-1
LD50,ng/ml,2,-1
Css-12w,pg/mL,2,0
Quench,%,2,1
Drugexcretion,umol,2,0
Kcat,mol/dm3,2,-1
Staining,%,2,1
Onset time,s,2,0
Activity,10'-5g,2,0
CI90,,2,0
Stenosis,%,2,1
Activity,A% min-1,2,1
K,10'2/M,2,-1
Level,mg g-1,2,0
IC50,10^-8nmol,2,-1
Level,fM mg-1,2,0
RVCF,%,2,1
Stimulation index,%,2,1
ED90,g/ha,2,1
LD80,mmol/Kg,2,1
Plasma,mM,2,0
Brain conc,ng/g,2,0
K inact,1/minute,2,-1
Vmax,mol/min/L,2,-1
Drug recovery,mg,2,0
Drug uptake,fmol/min,2,0
Stroke volume,ml,2,0
Drug recovery,ng/ml,2,0
Stroke work,g,2,0
Plasma Ca2+,mg dl-1,2,1
Vmax,mol/min,2,1
MAC,mg kg-1,2,-1
Absoption,,2,0
Sublethal dose,mg kg-1,2,1
LD50,pmol,2,-1
Efficacy,No. of mice tumor free,2,1
Substrate activity,mM,2,1
LD90,g/hm2,2,1
K,10'4/mol,2,-1
Tick action,%,2,1
Absorption,mg kg-1,2,0
Effective molarity,,2,-1
CPA,,2,0
Drug uptake,fmol/uL,2,-1
K inact,U s-1,2,-1
Activity,ng/cm2,2,1
LL,,2,0
Drug uptake,nCi/cc,2,0
Plasma Level,uM,2,0
Activity,ng ml-1 hr-1,2,1
relative signal,relative signal,2,0
Activity,nanometer,2,0
Activity,nM/ml,2,1
RTG,,2,1
Activity,10^9CFU,2,1
MBC,ug cm**-3,2,-1
Unchanged NDEA,% of dose,2,1
Time,pS,2,-1
Plasma [14C] cholesterol,dpm dl-1,2,0
Absorption,ul min-1,2,1
Hg,,2,0
Kc,M,2,-1
Ac,,2,0
K,10'6/min,2,1
Time,uM,2,0
Activity,10^8(p/s/cm^2/sr)/(uW/cm^2),2,0
Survival after 30 days,,2,0
K,10'6/mol,2,-1
Vmax,U mg-1,2,1
Drug uptake,pM,2,-1
Kbapp,10'-7M,2,-1
KbS,uM,2,-1
Activity,nM min-1,2,1
H2 activity,,2,0
Brain level,ng ml-1,2,0
Activity,10'-7/M/s,2,1
LD50 x 1/10,,2,1
OD max,,2,1
MIC90,%,2,0
Accumulated counts/30,,2,0
K,10'6Lmol,2,-1
Activity,mmol/L.min,2,1
Tumor area,,2,0
Survival time,min,2,1
Plasma conc,ng/ml,2,0
Accumulation,mU ml-1,2,0
Vmax,10^-5M/min,2,1
Kb,10^3L/mol,2,-1
LD50 x 1/20,,2,-1
Survivial / total,,2,0
Activity,mmHg s-1,2,1
LD10,g/hm2,2,1
solubility,10'-4mg/ml,2,0
Vmax,10'-7cpm/min,2,0
CI,l min-1,2,0
Survivors,day,2,1
MAD,10'-3microL,2,0
Survivors,ug ml-1,2,0
K inact,mM,2,-1
Vmax,10'-6mol/min/ug,2,1
Vmax,10'-6mM/min,2,1
ED90,KgAi/ha,2,1
-Log K B,,2,-1
permeability,10^-3cm/min,2,0
K,10'7/s/microM,2,-1
Vmax,10'-4 uM/s,2,1
Survivors at day 28,,2,0
Activity,ml min-1 kg-1,2,1
Vmax,10'-3umol/min/U,2,1
K inact,nM,2,-1
ED200,ug ml-1,2,1
Susceptibility,nM hr-1 (mg of protein)-1,2,-1
ED200,umol/Kg,2,1
IC40,uM,2,-1
ED50,nM hr-1 kg-1,2,-1
ED25,10'-4M,2,-1
Kapp,nM,2,-1
DI50,ppm,2,-1
Vmax,10'-3deltaA/s,2,1
Kapp,10^7/M,2,1
QH,ml/hr.kg,2,1
Kapp,10^6/M,2,-1
Brain levels,uM,2,0
MBEC,mg/L,2,-1
Synergy,%,2,1
ED50,umol/ml,2,-1
A50,mg Kg-1,2,1
Activity,microM/g,2,0
Growth zone,,2,0
Accumulation,nM/mg of dry wt,2,-1
Activity,microA,2,1
Molar equivalence bound,,2,0
Transporter production rate (r),fM mg-1 day-1,2,1
Vmax,/abs/min,2,-1
K,10'9/M,2,-1
Vmax,%/min,2,1
Drugexcretion,hr,2,0
OT interval,,2,0
Kapp,10'4/M/s,2,1
Activity,mg/min/kg,2,-1
KB,10'5/M,2,-1
ID50,10'-8mol/L,2,-1
Activity,mg/min/dl,2,1
MIC98,ug ml-1,2,-1
t1/2_ratio,,2,0
Log k,obs,2,0
K,10'9/s,2,0
PC95,microg/cm2,2,1
PC95,,2,1
CLH,ug/ml/hr,2,-1
GR50,uM,2,-1
GR50,ppb,2,-1
ID50,fM,2,-1
log10EID50/g,,2,-1
AUC,0-tIdc,2,0
GR50,gAe/L,2,-1
logEmax,,2,1
AUC,0-infinity,2,1
DeltaCp,kcal/mol.K,2,-1
Plasma insulin,uU ml-1,2,1
AUC,hr.ng/L,2,0
AUC,(umol/L).min,2,1
AUC,%.hr,2,1
Ratio EC50,uM,2,-1
rel k,,2,-1
Time of peak action,min,2,0
ID50,mg kg-1 b.i.d.,2,-1
ID30,10'-5M,2,-1
T max,ug ml-1,2,0
solubility,10^-3mg/ml,2,0
Activity,mg/hr/dl,2,1
AUC,hr.ug/g,2,0
ID50,mg kg-1 day-1,2,-1
ID100,mg kg-1,2,1
2T11,,2,0
Ratio IC50/EC50,10'6No_unit,2,-1
Kapp,10'-6M,2,-1
Vm,10'-5m3/mol,2,0
APPTT,uM,2,-1
Kapp,10'-4/M,2,-1
Protective dose,uM,2,-1
ID/g femur,,2,0
AUC,hr/ng.ml,2,0
IC50,10^-3mg/ml,2,-1
Cells arrested,,2,0
AUC,mU min dl-1,2,1
PD 50,mg kg-1,2,-1
MAD,10'-6microL,2,0
Ea,,2,0
Off-rate,min,2,-1
log(activity),PFU/ml,2,-1
Min oral dose,,2,1
log(activity),CFU/g,2,-1
T-cell binding,,2,0
log(activity),%,2,1
Time spent,s,2,1
Time to 30% BSR,min,2,-1
AUC,mg ml-1,2,0
AUC,microM.hr'2,2,0
PC50,nM,2,-1
ID50,pKi,2,-1
ALT/GPT,l,2,0
Brain/Plasma,%,2,1
ICdATP-50,uM,2,-1
PC50,microg/cm2,2,-1
Kq,10'7No_unit,2,-1
AUC,mmHg,2,0
Css,mg/L,2,1
I14,uM,2,-1
Time to max. BSR,s,2,0
ICL50,,2,-1
AUC,mmHg.day,2,1
NOAEL,ug ml-1,2,0
Brdu positive,%,2,1
Vinact,min-1,2,-1
Ratio ki,,2,0
log(1/K),,2,-1
AUC,nM hr-1 ml-1,2,0
AHA,,2,0
AUC,nM l-1 hr-1,2,1
CLH,umol/min/ml,2,-1
CLT,,2,0
p10 MIC,,2,-1
ID50,uM/ml,2,-1
Ka app,uM,2,-1
Activity,mg hr-1 kg-1,2,1
Ratio pIC50,hr,2,-1
log(1/C),ug ml-1,2,-1
-Log EC50,,2,-1
AUC,ng min,2,1
Left atrial pressure,mmHg,2,0
pA2,mg kg-1,2,-1
Ratio CC50/EC50,10'5No_unit,2,-1
Acid output,m equiv [H+] l-1,2,0
Ratio AUC(inf),,2,0
t0.9,day,2,0
pA2 app,,2,-1
Toxic,mg kg-1,2,-1
T/C (tumor vol),%,2,1
AED,mg kg-1,2,1
Bile flow,ml hr-1,2,0
EU,g-1,2,0
permeability,ug ml-1,2,0
x fold,100uM,2,0
Ka,micromol/min,2,1
Kq,10^14L/mol/s,2,1
ID50,umol/kg/h,2,-1
pBBB,%,2,1
Bioavailability Increase,%,2,1
EC2,,2,-1
K,10^-3/nM/min,2,-1
Drug transport,ug/hr,2,1
pBBB,microL/min/g,2,1
Kr,min-1,2,-1
kp,min-1,2,1
ID90,M,2,-1
Vi,ml/kg,2,1
kon,1/M1/S,2,1
koff,nM-1 min-1,2,-1
EC25(unbound),ng/ml,2,-1
PB,pmol/mg.hr,2,0
IC50L,uM,2,-1
Ratio,ng/kg,2,0
AD50,ug brain-1,2,0
PB,nmol/mg,2,0
Plasma levels,uM,2,0
Activity,10'-8No_unit,2,1
IC50/EC50,,2,-1
Glucuronidation rate,,2,0
Latency time,min,2,-1
pChange,%,2,1
ED90,%,2,1
ID90,ng/ml,2,-1
Of tumors,%,2,1
Kp,nm/s,2,0
Drugexcretion,/hr,2,0
PB,nmol,2,0
kik0/Ki,uM-1 min**-2,2,-1
IC50 ratio,%,2,0
Drugexcretion,%molar,2,0
keq,,2,-1
C,ng ml-1,2,0
EC30,10'-8M,2,-1
Activation,mU ml-1,2,1
Time to righting,min,2,-1
GI,cm/day,2,1
Ratio,ml/min/nmol,2,1
Kp,10^-4cm/hr,2,0
Reaction time,,2,1
Cmin,ng/dL,2,1
ka,10^6/M/s,2,1
ka,10^3/M/s,2,1
Activity,10'-9/min,2,1
IC100,10'-4M,2,-1
Ratio,microM/s,2,-1
Reactivation,,2,1
ED50,nM kg,2,-1
Cmin ss,ng/mL,2,0
Max PI,,2,0
EC30,10'-9M,2,-1
Activity,mM/min,2,1
IC50,microg/cm3,2,-1
Max delta,,2,0
C,,2,0
AUC,pmol.min/mg,2,1
Koff,1/nM.1/min,2,-1
Decrease of spontaneous firing rate,M,2,-1
Cytostatic concentration,ug ml-1,2,-1
Max BSR,%,2,1
AUC,pmolÂ·min/mg,2,1
Max delta FC,,2,1
T1/2,l kg-1,2,0
GH,%,2,1
kR,,2,0
ILS,day,2,1
Max,nM,2,-1
Max delta MABP,,2,1
Cmax_tumor,nmol/L,2,0
Max delta MAP,,2,1
Vdss,ng/ml,2,0
Ratio,mg/g,2,0
Difference,,2,0
Kobs,10^-3/s,2,-1
Cmax_ratio,(null),2,0
ILS,hr,2,0
kIAM',,2,0
Pro/Min/Enz,M,2,-1
Cmax_PTH,pg/ml,2,1
Cmin_ratio,,2,0
Drug uptake,%ID/cm3,2,1
kDPPH,,2,1
AUC,uM kg-1,2,0
Activity,10'-9No_unit,2,1
MIC,%v/v,2,0
Max fall in MAP,,2,-1
K,10^-4No_unit,2,0
Bactericidal,ug ml-1,2,-1
Vdss,kg/L,2,0
Max fold increase,,2,1
Ratio,mL/min.umol,2,0
LD90,mg kg-1,2,1
Activity,10^5/mm3,2,1
IC35,uM,2,-1
Bacterial counts,,2,-1
Ratio,m M-1 min-1,2,1
ED50,ng/kg,2,-1
Co,ug ml-1,2,0
Max inhibition concentration,uM,2,-1
Block of activity,%,2,1
MCC,ucm,2,0
Ratio,U M-1 s-1,2,0
-Delta G obs,kCal mol-1,2,-1
Vdss,hr,2,0
CMT,,2,0
k2/Ks,M-1 s-1,2,-1
Log Poct Z,,2,0
Max mean weight loss,%,2,1
INH,10'-4M,2,0
Max plasma level,uM,2,0
Colonic weight,mg cm-1,2,0
AUC,uM.h/L,2,0
pEC50,%,2,0
T3,,2,0
Blockade effect,,2,0
Log Poct N,,2,0
Blockage,%,2,1
BSR,uM kg-1,2,0
Complete survival dose,mg kg-1,2,1
Occulations,,2,0
Drug uptake,mg%,2,0
K,10^-5/nM/min,2,-1
LD50 x 1/40,,2,-1
PA,ml/s/g,2,0
MTD/16,mg kg-1,2,1
AUC,uM.min/ml,2,0
IC50,ucm/s,2,0
Max rev,,2,1
Compound Recovery,%,2,1
Max reversing rate,%,2,1
Cmax (Ratio),uM,2,0
ACR,,2,0
(kcat/KM)/kuncat,M-1,2,1
Cmax,ul ml-1,2,1
MTD,umol,2,0
BQL,,2,0
Ratio,CC/OC,2,0
Compound recovery,microg.hr/mL,2,0
Vdss,%,2,0
MTD,uM/ml,2,0
Ratio,10^6No_unit,2,0
No change,,2,0
Km,uM kg-1,2,-1
Max weight loss,,2,0
Last therapy day,%,2,0
ACAT activity,%,2,1
T50,,2,-1
Ratio,10^6/s/M,2,-1
Reduced_Cyp7a1_gene_exp,,2,0
LD33,mg kg-1,2,-1
MFC90,,2,-1
Reduced_Serpine1_gene_exp,,2,0
AUC,ug .hr/g,2,0
Cmax,ug hr ml-1,2,0
Reduced_Srebf1_gene_exp,,2,0
Reduced_circadian_oscillation,,2,0
Vd/F,ml,2,0
AUC,ug h ml-1 kg-1,2,1
Fungicidal,%,2,1
MTD,mg kg-1 day-1,2,1
CA activity,(ml of NaOH) min-1,2,-1
LD40,mmol/Kg,2,-1
INH,mol,2,-1
k(on)/k(off),,2,0
Vd/F,g/Kg,2,0
OT,,2,0
INH,ngequiv,2,-1
Km,Me-3,2,0
k'',,2,-1
LambdaZ,/min,2,-1
AUC,ug min g-1,2,1
Ratio,10^4/s/M,2,-1
AUC,ug.hr/ml/day,2,0
Mean,uM,2,-1
INH,umol/L,2,-1
MST,range,2,0
Cmax,pg/g,2,0
Tissue weight,g,2,0
IO,,2,0
Drugabsorption,mg/hr,2,0
Occlusion time,min,2,1
MST,g,2,0
Km,10'-5M/min,2,-1
k cat/Kuncat,M-1 s-1,2,1
Cmax,ng/hr/ml,2,0
Mean KD,M,2,-1
Log10 cfu,/ml,2,-1
Occ90,uM,2,-1
Fu,10'-5No_unit,2,0
Mean activity,,2,0
Log Pdod N,,2,0
Cmax,ng.hr/g,2,0
MRT(t),min,2,0
Concentration,ug 100ml-1,2,0
Activity,mCi animal-1,2,1
Activity,mBq,2,0
AUC,ug/L,2,1
Cmax,ng,2,1
Log P/Log D,,2,0
AUC,ug/g,2,1
k cat/Km,mM s-1,2,-1
Cmax,nM g-1,2,1
AUC,ug/g.min,2,0
Mean day,,2,0
Turns/1st,,2,1
Cmax,microM.hr,2,0
pMIC,ug ml-1,2,-1
Mean day survival,day,2,1
Km,10'-3mol/mol,2,0
Mean duration,hr,2,1
I50,M kg-1,2,-1
MPO release,,2,0
Reduction in arterial blood pressure,,2,-1
k cat/Km,1/(M*min),2,-1
Ka,10^4M,2,1
Cmax,mg,2,0
Cmax,kg/L,2,0
Concentration in Brain,uM,2,0
permeability,10^4cm2/sec,2,0
Molarity,M,2,-1
CPmax,uM,2,0
Cmax,U,2,0
Activity,10^4L/mol,2,1
No effect dose,,2,-1
Heart rate,mmHg,2,0
Concentration of max response,M,2,1
Cmax,%ID,2,1
k cat,uM min-1mg-1,2,-1
Production,ng (g of tissue)-1,2,-1
K x10e-5,,2,0
Concentration_plasma,ug ml-1,2,0
CLH,mL/mg/kg,2,-1
Clp,ng hr ml-1,2,-1
pKa_B3,,2,0
% injected dose/cm3,%,2,1
Hk,,2,0
Change in DA synthesis,%,2,1
k cat,1/min,2,-1
Clp,mg min-1 kg-1,2,1
CLH,L/hr/mg,2,-1
2aPTT,10'-4M,2,-1
LZ,/hr,2,1
Ka,10^3/min,2,0
AUC,umol/l.min,2,1
Activity,kiloU/hr,2,1
Clp,M min-1 kg-1,2,0
permeability,nmol/cm2/hr,2,1
IT50,hr,2,-1
Contractile force,,2,0
Vd,L/hr,2,0
Clonic,,2,0
Kkmax,10'-3 log10CFU/ml/hr,2,-1
AUC N,,2,0
Fraction excreted unchanged,%,2,1
Cell permeation,,2,0
ionization,%,2,1
inhibition (at 100uM),%,2,1
Mean time to death,day,2,1
AUC Npo,uM.h/dose,2,0
Days to tumor doubling,,2,1
Vd,L/1.73 m2,2,0
MMC,,2,-1
Mean tumor atency,day,2,1
Mean tumor delay,day,2,1
Activity,kg/kg,2,1
Control,uM kg-1,2,0
C24,ng mL-1,2,0
Vd,Kg,2,0
Control S/T,,2,0
Rel brain exposure,,2,0
Vc/F,L/hr/kg,2,0
CLH,/min/uL,2,-1
EC50,10'-2 ug/cm2,2,-1
TC50,ng/ml,2,-1
Activity,10^3pg/ml,2,1
IUP AD50,ug kg-1,2,-1
MIC,10'-2nmol,2,-1
Media area,10e3 um2,2,0
No. active,,2,1
Ratio,10^-3/uM/min,2,-1
grade,,2,0
BIC,uM,2,-1
Activity,10^3L/mol,2,1
gammaCMC,,2,0
g/30min,,2,0
fpKi,,2,-1
fp,,2,0
C0,ug.hr/ml,2,0
MLD,10^-8mol,2,-1
Ratio,10'8/M/min,2,-1
fm,,2,0
Activity,10'9CFU,2,1
Median tumor,day,2,1
BC,,2,0
IC50,10^-6nmol,2,-1
IC50,10'8nM,2,-1
Mem Rec,%,2,1
P50,mM,2,-1
Metabolic rate,%,2,1
Metabolic rate,nmol/min*mg of protein,2,1
Pm,mg/ml,2,0
MIW,,2,1
BBC,uM,2,-1
MED99.9,,2,-1
Decrease in life span,day,2,1
Cl,ml min-1,2,0
Gross kill,,2,0
MED90,,2,1
fc max,,2,0
A0.5,mM,2,0
%LBF,%,2,1
fc max,mg/L,2,0
AUC inf,nM l-1 hr-1,2,1
Choline uptake,,2,0
Vbeta,kg-1,2,0
K,10^3/M.s,2,1
Correct responses,%,2,1
MIC>99,ng/ml,2,-1
Fos,%,2,1
Activity,kBq/ml,2,0
K,10^3/Ms,2,-1
AUC nom,uM h kg/mg,2,0
AUC nom,uM*h*kg/mg,2,0
Ratio,10'7/M/min,2,-1
NcoR1_recruitment,,2,0
Min ID,uM kg-1,2,-1
Cp,fmol/uL,2,0
MED50,ug/kg,2,-1
fLOAEL,uM,2,-1
No. of active/no. of tested,,2,0
IZ,cm2,2,1
Kinetic_solubility(app),,2,0
CLb,ml/hr,2,1
Relative Vmax,%,2,1
K app x10e6,,2,0
fEC85,ng/ml,2,-1
Kinetic_solubility,ug/ml/min,2,0
Vascular relaxation,,2,1
Variation,,2,0
Ka,10^-5M,2,-1
Ka,10^-4/s,2,1
EC1000,,2,1
fCmin,ug ml-1,2,0
permeability,cm/hr,2,0
fCmin,uM,2,0
Activity,10'5/M,2,1
Drug uptake,ng.hr/g,2,0
CFU,10^5/g,2,-1
EC50,10'5pM,2,-1
Ratio,10'4/s/M,2,1
PKb,,2,-1
TD10,mg kg-1,2,1
Relative antiandrogenic activity,,2,1
ED50,ug/L,2,-1
fCmax/dose,nM,2,0
Ratio,10'4/M/min,2,-1
Tmax,ng.hr/ml,2,0
Relative binding affinity,nM,2,-1
Pmax,,2,0
EC50,10'9PFU,2,-1
CL/F,g/hr/kg,2,0
Imax,ug ml-1,2,1
Cell death,,2,0
Activity,g/cm3,2,0
Damage score,0-10,2,1
Relative cytotoxic activity,,2,0
AUC/dose,%,2,1
Kinact,10^3/s,2,-1
K1,1/M,2,-1
Kinact,10^-5/s,2,-1
EC50,10^-1microM,2,-1
POE score,,2,0
Average uterine weight,,2,0
Kuncat,M-1 min-1,2,-1
P-value,,2,0
Average tumor weight,g,2,1
Activity,fmol/ug,2,1
Kinact,10^-1/min,2,-1
EC50,10^-2microM,2,-1
Vagus,,2,0
ED50,10'-11 ug/ml,2,-1
ED50,10'-13 ug/ml,2,-1
Ct,ug/L,2,0
Ka,10'7/M.s,2,1
% of kinase activity,%,2,1
EC50,10^-4microM,2,-1
Ratio,10'-4/min.mol%'-4,2,1
Blood pressure,mM,2,0
Increase in [Ca+2],,2,1
dpm bound to protein,,2,0
Increase in cAMP,fold,2,1
deltapH,,2,0
AUC/dose,nM.hr/ml,2,0
K1,s-1,1,1
Cholesterol,,1,0
Cholesterol,mg kg-1 diet,1,0
Min lytic concentration,,1,-1
Cp,mM,1,0
Cp,mg kg-1,1,0
Cp,mg/min/kg,1,0
MIC=<90,uM,1,-1
Cp,microg.min/mL,1,1
AC50,g,1,-1
Chemosensitizing activity,mg l-1,1,0
Cp,ml/kg,1,0
Change of weight,g mouse-1,1,1
AC30,,1,-1
Molar ratio,,1,0
pGI50,uM,1,-1
Monomer,%,1,1
IC50,ug cm**-2,1,-1
MIC97,ug ml-1,1,-1
Cp,nmol/Kg,1,1
Change of body weight,,1,1
Mortality,nM,1,0
MIC95,mg/L,1,-1
Change non HDL-C,,1,0
Cp,pg/ml,1,0
Mortality ratio,,1,0
MIC82,uM,1,-1
Cp,uM/g,1,-1
Cp,ug/hr.ml,1,0
Cp,umol,1,0
Change in systolic pressure,,1,1
Cp(T),ug ml-1,1,0
Cp(f),nmol/L,1,0
Cp(f)/dose,nM/mg/kg,1,1
Change in ovarian follicular atresia,,1,0
Cp(f)max,uM,1,1
N/D,,1,0
Cp(f)ss,nM,1,0
Change in entry latency,,1,0
MIC,ug.hr/ml,1,-1
NBT reduction,%,1,1
Change in corpora lutea,,1,0
MIC,ucm/s,1,0
MIC,ucm,1,-1
Creatinine_CL,mg/dl,1,0
pH,ml 4hr-1,1,0
AC30,%,1,1
MIC,M-1,1,-1
MIC,IU/ml,1,-1
MIC,10^-6 uM,1,-1
NOAEL,mg,1,0
NOAEL,mg Kg-1,1,1
MIC,10^-3micromol/ml,1,-1
MIC,10'4pg/ml,1,-1
NOAEL,ng/kg,1,1
MIC,10'-4nmol,1,-1
NOL,mg kg-1,1,0
NOL,ug kg-1,1,0
Change,uM kg-1,1,1
Css min,mcg/mL,1,1
Css min,ng/mL,1,1
MHC,10'-6M,1,0
MHC,10'-5M,1,-1
MHC,10'-4M,1,-1
Ct,pg/ml,1,0
Ct,uM/L,1,-1
pH50,,1,-1
Ctau,ug ml-1,1,0
IC50,uM.hr,1,-1
Cumulative dose,mM kg-1,1,0
Curative Index,%,1,1
Net body weight delta,g,1,1
Cures,day,1,0
Net cell kill,,1,1
Cures@ 10mg/kg,,1,1
Cures@ 20mg/kg,,1,1
Cures@ 40 mg/kg,,1,1
Cures@ 40mg/kg,,1,1
Cures@ 80 mg/kg,,1,1
Cytocidal effect,%,1,1
Cytotoxic endpoint,,1,-1
No effective/ no. tested,,1,0
MED50,uM,1,-1
Cz,ug ml-1,1,0
Cell density,cells ml-1,1,-1
MED,ug min-1 kg-1,1,1
No. of axonal branchpoints/cell,,1,1
Ccontrol,%,1,1
Cbrain,ng g-1,1,0
Cav(ss),nmol.L-1,1,0
Cataleptic effect,,1,0
MED,mmol/Kg,1,1
Catalase rate,,1,1
D50,nM,1,-1
MED,g/Kg,1,0
IC50,uL/ml,1,-1
MED,M,1,-1
MEC2.0,uM,1,-1
MEC2.0,nM,1,-1
MEC1.5,uM,1,-1
IC50,nmol/min,1,-1
MEC,pM,1,-1
MEC,nmol/L,1,-1
IC50,ng/mg,1,-1
MEC,g/ml,1,-1
MEC,10'-8M,1,-1
MEC,10'-7M,1,-1
IC50,nM/g,1,-1
No. of rats died,,1,1
I50,10'5mol/L,1,-1
DC50,mmol/L,1,-1
DCmax,%,1,1
MDH Reactivation,,1,0
CTD50,ug ml-1,1,-1
CTD50,mM,1,-1
DIZ,ug ml-1,1,1
solubility,10'-1mg/ml,1,0
No. of survivors,48h,1,1
MCC50,mM,1,-1
MC100,ug ml-1,1,-1
MC100,uM,1,-1
DNA single strand breaks,,1,0
MBIC100,ug ml-1,1,-1
No_cures,,1,1
CS50,,1,-1
CPmax,,1,0
CPmax,ng ml-1,1,1
OD,M,1,-1
MBC99,ug ml-1,1,-1
MBC99,mM,1,-1
Decreace in BP,mM,1,-1
CO,uM,1,-1
Decrease in RFU,uM,1,-1
Decrease in arterial blood pressure,%,1,1
Occ50,uM/g,1,-1
Decrease in arterial blood pressure,,1,1
Occ90,ng/ml,1,1
Occupancy,mg kg-1,1,0
Decrease of spontaneous firing rate,,1,-1
Of viability,%,1,1
MAD,10'-4microL,1,0
CMI,ug ml-1,1,-1
MAD,10'-2microL,1,0
"Onset for sleep, min",,1,1
CMC,umol/dm3,1,0
Degree of activation,,1,0
Opsin shift activity,,1,1
CMC,mmol/dm3,1,0
Optimal dosage,,1,1
solubility,10'-1mol/L,1,0
Oral activity,%,1,1
Oral activity,ml min-1,1,0
M.A.D,,1,-1
IC50,microA,1,-1
Oral dose,mg kg-1,1,0
CLt/F,,1,0
CLt/F,L/hr,1,0
CLr,L/hr,1,0
Lowering activity,,1,0
Delta F75,,1,1
Oxidation,%,1,1
Loss of activity,,1,0
IC50,mg/kg/day,1,-1
P,pcm s-1,1,0
Delta IOP,,1,-1
P (Ei),Ei,1,0
P Increase,,1,1
Delta SBP,,1,1
P-450 loss,nM,1,0
Delta beats/min,,1,1
P50C,mmHg,1,0
CL_renal,mL/min/1.73 m2,1,0
solubility,10'-2g,1,0
CL_renal,l/h,1,0
CL_biliary,ml/min.kg,1,1
CL_biliary,%,1,1
PAO activity,pM min-1 mg-1,1,1
PAP,mM,1,0
PActivity,,1,0
PB,equiv,1,0
Log of inhibitory zone,mM,1,1
Delta non HDL-C,%,1,1
CLH,umol/min/kg,1,1
CLH,umol/min/g,1,1
DeltaBP,,1,1
DeltaCp,,1,0
Log geometric mean,ppfu mg-1,1,-1
PCaco-2,cm s-1,1,0
PD' 2,,1,-1
CLH,uL/hr,1,-1
IC50,mg/cm3,1,-1
pK3',,1,0
CLH,uL,1,-1
PD50,mg/ml,1,-1
PD50,pmg kg-1,1,-1
Diameter of inhibition zone,diameter mm,1,1
IC05,,1,-1
CLH,ml/min/10^6cells,1,1
CLH,ml/mg,1,0
Log Poct A,,1,0
Log Pn,cyh,1,0
Dispacement,%,1,1
CLH,mg/kg/min,1,0
Displacement,nM,1,-1
Dissociation,,1,-1
Log Kill,,1,1
A0.5,,1,0
CL/F,ug.hr/ml,1,0
Log Ki,uM.hr/L,1,-1
Diuretic activity,(m equiv [Na+]) 5hr-1 kg-1,1,1
Log Ke,M-1,1,-1
PIC seizure,,1,-1
Diuretic activity,(m equiv [Na+]) kg-1,1,1
Log KZ,,1,0
Dmax,%,1,1
Log KB,,1,-1
PLT,10E3/mm3,1,1
Log K4,,1,0
PPB,%ID,1,1
PPB,L/hr/kg,1,0
PPB,mM,1,0
PPB,mg/ml,1,0
CL/F,(mg/kg)/(microg/ml)/hr,1,0
A ctivity,,1,0
CL-renal,mL/min,1,0
CL-renal,L/hr,1,0
CL(app),L/min,1,0
PVCs,,1,0
Log IC50(uM),,1,-1
CL,umol/min/mg,1,-1
Papp,10'-3cm/s,1,0
CL,ug/ml/hr,1,-1
CL,ug/hr,1,0
CL,ug.hr/ml,1,0
CL,uM.hr,1,0
Papp,10'-6/s,1,0
Dose non renally cleared,%,1,1
Log EC50(uM),,1,-1
Dose per organ,,1,0
Papp,10'-9cm/s,1,0
Dose/g,,1,0
Drug,nM (mg of protein)-1,1,-1
Papp,10^-6cm2/s,1,0
CL,ng/ml/hr,1,1
CL,ng/min/kg,1,-1
Drug degradation,10'-5/s,1,-1
CL,nM/min/mg,1,-1
Papp,cm2/sec,1,0
Papp,microg/cm2,1,1
Papp,microg/cm3,1,1
pKP,,1,0
Papp,nanometer/sec,1,0
Papp,uL/min.mg,1,1
Drug degradation,10'-6/hr,1,1
pKa AN,,1,0
Parasite_Clearance,,1,1
Parasite_Clearance_time,,1,0
CL,ml,1,0
Drug metabolism,10'-2/s,1,1
CL,min.ug/ml,1,0
Parasites,,1,0
Drug metabolism,10'-4/s,1,1
CL,min,1,0
pKa AZ,,1,0
CL,micromol.hr/L/mg/kg,1,1
Drug metabolism,10^-2/s,1,1
Paw volume,ml,1,1
Paw weight increase,,1,1
Drug metabolism,fmol/ug,1,0
Peak GH,ug l-1,1,1
Peak concentration,%,1,1
Drug metabolism,mM,1,0
CL,mg/kg/microM.hrs,1,-1
CL,mg/hr/kg,1,1
Peak effect,%,1,1
Drug metabolism,mg,1,0
Log,(degrees C)-1,1,0
pKa BN,,1,0
CL,mg kg-1,1,0
Locomotor,Counts,1,1
pKa BZ,,1,0
CL,mL.min,1,0
CL,lL/min/million,1,0
CL,kg-1 hr-1,1,1
Performance,,1,1
Liver catalase,mg of protein,1,0
pKa E2,,1,0
CL,hr,1,0
Permeability,nM/s,1,0
Permeability,nm/s,1,0
Liphophilicity,sigma pi,1,0
Permeability limited,,1,0
Peroxidase rate,,1,1
Life span,%,1,1
Pharmacokinetic,%,1,0
CL,/hr,1,0
CL,(ml/min)/kg,1,0
Level in serum,mg dl-1,1,0
Level in serum,mM l-1,1,0
Drug metabolism,uM/g,1,0
pKa(1),,1,0
Phototoxicity,mg kg-1,1,1
CIp,mg kg-1,1,0
Photoxic reaction,mg,1,1
Level,nmol of pHB/min/mg of protein,1,-1
Level,mg/gof liver,1,0
PkB,,1,0
Pka2,,1,0
Plasma,ng ml-1,1,0
CI50,ug ml-1,1,-1
Plasma clearance,Clp,1,0
Plasma clearance,hkg,1,0
Plasma clearance,mg kg-1,1,0
Plasma clearance,mg.ml-1,1,0
Plasma clearance,,1,0
Plasma concentration,%,1,1
Plasma concentration,ug equiv ml-1,1,0
CI,10^-5No_unit,1,0
CI,10'7No_unit,1,0
CI,10'6No_unit,1,0
Lethal toxicity,mg kg-1,1,1
Lethal dose,ng ml-1,1,-1
Drug transport,%ID,1,1
CFU/ml,10'7/ml,1,-1
CFU/ml,10'4/ml,1,-1
CFU/ml,10'3/ml,1,-1
CFU,ml,1,-1
Plasma_IL-6,%,1,1
Plasma_NEFA,%,1,1
Plasma_cholesterol,%,1,1
Plasma_glucose,%,1,1
Plasma_insulin,%,1,1
Plasma_leptin,%,1,1
Plasma_triglyceride,%,1,1
Drug uptake,%ID/mg/ml,1,1
Platelet count,10e3 ul-1,1,1
Pm,/ml,1,0
Pm,10^-6 cm/s,1,0
CFU,10^6/g,1,-1
Pm,ucm/s,1,0
LV dp/dt,%,1,1
%AUC,%,1,1
IC50,10^5uM,1,-1
CFR,mg kg-1,1,1
CFC20,,1,0
CD50,mg/ml,1,0
CCID50,PuM,1,-1
Drug uptake,L/Kg,1,0
CC90,nM,1,-1
CC50,ucm,1,-1
Potency Ratio,,1,0
CC50,10'7uM,1,-1
CC50,10'5uM,1,-1
CC50,10'10uM,1,-1
CC10,,1,0
CC,uM,1,-1
LOAEL,ml/kg,1,0
Potentiation inflection point,uM,1,-1
Pressor activity,%,1,1
Pressor response,,1,-1
Pressure response,%,1,1
CAC,mg/ml,1,0
solubility,10'-7mol,1,0
Drug uptake,mg/L.hr,1,0
LDLO,mg kg-1,1,1
Drug uptake,microg.hr/mL,1,0
Progressed tumors,,1,1
Prolactin release,ng mg-1 hr-1,1,1
LDH50,uM,1,-1
CA,,1,-1
solubility,10'-8mol,1,0
C90,,1,0
Prolongation,,1,0
Prolonged QT,,1,1
LDH,U g-1,1,0
Protection,mg kg-1,1,1
LD95,,1,1
Drug uptake,ng/cm2/h,1,1
Protein,,1,0
Protein bound,%,1,1
C5 min,ug ml-1,1,0
LD70,ug ml-1,1,-1
LD60,mg kg-1,1,1
QA,,1,0
QH,L/Kg,1,0
5-HT Level,%,1,1
QH,L/min,1,0
QH,ml/min,1,0
LD50,ug/uL,1,-1
LD50,po,1,1
LD50,ng/kg,1,1
LD50,microM/g,1,-1
Drug uptake,uM/L,1,0
C10,,1,0
LD50,mg-1 kg-1,1,-1
Drug uptake,uM/ml,1,0
RBC,10E6/mm3,1,0
RBC,10e-6ul-1,1,0
RBC,10e3 ul-1,1,0
Drug uptake,ug.min/g,1,0
C0(unbound),ng/ml,1,0
LD50,g,1,-1
LD50,10'2umol/kg,1,1
solubility,10'3ug/ml,1,0
LD50,10'-8M,1,-1
RC50,10'-5mg/ml,1,-1
30 day survival/total,,1,1
Drug uptake(free),ug/g,1,1
C0,ng.hr,1,0
C0,ng ml-1,1,0
RD500,ug kg-1,1,1
LD30,mg kg-1,1,-1
Drugabsorption,ml/hr/kg,1,0
REM latency,,1,1
C(24h),mcg/mL,1,0
pKb(app),,1,-1
Drugabsorption,pmol,1,0
LD100,ug/kg,1,1
LD100,ng,1,1
3.3,uM,1,-1
LD10,umol/L,1,-1
LD10,ug/uL,1,-1
LD10,ug ml-1,1,1
Drugexcretion,Da,1,0
Drugexcretion,mg/day,1,0
Drugexcretion,ml/hr/kg,1,0
Brain levels,nM,1,0
Brain level,,1,0
Drugexcretion,ml/min.kg,1,0
Drugexcretion,ng,1,0
Drugexcretion,ug ml-1,1,0
LD,g,1,1
LCC99.9,uM,1,-1
Brain level,nM,1,0
Brain level,%,1,1
2xAPTT,,1,1
Brain concentration,uM,1,0
LCC99,uM,1,-1
Brain,weight,1,0
Drugexcretion,umol/L,1,0
Brain,ng g-1,1,0
Bound,,1,0
Boron incorporation,ug,1,0
LC95,ug/g,1,-1
Radioactivity remained,%,1,1
Duration of block,,1,1
Radiolabel recovery,ugequiv/ml,1,0
Body weight change,,1,0
LC50,ug.cm'-2,1,-1
Body weight,kg,1,-1
Range,ug ul-1,1,0
Range of MIC,ug ml-1,1,-1
Body temperature,,1,0
LC50,p.p.m.,1,-1
E2,,1,0
EAUC50,ng.hr/ml,1,-1
LC50,10^5uM,1,-1
LC50,10'5uM,1,-1
LC50,10'-4ppm,1,-1
Rate,ul min-1,1,0
Bmax2,,1,1
Rate constant,M s-1,1,0
Bmax2,fM (mg of protein)-1,1,1
% of Control Agonist Response,%,1,1
LC50,10'-13 ug/ml,1,-1
Bmax1,,1,1
Bmax1,fM (mg of protein)-1,1,1
EAUC50,ug.hr/ml,1,-1
LC25,ppm,1,-1
Bmax,sites cell-1,1,0
2x PT,,1,1
Bmax,pmol/g,1,0
Rate of formation,,1,0
Bmax,pg/mm2,1,1
Rate of metabolism,pM/mg/minute,1,-1
Bmax,fmol/ug,1,1
LC100,,1,-1
EBD20,,1,-1
Rate of reduction,,1,0
Rate of rotation,turns 5min-1,1,1
LC100,mg/L,1,-1
LC10,ppm,1,-1
Bmax,fM bound (mg of protein)-1,1,0
Ratio,%ID,1,1
Bmax,fM,1,1
LBF,ml/min.Kg,1,0
IC50,10^-5mg/ml,1,-1
LBF,ml/hr,1,0
LBF,L/hr/kg,1,0
LBF,L/hr,1,0
Bmax,10'-6pmol,1,1
EC10,,1,-1
Blood volume,HB g ml-1,1,1
LA,,1,0
L,%,1,1
Ratio,1/M1/s,1,1
Kup,ml/min,1,1
Ratio,10'-2/s,1,0
Kuncat,min-1,1,-1
Kuncat,M-1 s-1,1,1
Ratio,10'-5/M/s,1,-1
Ratio,10'-5/min.mol%'-4,1,0
Ratio,10'-6/nM/s,1,-1
Ratio,10'-6cm/min,1,0
Ratio,10'3/s/M,1,-1
Ratio,10'5/min/M,1,-1
EC10x,,1,1
Ks,10^6/M,1,-1
Ratio,10'6/s/M,1,1
Ratio,10'7/s/M,1,1
Blood Pressure,,1,0
Ratio,10^3/mM/s,1,1
Ratio,10^3No_unit,1,0
Ratio,10^4No_unit,1,0
Ratio,10^5No_unit,1,0
Ks,10'4/M,1,-1
Ratio,10^8/M/s,1,-1
Ratio,CPP/GLY,1,0
Ratio,KB 7d-1,1,0
EC14,M,1,-1
Ratio,M,1,0
EC16,M,1,-1
Bleeding time,uM,1,0
Ratio,mg kg-1,1,0
EC16,uM,1,-1
Ratio,microL/min/mg,1,1
IC50,10^-4mg/ml,1,-1
Ratio,ml g-1,1,0
2X PT,,1,-1
Ratio,ml/min/umol,1,1
Ratio,mole fraction,1,0
Ratio,ms,1,0
Kr,nM,1,-1
Ratio,umolequiv/umol,1,0
Kq,10^14/M/s,1,-1
Ratio CC50/EC50,10^10No_unit,1,-1
Ratio CC50/EC50,10^5No_unit,1,-1
EC200,,1,1
% inhibition in spleen,%,1,1
Kq,10'6No_unit,1,-1
Ratio EC50,10^-2No_unit,1,-1
Ratio EC50,10^-4No_unit,1,-1
Ratio EC50,10^-5No_unit,1,-1
Ratio EC50,10^-6No_unit,1,-1
Binding constant,1/M,1,-1
Ratio ED50/MIC50,,1,-1
Kq,10'4No_unit,1,-1
Kq,10'4L/mol,1,-1
Kq,10'14/M/s,1,-1
Ratio IC50,10^-3No_unit,1,-1
Ratio IC50,10^4No_unit,1,-1
Ratio IC50,nM,1,-1
EC24,uM,1,-1
Ratio IC50/EC50,10'3No_unit,1,-1
Ratio IC50/EC50,10'7No_unit,1,-1
Kq,10'13/mol/s,1,-1
Ratio Ki,10'-5No_unit,1,0
Ratio Ki,10'-7No_unit,1,0
Ratio Ki,10'4No_unit,1,0
Ratio Ki,10'7No_unit,1,0
Kq,10'12L/mol.s,1,-1
Kq,10'11L/mol.s,1,-1
Ratio Ki,10^-6No_unit,1,0
Kq,10'10L/mol/s,1,-1
Binding,mg kg-1,1,0
Ratio of distribution,,1,0
RatioGI50,10'4No_unit,1,-1
pMEC,,1,0
EC25(unbound),nM,1,-1
Ratio_Cmax_brain/plasma,,1,1
Kp,ml/min/g,1,0
Kp,10^-5cm/hr,1,0
Basal glucose,mg dl-1,1,1
Kon,10e3* M-1 s-1,1,1
Kobs,uM,1,-1
Recovered in bile,%,1,1
Kmax,/hr,1,1
EC37,%,1,1
Recovery rate,,1,0
BSA binding,,1,0
Km app,rel,1,0
Reduced food intake,%,1,1
Km,ng/ml,1,0
Km,min-1,1,-1
Km,10'-4M/min,1,0
BP increase,AUD30min,1,1
BP increase,%,1,1
2PT,nM,1,-1
Reduction in arterial blood pressure,%,1,1
Reduction in blood pressure,%,1,1
Reduction in heart rate,%,1,1
Reduction in movement,,1,1
Reduction in respiratoryvolume,ml,1,1
BP change,,1,0
Km,/min,1,0
BP (ED50),%,1,1
Reduction of prostate weight,%,1,1
BNa,,1,-1
EC50,10'-1ppm,1,-1
Relation,%,1,1
Relative,uM,1,-1
Kiuc,10'3nM,1,-1
EC50,10'-2mg/ml,1,-1
EC50,10'-2mol%,1,-1
BBB Impermeable,,1,0
BBB,,1,0
BBB,hr,1,0
BBB,10'-3cm/min,1,0
BBB,%,1,1
BAV,,1,0
EC50,10'-3 ug/cm2,1,-1
pMax,%,1,1
Relative Vmax/Km,rel,1,0
EC50,10'-6microg/cm2,1,-1
EC50,10'10PFU,1,-1
EC50,10'6pM,1,-1
Kinact,mV,1,0
EC50,10'8PFU,1,-1
Average weight gain,,1,1
Relative bioavailability,nM ml-1,1,0
Kinact,10^4nM,1,-1
Kinact,10^4/s,1,1
Relative contractile potency,,1,1
Kinact,10^-4/min,1,-1
Kinact,10^-2microM,1,-1
Average score,%,1,1
Relative inactivation,,1,0
Kinact,10'4nM,1,-1
Kinact,10'2/s,1,-1
Average peak Concn,ug ml-1,1,1
Kinact,10'2/M/s,1,1
Kinact,10'-9M,1,-1
Kinact,10'-8/s,1,1
Kinact,10'-7/s,1,-1
135,nM,1,-1
Kinact,10'-5/s,1,-1
EC50,10^-6 uM,1,-1
Relative oncentration,uM,1,-1
Relative peroxidation,%,1,1
Kinact,/M/s,1,-1
KinX,hr-1,1,0
Relative potency,nM,1,-1
Average bile flow,ml hr-1,1,0
IC50,10'7nM,1,-1
Kin,min-1,1,-1
Kin,10'-5ml/s/g,1,0
pRatio,,1,0
Kin,10'-3ml/s/g,1,1
EC50,PuM,1,-1
Kin,/min,1,-1
Killed,%,1,1
EC50,mM/L,1,-1
EC50,mgAi,1,-1
Asorbance,,1,0
EC50,mmol/Kg,1,-1
Relative weight loss,%,1,1
EC50,nM g-1,1,-1
EC50,nM kg-1,1,-1
Ki0,nM,1,-1
Ki/ki,uM,1,-1
Remained,%,1,1
Ki/Km,nM,1,-1
"Ki,app",nM,1,-1
% inhibition in liver,%,1,1
Anxiolytic affect,,1,0
Anxiolytic activity,,1,0
EC50,pnM,1,-1
Replacement,%,1,1
10E2 K1,min-1,1,-1
Rescued neurons,,1,1
Ki' uncomp,mM,1,-1
Ki obs / [I],M-1 s-1,1,-1
Ki inact,min-1,1,-1
HSF release,,1,0
EC50,ucm/s,1,0
Ki comp,mM,1,-1
Antipsychotic,,1,0
EC50,ug hr ml-1,1,0
Antihypertensive activity,mg kg-1,1,1
Antihypertensive,,1,0
EC50H,nM,1,-1
Resistance ratio,,1,0
EC50L,nM,1,-1
Ki,ml/min/g,1,0
Antidiuretic activity,IU mg-1,1,1
Ki,PuM,1,-1
EC70,mg kg-1,1,1
Anticonvulsant activityAnticonvulsant activity,,1,-1
Ki,Kg,1,0
Ki,10^6/M/s,1,-1
Ki,10^4/M/s,1,-1
Ki,10^2/M/s,1,-1
Anticoagulant activity,mg kg-1 hr-1,1,1
Anticancer activity,,1,0
Half duration,,1,0
EC70,ng/ml,1,-1
Antibody titer,log-2,1,-1
Ki,10^-9/min,1,-1
Ki,10^-4microM,1,-1
Ki,10^-2/min,1,-1
Anti-arhythmic,,1,-1
Ki,10^-12M,1,-1
Anti-HIV activity,,1,-1
Antagonist efficacy,%,1,1
EC70,uM,1,-1
Ki,10'5/M/s,1,-1
EC80,mgAi,1,0
Ki,10'5/M,1,-1
pWeight change,,1,1
solubility,mmol/ml,1,0
IC50,10'5uM,1,-1
1/Km,10'2/M,1,-1
solubility,ppb,1,0
Ki,10'22mM,1,-1
Ki,10'2/M/min,1,-1
Ki,10'11mM,1,-1
Anesthesia duration,,1,1
% inhibition in bone-marrow,%,1,1
Analgesicactivity,,1,1
Ki,/min,1,-1
"S20,w",s,1,0
Kel,min,1,0
Kel,L/Kg,1,0
EC90,mg/ml,1,1
EC90,microM,1,-1
SC50,ng/ml,1,-1
Anabolic activity,,1,0
SCW reduction,%,1,1
EC90,nmol/L,1,-1
EC91,nM,1,-1
SD90,,1,-1
1/2Kcat/Km,M-1 s-1,1,1
SDS,,1,0
SEC50,10'-10M,1,-1
SEC50,10'-8M,1,-1
Ke,10^-5M,1,-1
Ke,10^-4M,1,-1
EC98,uM,1,-1
EC98.6,nM,1,-1
EC99,mg/ml,1,1
Amine formed,,1,0
Kdiss,nM,1,-1
Alpha Ki,,1,-1
Kdiss,microM/s,1,-1
EC99,ng/ml,1,1
Kdiss,10^-8M,1,-1
AlDH activity,nM min-1,1,-1
Kdiss,10^-6M,1,-1
Kdiss,10^-5M,1,-1
Kdiss,10^-3M,1,-1
Kdiss,10^-2/Ms,1,-1
IC50,10'20 uM,1,-1
Kdiss,10^-1M,1,-1
Kdiss,10^-10M,1,-1
Kdiss,10^-1/s,1,-1
SUV,nCi/cc,1,1
Kdiss,10'-7M,1,-1
SUVmax,kBq/cm3,1,0
Kdiss,10'-6/s,1,-1
Agonism inflection point,nM,1,-1
IC50,10'16 uM,1,-1
EC99.6,uM,1,-1
Saldiuretic activity,(m equiv) 6hr-1 kg-1,1,-1
Kdiss,/hr,1,-1
Saline control,,1,0
KdSPR,uM,1,-1
KdSPA,mM,1,-1
Kd2,,1,-1
% dose,%,1,1
Kd1,,1,-1
Second order,M s-1,1,1
ECG,,1,0
Kd,microM/s,1,0
Kd,microL/min/mg,1,0
Adverse effect,,1,0
IC50,10'13nM,1,-1
ECMax,uM,1,1
Kd,M-1 s-1,1,-1
Selectivity Index,uM,1,0
Kd,10^6uM,1,-1
Selectivity in binding,,1,0
Selectivity index,Monkey,1,0
Actvity,,1,0
-TdeltaS,J/mol.K,1,0
Kd,10^4/M,1,-1
Selectivity ratio,uM,1,-1
Activty,%,1,1
ECmax,mg kg-1,1,1
Kd,10^3/M/s,1,-1
Kd,10^3/M,1,-1
Kd,10^3 uM,1,-1
ECmax,ng/ml,1,1
Kd,10^-52M,1,-1
Kd,10^-4/M,1,-1
Kd,10^-2M,1,-1
Kd,10^-1M,1,-1
Kd,10^-17M,1,-1
Kd,10^-15M,1,-1
Kd,10'7/M/s,1,-1
Activity,um3.um2/day,1,1
Kd,10'5/M,1,-1
Kd,10'1/s,1,-1
Kd,10'-9L/mol,1,-1
Kd,10'-9/M,1,-1
Kd,10'-7/s,1,-1
Activity,ul g-1,1,0
Kd,10'-5 cm/s,1,-1
Sleep latency,%,1,1
Activity,ug.hr/ml,1,1
Kd,10'-29M,1,-1
Kd,10'-2(1/s),1,-1
Kd,10'-11/M,1,-1
Activity,ug cm**-2 hr-1,1,1
Kd,10'-10L/mol,1,-1
Smax,IU/ml/hr,1,1
ED,umol/Kg,1,1
Kd,/nM/min,1,-1
ED 50,,1,-1
Kcat/Km,uM,1,-1
ED Arec,,1,0
Kcat/Km,10^8/M/s,1,1
Activity,uM kg-1 s.c.,1,-1
Specific activity,uM Pi/min/mg protein,1,-1
Activity,uCi/ml,1,1
Kcat/Km,10^2/M/s,1,1
Kcat/Km,10^1/M/s,1,1
Specific binding,,1,0
Specific incorporation,,1,0
Kcat/Km,10^-4/nM/s,1,-1
solubility,ug,1,0
Kcat/Km,10^-4/M/s,1,1
Kcat/Km,10^-3/M/s,1,1
Kcat/Km,10'7M/s,1,-1
Spontaneous reperfusion,%,1,1
Kcat/Km,10'5/Ms,1,-1
solubility,ug/kg,1,0
Stability,%/min,1,-1
Kcat/Km,10'4/M/min,1,-1
ED10,,1,-1
Kcat/Km,10'3/M.s,1,1
-Log LC50,,1,-1
permeability,10'-6/s,1,1
Kcat/Km,10'2/Ms,1,-1
Stability,microg.min/mL,1,0
Activity,pg/ug,1,0
Activity,pg/uL,1,1
Activity,pg/dl,1,1
Activity,pg.hr/ml,1,0
Activity,pM/min/ml,1,1
Activity,pM/min/mg,1,-1
ED100,M,1,-1
Stability,pM/mg/hr,1,-1
ED100,mg,1,1
IC50,10'-4umol/L,1,-1
permeability,10'-6cm2/s,1,0
Kcat/Km,/min.uM,1,-1
Activity,pKa,1,0
ED100,pmol,1,-1
Kcat,umol/min/nmol,1,-1
Stabilty,months,1,0
Kcat,10^4/s,1,1
ED100,ug day-1 kg-1,1,1
Stimulation,uM,1,1
Stimulatory activity,%,1,1
Stimulatory effect,nM min-1 (mg of protein)-1,1,1
Activity,ng/min/dl,1,1
Kcat,10'7/s,1,1
ED14.5,ug/kg,1,1
ED15,%,1,1
Kcat,10'2/s,1,1
Kcat,/hr,1,0
Suppression of parasitemia,,1,1
-Log Kb,,1,-1
IC50,10'-13 ug/ml,1,-1
Survival,10'3CFU/ml,1,-1
Activity,nM/g,1,-1
Kc,min-1,1,1
Activity,nM/10e6,1,-1
ED19.5,ug/kg,1,1
Kbapp,10'4/M,1,-1
Survival dose,,1,0
ED2,Na2,1,0
ED2,uM,1,-1
Kb,10^7L/mol,1,-1
Activity,mmol.h/L,1,1
ED20,ug/kg,1,1
Kb,10^3/M,1,-1
Kb,10^2/M,1,1
Survivors,mg kg-1,1,1
Kb,10^1/M,1,1
Kb,10^-5L/mol,1,-1
Kb,10'6/mol,1,-1
Activity,ml/cm,1,1
ED25,10'-11M,1,-1
Activity,micromol/dl,1,0
Synergistic effect,,1,0
ED25,10'-9M,1,-1
Kapp,10'7/M/s,1,1
ED25,pmg kg-1 day-1,1,1
Systolic blood pressure,SBP,1,1
Kapp,10'5L/mol,1,-1
Kapp,10'5/M/s,1,1
ED25,ug ml-1,1,-1
Kapp,10'4M,1,-1
Kapp,10'3L/mol,1,-1
T max,mg kg-1,1,0
Activity,mg/kg/hr,1,1
Kapp,10'-7M,1,-1
ppKb,,1,-1
T-cell,,1,0
Kact,mV,1,0
Kact,/s,1,-1
T/C,g,1,1
T/C,log10,1,1
Activity,mean,1,0
T/C @ 20mg/kg,%,1,1
T/C @ 30mg/kg,%,1,1
T/C @ 40mg/kg,%,1,1
T/C @ 50mg/kg,%,1,1
Ka,mM,1,0
t1/2,microsec,1,0
T/C value,,1,1
Activity,mN,1,1
Ka,10^7/M/s,1,1
T1/2,mg kg-1,1,0
T1/2,uM,1,0
T1/2 beta,,1,0
T1/2 h/min,,1,0
T1/2 h/s,,1,0
Ka,10^7/M.s,1,1
T1/2 iv,,1,0
ED35,ng,1,1
permeability,10^-6cm/min,1,0
T4,,1,0
permeability,10^-6m/s,1,0
permeability,10^-8cm/s,1,0
T50,ug,1,0
T>IC50,uM,1,-1
Activity,mCi/M,1,0
Ka,10^5/Ms,1,1
Ka,10^5/M.s,1,1
Ka,10^4/s,1,1
Activity,log10pfu/g,1,-1
Ka,10^4/M.s,1,1
Activity,l hr-1 kg-1,1,0
Ka,10^2/M/s,1,1
Ka,10^2/M,1,1
Ka,10^1/M,1,-1
Activity,kT/e,1,0
Ka,10^1 uM,1,1
Activity,kJ/cm2,1,0
IC50,10'-11uM,1,-1
Ka,10^-7M,1,-1
Ka,10^-7/M,1,-1
TCID50,log10/ml,1,-1
permeability,cm/min,1,0
ED5,umol/Kg,1,1
Ka,10'8M,1,-1
Ka,10'7/Ms,1,1
Activity,fM,1,-1
ED50,10'-13mol,1,-1
Ka,10'7(1/Ms),1,1
%max,ng/ml,1,1
Activity,dyn.s.cm'-5.10'4,1,0
Ka,10'6/Ms,1,1
IC50,/uM/s,1,-1
Activity,deltalog10/ml,1,-1
TG,mg kg-1 diet,1,0
ED50,10'-1umol/L,1,-1
permeability,microg/cm2,1,0
TG 2X lag,,1,0
Ka,10'4 /uL,1,1
TGI,10^5uM,1,-1
Activity,U/ml/min,1,1
Activity,U/min/ml,1,1
Ka,10'2L/mol,1,1
Ka,10'2/Ms,1,1
% reduction,%,1,1
TID20,mg kg-1,1,1
Ka,10'10M,1,0
Ka,10'10L/mol/s,1,1
Ka,10'1/M/s,1,1
Ka,10'-7M,1,-1
ED50,10'-8mol,1,-1
Activity,PbU,1,1
Activity,Osm/kg,1,1
Ka,/nM/min,1,-1
Ka,/nM,1,-1
TR,min,1,0
Ka,/min,1,1
ED50,10'1 ug/ml,1,-1
TT,nM,1,-1
Activity,M-1,1,1
ED50,10^-5 ug/ml,1,-1
ED50,DIUR,1,1
Activity,L/hr,1,1
Activity,L/Kg,1,0
KSV,10^5L/mol,1,-1
TdeltaS,10^2kJ/mol,1,0
Temperature change,(degrees C)-1,1,-1
KSV,10'4/mol,1,-1
KSV,10'-5M,1,-1
KSV,10'-4M,1,-1
Terminal elimination t1/2,hr,1,0
Terminal t1/2,hr,1,0
KSV,10'-4L/M,1,1
KS,uM,1,-1
ED50,mg g-1 day-1,1,1
KNa,M-1,1,-1
KL,M,1,-1
KI50,,1,-1
Activity,Ci/mmol,1,0
Therm_solubility,10'-1mol/L,1,0
KH,M,1,0
KH,%,1,1
ED50,mg/cm2,1,1
ED50,ml/kg,1,1
IC5,ng/ml,1,-1
ED50,mmol,1,-1
KD non ionic,mM,1,-1
KD hydro,,1,-1
Ti,,1,0
KBp,,1,-1
Activity,10^9CFU/ml,1,-1
Time,10'11min,1,0
KB1,,1,-1
Activity,10^8CFU/ml,1,1
Activity,10^7cm/s,1,0
Time after dose,,1,0
Activity,10^7CFU/g,1,1
Activity,10^7CFU,1,1
%Remaining,%,1,1
ED50,nM animal-1,1,-1
KB,mg kg-1,1,0
Time of dosing before antigen challenge.,hr,1,0
Activity,10^6/100microL,1,1
KB,10'3/M,1,-1
KA,uM l-1,1,-1
Activity,10^5PFU/g,1,1
IC40,nm,1,-1
Activity,10^5CFU,1,1
KA,10^8/M,1,1
Tissue levels,,1,0
Tissue swelling,uM g-1,1,-1
KA,10^4/M,1,-1
Activity,10^5/Ms,1,1
KA,10^-4/M,1,-1
Activity,10^4CFU/ml,1,1
Activity,10^4CFU/mg,1,1
KA,10^-3/M,1,-1
Activity,10^4/M/s,1,1
KA,10'8/M,1,1
Tm shift degreeC,degrees C,1,0
Tmax,ng/ml,1,0
Tmax/dose,hr,1,0
Tmin,day,1,-1
Tmin,min,1,0
Activity,10^3/M,1,1
Topical dosage,M,1,0
Activity,10^2CFU/ml,1,1
Total acid output,,1,0
K3,s-1,1,-1
permeability,nmol/sec,1,0
Activity,10^1/mm2,1,1
Activity,10^-9M,1,-1
ED50,uM ear-1,1,-1
permeability,pmol/min,1,1
K2,mM,1,-1
Activity,10^-6M,1,-1
Activity,10^-5No_unit,1,0
Activity,10^-3No_unit,1,-1
Activity,10^-3/s,1,1
Min concentration,,1,-1
Activity,10^-11M,1,-1
Activity,10'9CFU/ml,1,-1
ED50,ug animal-1,1,1
IC40,mM,1,-1
Activity,10'9/ml,1,1
Activity,10'8/ml,1,1
Activity,10'7PFU/ml,1,1
Toxicity,number of dead animals,1,1
Toxicity index,,1,0
Activity,10'7/M,1,1
Activity,10'6log10CFU/ml,1,-1
K-1,1/min,1,-1
Activity,10'6PFU,1,1
K+2/Ki,,1,-1
K+2,,1,0
"K(p,uu,brain)",%,1,1
Transcriptional activity,,1,0
K obs / s,,1,0
ED50,umol/g,1,-1
Activity,10'5L/mol,1,1
K obs,mM,1,-1
t1/2,ug.hr/ml,1,0
ED50 / ED50 (taxol),nM,1,-1
K inact/Ki,10e4 M-1 s-1,1,-1
K inact/I,M-1 s-1,1,-1
%Cleared,%,1,1
ED58,,1,-1
K inact,M-1 min-1,1,-1
Activity,10'4/M,1,1
ED60,mM,1,-1
K cat/Km,1/M.s,1,-1
K cat/Km,1/M*s,1,-1
K cat,1/sM,1,-1
ED70,ug/kg,1,1
Activity,10'2pg/ml,1,1
ED75,,1,-1
Tumour inhibition,,1,1
Activity,10'12L/mol/s,1,1
Turnover,ug ml-1,1,0
Activity,10'10L/mol/s,1,1
Twitch tension,,1,1
U/P,,1,0
pka,M-1,1,0
UV,ml kg-1,1,0
ED90,1/mg.1/kg.1/day,1,1
Activity,10'-8 ug/ml,1,1
Ulcer incidence,,1,1
K act,nM,1,-1
K act,M-1 s-1,1,1
Ultrafiltration,,1,0
Activity,10'-7 cm/s,1,0
Unchanged NDEA,%,1,1
Activity,10'-6No_unit,1,0
K H,%,1,1
Untreated control,,1,0
Uptake,% injected dose cm**-3,1,1
Histamine release,,1,-1
Activity,10'-5nmol,1,1
Uptake,nM 3s-1 (mg of protein)-1,1,-1
K B,nM,1,-1
IC33,uM,1,-1
Activity,10'-5 mol/L,1,-1
ED90,kg/ha,1,1
Activity,10'-4g,1,0
K,nM/min,1,-1
Activity,10'-3umol/min,1,1
Activity,10'-3nmol,1,1
ED97,,1,-1
K,microM/s,1,0
Activity,10'-3 ug/ml,1,1
Uterine activity,,1,1
K,fM,1,-1
Activity,10'-2M,1,-1
K,M-2,1,-1
Activity,10'-1microM,1,-1
EFF+/-SD,%,1,1
HD40,mg kg-1,1,1
Activity,10'-10s,1,0
Activity,10'-1/M/s,1,1
Activity,10'-1 ug/ml,1,1
K,10e4min-1,1,-1
K,10^9/M/min,1,1
K,10^7No_unit,1,0
V1,ml,1,0
V2,ml,1,0
t1/2(app),,1,0
Activity,/10^6mm3,1,1
Activity,/10^3mm3,1,1
K,10^5No_unit,1,0
K,10^5/s,1,1
K,10^5/min/M,1,1
VSV,,1,0
VV,,1,0
K,10^3No_unit,1,0
Variation of edema volume,%,1,1
K,10^3L/mol,1,-1
ER/PR,,1,0
Vasopressor activity,mg,1,1
Activity,%mg,1,0
K,10^2No_unit,1,0
Vc/F,L/hr,1,0
K,10^2/Ms,1,1
K,10^2/M/min,1,1
K,10^2/M,1,1
K,10^10No_unit,1,0
K,10^1/M/s,1,1
Activit y,,1,0
Vd,ml/mg,1,0
Vd app,L,1,0
Vd area,mg kg-1,1,0
Vd(app),L,1,0
Vd(app),L/hr,1,0
K,10^-8/M/s,1,1
t1/2/dose,hr,1,0
K,10^-6No_unit,1,0
K,10^-5/min,1,1
Vdss,L/hr.Kg,1,0
HD50,umol/Kg,1,-1
Vdss,mg/L,1,0
ERH,nM,1,-1
Vdss,ml/hr/kg,1,0
Vdss,ml/mg,1,0
Vdss(app),l,1,0
Vdss(app),ml/min.kg,1,0
Activation,uM,1,-1
K,10^-3No_unit,1,0
Vdu,,1,0
ET-1 level,pg ml-1,1,1
Vel rem,%,1,1
Velocity,,1,0
Activ ity,,1,0
Ventricular tachycardia,,1,0
Activ ity,%,1,1
IC30,10'-8M,1,-1
Acid output,(equiv of [H+]) 2hr-1,1,-1
Virucidal,ng/ml,1,-1
Acid hydrolysis,mol/mol,1,0
Ea,kcal/mol,1,0
K,10^-2/M/s,1,1
K,10^-12/min,1,1
K,10^-11/min,1,-1
K,10^-1(1/Ms),1,-1
Vm,rel,1,0
Vm,uM ml-1,1,-1
Edema,uM,1,0
K,10'8Lmol,1,-1
K,10'7L/mol,1,-1
Vmax,10'-2umol/min/U,1,1
%Bound_Albumin,%,1,1
Vmax,10'-6deltaA/s,1,0
Vmax,10'-6mol/s,1,1
Vmax,10'-7mol/s,1,1
Vmax,10'-8M/s,1,1
Vmax,10'-8cpm/min,1,1
Vmax,10'3mmol/min/mg,1,1
K,10'7/mol,1,-1
Vmax,10'7U/min,1,1
Edema inhibition,,1,1
Vmax,L/Kg,1,1
IC25,ug ml-1,1,-1
K,10'6/nM/min,1,1
t1/2eff,,1,0
K,10'5/mol,1,1
Effective dose,M,1,-1
Effective dose,ug kg-1,1,1
Vmax,deltaOD/hr,1,1
K,10'4/s/M,1,1
Vmax,mM/hr,1,1
Vmax,mOD/minute,1,1
Efficacy,mg/dl,1,0
K,10'3mol/dm3/s,1,1
K,10'3/s/M,1,1
Effllux,min-1,1,0
Vmax,nM/hr,1,1
K,10'2/M/min,1,1
Vmax,nanomol/min,1,1
K,10'1mol/dm3/s,1,1
Vmax,nmol/cm2/s,1,1
K,10'11/M,1,-1
K,10'10/s,1,0
K,10'10/M,1,-1
AbA/analogue ratio,,1,0
K,10'1/s,1,1
Vmax,nmol/min/kg,1,1
K,10'1/mol/s,1,1
Vmax,nmol/min/ml,1,1
K,10'1/M/s,1,1
Vmax,pM 0.5hr-1,1,-1
K,10'-8No_unit,1,0
Vmax,pM hr-1 mg-1,1,1
AUMCt,ug.hr2/L,1,1
K,10'-7/nM/min,1,1
IC25,PuM,1,-1
Vmax,pmol/min/U,1,1
Vmax,pmol/min/cm2,1,1
K,10'-7/M,1,-1
K,10'-6/hr,1,0
HDL-C change,,1,1
K,10'-5L/mol,1,-1
K,10'-53No_unit,1,0
Vmax,uM g-1,1,1
Vmax,uM hr-1,1,1
K,10'-51No_unit,1,0
Vmax,uM mg-1,1,1
AUMC,,1,0
K,10'-5/s/nM,1,-1
Eggs,,1,0
K,10'-5/hr,1,-1
K,10'-3No_unit,1,0
AUMC,ug.hr2/L,1,1
Vmax (uM),%,1,0
Hydrolysis rate constant,t/2,1,0
Emax,10'-1/hr,1,1
K,10'-3/M/s,1,-1
Vmax / Km,ml min-1 mg-1,1,1
K,10'-2M,1,-1
K,10'-2/s/M,1,-1
K,10'-2/nM/min,1,-1
I7,uM,1,-1
Vmax(app),nM/min,1,-1
Vmax(app),pmol/mg/min,1,1
K,10'-18No_unit,1,0
Vmax/Km,10'-4min,1,-1
Vmax/Km,10'-5L/min,1,1
Vmax/Km,10'-5min,1,0
Vmax/Km,10'3/M/s,1,1
K,10'-12/min,1,-1
K,10'-11M,1,-1
K,10'-10No_unit,1,0
% reduction,,1,1
K,/s/microM,1,-1
Emax,ug/kg,1,1
EmaxH,%,1,1
EmaxL,%,1,1
Jmax,pmol/min/mg,1,1
Emesis_ED,mg kg-1,1,1
Volume reduction,%,1,1
Vp/F,L/hr,1,0
Vss,L/m2,1,0
Vss/F,L,1,0
Vss/F,,1,0
Enoyl-CoA hydratase,uM min-1 (mg of protein)-1,1,-1
Intrinsic,,1,1
Intraperitoneal score,,1,0
WBC,10E3/mm3,1,0
WCC90,ug ml-1,1,-1
WCC99.9,uM,1,-1
AUCt/dose,,1,1
pinhibition,%,1,1
Weight (mg/g),%,1,1
Equieffective dose,,1,0
AUCt/dose,ngequiv.hr/ml/mg,1,1
Weight change,T-C,1,0
AUCt/dose,ng.hr/ml/mg,1,1
tCmax,hr,1,0
Hypnosis duration,,1,1
Injected dose (g),%,1,1
Weight increase,%,1,1
Injected,,1,0
Initial inhibition,ug ml-1,1,0
Initial heart rate,,1,0
XI50,nM,1,-1
XL50,nM,1,-1
AUCt,ml/min.kg,1,0
Inhibitory dose,mg kg-1,1,-1
Inhibition_index,10'27No_unit,1,0
AUCss(tau) normalised,(nmol.h.L-1)/(mg/kg),1,1
[3H] thymidinecpm/dish,,1,-1
[Ca2+],nM,1,1
F,ml/min.kg,1,0
AUClast/dose,ug.hr/ml,1,1
IC15,nM,1,-1
Inhibition at 10nM,%,1,1
FC,10'-4No_unit,1,0
alphaKi,mM,1,-1
Inhibition (500 ÂµM),%,1,1
AUClast,ug.min/g,1,0
average log GI50,M,1,-1
behavioral observation,,1,0
beta t1/2,%,1,1
Hypoglycemic,,1,0
AUClast,ngequiv.hr/g,1,1
Inhibition,umol,1,-1
AUClast,ng/hr,1,1
Inhibition,cm,1,1
Inhibition,c.p.m. 50ul-1,1,0
AUClast,nM,1,0
Hepatic blood flow,L.h.Kg-1,1,0
delta T,K,1,0
delta Vmax,%,1,1
AUC/dose,uM/hr/Kg/mg,1,1
deltaA,degrees C,1,1
Infection score mean,,1,0
FRP at 10microM,%,1,1
AUC/dose,uM.hr/ml,1,0
deltaG,10^2kJ/mol,1,-1
Increases,%,1,1
deltaH,10'4cal/mol,1,0
deltaH,10^3kJ/mol,1,0
AUC/dose,ngequiv.hr/ml/mg,1,1
AUC/dose,ng/hr.ml,1,1
deltaS,J/mol,1,0
Increased,%,1,1
Increase in heart rate,,1,1
Increase in heart rate,beats min-1,1,1
Increase in heart rate,%,1,1
deltaS,kcal/mol,1,0
deltaTm,Â°C,1,-1
IC15,10'-7M,1,-1
Increase in blood pressure,,1,1
Fez,%,1,1
duration of action,hr,1,0
eduction,%,1,1
AUC/dose,min.g/L,1,1
f %t > MIC,%,1,1
Increase in MAP,%,1,1
fAUC,mg/L,1,1
fAUC,nM,1,1
Increase,ml min-1,1,1
Incorporated,,1,0
Fluorescence,,1,0
Fluoroscence,,1,0
Heme loss,nM,1,0
fAUC/dose,hr.Kg/L,1,1
Fmean,%,1,1
Fold IC50,,1,-1
fAUClast,uM.hr,1,0
fCmax,ng/g,1,1
fCmax,nmol/L,1,1
permeability,ug/cm2.hr,1,1
fCmax,nmol/ml,1,1
AUC(0-24) normalised,(nmol.h.L-1)/(mg/kg),1,1
fCmax,umol/L,1,1
Imax,ng/ml,1,1
fCmin,ng/ml,1,1
Imax,min,1,1
Food intake,g 5mice-1 5days-1,1,1
IZ/AAR / AAR/LV,,1,1
IZ/AAR / AAR/LV,%,1,1
fIC80,nM,1,-1
fKi,uM,1,-1
fMEC,nM,1,-1
fMEC,ng/ml,1,1
IC100,mg/kg/day,1,-1
fc max,mg L-1,1,1
AUC glu reduction(mM x min),%,1,1
food intake,g mouse-1 day-1,1,1
g/mouse,,1,0
hSlo current,,1,-1
AUC Npo,,1,0
IC100,mM,1,-1
k cat,*10e-3,1,1
IP,nm/s,1,0
k cat,hr-1,1,1
AUC,ug/mg/day,1,0
Fu,%ID,1,1
Fu,microg.hr/mL,1,0
AUC,ug min/mL,1,1
INH,ug/kg,1,0
Fu,nmol/Kg,1,0
Fu,umol/L,1,0
INH,pmol,1,0
Full inhibition,uM,1,-1
INH,L/hr/kg,1,0
INH,E^1%,1,1
INH,E^-1%,1,1
k1,,1,0
k12,/hr,1,0
INH,10^-8mol/L,1,-1
INH,10^-10mol/L,1,-1
INH,10'6/M/s,1,-1
AUC,uN h kg/mg,1,0
INH,10'4/M/s,1,-1
INH,10'-9mol/L,1,-1
INH,10'-8mol/kg,1,-1
AUC,uM.hr/mg,1,0
INH,10'-7mol/kg,1,-1
INH,10'-7mol/L,1,-1
AUC,uM.hr.kg,1,0
INH,/min,1,-1
k2/Ki,,1,-1
k21,/hr,1,0
INCC50,,1,-1
INCC50,ug ml-1,1,-1
INCC50,%,1,0
IN,,1,-1
k3/K1,uM,1,-1
ILSmaxOD,,1,0
G1,,1,0
k3/ki,,1,0
GC200 [d],%,1,1
ILS (Sur),%,1,1
kOH-,,1,0
ILA,,1,1
IFN gamma concentration,pg ml-1,1,1
ka,10^5L/mol,1,1
GI,%/hr,1,1
GI,10'-6M,1,-1
GI,10'-7M,1,-1
GI,ng/ml,1,-1
kinact,uM,1,-1
kmax,s-1,1,0
kmax/KS,M-1 s-1,1,1
I10,M,1,-1
ID90,nM,1,-1
kobs,,1,0
GI clearence,,1,0
AUC,ng/L,1,0
GI tolerance,,1,0
I13,uM,1,-1
ID60,mg kg-1,1,1
GI50,10'-8cm/s,1,0
GI50,10^3nM,1,-1
GI50,PuM,1,-1
GI50/EC50,uM,1,-1
log Kp,10'-6 cm/s,1,0
AUC,ng.h-1.ml-1,1,1
ID50,ug/hr.kg,1,0
AUC,ng.Eq/ml,1,1
log Pe,10^-6 cm/s,1,0
GI75,nM,1,-1
AUC,ng ml kg-1,1,1
AUC,ng hr g-1,1,1
ID50,ug kg-1 min-1,1,-1
AUC,nM/L.hr,1,0
ID50,pug ml-1,1,-1
ID50,pmg kg-1,1,-1
log(1/IC50),mM,1,-1
log(1/ID50),uM,1,-1
ID50,pg kg-1,1,-1
I16,uM,1,-1
AUC,min.ng/g,1,0
ID50,pM,1,-1
ID50,microg/cm2,1,-1
AUC,mg.hr,1,1
log(activity),/min,1,1
ID50,mg/kg/hr,1,-1
GR control,%,1,1
ID50,mg kg-1 day-1 b.i.d.,1,-1
AUC,hr.nmol/g,1,1
I20,uM,1,-1
log10CFU/ml,mg/L,1,-1
ID50,10'-9mol/L,1,-1
ID50,10'-7mol/L,1,-1
AUC,L/hr.Kg,1,1
AUC,10^6nM,1,1
AUC,0-tldc,1,1
ID50,10'-3microM,1,-1
ID50,10'-3M,1,-1
logD,,1,0
ID50,10'-2microM,1,-1
logD7.5,,1,0
ID50,10'-1microM,1,-1
I23,M,1,-1
AUBC,ng.hr/ml,1,1
AT1 affinity,,1,-1
logP,10'-2No_unit,1,0
logP,c.p.m.,1,0
ID100,M,1,-1
APD95,,1,-1
APD95,uM,1,-1
ID/animal,%,1,1
APD,%,1,1
GTPshift,,1,-1
Gain,,1,1
I28,uM,1,-1
APA,ms,1,0
Gastric concentration,,1,0
max activation,pmol,1,1
max activation,pmol/mg/min,1,1
Gastric emptying,,1,0
I30,uM,1,-1
Halucinogenic activity,,1,0
mequiv of Na+/kg,,1,1
I42,uM,1,-1
n/N,/ 7,1,0
ALP_CHANGE_TO,,1,0
nKa,mM-1,1,1
Gastric lesions,,1,1
Generalization,,1,0
I5,uM,1,-1
IC90,PuM,1,-1
IC90,Gy,1,-1
IC90,%,1,0
Glucose,mg dl-1,1,1
Glucose level,%,1,1
AFLCl,ms,1,0
AE score,%,1,1
washout,%,1,1
Glucose lowering ob/ob dose,mg kg-1,1,1
pBBB,10'-3cm/s,1,0
IC75,mg kg-1,1,-1
pBBB,cm/s,1,0
Glucose lowering relative to positive control,%,1,1
IC60,10'-2 ug/ml,1,-1
AD90,ug/kg,1,1
AD50,umol/Kg,1,-1
pCB,,1,-1
IC50H,uM,1,-1
AD50,ng,1,1
% Inhibition of Control Agonist Response,%,1,1
AD50,day,1,1
IC50 reduction,,1,-1
pDelta IOP,mmHg,1,-1
AD100,mg kg-1,1,1
AD,,1,1
Cmin,ng/g,1,0
Max cAMP,,1,1
Cmin,nmol/L,1,-1
Max contractile activity,mg,1,0
Cmin,ug/g,1,0
Cmedia,ug of B g-1,1,0
Max MBP,,1,1
Max IOP reduction,,1,1
Cmin(1),nmol.L-1,1,1
Max delta BP,mg kg-1 p.o.,1,1
Cmin(80hr),pg/mL,1,1
Max APD95,%,1,1
Cmin(ss),nmol.L-1,1,1
Cmax_triphosphate,uM,1,1
Cmax_triphosphate,pmol/10^6cells,1,0
Co,ng ml-1,1,0
Margin before onset of tachycardia,mg kg-1,1,0
Cmax/dose,nmol,1,1
Cmax/dose,ngequiv/ml/mg,1,1
Cmax/dose,ng/ml/mg,1,1
Margin before onset of hypokalemia,mg kg-1,1,0
Max inhibition,uM,1,1
Cmax/Tmax,hr,1,0
MTT,mg/ml,1,0
MTT,hr,1,0
MTL,,1,0
pEC50,uM,1,-1
Max reduction,mg kg-1,1,1
Compound in urine,%,1,1
MTD,ug/m2/day,1,1
Compound recovery,ml/hr,1,0
Compound recovery,ug ml-1,1,0
Conc_brain,,1,0
Cmax,ug/ml.hr,1,0
MTD,ng,1,1
Cmax,ug m-1 min-1,1,0
Maximal activation,uM,1,1
IC50,ug/kg,1,-1
MTD,mg/g,1,1
Concentration,PuM,1,-1
Concentration,mequiv/L,1,0
MTC,%,1,1
pED50,mg kg-1,1,-1
MST,MST,1,0
Cmax,ng/10^6â¯cells in 4â¯h,1,1
Cmax,ng/10^6â¯cells,1,1
Cmax,ng.hr,1,1
Cmax,ng kg-1,1,1
AC50,mg,1,-1
MRT,ng/ml,1,0
Concentration,ug min-1 kg-1,1,0
MRC,mg kg-1,1,1
Concentration,ug of B/ml,1,-1
Mean effective dose,,1,1
MPE,uM,1,-1
Concentration in Brain,,1,0
Concentration in serum,,1,0
Concentration of Cl-,m equiv 6hr-1 kg-1,1,-1
MPC,ng/ml,1,-1
MPA,,1,0
AC50,hr.nmol/L,1,-1
Mean maximumtemp drop,degrees C,1,1
AC50,g/dl,1,-1
Clp,ml mg-1 kg-1,1,0
Clp,ml hr-1,1,0
Clp,l kg-1,1,0
MNTD,mg,1,0
Contractility,mg kg-1,1,1
Clinical reference,,1,0
Clerance,l hr-1 kg-1,1,0
Control,mg kg-1,1,0
Control,ng ml-1,1,0
Control,pfu/ml,1,1
MLD50,,1,-1
Clearance_blood,Not_given,1,0
Control at the dose of 5.0microg/mouse,%,1,1
Clearance,ml min-1,1,0
Med tumor area,mg,1,1
Control at the dose of 50.0microg/mouse,%,1,1
Median,%,1,1
Control current,,1,0
Clearance,l kg-1,1,0
Clearance,l hr-1,1,0
Clast,ug.hr/ml,1,0
MLD,ug/kg,1,1
Control level,ng ml-1,1,0
Clast,ng/mL.hr,1,0
Median toxicity,mg kg-1,1,1
MLC,pug ml-1,1,-1
MLC,ml/min.kg,1,0
MLC,mg/ml,1,0
MITC95,,1,-1
Cl-,,1,0
Cl,ml hr-1,1,0
Cl,l hr-1,1,0
Cp,L/Kg,1,0
Cp,M,1,0
MIC=>90,mg/ml,1,-1
